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Abstract 
New psychoactive substances (NPSs) have appeared on the recreational drug 
market at an unprecedented rate in recent years. Many are not new drugs but 
failed products of the pharmaceutical industry. The speed and variety of drugs 
entering the market poses a new complex challenge for the forensic toxicology 
community. The detection of these substances in biological matrices can be 
difficult as the exact compounds of interest may not be known. Many NPS are 
sold under the same brand name and therefore users themselves may not know 
what substances they have ingested.  
The majority of analytical methods for the detection of NPSs tend to focus on a 
specific class of compounds rather than a wide variety. In response to this, a 
robust and sensitive method was developed for the analysis of various NPS by 
solid phase extraction (SPE) with gas chromatography mass spectrometry (GC-
MS). Sample preparation and derivatisation were optimised testing a range of 
SPE cartridges and derivatising agents, as well as derivatisation incubation time 
and temperature. The final gas chromatography mass spectrometry method was 
validated in accordance with SWGTOX 2013 guidelines over a wide concentration 
range for both blood and urine for 23 and 25 analytes respectively. This included 
the validation of 8 NBOMe compounds in blood and 10 NBOMe compounds in 
urine. This GC-MS method was then applied to 8 authentic samples with 
concentrations compared to those originally identified by NMS laboratories.  
The rapid influx of NPSs has resulted in the re-analysis of samples and thus, the 
stability of these substances is crucial information. The stability of mephedrone 
was investigated, examining the effect that storage temperatures and 
preservatives had on analyte stability daily for 1 week and then weekly for 10 
weeks.  
Several laboratories identified NPSs use through the cross-reactivity of these 
substances with existing screening protocols such as ELISA. The application of 
Immunalysis ketamine, methamphetamine and amphetamine ELISA kits for the 
detection of NPS was evaluated. The aim of this work was to determine if any 
cross-reactivity from NPS substances was observed, and to determine whether 
these existing kits would identify NPS use within biological samples. The cross-
xxii 
 
reactivity of methoxetamine, 3-MeO-PCE and 3-MeO-PCP for different 
commercially point of care test (POCT) was also assessed for urine.  
One of the newest groups of compounds to appear on the NPS market is the 
NBOMe series. These drugs pose a serious threat to public health due to their 
high potency, with fatalities already reported in the literature. These 
compounds are falsely marketed as LSD which increases the chance of adverse 
effects due to the potency differences between these 2 substances. A liquid 
chromatography tandem mass spectrometry (LC-MS/MS) method was validated in 
accordance with SWGTOX 2013 guidelines for the detection for 25B, 25C and 25I-
NBOMe in urine and hair.  
Long-Evans rats were administered 25B-, 25C- and 25I-NBOMe at doses ranging 
from 30-300 µg/kg over a period of 10 days. Tail flick tests were then carried out 
on the rats in order to determine whether any analgesic effects were observed 
as a result of dosing. Rats were also shaved prior to their first dose and re-
shaved after the 10-day period. Hair was separated by colour (black and white) 
and analysed using the validated LC-MS/MS method, assessing the impact hair 
colour has on the incorporation of these drugs. Urine was collected from the 
rats, analysed using the validated LC-MS/MS method and screened for potential 
metabolites using both LC-MS/MS and quadrupole time of flight (QToF) 
instrumentation.  
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Chapter 1: New Psychoactive Substances  
1.1 Introduction 
New psychoactive substances (NPSs) are defined by the United Nations (UN) as 
“substances of abuse, either in a pure form or a preparation, that are not 
controlled by the 1961 Convention on Narcotic Drugs or the 1971 Convention of 
Psychotropic Substances, but which may pose a public health threat”.(1) The 
majority of these drugs are not new but simply newly abused with many being 
failed by-products of the pharmaceutical industry such as 2-desoxypipradol (2-
DPMP) and methylone.(2) Other NPSs are manufactured solely with the intent to 
provide users with similar effects to those felt when taking already banned 
substances such as 3,4-methylenedioxy-methamphetamine (MDMA). These NPSs, 
however, chemically differ sufficiently from their predecessors to avoid control 
via the Medicines Act or the Misuse of Drugs Act (MoDA).(3)  
NPSs pose an unprecedented threat by the speed at which they are launched 
onto the recreational drugs market. In the time taken for a substance to be 
detected, for reference standards to become available and legislation to be 
passed, a new compound will have already taken its place. This means that 
toxicologists and law enforcement agencies are constantly one step behind in 
this “cat and mouse” chase.(4)  
The 2013 United Nations Office on Drugs and Crime (UNODC) Global Synthetic 
Monitoring: Analyses, Reporting and Trend (SMART) programme report titled the 
“The Challenge of new psychoactive substances” found that 87% of 80 countries 
and territories had noticed the appearance of NPSs on the recreational drugs 
market.(5) This report also stated that the appearance of NPSs was most 
prevalent in Europe which accounted for 44% of countries reporting NPS use 
within the population. This is in part due to the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) early warning system (EWS), an information 
sharing network between European Union (EU) member states. When a NPS is 
detected in Europe information is sent to the EMCDDA or the European Police 
Office (EUROPOL).  This information is then disseminated throughout Europe via 
Europol National Units (ENU), ReiTox (Réseau Européend´Information sur les 
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Drogues et les Toxicomanies), the European Commission and the European 
Medicines Agency (EMA).(6) As a result of this framework EU members are rapidly 
alerted to NPSs, increasing their chance of detection within each country. The 
number of NPSs detected by the EMCDDA continues to grow yearly as shown in 
Figure 1-1.(7) 
 
Figure 1-1: Number of NPSs identified by the EMCDDA 2007-2014(7) 
 
NPS use has become an integral part of the UK club scene as their effects are 
similar to those of amphetamines, cocaine and MDMA.(8, 9) MDMA and cocaine 
purities were low in 2009 having reportedly decreased to 22%, whereas 
mephedrone purities were reported as high as 87%.(10) This in itself may be an 
important factor in the acceleration and decline of these substances respectively 
in the recreational drug market as shown in Figure 1-2.(11) In 2009 a survey of 
MixMag (a British electronic dance and clubbing magazine) readers found that 
mephedrone was the sixth most frequently used drug that year, following 
alcohol, tobacco, cannabis, cocaine and MDMA, again highlighting how quickly 
this substance infiltrated this demographic.(12)  
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Figure 1-2: MDMA, piperazines and cathinone derivative seizures: July 2005- March 
2010.(11)  
 
NPSs can be classified into 7 categories as shown in Figure 1-3. This thesis 
focuses mainly on synthetic cathinone’s and substituted phenethylamines 
although does cover all classifications with the exception of synthetic 
cannabinoids. 
 
Figure 1-3: UN categorisation of NPSs 
SYNTHETIC 
CATHINONES
PIPRAZINES PHENETHYLAMINES
KETAMINE
PLANT-BASED 
SUBSTANCES
SYNTHETIC 
CANNABINOIDS
MISCELLANEOUS
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1.2 Synthetic Cathinone’s  
1.2.1 Background 
Synthetic cathinones are monoamine alkaloids derived from the psychoactive 
substance found in the young leaves of the Catha edulis plant, commonly known 
as khat. This plant is native to East Africa and the Arab peninsula, and its use is 
deeply rooted in everyday life and folklore in these areas; in the Harar region of 
Ethiopia, khat is included in 501 different medical treatments.(13) The use of 
khat leaves is now illegal in the UK as it is a Class C drug under the MoDA (1971) 
and licensed as a medicinal product under the Medicines Act 1968.(14) Khat use 
is rare in the UK and its use is mainly restricted to migrant communities, 
although there is documentation of its use amongst the student population.(15, 
16)  
Cathinone levels in fresh leaves range from 0.3 to 2.1%, although these rapidly 
decline after harvest, thus khat must be consumed quickly.(17) It is thought that 
this has contributed to its lack of popularity amongst the wider UK 
population.(15)  
Recently, synthetic variations of cathinone have appeared in the UK with the 
most well-known being mephedrone and methylone. Methylone, a patented anti-
depressant and anti-Parkinson’s medication was the first synthetic cathinone to 
be identified by the EMCDDA in 2005 followed by mephedrone in 2007.(18-20). 
The only synthetic cathinone currently to have any legitimate use is bupropion 
which is prescribed as an anti-smoking aide and for treatment of depression.(11) 
Many of the current synthetic cathinones have been produced in response to this 
legal action and are marketed online as “next generation” mephedrone as was 
the case for naphyrone. These alternatives are then banned and so the cycle of 
new legal alternatives began.  
Currently synthetic cathinones are the second biggest drug group (after synthetic 
cannabinoids) monitored by the EMCDDA with over 70 substances identified to 
date.(21) 
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1.2.2 Chemical Structures  
The chemical structures and street names associated with the synthetic 
cathinones discussed in this thesis are shown in Table 1-1.  
Table 1-1: Chemical structures and street names of synthetic cathinones. 
Name Street Names Chemical Structure 
4-FLUOROEPHEDRONE 
(FLEPHEDRONE) 
4-FMC 
 
BENZEDRONE 
 
4-MBC 
 
BUTYLONE 
Explosion 
Ease 
Arlone 
 
ETHYLONE 
(βk-MDEA) 
(βk-MDEA) 
 
MEPHEDRONE 
M-Cat 
Meow Meow 
White Magic 
Drone 
Bubble 
 
METHEDRONE 
Bubbles 
Bristol Meth 
Dolley 
 
METHYLENEDIOXY-
PYROVALERONE 
(MDPV) 
Bath salts 
Magic 
Super Coke 
Lunar Wave 
Vanilla Sky 
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Table 1:1 Chemical structures and street names of synthetic cathinones (cont.) 
Name Street Names Chemical Structure 
METHYLONE 
Explosion 
Ease 
Arlone 
 
NAPHYRONE 
 
NRG-1 
Energy-1 
Rave 
 
 
1.2.3 Administration 
Ingestion of cathinones is typically via oral administration or inhalation, with 
different preferred routes dependant on the cathinone being administered, e.g. 
methylone is typically taken orally, allowing users to avoid its strong nasal 
irritancy.(22) Reports by users suggest that the majority of these drugs taste 
unpleasant and if administered orally are done so as “bombs”; small amounts of 
drug wrapped in paper to avoid the unpleasant taste.(23) Other routes such as 
rectal administration and injection have been noted through a survey on MDPV 
users showing that the majority chose to inject this substance.(24, 25) 
Van Hout’s study into the injection of mephedrone head shop products found 
that all participants interviewed had prior experience of intravenous (IV) drug 
use and that 81% of injecting users had injected mephedrone on first use.(25) 
Injection of synthetic cathinones has also been reported in Hungary and 
Romania. Hungary reported that up to 58% of individuals enrolled in needle and 
syringe programmes were injecting synthetic cathinones as their main drug. 
Opioid substitution programmes in Hungary also reported 10-50% of those 
enrolled were injecting synthetic cathinones. It should be noted that the 
synthetic cathinones being injected did change over time in line with changes to 
availability as substances were controlled as shown in Figure 1-4. Mephedrone 
was legal in Hungary in 2010, and controlled in Jan 2011. This explains the large 
decrease in seized paraphernalia associated with this substance and its 
replacement with 4-MEC and MDPV in 2011.  
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Figure 1-4: Analysis of seized injecting equipment (needle, syringe, filter, and spoon) in 
Hungary 
 
Oral synthetic cathinones doses are typically in the range of 15-250 mg, although 
doses of over 1 g have been reported in forums, with lower nasal doses reported 
of 5-125 mg.(26) Due to the nature of the product, users cannot be sure of purity 
or contents, which may affect dosing.(27) 
1.2.4 Effects 
Effects of synthetic cathinones are thought to be similar to those of 
amphetamines, particularly MDMA. Euphoria, empathy, increased sex drive, 
alertness and becoming more talkative are all positive effects commonly 
mentioned by users. (28) The oral onset and duration of effects for mephedrone, 
methylone and MDPV are shown in Table 1-2. The onset of nasal doses is much 
quicker, typically taking 2-3 minutes, and the effects for injecting users last 
anywhere up to 30 minutes.  
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Table 1-2: Duration of oral effects for mephedrone, methylone and MDPV. 
 MEPHEDRONE METHYLONE MDPV 
TOTAL DURATION 2-5 hours 3-5 hours 2-7 hours 
ONSET 15-45 mins 20-60 mins 15-30 mins 
COMING UP 15-30 mins 30-45 mins 30-60 mins 
COMING DOWN 30-90 mins 60-120 mins 30-120 mins 
 
As expected with any drug, there are also unwanted side effects, most 
commonly agitation and combative behaviour. Figure 1-5 shows a full list of 
synthetic cathinone adverse effects as well as their prevalence in Kentucky and 
Louisiana patients (Aug 2010 – Feb 2011).(29) These reported side effects are 
consistent with other accident and emergency (A&E) reports. MDPV is thought to 
have slightly more severe side effects than other synthetic cathinones with 
patients reporting “flash backs” serotonin syndrome and hallucinatory 
delirium.(30-32)  
 
Figure 1-5: Prevalence (%) of adverse synthetic cathinone effects seen in 236 patients in 
Louisiana and Kentucky, USA (Aug 2010 -Feb 2011). 
 
Four synthetic cathinone IV users admitted to A&E in Dublin showed added soft 
tissue complications, presenting with cellulitis, thrombophlebitis, and abscesses. 
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These individuals would therefore have had already weakened immune systems 
which may have exacerbated their symptoms. The use of contaminated injection 
equipment may have also contributed. No toxicological findings were presented 
in this paper to confirm that these adverse effects were the result of synthetic 
cathinone abuse or which synthetic cathinone was responsible. Additional soft 
tissue problems have also been reported such as rhabdomyolysis and acute 
compartment syndrome.(33, 34)  
Synthetic cathinones should not be ingested with other compounds such as 
alcohol, which may enhance their effects. Recently, there have been reports 
linking these substances to drug related crime (DFC), in particular drug- related 
sexual assault (DFSA).(35, 36) A study analysed 45 urine samples from DFSA cases 
and found 13% were positive for methylone. Two cases contained this substance 
only, whereas, the remaining cases all additionally contained THC or 
alcohol.(35) As these drugs are particularly popular with younger people, it may 
be that their drug taking behaviour makes them more at risk to DFSA, rather 
than perpetrators of DFSA selecting these substances specifically in order to 
carry out these crimes.  
Dependency has been reported with synthetic cathinone use, with users needing 
to re-dose on a frequent basis.(37, 38) This has also been demonstrated using 
animal models. Sprague-dawley female rats trained to self-administer 
mephedrone did so more than those trained to self-administer methylone and 
MDMA.(39) This highlights that the synthetic cathinone being used will also 
affect the level to which dependency is shown.  
1.2.5 Toxicity 
The toxicity of NPSs are not fully understood as the majority of post mortem 
cases involve polydrug use; therefore death cannot be attributed to one drug 
alone. In the case of acute toxicity where patients attend A&E, treating the 
patient is the number one priority for medical staff, and therefore identification 
of the exact substance taken may never happen. This is also in part due to 
budget constraints which are affecting hospital priorities. As synthetic 
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cathinones have been around for the longest period of time, they are the most 
commonly encountered in A&E and therefore the most understood.  
60 mephedrone related UK fatalities were reported which had confirmed 
toxicology, and concluded inquests. Of the 60 cases, 16 individuals terminated 
their own lives through hanging or other violent means. The coroner ruled cause 
of death for these 60 cases is shown in Figure 1-6. In the majority of these cases 
mephedrone use was thought to have played a role, and therefore its use may 
have the ability to intensify psychosis and depression. Between March and July 
2010 ROAR Forensics, (UK) received 16 urine and/or blood samples which tested 
positive for mephedrone. Of these, 6 (37.5%) were from suicide cases (5 due to 
hanging, 1 due to gunshot wound).(20) A report into mephedrone-related 
fatalities in the UK also highlighted the large number of deaths (20.7%) 
attributed to suicide where mephedrone was found in post mortem biological 
samples. (40, 41) It is not known whether these individuals experienced suicidal 
thoughts prior to intoxication and therefore a direct correlation between 
mephedrone use and suicide cannot yet be made.  
 
Figure 1-6: Cause of death verdict in 60 cases identified in the UK. 
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MDPV was detected in 13 fatalities in Finland in 2010. All of the deceased were 
male known drug users. Urine concentrations ranged from 0.02-4.8 mg/L; 
however MDPV was not listed as the sole cause of death in any of these 
cases.(42) In Michigan, (USA) a number of MDPV intoxications were reported in 
2010 along with 1 fatality where MDPV was noted as the main factor contributing 
to death.(24) Although toxicology was done on this case the concentrations 
detected were not provided in the paper.  
Fatal serotonin syndrome was reported in a 24-year old female who ingested 2 
“ecstasy” pills. On analysis, these pills were found to contain methylone and 
butylone only. On arrival at A&E the patient had a temperature of 41.8oC 
alongside other previously discussed side effects such as tachycardia and 
minimal reactivity. Despite extensive effort by the A&E team the patient 
suffered multi-organ failure and died.(43)  
Methylone was also deemed the cause of death in three patients admitted to 
hospital in Florida. Methylone blood concentrations were found at 0.84, 3.3 and 
0.56 mg/L. Using this data it was suggested that methylone blood concentrations 
above 0.5 mg/L may result in death.(44) 
1.2.6 Pharmacology 
Little information is available on the pharmacokinetics of many synthetic 
cathinones. Seven metabolites of mephedrone have been identified along with a 
suggested metabolic pathway for its breakdown.(45) Hydroxytolyl mephedrone 
and nor-hydroxytolyl mephedrone are thought to be partially excreted as 
glucuronides and sulphates.(45, 46) There is no information currently available 
on the stability of mephedrone metabolites or how long they can be detected in 
biological fluids.(20) 
Urine samples were collected from individuals identified as recreational drug 
users through a previous telephone drug survey. Analysis of these samples 
showed limitations associated with mephedrone metabolite detection by GC-MS. 
This work stated that the peak areas of mephedrone and its metabolites did not 
appear to be dose related. This was not a controlled study however, and 
therefore the time of ingestion would have a much bigger impact upon the 
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parent drug to metabolite ratio than that of dose. At the time however there 
was no information regarding metabolic kinetics of mephedrone and thus it was 
not possible to confirm that metabolite peaks were dependent on the time 
mephedrone was taken.(47) 
1.2.7 Prevalence 
Despite the 2010 classification of mephedrone as a class B substance in the UK, 
its use in the UK is still widely reported both online and in recent 
publications.(48) A survey interviewing attendees of London “gay friendly” 
nightclubs showed that mephedrone was the most commonly used drug with 41% 
reporting they had taken the drug or were planning to take it over the course of 
the evening. During this survey individuals were also asked to name their 
favourite drug; again mephedrone came out on top at 20.4%, ahead of GHB/ GBL 
(24%) and cocaine (17%).(49) 
A focus group study on mephedrone use amongst 145 Irish school children (14-15 
years old) found that all pupils had heard of mephedrone. Of these teenagers, 
40% admitted trying the drug, and 70% reported mephedrone use amongst 
friends. It should be noted that these pupils were selected from schools in areas 
known to have a high prevalence of drug use and where paramilitary violence 
was high and so are not necessarily a true indicator of mephedrone use in school 
children across the whole of Ireland.(50) 
Analysis of naphyrone based products prior to its classification detected the 
already illegal substance mephedrone alongside other controlled substances. 
(51) Mephedrone was added to the British Crime Survey in 2010/11 with 1.4% of 
surveyed people reporting to have taken the drug within the last year.(52) LGC 
also published data on seizures received between 1st January and 10th June 2011, 
during which they recorded 176 seizures weighing 15.2 kg containing only 
mephedrone. They also reported 13 seizures of mephedrone and ketamine 
mixtures weighing 33.8 kg.(53) 
One study in Finland analysed blood samples from 3000 drivers suspected of 
driving under the influence of drugs over the course of a year. Of these samples 
8.6% tested positive for MDPV. The individuals who provided these samples were 
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noted at time of sample collection as being impaired (86%) or severely impaired 
(7%). The majority of individuals testing positive were male (87%) from 24-44 
years of age (76%). As well as MDPV, 80% tested positive for amphetamines and 
67% for benzodiazepines. Only 4 samples contained MDPV alone.(54)  
Research into the prevalence of mephedrone, methylone and benzylpiperazine 
(BZP) amongst attendees of a drug treatment centre in the Republic of Ireland 
(ROI) found that 13.3% and 3.3% of 209 samples tested positive for mephedrone 
and methylone respectively. BZP was much less prevalent amongst subjects with 
only 0.5% of samples testing positive for this substance.(55)  
Synthetic cathinones have also been problematic in the USA with phone calls to 
the American Association of Poison Control Centres (AAPCC) regarding “Bath 
Salts” sharply increasing. A total of 2371 calls had been made from Jan – May in 
2011 in comparison to 303 calls in 2010, a 682% rise. (11) It is possible that the 
dramatic increase in calls was a result of the media attention these new 
substances were given. MDPV has been the most commonly encountered 
synthetic cathinone in the U.S.(56)  
The UNODC Global SMART report (2013) found that all continents reported the 
emergence of synthetic cathinones with the exception of Africa, highlighting the 
world wide spread of these substances.  The data in this report was collect via 
questionnaire from 80 different countries of which 10 were African. It is possible 
that although the African laboratories had not detected synthetic cathinones, 
their laboratories may not have been testing for them, or were sufficiently 
equipped to detect them. (57)  
1.3 Ketamine, Phencyclidine-type substances and 
Methoxetamine 
1.3.1 Background 
Ketamine was developed in 1962 by Calvin Stevens and patented the following 
year in Belgium. It was originally marketed as a fast acting anaesthetic with 
fewer side effects than its precursor phencyclidine (PCP).(58) Despite this claim 
ketamine was shown to share some of the psychedelic properties although these 
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were not as extreme. Ketamine has now completely replaced PCP in the U.K. 
and is routinely used for both medical and veterinary purposes, most famously as 
a horse tranquillizer.(59, 60)  
The first official record of ketamine misuse was in 1971. Ketamine misuse in the 
UK became more common during the 1990’s as it was routinely sold in clubs. 
This correlates with data from a 1997 study where 32% of interviewed club goers 
had taken ketamine. Increased ketamine use correlated with the rise of the 
“club” and “rave” culture within the UK. Ketamine was routinely sold as Ecstasy 
as it has a similar appearance and was cheaper to synthesise.(61)  
It has only recently become apparent that chronic and long-term ketamine abuse 
is associated with chronic bladder problems.(62-66) This recent bad press has 
resulted in an influx of new substances such as Methoxetamine (MXE), 3-
methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyeticyclidine (3-MeO-PCE), all 
marketed “bladder safe”. This marketing was aimed at existing ketamine users 
wishing to change substance to avoid these negative side effects. Unfortunately 
current research shows that repeated administration of MXE is likely to produce 
similar renal and bladder harms to that of ketamine.(67) 
1.3.2 Chemical Structures 
MXE is structurally related to ketamine and PCP. The chemical structures and 
street names of ketamine, MXE and other phencyclidine-type substances are 
shown in Table 1-3.  
Table 1-3: Chemical structures and street names of ketamine, phencyclidine-type substances 
and methoxetamine. 
Name Street Names Chemical Structure 
KETAMINE 
K 
Special K 
Kit Kat 
Vitamin K 
Super Acid  
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Table 1-3: Chemical structures and street names of ketamine, phencyclidine-type substances 
and methoxetamine (cont.) 
Name Street Names Chemical Structure 
METHOXETAMINE 
(MXE) 
MXE 
ROFELCOPTER 
MexxyR 
 
3-MeO-PCP 3-MeO-PCP 
 
3-MeO-PCE 3-MeO-PCE 
 
 
1.3.3 Administration 
The majority of “street” ketamine is diverted from legitimate veterinary 
supplies and is sold in either its original liquid form, or as a hydrochloric 
salt.(68) The issue of ketamine veterinary thefts was raised in 2009 by the House 
of Commons. The true prevalence of ketamine thefts remains unknown as these 
are currently listed under “other” theft and cannot be distinguished from other 
miscellaneous theft. As a result of this, impurities are rarely seen in seized 
ketamine.(69, 70) 
Ketamine doses given via IV injection normally range between 1 to 4.5 mg/kg of 
body weight. Intramuscular doses normally range from 6.5 to 25 mg/kg body 
weight.(58, 71) Oral ketamine doses range from 40mg to over 500mg depending 
on tolerance, common doses range from 75-300 mg.(72)  
MXE is routinely sold as a white or off-white crystalline powder which can be 
insufflated or dissolved in solution for oral and IV administration.(73) Oral and 
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insufflation doses typically range between 10-15 mg. There are also reports of 
rectal and IV administration.(74) Dependency is mentioned in the literature with 
chronic users expressing the need to re-dose on a frequent basis.(75)  
3-MeO-PCE and 3-MeO-PCP are administered via the same routes as ketamine 
and MXE, although are reported to be slightly more potent than PCE, thus 
require lower doses. Doses of 3-4 mg are typical with strong dissociative effects 
felt after 10-20 mg.(76)  
1.3.4 Effects 
Ketamine is a known dissociative anaesthetic, meaning patients administered 
the drug although not unconscious, are unaware of their surroundings. It also 
works as an analgesic reducing pain and results in mild amnesia.(68, 77-79) 
Ketamine stimulates the cardiovascular system, increasing heart rate, cardiac 
output and blood pressure. There is a marked increase in muscle tone which in 
worst case scenarios produces seizure like symptoms by reducing the fluxes of 
sodium and potassium.(58, 60, 80, 81) It does not, however, have an effect on 
the pharyngeal and laryngeal reflexes; meaning that airways are easily 
maintained and there is no suppression of the gag reflex as seen in other 
anaesthetic drugs.(82) It is therefore advised that Ketamine should not be 
administered to any individual with existing cardiovascular problems such as high 
blood pressure. Ketamine also has the ability to cross the placenta, although to 
date there have been no reports of birth defects or abnormalities caused by 
ketamine administration during pregnancy.(82) 
As ketamine is a central nervous system (CNS) depressant, mixing the drug with 
other CNS depressants is not advised. Combinations with alcohol and diazepam 
can result in respiratory problems at high doses. It can also cause nausea and 
vomiting in individuals who do mix these drugs, especially alcohol.(82) The 
psychedelic aspects of the drug are enhanced by the use of other similar drugs 
such as LSD.  
Those who use ketamine recreationally, seek to gain “out of body experiences” 
where the dissociative effects of the drug make the user feel they are looking 
down upon themselves.(60) This is commonly referred to as the K-hole. Whilst in 
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this state users may lose the ability to move and struggle to communicate with 
those around them. There are also reports of ketamine being used as a drug to 
facilitate sexual assault.(83) The amnesia properties of the drug and the 
dissociative effects have made it an increasingly popular drug for carrying out 
these crimes along with its fast acting nature.(84) 
Adverse side effects of ketamine use include cystitis, severe gastric cramping 
resulting in intense abdominal pain and memory impairment.(59, 60, 62, 63, 65, 
69, 85) In 2007 Professor D Nutt published a rational scale to assess the harm of 
drugs of potential misuse in The Lancet. This paper named ketamine as the 8th 
most harmful drug tested in the research above ecstasy (16th) and LSD (17th).(86) 
The main effects of MXE are similar to that of ketamine with users seeking 
dissociation, euphoria, and hallucinations. The onset and duration of effects are 
shown in Table 1-4, with after effects reported as lasting 2-48 hours after 
administration. Adverse effects have been reported in the literature, such as 
tachycardia, rotary nystagmus, nausea, paranoia, diarrhoea and anxiety.(87) 
There have also been reports of MXE alleviating phantom limb pain, again similar 
to ketamine.(88) 
Table 1-4: Onset and duration of methoxetamine effects in relation to routes of 
administration.(89) 
 ORAL/ SUBLINGUAL INSUFFLATION 
TOTAL DURATION 3-5 HOURS 2.5-4 HOURS 
ONSET 10-20 MINS 10-20 MINS 
COMING UP 15-30 MINS 15-30 MINS 
COMING DOWN 60-120 MINS 60-120 MINS 
 
Although similar to ketamine, the effects of MXE, 3-MeO-PCE and 3MeO-PCP are 
regarded by drug forum users as being inferior, however, they are a sufficient 
substitute should money and/or availability prevent the user from accessing 
ketamine. 
There have been suggestions of ketamine dependence and many of the 
individuals questioned by Muetzefeldt et al (2008) hinted at this.(90) The book 
“The Scientist” also mentions John Lilly’s personal experience with ketamine 
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dependence.(91) Tolerance to ketamine can be quickly acquired and this may 
lead to psychological based dependence rather than physical. However, there 
have been no proven studies to back up these suggestions and the ACMD 
reported ketamine dependence to be a very rare phenomenon.(69) To date 
there have been no studies conducted on the dependency of MXE, 3-MeO-PCE or 
3-MeO-PCP.  
1.3.5 Toxicity 
Ketamine has a wide therapeutic window and as a result overdose of the drug on 
its own is extremely unlikely. A review into 114 ketamine related deaths found 
blood concentrations ranging 2.4-3.6 mg/L.(92) Severe overdoses can be higher, 
with one case resulting in a blood concentration of 27.4 mg/L.(93) The EMCDDA 
reported only 12 deaths where ketamine contributed or was the cause of death 
between 1987 and 2000. Only 3 of these were from ketamine abuse alone.(82) 
MXE use was attributed to the death of a male in Milwaukee, USA, although no 
toxicological data was provided.(94) Despite this instance, MXE fatalities have 
been rare to date with the majority of case reports focusing on acute toxicity. 
Acute toxicity was seen in 3 patients in London with serum levels ranging from 
0.09 to 0.2 mg/L. One of the patients admitted also had 6-APB/5-APB present in 
their system; highlighting poly drug use amongst this population.(95)  
Hofer published the case of a 19-year old male with a history of drug abuse and 
attention deficit hyperactivity disorder (ADHD) who injected an unknown 
quantity of MXE. MXE was analytically confirmed by liquid chromatography 
tandem mass spectrometry (LC-MS/MS), however, concentrations were not 
reported.(96) A review of 6 patients identified MXE urine concentrations ranging 
from 2µg/mL to 165.3µg/mL.(97) 
Another post-mortem case identified MXE concentrations of 8.6 µg/g in femoral 
blood.(98) This was significantly higher than non-fatal concentrations identified 
in 4 cases which ranged from 0.21-0.49 µg/g.(98) As of yet there is no ED50, TD50 
or LD50 information for MXE, 3-MeO-PCE and 3-MeO-PCP.  
19 
 
 
1.3.6 Pharmacology 
Ketamine exists as 2 separate isomers, R and S, with the S isomer believed to be 
3-4 times more potent than the R isomer. Ketamine is lipid soluble and is quickly 
distributed throughout the body following injection or infusion with a half-life 
ranging from 2 – 3 hours.(92) The elimination of ketamine occurs through two 
phases, alpha and beta with half-lives of 10-15 minutes and 2.5 hours 
respectively. It is during the alpha phase that ketamine affects the CNS.(82) 
Once in the body ketamine is metabolized via N-demethylation to norketamine 
which is then dehydrogenated to form dehydronorketamine. Metabolism takes 
place in the liver by CYP3A4, CYP2B6 and CYP2C9 enzymes.(99)  
As MXE is structurally similar to ketamine it is predicted to have a similar 
mechanism of action, acting as a NMDA receptor antagonist, thus inhibiting 
dopamine reuptake.(28, 100, 101) Unlike ketamine, MXE also has affinity to the 
serotonin receptor. MXE does not possess the same analgesic and anaesthetic 
properties as ketamine due to the alteration from 2-chloro to a 3-methoxy 
group.(28) 3-MeO-PCE and 3-MeO-PCP have also been shown to be NMDA 
receptor agonists with 3-MeO-PCP being particularly active.(102) 
The metabolism of MXE was identified in rat and human urine by Meyer. This 
research identified nor-MXE as the most important human metabolites for aiding 
identification.(101) CYP2B6 and CYP3A4 are thought to be involved in the initial 
metabolism of this compound.(101) No pharmacokinetic data is currently 
available for 3-MeO-PCE or 3-MeO-PCP. The absorption, distribution or excretion 
of these compounds has yet to be investigated.  
1.3.7 Prevalence 
Due to the length of time ketamine has been used, prevalence for this drug has 
been well documented. Its use continues to increase in the UK, in particular with 
the “underground dance scene”. Despite its popularity, negative-effects from 
long-term use are now common knowledge with underground DJ Seth Troxler 
claiming “Ketamine is the heroin of our time, it’s horrible”.(103) 
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MXE was first detected and reported to the EMCDDA in 2010. Initially reports 
originated from the UK with other EU countries reporting this substance shortly 
after. UK research analysing pooled urine from portable urinals found that 50% 
of the urinals contained ketamine, with 1 urinal tested positive for the presence 
of MXE.(104) Urinals were placed in 12 sites throughout an area of London and 
used for 1 night during March. This data is limited because the urinals could only 
be used by men and it is unknown whether MXE was purposely ingested or used 
as an adulterant in a ketamine sample. Despite its limitations this research did 
provide a strong indication of drugs currently being abused within the night time 
economy.  
A total of 120 non-fatal intoxications of MXE were reported to the EMCDDA by 5 
member states, highlighting the spread of this drug throughout Europe.(73)  
1.4 Aminoindanes & Methiopropamine  
1.4.1 Background 
Aminoindanes, are a sub-group of phenethylamine and include substances such 
as 5,6-methylenedioxy-2-aminoindane (MDAI) and 5-Iodo-2-aminoindane (5-IAI), 
which have both been detected in Australia, Belgium, Finland, Latvia and the 
UK.(57) Although not an aminoindane, methiopropamine (MPA) is commonly 
encountered alongside these compound types, and thus is discussed here.   
5-IAI was developed in the 1990’s by David Nichols at Purdue University as was 
MDAI during research into the pharmokinetics of MDMA. Methiopropamine (MPA) 
was synthesized much earlier in the 1940’s and again is another failed 
pharmaceutical product.(105) Recreational abuse of these substances was not 
recognised until 2010. This is likely to have been a response to the banning of 
mephedrone and the aggressive marketing taking place offering these products 
as its alternative. 
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1.4.2 Chemical Structures 
The chemical structures and street names of aminoindanes (discussed in this 
thesis) and MPA are shown in Table 1-5. These are chemically similar to MDMA 
which is also shown for comparison. 
Table 1-5: Chemical structures and street names of aminoindanes. 
Name Street Names Chemical Structure 
MDMA 
Ecstasy 
E 
 
MDAI 
Woof Woof 
Stardust 
Sheet 
Mystic 
 
 
5-IAI 
Bounce 
Charge 
 
 
 
METHIOPROPAMINE 
MPA 
Blow 
 
 
1.4.3 Administration 
MPA is an off-white powder with a bitter taste and slight aniseed odour. It can 
be administered orally, insufflated, or inhaled as a vapour with doses varying 
depending on the route taken.(106) Smoking MPA has also been mentioned in 
literature with this providing the quickest onset of effects.(105)  
The first MDAI samples to be detected in the UK were brown powders with 
further seizures of capsules (n=17) in 2010. MDAI is typically administered orally, 
although it can also be snorted, and administered rectally. Typical doses range 
from 150-200 mg, and re-dosing appears to be common.(107)   
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1.4.4 Effects 
Positive effects for MPA users include mild euphoria, increased alertness and 
sexual arousal. Negative effects include anxiety, difficulty urinating, laboured 
breathing, heart palpitations and nausea. Effects are thought to be similar to 
methamphetamine, effects are shown in Table 1-6.  
Table 1-6: Onset and duration of MPA effects following insufflation. (89) 
 INSUFFLATED 
TOTAL DURATION 2-4 hrs 
ONSET 5-10 mins 
COMING UP 5-10 mins 
COMING DOWN 30-120 mins 
 
The effects of MDAI are similar to that of MPA, with the effects and their 
duration being dependent on the route of administration. Effects are felt 
normally within the first 10 minutes, although this can change depending on the 
users own tolerance of this substance. The effects of 5-IAI are also similar to 
MDMA, without the long-term neurotoxicity. (108) 
1.4.5 Toxicity  
Analytically confirmed toxic cases for these substances remain rare. The cause 
of death for a 27-year old female was linked to MPA use with this substance 
detected at a concentration of 400 ng/mL in urine. Although this was not the 
only drug detected it was thought to have played a significant role in her 
death.(109)  
A&E presentations due to MDAI are rare, as are fatalities. A MDAI concentration 
of 26.3 mg/L was identified by HPLC-DAD in one female fatality; ethanol was 
also identified in this case at a concentration of 14 mg/dL. A second fatality 
involving a male identified a MDAI blood concentration of 3.3 mg/L. A urine 
screen identified the presence of other substances which were later confirmed 
using the blood sample; APB (0.34 mg/L), BZP (0.19 mg/L, MDMA (0.1 mg/L) and 
caffeine (19.2 mg/L). (107) 
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1.4.6 Pharmacology 
MPA for the most part remains un-metabolised with the parent compound 
excreted in both rat and human studies.(110) MPA works on the CNS, acting as a 
norepinephrine and dopamine reuptake inhibitor as well as a serotonin reuptake 
inhibitor.(111) As of yet there have been no studies on the dependence or 
tolerance of this substance, however it is likely that this will be similar to other 
stimulant compounds.(111) 
To date there is very little information on the pharmacology of MDAI or 5-IAI, 
although they are thought to be similar to that of MDMA.  
1.4.7 Prevalence 
The prevalence of these drugs is especially difficult to determine due to the 
large number of products mis-sold online. 5-IAI was one of the most sold NPS on 
websites between 2011 and 2012, however it may be that although many 
retailers were offering this product, they were in fact selling something 
different. Analysis of aminoindane products purchased online found that 6/7 
contained large amounts of caffeine, with only 1 containing the intended 
aminoindane (MDAI).(112) Case reports involving these substances have also 
been comparatively low suggesting that use of these substances is not as 
common, or that few laboratories are screening for these substances.  
The use of MPA has been identified in the night-time economy being the 12th 
most commonly detected drug in a London study of urine collected from public 
urinals.(104) 
1.5 Benzofurans  
1.5.1 Background 
Identified in 2010 in the UK 5-(2-aminopropyl)benzofuran (5-APB), and its 
positional isomer 6-(2-aminopropyl)benzofuran (6-APB) (identified in 2011 in 
Hungary) are phenylethylamine analogues, specifically MDMA. Benzofurans were 
initially investigated in the early 1990’s as potential anti-depressants. This work 
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is ongoing with some compounds of this class now having patents for such 
use.(113-115)  
1.5.2 Chemical Structure 
The chemical structures and street names of 5-APB and 6-APB are shown in Table 
1-7. These compounds differ only in the position of the oxygen atom in the furan 
ring, relative to the amine. These compounds are similar to 
methylenedioxyamphetamine, with the oxygen in the methylenedioxy ring 
replaced by a carbon, and an additional double bond.  
Table 1-7: Chemical structures and street names of benzofurans. 
Name Street Names Chemical Structure 
5-APB 
Benzo Fury 
White Pearl 
 
 
6-APB 
Benzo Fury 
White Pearl 
 
 
 
1.5.3 Administration 
Benzofurans are sold in powder, pill, pellet or gel capsule form, with powders 
being white or slightly tan in colour depending on purity. Benzofurans can be 
ingested orally, insufflated or taken rectally. Typical oral doses range from 50-
100 mg however stronger doses over 170 mg have been mentioned in drug 
forums.(116)  
1.5.4 Effects 
Both 5 and 6-APB have amphetamine like effects on the body. Positive effects 
result in increased visual and tactile stimulation, mild euphoria, hallucinations 
both auditory and visual. Common side effects include bruxism, nystagmus, 
headaches and nausea. The onset and duration of these effects are shown in 
Table 1-8.  
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Table 1-8: Duration of APB effects. 
 ORAL/ SUBLINGUAL 
TOTAL DURATION Up to 14 hours  
ONSET 15-90 mins 
COMING UP 2-3 hours 
 
1.5.5 Toxicity  
Acute psychosis was reported in 1 patient with a 6-APB urine concentration of 2 
mg/L. Psychological treatment and diazepam administration was used to treat 
symptoms before the patient was discharged. Synthetic cannabinoid metabolites 
were detected at much lower concentrations, and deemed not to have played a 
significant part in the patient’s symptoms.  
Post mortem toxicology was carried out on a 21-year-old male who collapsed, 
and eventually died despite intensive medical intervention. Analysis was done on 
peripheral blood, central blood and urine with 5-APB detected at 2.5 mg/L, 2.9 
mg/L and 23 mg/L respectively. Other matrices were also tested including liver, 
vitreous and gastric contents and found to contain 16 mg/kg, 1.3 mg/L and 6 
mg/L respectively.  
1.5.6 Pharmacology 
5-APB has been shown to inhibit the dopamine transporter system and act as an 
agonist to both the 5-HT2A and 5-HT2B receptors. It was also noted in this study 
that 5-APB caused vasoconstriction of the aorta, and suggested that its activity 
at the 5-HT2B receptor may result in cardiotoxicity.(117) 
1.5.7 Prevalence  
There is little prevalence data regarding these compounds due to their apparent 
limited use. The National Poisons Information Service TOXBASE received 65 
phone enquiries and 741 online requests for information relating to 5 and 6-APB 
between 2009-2013. 
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1.6 NBOMe’s 
1.6.1 Background 
Another group derived from phenethylamines are the NBOMe’s, a derivative of 
the 2C-X series (developed by Alexander Shulgin in the 70’s and 80’s as part of 
his research on phenethlamines), the first NBOMe was mentioned in Ralf Heim’s 
PhD thesis in 2004.(118) NBOMe’s were further developed by David Nichol with 
the addition of a 2-methoxybenzyl (MeOB) on the nitrogen (N) of the 
phenethylamine, hence the term NBOMe. Recreational abuse is thought to have 
begun in 2010.(119)  
1.6.2 Chemical Structures  
The generic chemical structure of the NBOMe series is shown in Table 1-9 along 
with their street names.  
Table 1-9: The generic chemical structure for the NBOMe series, alongside street names. 
Name R= 
Street 
Names 
Chemical Structure 
25I-
NBOMe 
I  
Smiles 
Bomes 
 
 
25B-
NBOMe 
B 
25N-
NBOMe 
N 
25P-
NBOMe 
P 
25D-
NBOMe 
D 
25E-
NBOMe 
E 
25H—
NBOMe 
H 
25T2-
NBOMe 
Methylthio 
Group 
25T4-
NBOMe 
Isopropylthio 
Group 
25T7-
NBOMe 
Propylthio 
Group 
R
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Table1-9: The generic chemical structure for the NBOMe series, alongside street names 
(cont.) 
Name R= 
Street 
Names 
Chemical Structure 
25C-
NBOMe 
C   
Mescaline-
NBOMe 
Mescaline 
group 
 
 
 
1.6.3 Administration  
Phenethylamines are routinely associated with the “club drug” scene and as a 
result are administered commonly using routes compatible with these settings, 
i.e. oral or insufflation.  
NBOMes are administered either in liquid form or on blotters due to their high 
potency and similarities to LSD. Oral and sublingual administrations were the 
reported methods of administration by 81.2% of users taking part in the Global 
Drug Survey.(120) Insufflation has been noted in the literature although this 
route of administration is associated with toxicity and even death. 
Oral doses of all NBOMes (except mescaline-NBOMe) reportedly range from 50-
1200 µg with hallucinogenic effects felt at doses of 50-200 µg. Sublingual doses 
for hallucinogenic effects range from 100-250 µg with strong effects being felt 
above 800 µg. Low insufflation doses are in the range of 50-200 µg with doses 
over 700 µg considered as extremely strong. Alternative administration routes 
have been mentioned in drug forums, such as injection (830 µg), smoking (50-200 
µg), rectal (400 µg), and vaginal (500 µg).(121)  
Mescaline-NBOMe appears to be an anomaly due to the fact that drug users in 
forums report requiring a much higher dose in order to achieve psychoactive 
effects, with one forum user reporting to have insufflated 75 mg over the course 
of a 20 minute period.(122)   
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1.6.4 Effects  
The NBOMe and 2C-X series differs from other phenethylamines as these produce 
hallucinogenic effects which are not normally observed for other 
phenethylamines such as MDMA unless very strong doses are administered. 
Sublingual users of NBOMes report an unpleasant metallic taste, alongside 
numbness. According to user forums it is this metallic taste and sublingual 
numbness that allows users to differentiate this substance from LSD. Psychedelic 
effects differ from user to user, however many report only visual hallucinations 
with less of the “spiritual” high experienced when taking LSD.(123)  
Table 1-10: Onset and duration of 25C-NBOMe effects in relation to routes of administration. 
 ORAL/ SUBLINGUAL INSUFFLATION 
TOTAL DURATION 6-10 hrs 4-8 hrs 
ONSET 0-15 mins 0-5 mins 
COMING UP 30-90 mins 15-30 mins 
COMING DOWN 1-4 hrs 1-3 hrs 
 
1.6.5 Toxicity 
Due to the high potency of NBOMe’s adverse effects, fatalities have been 
reported. The case of a 19-year-old man was reported by Poklis et al who was 
found to have overdosed on 25I-NBOMe. A range of matrices were tested 
including blood and urine, identifying concentrations of 0.441 ng/mL and 2.860 
ng/mL respectively.(124) Kueppers and Cooke reported a fatality attributed to 
25I-NBOMe. In this case 3 NBOMes were identified, 25I-NBOMe (2.800 ng/mL), 
25H-NBOMe (1 ng/mL) and 25C-NBOMe (0.7 ng/mL).(125) This is the second 
publication where individuals have ingested multiple NBOMes with Stellpflug et 
al. identifying 25I-NBOMe (7.5 ng/mL) and 25H-NBOMe (0.9 ng/mL).(126) 
1.6.6  Pharmacology 
Rat and mice studies have shown NBOMes to be potent 5-HT2A receptor agonists 
and it is this activity at the 5-HT2A receptor which leads to the hallucinogenic 
effects of these drugs.(127, 128) The metabolism of the NBOMe series is 
reported to be similar to that of the 2C-X series. Screening of urine case samples 
revealed the presence of O-demethylated metabolites, although the parent drug 
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was still the most abundant. Other metabolites include N-dealkylation, phenolic 
hydroxylation and conjugation.(126, 129)  
1.6.7 Prevalence 
Due to the recent launch of NBOMe’s onto the market, their prevalence remains 
unknown. They are not included as yet in major surveys such as the Crime Survey 
for England, but were added to the MixMag drug survey in 2013.This survey was 
completed by 22,289 individuals of which 2.6% had reported ever using NBOMe 
drugs.(120, 130) 
Information provided to the ACMD by the Serious Organized Crime Agency 
suggested that large quantities of the drug had already arrived into the UK from 
China.(123, 131, 132) Prevalence studies are further complicated by the false 
advertising of this substance as LSD, and as a result many users may unwillingly 
be taking this substance.  
Reports of mescaline-NBOMe use are rare and there are no scientific papers 
published on this compound. It has been suggested that its relatively short life-
span as a recreational drug was due to the high cost in synthesis. This coupled 
with low potency has resulted in manufacturers ceasing production in favour of 
more lucrative compounds. (133) 
1.7 Pipradols 
1.7.1 Background 
2-desoxypipradol (2-DPMP) was first synthesized for the treatment of narcolepsy 
and ADHD in 1954, although it was never used for these purposes due to its long 
elimination time (16-20 hours).(2) Recreational abuse of this substance seems to 
have begun in 2007; however drug seizures were not reported until 2009 in 
Finland.(134, 135) Due to the relatively low prevalence of this substance very 
little is known about it and the number of individuals reporting to A&E, or drug 
treatment programmes appears to be few. (136) 
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1.7.2 Chemical Structure 
The chemical structure of 2-DPMP and its associated street names is shown in 
Table 1-11. This compound is structurally similar to both methylphenidate and 
pipradol.  
Table 1-11: Chemical structures and street names of 2-DPMP. 
Name Street Names Chemical Structure 
2-DESOXYPIPRADOL 
2-(DPMP)  
Ivory Wave 
Purple Wave  
Vanilla Sky  
Whack  
 
 
 
1.7.3 Pharmacology  
There is little pharmacological data reported for 2-DPMP, however it appears to 
be metabolised via hydroxylation, dehydrogenation and oxidation, with these 
processes resulting in 6 phase I metabolites.(137) Although these metabolites 
have been identified in urine case samples, the levels detected varied between 
cases and thus the main metabolite could not be identified. This may in part be 
due to drug-drug interactions taking place as all case studies contained other 
substances.  
1.7.4 Administration  
2-DPMP is a white crystalline powder typically snorted or administered orally. 
Doses range from 0.5 mg-10 mg depending on the tolerance of the user and the 
method of administration.(138) Again due to the limited use of this substance 
information seems to be mainly from drug forums and thus may not be accurate.  
1.7.5 Effects 
Effects are typically felt within the first 60 minutes after ingestion, and can be 
felt up to 48 hours later. Desired effects are similar to MDMA with users seeking 
31 
 
 
euphoria, increased energy, alertness and sociability.(134) Table 1-12 shows the 
duration of these effects.  
Table 1-12: Onset and duration of 2- DPMP effects when insufflated.  
 
INSUFFLATION 
TOTAL DURATION Up to 48 hrs 
ONSET 0-20 mins 
COMING UP 1-2 hrs 
COMING DOWN 12-24 hrs 
 
Adverse side effects following recreational use of 2-DPMP have been reported 
and these include hallucinations, paranoia, agitation, chest pain, palpitations 
and tachycardia. It has also been noted that adverse effects may still be felt 5-7 
days after initial ingestion.(139)  
1.7.6 Toxicity 
Several deaths and hospitalisations have been reported as a result of 2-DPMP 
abuse. The UK reported 3 deaths due to 2-DPMP in 2010 involving 2 males and 1 
female. 2-DPMP concentrations were 1.16 mg/L, 0.79 mg/L and 0.025 mg/L 
respectively. In the third case, the individual had lost consciousness, gone into a 
coma, and developed severe swelling of the brain. She was kept in intensive 
care for 12 days on life-support which was removed 2 days later resulting in 
heart failure. Due to the extended time period between death and ingestion, 
initial concentrations would have been significantly higher than was determined 
post-mortem.(134)  
Five post mortem cases from Finland were reported positive for 2-DPMP between 
Oct 2010 and May 2012. Of these 5 cases, 2-DPMP was listed as contributing to 
death in 2, with both of these cases having blood concentrations of 1.4 
mg/L.(140)  
1.7.7 Pharmacology 
2-DPMP is metabolised by the liver with a bioavailability of over 90%. Six 
metabolites have been identified using human liver microsome (HLM) and 
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analysing human urine samples. These metabolites are formed through 
hydroxylation, dehydrogenation and oxidation.(137) Animal studies have shown 
that 2-DPMP increases the release of dopamine and decreases dopamine re-
uptake similar to cocaine.(141)  
1.7.8 Prevalence 
From the literature, it would appear that 2-DPMP use is most prevalent in the UK 
and Ireland, however it does not currently appear on any national surveys and 
thus assessment of prevalence is difficult. 2-DPMP was found to be contained 
within the “legal high” product Ivory Wave which had originally contained MDPV, 
further complicating prevalence assessment as many individuals may not be 
aware that this was the substance they were ingesting.  
Searching google trends with the key words “2-DPMP” and “ivory wave” shows 
main interest in this substance peaked in 2011, with ivory wave having a second 
peak in June 2012 as shown in Figure 1-7. The blue line represents google 
searches involving the term “ivory wave” whereas the red relates to the 2-DPMP.  
 
Figure 1-7: Screenshot of Google Trends search data for Ivory Wave and 2-DPMP (last 
accessed 06/08/2015)  
 
A study carried out in Finland examined the prevalence of 2-DPMP in drugged 
drivers and found 1.7% of cases examined between October 2010 and May 2012 
to be positive for this drug.(140) All of the 106 cases involving 2-DPMP also 
tested positive for other substances (mainly amphetamines and 
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benzodiazapines), again highlighting polydrug use amongst this drug-taking 
population.  
1.8 Marketing 
The rise of legal highs has been increased by the ease at which products can be 
bought and sold. The internet has played a key part in this with many drugs 
being marketed online as “bath salts”, “plant food” or “research chemicals” 
labelled “not fit for human consumption” to avoid penalties under the Medicines 
Act 1968.(142)  
NPSs are normally sold as white powders or pressed into pills, similar to MDMA. 
Products are sold in packaging which is already familiar to the user as seen 
below in Figure 1-8. It is thought that this may increase the appeal of these 
products and falsely enhance the idea of safety.(143)  
 
Figure 1-8: Legal high packaging. This product was found to contain MDAI (143). 
 
The internet has also allowed users to discuss these drugs in forums, providing 
information on side effects and suitable doses.(144) These on-line community 
forums have also given rise to the cyber-pyschonaut- individuals who specifically 
seek out new substances and document their experiences in detail. These 
individuals are committed to harm-reduction and therefore view it as their duty 
to provide as much information as possible to these online forums, viewing their 
drug use as research. (145)  
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Internet retailing allows companies to monitor purchases and build personalized 
customer profiles. These marketing strategies have also been applied to NPSs, 
with customers being notified of flash sales, given free samples to try and being 
alerted to new products which the retailer feels may be of interest to the 
customer.(146) This aggressive marketing could in theory lead to individuals 
trying products which they otherwise would not have considered and which may 
pose higher health risks than what they had originally ordered.  
A 2010 investigation into the source of legal highs online found that 52.2% of 
shops identified were based in the UK, further emphasizing the popularity of 
these drugs in the UK.(142) In 2013 the EMCDDA identified 651 websites openly 
selling ‘legal highs’ to Europeans illustrating the rapid growth of this market. 
This figure does not include sites found only in the deep web such as Silk Road, 
Agora and Evolution. These websites can only be accessed using onion browsers 
such as Tor which provide added anonymity for the user by clouding IP 
addresses. Illicit substances are then sold using bitcoin, an electronic currency 
which the user purchases and which cannot be easily traced back to the 
individual.(147)  
Studies into the use of these dark net sites have shown that the majority of 
purchases are made in bulk for re-sale. Although transactions of this nature are 
currently small in comparison to traditional routes it is thought that these will 
increase as new regulation is passed and drug use is pushed further underground.  
In 2015, the Global Drug Survey focused on purchases made through the “dark 
net” and found that 30% of individuals purchased a wider range of drugs than 
they would previously have done. Despite this, the most commonly purchased 
“dark-net” products were MDMA, LSD and cannabis, with 37%, 30% and 26% of 
individuals opting to purchase these. In contrast only 7% and 4% of people 
surveyed purchased 25I and 25C-NBOMe, indicating that the majority of legal 
high purchases are made when traditional alternatives are not available.  
Manufacturing of these drugs seems to be restricted to Asia, in particular China 
and India. There is no indication of manufacturing taking place in Europe 
although packaging does appear to take place, with three tableting machines 
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being seized in Holland, one in 2009 and two in 2010.(148) It is likely that after 
tableting, these pills would have entered the market to be sold as Ecstasy. 
1.9 Legality  
Due to the speed at which NPSs appear on the recreational drug market 
governing bodies have struggled to control these. As a result, the number of 
uncontrolled substances now detected outnumbers those that are controlled by 
the UN. Many countries have tried to solve this problem with none having found 
a solution. A range of measures have been used throughout Europe to control 
and limit the supply of NPSs such as consumer safety legislation, the application 
of existing legislation or the creation of new legislation. 
UK law requires that substances need only pose a threat to public health, or 
society before scheduling. This has meant that the UK government is in a 
position to quickly respond when a new substance is detected without having to 
identify its pharmacology etc. This may result in compounds being unnecessarily 
controlled, impeding the pharmaceutical industry, however, this is viewed as a 
worth-while risk.  
The UK government, in response to NPS use, created a temporary drug class 
order, which places a compound temporarily under control while further 
scientific work is carried out to assess its potential threat. Possession of 
substances controlled under this legislation will not be an offense, however 
importing these substances or supplying them will remain an offence. This again 
has resulted in faster scheduling of compounds; however, it is unlikely that a 
drug placed in this category would ever be removed from it without further 
classification as this would be viewed as the government effectively “okay-ing” a 
psychoactive compound. Methoxetamine and 2-DPMP were the first compounds 
to be subject to this level of control, both are now class B substances. The 
current classifications for drugs mentioned in this thesis are shown in Figure 1-9. 
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Figure 1-9: MoDA classification for the NPSs discussed in this thesis. 
 
The Home Office announced in the Queens Speech that there is to be a blanket 
ban on NPSs through the implementation of the Psychoactive Substances 
Bill.(149) This Bill currently proposes to outlaw the importation, exportation and 
supply of psychoactive substances, or substances suspected of having 
psychoactive effects. Anyone convicted of such offences will face up to 7 years 
imprisonment depending on the severity of the case. Personal possession carries 
no penalties and is not controlled in this Bill. Due to the wide range of this Bill 
there are exclusions such as substances which are already under control, 
medicinal products, alcohol, nicotine, tobacco, caffeine and food.(150) This Bill 
is similar to that implemented in the ROI to curve the number of NPS 
retailers.(151) Although based on the ROI legislation, the Bill as it currently 
stands has been met with strong opposition and criticism and changes are likely 
to occur before it is finalized and implemented by early April 2016.(152-154)  
Class A
• NBOMeS
Class B 
• 2-DPMP
• Mephedrone
• MDPV
• Naphyrone
• 5-APB
• 6-APB
• 3-MeO-PCP
• 3-MeO-PCE
• Methoxetamine
• Butylone 
• Ethylone
• Methylone 
• Methedrone
• Flephedrone
Temporary Drug Class Order
• Methiopropamine
Uncontrolled
• Benzedrone
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1.10 Literature Review & Gap Analysis 
To date there have been several methods published for the analysis of NPS 
compounds however these only focus on single chemical groups such as synthetic 
cathinones or NBOMes as shown in Table 1-13. This means that should analysts 
encounter more than 1 classification of substance in a sample, not all may be 
detected. This limitation also results in existing methods becoming outdated 
rapidly, or several methods having to be run, thus increasing laboratory turn-
around times. This is particularly true when looking at GC-MS methods, as a lot 
of the new screening methods utilise quadrupole time of flight (QToF) 
instruments and LC-MS/MS which not all laboratories can afford. 
Although the different isomers of APB have been identified for drug analysis 
purposes, there are very limited publications quantifying doses in biological 
matrices. Publications which do quantify the levels present, report only the 
presence of APB unable to determine which isomer is present, i.e. 5-APB or 6-
APB.(155, 156) 
Publications for NBOMes are scarce with methods only available for traditional 
matrices such as blood and urine as shown in Table 1-13. The majority of 
publications focus on a single NBOMe rather than the simultaneous detection of 
several different NBOMes. (125, 126, 128, 131, 157, 158) To date, all NBOMe 
analysis methods have used LC-MS/MS or QToF instruments with GC-MS only 
being used when analysing powders for drug analysis. As prevalence of these 
compounds remains unknown and limiting detection to these 2 matrices may 
result in users going undetected.  
The lack of publications including toxicological data not only causes problems for 
medical practitioners, but also for forensic laboratories, as without this 
information forensic toxicologists are left to guestimate appropriate calibration 
concentrations. This is particularly true for alternative matrices such as hair.  
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Table 1-13: Summary of screening methods published for the detection of multiple NBOMe’s 
 
(159) (160) (161) (162) (163)  (164)  (165) (166)  (160) (167) (168) 
INSTRUMENT LC-MS/MS UPLC-QToF LC-MS/MS LC-MS/MS 
UHPLC-
MS/MS 
GC-MS 
& LC-
MS/MS 
LC-
MS/MS 
GC-MS 
UPLC-
QToF 
HPLC-
MS/MS 
LC-
MS/MS 
MATRIX BLOOD BLOOD BLOOD & URINE URINE BLOOD 
BLOOD 
& URINE 
BLOOD 
DRUG 
POWDER 
BLOOD URINE HAIR 
25B-NBOME X X X X      X  
25C-NBOME X X X X      X  
25D-NBOME 
  
X X      X  
25E-NBOME 
  
X 
 
       
25H-NBOME X X X X      X  
25I-NBOME X X X X      X  
25N-NBOME 
  
X 
 
       
25P-NBOME 
  
X 
 
       
25T2-NBOMe   X       X  
25T4-NBOME 
  
X 
 
       
25T7-NBOME 
  
X 
 
       
MECALINE-NBOME 
  
X 
 
       
2-DPMP            
3-MeO-PCE            
3-MeO-PCP            
5-APB            
6-APB     X       
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Table 1-13: Summary of screening methods published for the detection of multiple NBOMe’s (cont.) 
 (159) (160) (161) (162) (163)  (164)  (165) (166)  (160) (167) (168) 
BENZEDRONE        X    
BUTYLONE     X X X X X  X 
ETHYLONE     X      X 
FLEPHEDRONE       X X X  X 
MDPV     X X  X X  X 
MEPHEDRONE     X X X X X   
METHEDRONE     X X X X X   
METHIOPROPAMINE            
METHYLONE     X X X X   X 
MXE     X       
NAPHYRONE     X   X X   
 
1.11 Aims & Objectives 
The literature indicates that although substantial work has been carried out and 
published in the field of NPSs clearly more is required. Although there are 
several published methods for the detection of single NPS groups, there is a lack 
of methods covering a wide range of NPS groups. The speed at which additional 
NPSs appear on the recreational drug market means that laboratories who are 
able to screen for a wide variety of NPS groups using singular methods are much 
more likely to detect substances not commonly encountered. The aims and 
objectives of this study and how they will be achieved are listed below:  
1. To develop a GC-MS method for the detection and quantification of a wide 
variety of NPSs compounds in biological matrices.  
 This involves the optimisation of GC conditions such as column 
type, injection port temperatures and oven temperatures, as well 
as altering MS parameters.  
 To determine the optimum extraction technique for the analysis of 
a wide range of NPSs. This will be achieved by comparing different 
SPE cartridges to identify the optimum cartridge for extraction, 
and comparing this against SLE and LLE methods for blood, urine, 
plasma and serum.  
 To identify the optimum derivatization method for the analysis of 
NPS compounds by GC-MS by altering the derivatization reagent, 
temperature and incubation period.  
 The validation of this method in accordance with ISO/IEC 17025 
and SWGTOX validation guidelines. 
 Testing this method against “real-life” case samples.  
2. To investigate the stability of mephedrone in blood under different 
temperature and preservative conditions.  
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 Analysing blank blood spiked with mephedrone with or without the 
addition of different preservatives and stored at room, fridge and 
freezer temperature over time.  
3. To investigate the use of ELISA and other Point of Care Testing kits for the 
detection of NPSs. 
 Assessing the cross reactivity of ELISA with a wide selection of NPS 
compounds 
 To determine if any cross reactivity for ketamine POCT’s is 
observed with any of the “newer” ketamine alternatives such as 
MXE.  
4. To assess the effects of NBOMes and to test for their presence in rat hair 
and urine.  
 Administer 25B-, 25C, and 25I-NBOMe at different concentrations to 
Long Evans rats over a period of 8 days and assess if any analgesia 
is observed through tail flick tests.  
 To identify the presence of parent NBOMe compounds and their 
metabolites in rat urine after administration. 
 To identify the presence of NBOMes in rat hair, and determine 
whether hair colour has any impact on the incorporation of these 
drugs into the hair.  
 To validate the hair and urine methods in accordance with ISO/IEC 
17025 and SWGTOX.  
42 
 
Chapter 2: GC-MS NPS Method Optimisation 
2.1 Gas Chromatography- Mass Spectrometry  
Gas chromatography (GC) was first mentioned in 1941 by Martin and Synge who 
suggested using gas-liquid partition chromatography for analytical purposes.(169) 
A liquid sample is injected into the system where it is volatilised into the 
gaseous phase. This gas sample is then transported through the column by the 
carrier gas (mobile phase). Analytes are separated out whilst travelling through 
the column based on the degree of their interaction with silica particles lining 
the inside of the column (stationary phase). The stronger the chemical 
interactions between analytes and stationary phase, the longer the analytes will 
be retained in the column. Analyte size and shape can also affect retention time 
in the column, with smaller analytes retained less than larger analytes.  
In mass spectrometry the molecules contained within the sample are ionised 
either by electron ionisation (EI) or chemical ionisation (CI) (170). EI is the most 
commonly used ionisation technique and is the technique used in this research. 
In EI, molecules travel through the interface to the ionisation chamber, where 
they are bombarded by a stream of electrons. These electrons are emitted from 
a heated filament and propelled across the ionisation chamber within the 
source. By colliding with the electrons the molecules lose an electron, therefore 
becoming positively charged as shown in Equation 2-1. (171) 
Equation 2-1: The electron ionisation of an atom or molecule. 
𝑀 + 𝑒− → 𝑀+ + 2𝑒− 
The ionised molecules are then pushed through the ionisation chamber by a 
positively charged repeller, before travelling through a series of focusing lenses 
eventually reaching the mass analyser. In this case a quadrupole mass 
spectrometer (MS) as shown in Figure 2-1.(172)  
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Figure 2-1: Schematic of an EI chamber.  
 
The majority of mass analysers separate out positively charged molecules by 
their mass to charge ration (m/z).(173) A quadrupole MS consists of 4 parallel 
rods, to which a direct current (DC) and an oscillating radio frequency (RF) 
signal are applied. To one set of oppositely paired rods a DC current is applied 
and to the other 2 oppositely paired rods a RF signal is applied. This creates an 
electrostatic field inside the rods, to which only ions with the correct m/z ratio 
can travel through. Ions which do not have the correct m/z ratio collide with the 
rods, become discharged and go to waste.(172, 174)  
The mass spectrometer can either be used in total ion chromatogram mode (TIC) 
where all ions over a set range are scanned or in selective ion monitoring (SIM) 
mode where pre-selected ions only are monitored. TIC is advantageous when it is 
not known what compounds may be present, whereas SIM analysis is more useful 
for targeted analysis providing greater sensitivity as only selected ions are being 
monitored.  
The fragmented ions are then detected by an electron multiplier diode which 
converts the ionized mass fragment to an electronic signal. A schematic of a GC 
coupled to a mass spectrometer is shown in Figure 2-2.  
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Figure 2-2: Schematic of a GC-MS instrument.  
 
2.2 Sample Preparation 
Prior to analysis biological samples must undergo an extraction “clean-up” 
process, removing proteins and other contaminants. This allows for better 
analyte detection, increases the life span of the analytical instrument and 
improves the productivity of the laboratory by reducing maintenance time.(175) 
As part of the sample clean-up process it is necessary to remove any particulate 
matter, such as proteins from blood and urine, by centrifugation or filtration. 
Chemical adjustments may be required in order to free any bound analytes, or 
to enhance the analyte retention if the sample is to be passed through a sorbent 
during extraction. There are various sample clean-up methods available, varying 
in their effectiveness, cost and the time they take to carry out. Recovery of 
analytes from the sample matrix will differ depending on the method chosen and 
as a result it is important to test as many possible options to ensure that 
optimum analyte recovery is achieved. As sample preparation is the timeliest 
part of sample analysis, typically accounting for 80% of sample analysis time, it 
is important to ensure that the best method chosen is also suitable for the 
specific needs of the laboratory and that unnecessary steps are avoided.(176) 
2.2.1 Derivatisation  
In order to improve analyte detection it is sometimes necessary to derivatize 
analytes prior to injection to improve the volatility, thermal stability of the 
analytes and to make them amenable to GC-MS analysis. Silylation, alkylation 
45 
 
and acetylation are the most commonly used derivatisation reactions and the 
appropriate method is chosen based upon the chemical structure of the analyte. 
The chemical structures of the 4 derivatisation agents, pentafluoropropionic 
anhydride (PFPA), trifluoroacetic anhydride (TFAA), N-Methyl-N-(trimethylsilyl) 
trifluoroacetamide (MSTFA), N-trimethylsilylimidazole (TMSI), used in this study 
are shown in Table 2-1. TMSI is used alongside pyridine for the derivatisation of 
wet sugar samples, hindered hydroxyl groups and alongside fluorinated acylation 
reagents.  
Table 2-1: Chemical structures of derivatisation agents used.  
Derivatisation Agent Reagent Type  Structure 
Pentafluoropropionic 
anhydride  
(PFPA) 
Acylation  
 
trifluoroacetic 
anhydride  
(TFAA) 
Acylation 
 
N-Methyl-N-
(trimethylsilyl) 
trifluoroacetamide 
(MSTFA) 
Silylation 
 
N-
trimethylsilylimidazole 
(TMSI)   
Silylation 
 
 
The limited analytical application notes for the detection of synthetic 
cathinones via GC-MS also make use of derivatisation to improve peak shape and 
resolution. Although acetylation appears to be the dominant derivatisation 
reaction for the detection of NPSs, reagents, temperatures and incubation times 
vary.(45, 131, 177-180)  
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2.2.2 LLE 
Liquid liquid extraction (LLE) is the crudest method of extraction tested here. 
LLE involves the addition of an immiscible solvent to the sample resulting in the 
partitioning of analytes and contaminants between the 2 phases.(181) The main 
advantage of LLE is that it is extremely simple to carry out and allows for rapid 
method development. LLE is however difficult to automate and as a result 
labour costs can be quite high. This is particularly important for high-throughput 
laboratories.(182) Although the glassware and chemicals used themselves are 
relatively inexpensive, LLE generally uses higher solvent volumes than the other 
clean up methods. The disposal costs of these chemicals is an additional factor 
which must be considered when deciding on an extraction method. Another 
downfall of LLE is the possibility of emulsion formation, where the organic and 
inorganic layers do not fully separate, these can usually be broken, but again 
this leads to additional labour costs.(183) 
2.2.3 SPE  
Solid phase extraction (SPE) is probably the most commonly used sample 
preparation technique, especially in forensic toxicology. A sample is passed 
through a column containing a chromatographic sorbent which retains the 
desired analytes and other sample components.(184) The column is then washed 
to remove additional contaminants and the clean extract is then eluted. 
Alternatively, the contaminants may be retained by the sorbent, allowing the 
analyte to pass through.(185) There is now a wide variety of SPE columns 
available commercially, using different sorbent materials, different bed sizes 
and varying amount of steps. SPE although more complex does allow for 
automation and the varying sorbent types available also allow for cleaner 
extracts than using LLE.(186) 
2.2.4 SLE  
Supported liquid extraction (SLE), sometimes referred to as support assisted 
liquid liquid extraction is a technique available as an alternative to LLE. SLE 
comprises of cartridges packed with diatomaceous earth which the sample is 
passed through. Although not a new technique its application to forensic 
toxicology is relatively recent. This is in part due to the development of 
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chemically reproducible diatomaceous earth which previously hindered the 
reproducibility of this method. SLE offers cleaner extracts than LLE as either 
contaminants or analytes are retained in the diatomaceous earth, depending on 
solvents used. Based on similar principles to LLE, SLE is also extremely simple to 
perform, however it uses less solvent and can be automated.(187) Another main 
advantage of SLE is that due to the gravitational flow of sample through the 
cartridge, the possibility of emulsion formation is significantly reduced.(188)  
2.3 Aims 
This research aimed to develop a method for the detection of a wide range of 
NPSs by GC-MS, and determine the optimum sample preparation conditions to 
enhance sensitivity. This was to be achieved by determining the optimum 
derivatisation conditions, i.e. reagent, incubation time and incubation 
temperature for their simultaneous analysis. In order to determine the optimum 
sample extraction procedure, the recoveries of various NPSs using LLE, SPE and 
SLE methods were to be assessed and compared.  
2.4 Materials & Methods 
2.4.1 Materials  
2.4.1.1 Chemicals & Reagents 
Mescaline, 25P, 25T4, and 25T7-NBOMe reference standards were purchased 
from LIPOMED (MA, USA), as were ethylone, MDPV, naphyrone and butylone. 
25B, 25C, 25D, 25E, 25H, 25I, 25N and 25T2-NBOMes were purchased from 
Cayman Chemical (MI, USA). Flephedrone, mephedrone, methylone, 2-DPMP and 
MXE were purchased from Cerilliant (TX, USA). 3-MeO-PCE, 3-MeO-PCP, 5-APB, 6-
APB, benzedrone, methedrone and methiopropamine were purchased from 
Logical (MA, USA).   
PFPA and TFAA were purchased from Sigma Aldrich (MO, USA). MSTFA was 
purchased from Pierce (Ill, USA), and TMSI:pyridine (1:4) was purchased from 
Supelco (PA, USA). All other chemicals were of analytical grade and purchased 
from Honeywell (MI, USA).  
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Blank human whole blood, plasma and serum were purchased from Golden West 
Biologicals Inc® (CA, USA). Blank human urine was collected in house from a 
willing donor.  
All SPE cartridges were supplied by United Chemical Technologies (PA, USA), 
except Oasis® cartridges which were supplied by Waters (MA, USA). SLE 
ISOLUTE® cartridges were supplied by Biotage (MN, USA).  
2.4.1.2 Saline Solution (0.95%) 
Saline solution was prepared by weighing 9.5 g of sodium chloride in a beaker to 
which approximately 500 mL of dH2O was added. The solution was then 
transferred to a 1 L volumetric flask and made up to the 1 L mark using dH2O. 
2.4.1.3 Blank Blood Preparation  
Blank (drug-free) human whole blood (500 mL) was measured in a volumetric 
cylinder. To this an equal amount of 1% saline solution was added. The blood 
saline solution was then mixed thoroughly, transferred to an amber bottle, and 
stored in the fridge (4 oC) for a maximum of 3 months.  
2.4.1.4 Phosphate Buffer Preparation 
Phosphate buffer (0.1 M, pH 6) was prepared by dissolving 1.7 g Na2HPO4 and 
12.14 g NaH2PO4 in 500 mL of dH2O in a beaker. This solution was then 
transferred to a 1 L volumetric flask and made up to the mark using dH2O used 
to rinse the original beaker. The volumetric flask was then stoppered and 
inverted several times to ensure thorough mixing. The pH was adjusted using 
monobasic sodium phosphate (to lower pH) or dibasic sodium phosphate (to 
increase pH). The buffer was then stored at 4oC for a maximum of 3 months.  
2.4.1.5 0.1M Acetic Acid  
2.9 mL of glacial acetic acid was transferred to a 500 mL volumetric flask in a 
fume hood. This was then made up to the mark with dH2O and mixed. This 
solution was then stored for up to 6 months at room temperature.  
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2.4.1.6 2% Acetic Acid 
2 mL of glacial acetic acid was transferred to a 100 mL volumetric flask in a 
fume hood. To this 98 mL of dH2O was added. The solution was then mixed 
thoroughly and stored for up to 6 months at room temperature.  
2.4.1.7 2% Acetic Acid in Methanol  
2 mL of glacial acetic acid was transferred to a 100 mL volumetric flask in a 
fume hood. This was then made up to the mark with the addition of 98 mL of 
MeOH. The solution was then mixed thoroughly and stored for up to 6 months at 
room temperature.  
2.4.1.8 MeOH/NH4OH 
To a 100 mL measuring cylinder 95 mL of MeOH was added. To this a further 5 
mL of 28% NH4OH was added. This was then transferred to a glass bottle and 
stored for 6 months at room temperature.  
2.4.1.9 CH2Cl2/IPA/NH4OH 
Concentrated 28% NH4OH solution (2 mL) was added to 20 mL of isopropanol and 
mixed. To this solution 78 mL of methylene chloride was then added before 
mixing again. This solution was stored at room temperature and made fresh each 
day of use. Solution preparation was carried out in a fume hood.  
2.4.1.10 PFPA/EtOAc (2:1) 
PFPA (2 mL) was transferred to a 7 mL glass vial in a fume hood. To this 1 mL of 
EtOAc was added. The vial was then capped and inverted several times to ensure 
thorough mixing. This solution was prepared fresh upon use as required.  
2.4.1.11 Tris solution (0.02M) 
Tris(hydroxymethyl)aminomethane (Tris) (2.43 g) was weighed and transferred 
to a 500 mL beaker. To this approximately 300 mL of dH2O was added. This 
solution was then transferred to a 1 L volumetric flask which was then made up 
to the mark using additional dH2O. This solution was then inverted several times 
to ensure through mixing. 
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2.4.1.12 Preparation of Stock Solutions 
Stock solutions were produced for each drug individually (25B, 25C, 25D, 25E, 
25H, 25I, Mescaline, 25N, 25P, 25T2, 25T4, 25T7-NBOMe, 2-DPMP, 3-MeO-PCE, 3-
MeO-PCP, 5-APB, 6-APB, benzedrone, butylone, ethylone, flephedrone, MDPV, 
mephedrone, methedrone, methiopropamine methylone, MXE and naphyrone) 
giving a concentration of 100 µg/mL. This was achieved by transferring 1 mL of 
each reference drug (1 mg/mL) to a 10 mL volumetric flask and making the 
solution up to the meniscus using MeOH. The flasks were then inverted several 
times before each solution was transferred to individual amber glass bottles and 
stored for 1 year at -20oC.  
I.S. stock solutions of mephedrone-D3, methylone-D3, ethylone-D5 and MDPV-D8 
were made by transferring 1 mL of each 1 mg/mL solution into separate 10 mL 
flasks. These were then made up to the mark using MeOH, inverted several times 
and stored in amber bottles for 1 year at -20oC. This was not necessary for 25I-
NBOMe-D3 as this was purchased as a 100 µg/mL reference solution.  
2.4.1.13 Working Solutions 
Using the stock solutions as outlined in 2.4.1.12 four working solution mixtures 
(10 µg/mL) were made. These mixtures were prepared by transferring 1 mL of 
each working solution to a 10 mL volumetric flask and making it up to the mark 
using MeOH. The resulting mixtures were then stored at -20oC for up to 3 months 
and replaced as and when necessary. Table 2-2 shows the drugs contained in each 
drug mixture. Several working solutions ran out throughout the course of these 
experiments which could not be replaced due to time restrictions, and thus the 
contents of each mixture slightly varied over time. Analytes which were not 
consistently present for all experimental procedures are highlighted with an * 
and additional information provided below Table 2-2. 
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Table 2-2: Analytes contained in each working mix solution. 
MIX 1 MIX 2 MIX 3 MIX 4 
Benzedrone 
Butylone 
Ethylone 
Flephedrone 
Mephedrone 
*Methedrone  
***Methylone 
Naphyrone 
**2-DPMP 
3-MeO-PCE 
***3-MeO-PCP 
5-APB 
6-APB 
MDPV 
Methiopropamine 
MXE 
25B-NBOMe 
25C-NBOMe 
25D-NBOMe 
25E-NBOMe 
25H-NBOMe 
25I-NBOME 
Mescaline-NBOMe 
25N-NBOMe 
25P-NBOMe 
**25T2-NBOMe 
**25T4-NBOMe 
**25T7-NBOMe 
*Only used for LLE work.     
**Unavailable at time of LLE extraction work.  
*** Unavailable at time of SPE work.  
 
2.4.1.14 I.S. Working Mix  
An internal standard (I.S) working solution mixture was prepared by transferring 
1 mL of each 100 µg/mL I.S. working solutions described in section 2.4.1.12 to a 
10 mL volumetric flask. To this flask 1 mL of a 100µg/mL of 25I-NBOMe-D3 
reference solution was also added. This flask was then made up to the meniscus 
using MeOH before being stoppered and inverted several times to ensure 
thorough mixing to produce a working solution of 10 µg/mL. This mixture 
contained all 5 I.Ss (mephedrone-D3, methylone-D3, ethylone-D5, MDPV-D8 and 
25-NBOMe-D3).This was then transferred to a labelled amber glass bottle and 
stored in the freezer (-20oC) for a maximum of 6 months.  
2.4.1.15 Instrumentation  
2.4.1.15.1 GC-MS Method Optimisation  
Initial method development was carried out on a Thermo Trace GC 2000, 
equipped with an AS2000 autosampler and Trace Plus mass spectrometer. The 
GC was fitted with a J&W Agilent DB-5ms low bleed column (30 m x 0.32 mm 
i.d.; film thickness 0.25 µm). The injection port was operated in splitless mode 
initially at 250oC. Helium was used as a carrier gas at a flow rate of 1.5 mL/min. 
The GC transfer line was operated at 250oC and the source at 200oC. The mass 
spectrometer was operated in EI mode (scan range 40-500 m/z). Data was 
processed using Xcaliber 1.4 software. Initial method optimisation was carried 
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out at the University of Glasgow before the method was transferred to a new 
instrument at the Fredric Rieders Family Renaissance Foundation (FRFRF).  
2.4.1.15.2 Sample Preparation  
Sample preparation optimisation analysis was carried out using an Agilent GC-
MSD 5975C series instrument fitted with a J&W DB-5ms low bleed column (30 m 
x 0.32 mm i.d.; film thickness 0.25 µm). The GC-MS was operated in full scan 
mode with an EI source and a splitless injection. The injection port temperature 
was 225oC; the transfer line temperature was 250oC with a MS source 
temperature of 200oC. The initial oven temperature was 80oC, which was held 
for 2 mins, before ramping to 170oC at a rate of 25oC /min and being held for 1 
min. The temperature was then further increased to 200oC at 5oC /min and held 
for 1 min before being increased to 250oC at a rate of 15oC /min. Finally, the 
oven temperature was increased to 300oC at a rate of 5oC and held for 3 
minutes. The total run time was 30 minutes. Data was analysed using Agilent’s 
ChemStation software.  
Samples were either evaporated by nitrogen using a Pierce 18830 Reacti-Therm 
III heating module with Pierce Reacti-Vap or air-dried using a TurboVap® LV 
sample concentrator (American Instrument Exchange, MA). Samples were spun 
using a Combo V24 centrifuge (LW Scientific, GA). All pipetting was carried out 
using Capp Bravo accurate pipettes (Pipette.com, CA). Positive displacement 
pipettes used were Gilson Microman® (Pipette.com, CA).  
2.4.2 Methods 
2.4.2.1 GC-MS method optimisation 
All drugs were run individually as standards in order to obtain their mass spectra 
and retention time. This was achieved by evaporating 10 µl of each stock 
solution (100 µg/mL) at room temperature, derivatising using 50 µl PFPA:EtOAc 
(2:1) for 40 minutes at 70oC before evaporating to dryness again. These 
reference standards were then reconstituted in 100 µl of EtOAc, and transferred 
to labelled GC-MS vials.  
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In order to separate compounds as fully as possible different oven temperature 
programs and injector port temperatures were tested. An adapted version of the 
in-house FMS amphetamine method (method 1) was used as a starting point, 
having previously resulted in successful identification and quantification of 
mephedrone.(189) Varying GC-MS oven parameters were tested (Table 2-3) 
during initial phases of method development. The GC oven parameters were 
altered several times as new compounds were added to the method to ensure 
chromatographic separation where possible. The injection port temperature was 
altered during method development, using 250oC, 225oC and 200oC.  
Table 2-3: Optimisation of GC oven conditions 
 
Method Number 
1 2 3 4 5 
Initial 
Temperature 
55OC 80OC 80OC 80OC 80OC 
Hold Time 2 min 2 min 2 min 2 min 2 min 
Ramp 1 
20OC/min 
to 200oC 
20OC/min 
to 200oC 
25oC/min 
to 170oC 
25oC/min 
to 170oC 
25oC/min 
to 170oC 
Hold - - 3 min 3 min 1 min 
Ramp 2 
10oC/min 
to 250oC 
10oC/min 
to 250oC 
5oC/min to 
200oC 
5oC/min to 
250oC 
5oC/min to 
200oC 
Hold - - 2.5 min 2.5 min 1 min 
Ramp 3 - - - - 
15oC/min 
to 300oC 
Final Ramp 
25oC/min 
to 300oC 
25oC/min 
to 300oC 
25oC/min 
to 300oC 
50oC/min 
to 300oC 
5oC/min to 
300oC 
Final Hold 3 min 3 min 2 min 2 min 3 min 
Total Run 
Time 
18.5 min 17 min 23 min 30 min 30 min 
 
2.4.2.2 Derivatisation  
To 120 test tubes 100 µl of each drug mix (10 µg/mL) was added. Samples were 
then evaporated to dryness using the TurboVap® LV sample concentrator. To 30 
test tubes, 50 µl of PFPA:EtOAc (2:1) was added. To another 30 samples 100 µl 
of MSTFA:Toluene (1:3) mixture was added. A further 30 samples were 
derivatized using 100 µl TMSI:pyridine (1:4) and the final 30 samples were 
derivatized using 100 µl of TFAA:EtOAc (2:1). Each set of derivatized samples 
was then incubated at room temperature (24oC), 37oC, 50oC or 70oC for 20 or 40 
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minutes as illustrated by Figure 2-3. Each temperature and incubation time was 
analysed in triplicate. Samples were then evaporated to dryness using the 
TurboVap® LC before being reconstituted in 100 µl of EtOAc and analysed by GC-
MS. The GC-MS was operated in full scan mode as each derivatisation agent 
would result in its own specific ions. 
 
Figure 2-3: Diagram of derivatization at 24oC for 20 minutes and 40 minutes. 
 
2.4.2.3 Unextracted standards 
In order to assess the recovery for each extraction method, unextracted 
standards were prepared. These were made separately for each of the 
experiments so that any inter day instrumentation differences would not affect 
the comparison results. Unextracted standards were made by pipetting 100 µl of 
each 10 µg/mL solution mixture and I.S. mixture into a glass culture tube. This 
was completed in triplicate, before evaporating each tube to dryness using a 
steady stream of nitrogen, with no added heat. The unextracted standards were 
then derivatised using 50 µl of PFPA:EtOAc for 40 minutes at 70oC before being 
evaporated to dryness once again. The unextracted standards were run on GC-MS 
alongside their extracted counterparts.  
2.4.2.4 LLE Methods 
LLE was investigated as an extraction method for urine only. This is due to the 
relative simplicity of this matrix in comparison to blood which requires much 
more clean up prior to analysis by GC-MS. As LLE is a relatively crude extraction 
method it is typically used when analysing by LC-MS rather than GC-MS.  
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Two different LLE methods were analysed and compared for the extraction of 
analytes from urine. Method 1 had previously been published for the extraction 
of NBOMes from blood and urine; however this method only examined the use of 
this method for this specific group. The second method was based upon that 
published for the detection of 2,500 toxic compounds.(190) As this method had 
been utilised for the detection of such a wide and varied number of compounds 
it was surmised that it may be applicable to NPSs. Although this method used 
CH2Cl2 it was exchanged for t-MTBE which has been shown to be effective on the 
extraction of amines.(191)  
Blank urine (1 mL) was added to 6 different culture tubes. These were then each 
spiked with 100 µl of all 4 working solutions (10 µg/mL) detailed in section 
2.4.1.1. Three of these were then extracted using method 1, 0.1 M NaOH 
solution and 3 mL of extraction solvent (hexane:EtOAc (50:50)). The remaining 3 
were extracted using method 2, by adding 3 mL of t-MTBE and 200 µl of tris 
solution. These methods are shown in Figure 2-4. 
 
Figure 2-4: Schematic of the two LLE methods. 
 
The culture tubes were then capped and placed on the sample rotator for 10 
minutes after which they were centrifuged at 4000 rpm for 10 minutes. After 
centrifugation the top layer was transferred to a new culture tube, spiked with 
100 µl of I.S. mixture and vortexed for 30 seconds. The contents of each culture 
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tube were then evaporated to dryness under a steady stream of nitrogen at room 
temperature (23oC). PFPA:EtOAc derivatising agent (50 µl) was then added and 
each culture tube was then re-capped and left to incubate for 20 minutes at 
37oC. The derivatising agent was then evaporated off and samples were 
reconstituted in 100 µl of EtOAc and transferred to GC autosampler vials for 
analysis. Unextracted standards were analysed alongside these.  
2.4.2.5 SPE Method 
Blank MeOH, urine, blood, plasma and serum samples (1 mL) were all spiked 
with 100 µL of each 10 µg/mL working solution mixture. To each sample, 1 mL of 
0.1 M phosphate buffer (pH 6) was added before centrifugation for 10 minutes at 
4000 rpm. Samples were then extracted in triplicate using various solid phase 
extraction cartridges; UCT’s XCEL® I, ZSDAU020, CSDAU133, XRDAH206, 
XRDAH502, XRPCH50z as well as Waters Oasis® MCX.  
ZSDAU020 cartridges are routinely used at the University of Glasgow where as 
CSDAU133 are the cartridge of choice at the Frederic Rieders Family Renaissance 
Foundation, hence the comparison of these cartridges. DAU cartridges are UCT’s 
main cartridge type for forensic analysis and are the most commonly 
encountered in publication applicable to acid, basic and neutral drugs. XCEL® I 
cartridges require no cartridge conditioning and so are popular in clinical 
settings due to the reduced extraction time. As it has been shown that many NPS 
users present to A&E with adverse effects, it is important to assess how clinical 
SPE cartridges may perform for the extraction of these substances. XTRACKT 
cartridges use similar co-polymeric bonded phases to that of the Clean Screen 
varieties; however the sorbent bed weight is much larger as these cartridges are 
designed for larger particles. Oasis® MCX cartridges claim to be able to “achieve 
higher selectivity and sensitivity for extracting basic compounds with cation-
exchange groups”. The individual specifications of each cartridge are shown 
below in Table 2-4. 
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Table 2-4: Cartridge specifications 
Cartridge 
Sorbent 
Type 
Sorbet Bed 
Weight 
(mg) 
Load 
Volume 
(mL) 
Phase 
Clean 
Screen® 
ZSDAU020 200 10 
Co-polymeric bonded 
phase 
Clean 
Screen® 
CSDAU133 130 3 
Reverse phase, ion 
exchange co-polymeric 
bonded phase 
Clean 
Screen® 
XCEL® I 130 3 
Sample prep phase 
designed to reduce 
extraction steps 
XTRACKT® XRDAH206 200 6 
Co-polymeric bonded 
phase, gravity flow-large 
particle 
XTRACKT® XRDAH502 500 3 
Copolymeric bonded 
phase, gravity flow-large 
particle 
XTRACKT® XRPCH50z 500 10 
Propylsulfonic acid cation 
exchanger 
Oasis® MCX 6cc 500 6 
Mixed-mode polymeric 
sorbent 
 
ZSDAU020, CSDAU133, XRDAH206, XRDAH502, XRPCH50z cartridges were 
conditioned using 2 mL MeOH, 2 mL dH2O and 2 mL phosphate buffer before 
loading samples. Cartridges were washed using 2 mL dH2O, 1 mL 0.1 M acetic 
acid and 2 mL MeOH. The cartridges were then left to dry at full vacuum for 5 
minutes. Samples were eluted using 3 mL CH2Cl2/IPA/NH4OH (78:20:2) solution. 
Samples were loaded directly to the XCEL® I cartridges and washed with 1 mL 2% 
acetic acid/98% MeOH before elution with 3 mL CH2Cl2/IPA/NH4OH (78:20:2). 
Oasis® cartridges were conditioned with 1 mL MeOH and 1 mL dH2O prior to 
loading samples. These were then washed using 2 mL 2% acetic acid and 1 mL 
MeOH prior to elution with 2 mL MeOH/NH4OH (95:5) solution. Due to a limited 
number of available cartridges only blood and urine were extracted using these. 
The different SPE procedures are illustrated in Figure 2-5. 
I.S. mix (50 µl) was added to the collection tubes prior to elution. Post 
extraction, samples were evaporated using a stream of nitrogen, derivatised 
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using 50 µL of PFPA:EtOAc (2:1) at 70oC for 40 minutes, before being evaporated 
again and reconstituted in 100 µL of EtOAc. Samples were analysed in triplicate 
by GC-MS. Fresh unextracted standards were analysed alongside these samples.  
 
Figure 2-5: Diagram showing different extraction procedures for each type of SPE cartridge. 
ZSDAU020, CSDAU133, XRDAH206, XRDAH502, XRPCH50z were extracted using method (a). 
XCEL® I were extracted using method (b) and Oasis® were extracted using method (c).  
 
The recovery for each extraction method was calculated using Equation 2-2. The 
recovery values were then averaged across all 3 replicates.   
Equation 2-2: Calculation used to determine analyte recovery 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
 𝑃𝐴𝑅 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑
 𝑃𝐴𝑅 𝑈𝑛𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑒𝑑
× 100% 
 
2.4.2.6 SLE Method  
Blank MeOH, urine, blood, plasma and serum samples (1 mL) were all spiked 
with 100 µL of each 10 µg/mL work solution mixtures (section 2.4.1.1). Samples 
were pH adjusted using 1% NH4OH, centrifuged for 10 minutes at 4500 rpm and 
loaded directly to Biotage’s® ISOLUTE® SLE+ columns. These columns have a 
sample load volume of 2 mL (including any pre-treatment solution required) and 
allow for the extraction of a wide range of analytes from aqueous samples.(192) 
Previous application notes have been published for the extraction of NBOMes 
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from oral fluid using these cartridges and thus they were investigated for their 
use of these compounds plus additional NPSs from additional matrices. (193)  
The samples were held on the columns for 5 minutes before being eluted twice 
with 4 mL of EtOAc as depicted in Figure 2-6. I.S. mix (50 µl) was added to the 
collection tubes prior to elution. Post extraction, samples were evaporated using 
a stream of nitrogen, derivatised using 50 µL of PFPA:EtOAc at 70oC for 40 
minutes, before being evaporated again and reconstituted in 100 µL of EtOAc. 
Samples were analysed in triplicate by GC-MS.   
 
Figure 2-6: Diagram of SLE method 
 
The extraction efficiency of the SLE cartridges was compared to that of SPE. SPE 
extraction was carried out in triplicate using CSDAU020 cartridges using the 
method described in section 2.4.2.5. SPE and SLE results were compared against 
methanolic unextracted standards to determine % recovery using Equation 2-2. 
The difference between the SLE and SPE results was calculated using Equation 
2-3. 
Equation 2-3: Calculation used to determine the difference between SPE and SLE recovery 
𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒% = 𝑆𝐿𝐸 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) − 𝑆𝑃𝐸 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) 
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2.5 Results & Discussion  
2.5.1 GC-MS Method Optimisation Results  
The GC-MS temperature alterations listed in Table 2-3 occurred as more drugs 
were added to the method. The stage at which each drug was added to the 
method is shown in Figure 2-7. The corresponding deuterated I.S. was added at 
the same time as their un-deuterated counterparts. Drugs were added in stages 
as reference standards became available, and as standards were received by FMS 
as part of the EWS.  
 
Figure 2-7: Point at which each drug was added during method development.  
• Mephedrone 
• 2-DPMP
• Naphyrone
Method 1
• N/A
Method 2
• 5-APB
• 6-APB
• Butylone
• Ethylone
• Flephedrone
• Methylone
• MDPV
Method 3
• 3-MeO-PCP
• 3-MeO-PCE
• Benzedrone
• Methiopropamine
• Methoxetamine
Method 4
• All NBOMe compounds
Method 5
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Method 1 was used when only 2-DPMP, mephedrone, and naphyrone were 
included. Initially mephedrone eluted at 13 minutes, and so the starting 
temperature was increased from 50oC to 80oC as shown in method 2.  
After the development of method 2, 5-APB, 6-APB, butylone, ethylone, 
flephedrone, methylone and MDPV were added to the method. The initial 
temperature ramp was increased to 25oC until 170oC was reached and a 3-minute 
hold was added to enhance separation of 5-APB and 6-APB. In order to separate 
butylone and ethylone, the 2nd temperature ramp rate was reduced to 5oC/min 
and a 2.5-minute hold was added. The initial ramp was increased to compensate 
for the additional hold times to keep the method as short as possible.  
The addition of 3-MeO-PCE, 3-MeO-PCP, benzedrone, methiopropamine and 
methoxetamine to the method meant that the 2nd ramp of 5oC/min was 
extended until the oven temperature reached 250oC. This was to try and 
chromatographically separate out 3-MeO-PCP and 2-DPMP.  
Finally, the addition of NBOMe compounds to the method resulted in oven 
method 5 in Table 2-3. Chromatographic separation of these compounds was 
extremely difficult as they eluted during the final hold at 300oC. As higher 
temperatures are required to elute NBOMes it was necessary to slow the final 
oven ramp to 5oC/min and extend the final hold time to ensure maximum 
chromatographic separation. It was also necessary to add in a third ramp of 
15oC/min prior to this to help separate earlier eluting NBOMe compounds. 
Temperature ramps 1 and 2 were then reduced where possible in order to keep 
the total run time at 30 minutes. Using a lower injection port temperature 
(225oC) was deemed more favourable in order to avoid any analyte degradation 
in the injection port.  
Alterations to the GC-MS oven methods were limited by a maximum column 
temperature of 325oC and as a result total chromatographic separation of all 
NBOMe compounds was not possible. It was also not possible to fully 
chromatographically separate 2-DPMP and 3-MeO-PCE either. The separation of 
these analytes however was possible using their mass spectra which was 
significantly different after derivatization using PFP:EtOAc as highlighted in 
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Figure 2-8. The mass spectra of each PFPA derivatised analyte in order of elution 
time is shown in Appendix 1.  
 
Figure 2-8: Chromatogram showing the elution of all compounds. Closely eluting compounds 
are highlighted, and their separation is shown using ions. 
 
Due to the high potency of NBOMes and the low concentrations detected in 
reported fatalities the GC-MS method was altered from total ion chromatogram 
(TIC) to selective ion mode (SIM), thus allowing for lower limits of detection 
(LOD). The reconstitution amount was also lowered to 50 µl rather than the 
initial 100 µl to further enhance sensitivity. A chromatogram showing all drugs 
and their retention times when possible is shown in Figure 2-8. 
The retention times, target ions and qualifier ions used for the detection and 
identification of each analyte are shown in Table 2-5.  
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Table 2-5: Retention times and ions used for the identification of each analyte.  
Drug RT (min) TGT Ion Q1 Q2 
METHIOPROPAMINE 7.99 124 204 160 
FLEPHEDRONE 8.11 123 204 160 
MEPHEDRONE-D3 9.56 207 163 326 
MEPHEDRONE 9.61 204 160 323 
5-APB 10.33 131 158 190 
6-APB 10.39 131 158 190 
METHYLONE-D3 13.21 207 163 356 
METHYLONE 13.26 204 160 353 
3-MeO-PCE 13.30 190 233 176 
BUTYLONE 14.14 149 218 121 
ETHYLONE-D5 14.29 223 191 372 
ETHYLONE 14.36 218 190 367 
MXE 15.14 190 219 134 
BENZEDRONE 17.19 91 119 148 
3-MeO-PCP* 17.63 272 230 188 
2-DPMP* 17.68 165 230 176 
MDPV-D8 17.80 134 133 135 
MDPV* 17.86 126 149 110 
NAPHYRONE 19.76 126 155 127 
25H-NBOMe 20.74 164 121 447 
25D-NBOMe 21.01 178 121 461 
25E-NBOMe 21.52 192 475 121 
Mescaline-NBOMe 22.06 194 181 477 
25P-NBOMe 22.28 206 193 489 
25C-NBOMe 22.32 198 481 185 
25B-NBOMe 23.30 121 244 525 
25I-NBOMe-D3 24.43 124 576 188 
25I-NBOMe 24.52 121 573 185 
25T4-NBOMe 24.68 238 521 183 
25T2-NBOMe 24.71 211 507 224 
25T7-NBOMe 25.54 225 238 521 
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2.5.2 Derivatization 
The optimum derivatization temperature and time for each compound using 
each reagent is shown in Table 2-6, alongside the peak area response. From this 
table it is evident that PFPA is the optimum derivatising agent which should be 
used when derivatising NPSs, as it provided the most abundant peak areas for 
the majority of compounds, correlating with previously published work.(194)  
Cathinones generally derivatised better at lower temperatures (24-37oC) with 
the exception of PFPA:EtOAc where they were able to withstand much higher 
temperatures, with 5 out of 8 compounds having their largest peak area at 70oC. 
It is unsurprising that lower temperatures were favoured with some of the more 
amphetamine type compounds, as it is known that these drugs are extremely 
volatile. Longer incubation times also appeared more favourable for MSTFA and 
TFAA derivatizations.  
NBOMes also preferred lower incubation temperatures, which contradicts 
previously published methods using higher temperatures. Previously published 
literature incubated these samples at 70oC for 40 minutes, which this study 
found not to be necessary and could in fact be detrimental to the concentrations 
detected. The previous research focused on the detection of NBOMes in blotter 
papers, thus concentrations are much higher and as a result it may be that any 
compound loss would only have an effect on GC-MS analysis when trying to 
identify these compounds for toxicological purposes.  
Out of the remaining analytes (2-DPMP, 3-MeO-PCE, 3-MeO-PCP, 5-APB, 6-APB, 
methiopropamine and methoxetamine) all except 2-DPMP were best derivatised 
using PFPA:EtOAc. Again lower temperatures (24/37oC) were favoured by all 
compounds with the exception of methiopropamine (70oC) using PFPA:EtOAc.  
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Table 2-6: Optimum conditions for each derivatization agent.  
Drug PFPA MSTFA TFAA TMSI 
 
Temp 
(OC) 
Time 
(mins) 
Peak 
Area 
Temp 
(OC) 
Time 
(mins) 
Peak 
Area 
Temp 
(OC) 
Time 
(mins) 
Peak 
Area 
Temp (OC) 
Time 
(mins) 
Peak 
Area 
25B-NBOMe 37 20 4244681 50 20 1099776 50 40 943432 37 20 1570304 
25C-NBOMe 37 20 5022450 50 20 1198676 50 40 1277952 37 20 1144834 
25D-NBOMe 37 20 7346805 50 20 2302976 50 40 1189888 37 20 1333760 
25E-NBOMe 37 20 364609 50 20 2108928 50 40 754488 37 20 1756672 
25H-NBOMe 24 40 7005366 50 20 2195968 50 40 1187328 37 20 1421312 
25I-NBOMe 37 20 5491689 50 20 1747968 50 40 746481 37 20 1193472 
25N-NBOMe 70 20 1612858 50 20 420480 50 40 292736 37 20 1637376 
25P-NBOMe 37 40 5828767 50 20 2041856 50 40 1161216 37 20 535616 
25T2-NBOMe 37 20 1866410 50 20 420480 50 40 292736 37 20 1637376 
25T4-NBOMe 37 20 1868777 50 20 1181184 50 40 207744 37 20 790656 
25T7-NBOMe 37 20 1188352 50 20 423040 50 40 190720 37 20 612736 
2-DPMP 24 40 247792 24 40 1246720 37 40 1907712 37 20 1475072 
3-MeO-PCE 24 40 5064590 24 40 971392 37 40 621056 37 20 794624 
3-MeO-PCP 37 20 2806468 24 40 387648 50 40 141440 37 40 1052160 
5-APB 24 40 7344962 24 40 1523712 24 40 3688627 UNDETECTED 
6-APB 24 40 7630914 24 40 845681 24 40 3761448 UNDETECTED 
BENZEDRONE 70 20 7931314 24 40 455424 37 40 2001920 UNDETECTED 
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Table 2-6: Optimum conditions for each derivatization agent (cont.) 
Drug 
PFPA MSTFA TFAA TMSI 
Temp 
(OC) 
Time 
(mins) 
Peak 
Area 
Temp (OC) 
Time 
(mins) 
Peak 
Area 
Temp 
(OC) 
Time 
(mins) 
Peak 
Area 
Temp (OC) 
BUTYLONE 24 40 917665 24 40 139712 37 40 1661440 UNDETECTED 
ETHYLONE 24 40 2831935 24 40 676800 37 40 1603072 UNDETECTED 
FLEPHEDRONE 70 20 2635889 UNDETECTED 37 40 520128 UNDETECTED 
MDPV 24 40 8579133 24 40 1329664 37 40 2387968 37 20 2707456 
MEPHEDRONE 70 20 1148247 24 40 561088 37 40 886208 UNDETECTED 
MESCALINE-NBOMe 37 40 5826486 50 20 1088512 50 40 1156608 37 20 4419072 
METHIOPROPAMINE 70 20 2668526 UNDETECTED 37 40 307264 UNDETECTED 
METHOXETAMINE 24 40 3509882 24 40 351168 37 40 330816 37 20 648260 
METHYLONE 70 20 1892738 24 40 905728 37 40 1285623 UNDETECTED 
NAPHYRONE 70 20 7107450 24 40 2045440 37 40 914496 37 20 2280448 
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Figure 2-9 shows the percentage of analytes which had an optimum incubation 
temperature of 24oC, 37oC, 50oC and 70oC with PFPA derivatisation. This shows 
that 37oC was the overall optimum incubation temperature for analytes 
derivatised with PFPA:EtOAc. At higher temperatures the caps on the culture 
tubes would “pop” off due to the build-up of gases inside, and as a result we see 
much higher %CVs for 70oC, as shown in  
Appendix 1 through Appendix 4 . This could be remedied by using screw top 
culture tubes although these are costlier. The optimum incubation time was 20 
minutes which accounted for 80% of optimum PFPA:EtOAc derivatisations as 
shown in Figure 2-10.  
 
Figure 2-9: Chart showing % of NPS analytes (n=20) with optimum incubation temperatures 
of 24oC, 37oC,50oC, or 70oC 
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Figure 2-10: Chart showing % of NPS analytes (n=20) with optimum incubation times of 20 or 
40 minutes. 
 
Overall PFPA:EtOAc (Figure 2-11) worked much better as a derivatising agent 
than MSTFA, TFAA or TMSI. TFAA did however allow for the detection of all NPSs 
contained within the GC-MS method which was not the case for MSTFA or TMSI.  
 
Figure 2-11: Chromatogram of various NPSs derivatised using PFPA:EtOAc (1 mg/L). 
 
A chromatogram of all analytes after TFAA derivatisation is shown in Figure 2-12. 
TFAA produced similar mass spectra to that of PFPA:EtOAc which is unsurprising 
as both are acylation agents. The peak areas however, were much lower than 
those of PFPA:EtOAc showing that PFPA:EtOAc is the preferred acylation agent 
out of the two. This could be in part due to the use of EtOAc with PFPA which 
acts as an acid receptor and promotes reactivity. Had a suitable base been used 
alongside TFAA an improvement in the resulting peak areas may have been seen.  
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Figure 2-12: Chromatogram of various NPSs derivatised using TFAA (1 mg/L) 
 
A chromatogram of all analytes after derivatisation with MSTFA is shown in 
Figure 2-13. This derivatisation agent led to the identification of all analytes 
with the exception of methiopropamine and flephedrone. This may be due to the 
increased interferences found at the beginning of this chromatogram which 
could have masked these analytes or that these analytes eluted before the 
5minute solvent window. The use of MSTFA lead to the NBOMe compounds all 
producing similar mass spectra, and thus do not allow for the identification of all 
NBOMes when in a mixture. This is due in part to the derivatising agents having 
no effect on the structure of these analytes failing to actually derivatise. This 
highlights the need to derivatise analytes to enhance their uniqueness.  
 
Figure 2-13: Chromatogram of various NPSs derivatised using MSTFA (1 mg/L). 
 
The use of TMSI is not advised as 7 of the 25 analytes tested were not detected 
after derivatisation with this reagent. This is unsurprising as TMSI directly does 
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not react with amines and amides and hence would have no impact on these 
substances. The use of TMSI does however highlight the importance of 
derivatising these compounds in order to detect them. In order for TMSI to 
derivatise amines and amides the reagent must be used as part of a multi-
derivatising protocol, which is both time consuming and more costly.(195) The 
use of TMSI also resulted in a large solvent peak lasting 8 minutes as shown in 
Figure 2-14, which could lead to the masking of early eluting compounds such as 
methiopropamine and flephedrone. 
 
Figure 2-14: Chromatogram of 28 NPSs derivatised with TMSI (1 mg/L). 
 
The NBOMe spectra produced using TMSI also failed to produce unique spectra, 
with the main ions repeating throughout the series (91, 121, 150 and 194) as 
shown in Appendix 4. This is particularly problematic for compounds such as 25P-
NBOMe and 25C-NBOMe which could not be chromatographically resolved, and 
therefore depending on unique ions being extracted to confirm identify of the 
NBOMe in question.  
One limitation of this study is the lack of suitable I.S. available resulting in the 
comparison of peak areas rather than PARs. This is particularly important as 
these results were obtained over a 3-day period. In order to overcome this, 
system suitability mixtures ran before each batch were compared and assessed 
to ensure that the instrument was working to the same standard each day. When 
overlaid (Figure 2-15) it is clear that the instrument was performing to the same 
standard and thus the differences observed during this study are not due to 
instrumental deterioration but due to the effects of the derivatising agents 
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themselves. The system suitability mixtures contained various amphetamines 
and benzodiazepines.  
 
Figure 2-15: Overlaid chromatograms of system suitability mixtures ran for each of the 3 
days (1 mg/mL) 
 
2.5.3 LLE 
Table 2-7 shows a comparison of the two LLE methods used for the 23 NPSs 
studied in urine. These results show that for 15 of the 23 analytes tested method 
2 was the better LLE method; neither method allowed for the extraction of all 
analytes from urine. Method 1 was unable to extract flephedrone or 
methiopropamine and method 2 was unable to extract methoxetamine from 
urine.  
Method 1 resulted in an average recovery of 55.4% (ranging 0-88.4%), whereas 
method 2 resulted in an average recovery of 68.9% (ranging 0- 129.5%), a 13.5% 
improvement. 25I-NBOME saw the highest recovery of 88.4% using method 1, 
whereas flephedrone was the highest recovered analyte of method 2 (129.5%).  
Synthetic cathinones failed particularly using LLE method 1, with average 
recovery rates of 40.3%. NBOMes compared to other NPSs fared much better with 
recovery rates of 81.2% and 75.8% respectively for each method. This is less 
surprising as this method has been previously used in the literature for the 
analysis of NBOMes using LC-MS/MS.(161) Both methods produced clean extracts 
with no visible matrix contamination.  
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Table 2-7: LLE extraction recovery (%) results  
Analyte 
Method 1 Method 2 Difference 
between 
method 1& 
2 (%) 
Recovery 
(%) 
%CV 
Recovery 
(%) 
%CV 
25C-NBOMe 84.5 8.6 100.5 4.5 (-16.0) 
25D-NBOMe 86.3 5.4 88.0 7.6 (-1.7) 
25ENBOMe 79.9 9.6 93.9 9.2 (-14.0) 
25H-NBOMe 87.3 10.5 79.6 5.6 7.8 
25I-NBOMe 88.4 13.7 118.9 3.1 (-30.5) 
25N-NBOMe 79.9 6.5 102.7 10.5 (-22.8) 
25P-NBOMe 68.7 8.6 112.6 6.5 (-43.9) 
3-MeO-PCE 67.0 7.3 12.8 7.9 54.2 
3-MeO-PCP 85.2 14.2 13.2 8.9 72.0 
5-APB 11.2 13.9 16.8 3.4 (-5.6) 
6-APB 11.1 12.8 18.6 6.7 (-7.5) 
BENZEDRONE 87.5 6.3 74.2 9.2 13.3 
BUTYLONE 65.6 9.7 66.3 6.2 (-0.8) 
ETHYLONE 41.6 9.6 29.0 13.6 12.7 
FLEPHEDRONE N.D. 12.1 129.5 12.6 (-129.5) 
MDPV 87.4 9.2 63.0 10.5 24.4 
MEPHEDRONE 2.6 9.2 82.0 5.5 (-79.4) 
MESCALINE-NBOMe 87.7 5.6 60.1 9.5 27.6 
METHEDRONE 29.1 7.9 38.4 11.5 (-9.4) 
METHIOPROPAMINE N.D. 9.5 46.4 5.6 (-46.4) 
METHOXETAMINE 15.5 10.2 N.D. 6.8 15.5 
METHYLONE 13.7 13.1 69.5 4.5 (-55.9) 
NAPHYRONE 93.8 7.5 100.0 9.6 (-6.2) 
*N.D. – none detected 
 
2.5.4 SPE Cartridges 
All cartridges were able to extract each NPS from each matrix, with the 
exception of the XRPCH50z cartridge which failed to extract any of the 25 NPSs 
tested as shown in Table 2-8. 
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Table 2-8: Optimum cartridge for the extraction of various NPSs from blood, urine, plasma and serum (% recovery). 
DRUG 
BLOOD URINE PLASMA SERUM 
Cartridge 
Type 
% Recovery 
Cartridge 
Type 
% Recovery 
Cartridge 
Type 
% Recovery 
Cartridge 
Type 
% Recovery 
25B-NBOMe CSDAU 86 CSDAU 85 ZSDAU 117 XCEL 1 71 
25C-NBOMe CSDAU 83 CSDAU 85 ZSDAU 76 ZSDAU 85 
25D-NBOMe CSDAU 102 XRDAH 206 109 ZSDAU 117 ZSDAU 111 
25ENBOMe CSDAU 110 CSDAU 110 ZSDAU 111 ZSDAU 108 
25H-NBOMe CSDAU 99 CSDAU 139 XCEL 1 51 ZSDAU 81 
25I-NBOMe CSDAU 90 ZSDAU 90 XCEL 1 47 ZSDAU 118 
25N-NBOMe ZSDAU 81 ZSDAU 98 ZSDAU 105 ZSDAU 118 
25P-NBOMe XRDAH 206 69 ZSDAU 76 ZSDAU 63 ZSDAU 62 
25T2-NBOMe XRDAH 206 111 XRDAH 206 108 ZSDAU 66 XCEL 1 81 
25T4-NBOMe CSDAU 105 CSDAU 105 ZSDAU 64 XCEL 1 70 
25T7-NBOMe XCEL 1 106 XCEL 1 106 ZSDAU 115 ZSDAU 107 
2-DPMP CSDAU 88 CSDAU 115 CSDAU 89 CSDAU 97 
3-MeO-PCE XRDAH 206 45 XCEL 1 96 XRDAH 206 60 ZSDAU 50 
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Table2-8: Optimum cartridge for the extraction of various NPSs from blood, urine, plasma and serum (% recovery). 
Drug 
BLOOD URINE PLASMA SERUM 
Cartridge 
Type 
% Recovery 
Cartridge 
Type 
% Recovery 
Cartridge 
Type 
% Recovery 
Cartridge 
Type 
% Recovery 
5-APB CSDAU 49 XCEL 1 95 CSDAU 63 CSDAU 71 
6-APB ZSDAU 27 XCEL 1 94 ZSDAU 45 CSDAU 51 
BENZEDRONE XRDAH 206 47 OASIS® 124 XRDAH 206 48 XRDAH 502 47 
BUTYLONE XCEL 1 80 OASIS® 119 XCEL 1 101 XCEL 1 87 
ETHYLONE ZSDAU 115 OASIS® 87 XCEL 1 79 XCEL 1 79 
FLEPHEDRONE CSDAU 65 CSDAU 81 CSDAU 67 CSDAU 63 
MDPV CSDAU 106 XCEL 1 105 XCEL 1 109 XCEL 1 100 
MEPHEDRONE CSDAU 112 CSDAU 101 CSDAU 88 CSDAU 126 
Mescaline-NBOMe XCEL 1 49 XCEL 1 50 ZSDAU 41 XRDAH 502 90 
METHIOPROPAMINE OASIS® 52 XCEL 1 80 XCEL 1 27 ZSDAU 43 
METHOXETAMINE XRDAH 206 56 XCEL 1 70 XRDAH 206 66 ZSDAU 58 
NAPHYRONE XRDAH 502 40 XCEL 1 113 XRDAH 502 42 XRDAH 502 47 
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Figure 2-16 shows the cartridge which provided the highest % recovery for each 
analyte from blood. From this data it is shown that the CSDAU033 cartridge was 
the most efficient overall, accounting for 48%. This was followed by the 
ZSDAU020 cartridge which accounted for 12%. Both these cartridges contain a 
reverse phase and an ion exchange co-polymeric bonded phase, and only differ 
by their bed weight, 130mg and 200mg respectively. Both have already been 
used for the extraction of NPSs from biological matrices in literature and it is 
therefore unsurprising that these provided the best results. (189, 196, 197)  
 
Figure 2-16: The % of analytes (n=25) with the highest recovery using each cartridge from 
blood.   
 
Figure 2-17 shows the cartridge which provided the highest % recovery for each 
analyte from urine. From this data it is apparent that XCEL I cartridges favoured 
this matrix (36%), followed by CSDAU cartridges (32%). This cartridge is 
commonly used in clinical toxicology as it requires no column conditioning, 
importantly reducing sample analysis time. As a result however it typically 
performs better for simple matrices.  
Waters Oasis® cartridges although able to extract drugs from blood (4%), were 
unable to do so without significant sample breakthrough, leading to discoloured 
samples. This in turn would increase instrument maintenance down-time which 
is an additional cost to consider, especially for high-throughput laboratories. 
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These cartridges did however favour slightly better when extracting analytes 
from urine (12%), providing the highest recoveries for benzedrone (124%), 
butylone (119%) and ethylone (87%). Vazquez-Roig was able to analyse 14 
different illicit drugs from surface water samples using the Waters Oasis® MCX 
cartridge. This research combined with previous research suggests that these 
cartridges could be more useful when analysing less complex matrices. This 
cartridge had a bed size of 500 mg and this may have played a role in sample 
breakthrough.  
 
Figure 2-17: The % of analytes (n=25) with the highest recovery using each cartridge from 
urine.   
 
Figure 2-18 shows the cartridge which provided the highest % recovery for each 
analyte from plasma. ZSDAU performed significantly stronger than any other 
cartridge type here, providing the highest recovery for 44% of analytes. XCEL I 
performed better extracting the 25 NPSs from plasma (24%) in comparison to 
blood (12%).  
No difference was observed when using XRDAH 502 cartridges to extract these 
substances from blood or plasma with only 4% of analytes having the highest 
recovery using these cartridges. Previous research showed the successful use of 
the XRDAH506 cartridges for the recovery of MDPV, mephedrone and other 
stimulant compounds from waste water, however this was not the case here, as 
shown in Table 2-8.(198)  
77 
 
 
Figure 2-18: The % of analytes (n=25) with the highest recovery using each cartridge from 
plasma.   
 
 
Figure 2-19: The % of analytes (n=25) with the highest recovery using each cartridge from 
serum.   
 
Figure 2-19 shows the cartridge which provided the highest % recovery for each 
analyte from serum. XRDAH 502 cartridges performed slightly better than 
previous matrices (12%). ZSDAU cartridges again performed strongly providing 
the strongest recovery for 44% of analytes tested. CSDAU cartridges performed 
slightly better extracting the various NPSs from serum (20%) in comparison to 
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plasma (16%). XRDAH 206 cartridges did not provide the highest recovery for any 
analytes extracted from serum.  
2.5.5 SLE / SPE Cartridge Comparison 
Similar to SPE, SLE extracted all analytes from all matrices. Results are shown in 
Figure 2-20 through to Figure 2-23. SLE provided higher recoveries than SPE 
when extracting drugs from blood as shown in Figure 2-20, with 17 out of the 26 
analytes (65%) having higher recoveries when SLE was used. Naphyrone saw the 
biggest increase (47%) when compared to SPE. The poorest recovered analyte 
using SLE in comparison to SPE was methiopropamine which decreased 47% 
against SPE.  
SPE proved to be the better technique when extracting from urine, producing 
higher recoveries for 17 (65%) of the 26 analytes tested, as shown in Figure 2-21. 
SPE was significantly better at extracting ethylone from urine showing a 51% 
increase versus SLE. Conversely to blood, methiopropamine was the most 
successfully recovered analyte versus SPE, with the SLE recovery showing a 47% 
increase.  
Plasma samples showed a strong preference for SPE with all except 3 analytes, 
25N-NBOMe, flephedrone and methiopropamine, having higher recoveries using 
this method versus SLE (+88%) as shown in Figure 2-22. 25N-NBOMe was the best 
analyte recovered from SLE (143%), and ethylone was the poorest (15%). 2-DPMP 
showed a recovery of 70% using both methods. The recovery of 6-APB from 
plasma using SLE and SPE saw the biggest difference in the comparative % 
recoveries. When extracted using SPE, 98% of this analyte was recovered in 
comparison to using SLE where only 34% of analyte was able to be recovered, a 
decrease of (-64%). Similar results were seen with MXE (-63%), ethylone (-58%) 
and 5-APB (-52%), showing that SPE really is the favoured extraction method for 
these analytes from plasma. Oppositely methiopropamine saw the largest 
comparative difference between the 2 methods, with SLE improving recovery by 
62% in comparison to SPE.  
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Figure 2-20: Comparison of SPE and SLE for the extraction of NPSs from blood. 
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Figure 2-21: Comparison of SPE and SLE for the extraction of NPSs from Urine. 
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Figure 2-22: Comparison of SPE and SLE for the extraction of NPSs from plasma. 
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Figure 2-23: Comparison of SPE and SLE for the extraction of NPSs from serum. 
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Again all analytes were extracted from serum samples as shown in Figure 2-23. 
2-DPMP gave a good recovery with SLE, showing a 94% improvement when 
compared against SPE. 25T7-NBOMe on the other hand showed a strong affinity 
for SPE, with recovery improving 76% when this technique was used. Overall 
samples were better extracted using SPE with 17 analytes (68%) showing better 
recoveries using SPE than SLE.  
The differences observed between blood, plasma and serum may be due to the 
different components contained within each matrix. Blood contains plasma, 
serum, white blood cells and red blood cells. Plasma and serum both consist of 
water, albumin, globulins, amino acids, hormones, enzymes, nitrogenous waste 
nutrients and gases. In addition to this, plasma also contains fibrinogen which is 
responsible for the clotting of blood. It is therefore normal that serum, in 
comparison to plasma and blood, produces the higher extraction recovery 
results, as this has had the majority of the matrix already removed. This was not 
the case for the SLE experiments carried out here. No information is available 
regarding the size of diatomaceous earth particles biotage use. These particle 
sizes can vary and thus this could be favouring the retention of larger molecules 
such as whole blood particles than that of plasma and serum, leading to more 
sample break through. Alternatively, it could be that the method was not 
optimised to these alternative matrices and that slight variances in pH may also 
be impacting upon the recovery values. Although plasma, blood and serum all 
have pH values typically ranging from 7.35-7.45, the blood, plasma and serum 
purchased were from different donors and therefore small differences may have 
been present.  
The chromatograms of the resulting serum and plasma samples had more 
contamination at the front of the chromatogram, and dirtier base lines than 
those of the whole blood and urine. This suggests that matrix breakthrough may 
be a contributing factor for the poor recoveries seen for the NPS’s tested as 
shown in Figure 2-24 through Figure 2-27. 
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Figure 2-24: Chromatogram of all 26 NPSs extracted from blood by SLE (1 mg/L). 
 
 
Figure 2-25: Chromatogram of all 26 NPSs extracted from urine by SLE (1 mg/L). 
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Figure 2-26: Chromatogram of all 26 NPSs extracted from plasma by SLE (1 mg/L). 
 
 
Figure 2-27: Chromatogram of all 26 NPSs extracted from serum by SLE (1 mg/L). 
 
Another anomaly of this research was the difference in recoveries between 
ethylone and butylone. Although both were recovered to relatively the same 
degree using SPE there were significant differences between these two analytes 
when extracted using SLE. Butylone recovery ranged 61-83% in comparison to 
ethylone which ranged 15-20% across all 4 matrices. There is no real explanation 
for these observed differences, as the chemistry between these two compounds 
is very similar, with the only variation being the position of a methyl group. In 
order to assess this better these drugs should be repeated, thus determining if 
this was a “one off” anomaly.  
86 
 
When choosing extraction methods analyte recovery and cleanliness of extract 
must be weighed against sample preparation time and cost. Although SPE 
involves many more steps than SLE overall both techniques took equal time from 
start to finish. This is because 2x 4 mL of EtOAc was used as the elution solvent 
for the SLE cartridges, and this took significantly longer to evaporate than the 3 
mL of CH2Cl2:IPA:NH4OH (78:20:2) elution solvent used in SPE. This is due to the 
different volatilities of each solvent with EtOAc being less volatile than the 
CH2Cl2:IPA:NH4OH mixture. Solvent waste was heavily reduced however when 
using SLE in comparison to LLE as although a high volume of solvent is required 
for elution in SLE this is evaporated off, and thus solvent disposal is not 
required. This differs to LLE where the bottom aqueous layer is left behind 
which will need to be disposed of and depending on the number of samples being 
processed each day, this could result in a significant volume of waste.  
2.6 Conclusion 
By adapting the in-house FMS amphetamine method the detection of a much 
wider range of compounds was possible, in particular that of NBOMes. Altering 
the injection port temperature parameters prevented degradation of compounds 
in the injection port. Derivatisation using PFPA:EtOAc (2:1) resulted in individual 
spectra for all compounds with the exception of ethylone and butylone, 5-APB 
and 6-APB and 25T4 and 25T7-NBOMe. These were however separated 
chromatographically. The altering of the oven temperature programme provided 
significant chromatographic separation for the identification of each of these 
analytes. This meant that all compounds were easily identifiable, using both 
chromatographic RTs and mass spectra.  
Across all of the drugs evaluated, PFPA:EtOAc (2:1) at 37°C yielded the most 
consistently high recoveries and therefore it is recommended that these 
conditions are used when multiple cathinones and NBOMEs are being analysed 
simultaneously by GC/MS. Due to the low concentrations typically detected 
during the analysis of NBOMes these compounds take priority. For specific drug 
analysis other conditions may improve detectability as shown in Table 2-4. 
TMSI should not be used for the analysis of synthetic cathinones as the majority 
of these were undetected using this derivatising agent. It also failed to produce 
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unique spectra for each NBOMe. As the NBOMes all elute during the final hold 
time some such as 25P and 25C-NBOMe are unable to be separated 
chromatographically through retention times. This in turn makes the 
identification of a specific NBOMe more difficult or inconclusive depending on 
the NBOMe present.  
From the data it has been shown that the LLE methods were not suitable for the 
extraction of NPSs in urine. This is particularly true if the NPS is unknown as 
neither method allowed for the extraction of all analytes tested. LLE is however 
a suitable method for the extraction of NBOMes from urine.  
This SPE study showed that when analysing urine and blood samples, the smaller 
bed size of the CSDAU cartridges is preferable, in contrast to analysing plasma 
and serum samples where ZSDAU cartridges should be used. XRPCH50z 
cartridges, using the method tested, are not recommended for sample clean-up 
of NPS compounds.  
From the SLE/SPE comparison data it is clear that SPE remains the favoured 
extraction technique when extracting a wide range of NPSs from urine, serum 
and plasma. SLE did however prove to be the better technique when extracting 
these analytes from blood. Although carrying out the SLE process was rapid, the 
evaporation of such large amounts of elution solvent took additional time, 
making the time scale of SLE versus SPE similar. Further work should be done to 
optimise the SLE protocol for these drugs as altering the elution solvent may 
have a positive impact on the urine, serum and plasma recoveries.  
2.7 Future Work  
Although this research indicates which SPE cartridge should be used for 25 
different analytes in different matrices, there are some limitations to these 
results which require further work. The cartridges themselves were not 
optimised, therefore they each only had one method applied, which did or did 
not work. Thus it might be that one cartridge performed much better than 
another and that this might not be the case had different solvents been used. 
This may be particularly important when evaluating the XRPCH50z cartridge 
which failed to extract any analytes from all matrices tested.  
88 
 
This study did not examine the potential loss of analytes during evaporating 
steps. This is something which could be further investigated as this has been 
shown to occur for amphetamine, methamphetamine and MDMA.(199)    
As with all research there is a need to keep up to date with commercial 
developments, and this research should be repeated as new cartridges are 
released.   
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Chapter 3: GC-MS NPS Method Validation  
3.1 Introduction 
In order to determine whether an analytical method is fit for purpose, it should 
be thoroughly tested and validated. This is extremely important in the context 
of forensic toxicology where the results will have significant impact on 
individuals coming into contact with the criminal justice system.  
The need for validating scientific methods has grown in recent years with the 
U.S. Department of Justice and the U.K. Home Office highlighting the lack of 
standards within the field of forensic science. There are a number of governing 
bodies who produce standards for the work carried out in laboratories ensuring 
work is of the highest quality, such as the U.K. Accreditation Service (UKAS) and 
the Scientific Working Group for Forensic Toxicology (SGWTOX). The latter is 
now under the control of the Organisation of Scientific Area Committee 
(OSAC).(200) 
3.2 Aims 
The aim of this work was to develop a GC-MS method for the detection of 
multiple NPS’s and validate it in accordance with SWGTOX guidelines, 
investigating the below parameters –  
 Precision & Bias 
 Linearity and linear range 
 Carryover 
 Specificity 
 Limit of detection (LOD)  
 Limit of quantitation (LOQ) 
 Stability 
o Cool/ warm and freeze/ thaw cycles 
o Autosampler stability  
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This method will be validated for both blood and urine as these are the 2 most 
commonly encountered matrices. It will then be further tested using “real- life” 
case samples supplied by NMS laboratories.  
3.3 Materials & Methods 
3.3.1 Chemicals & Reagents 
All reference standards, derivatising agents, blood and other analytical grade 
chemicals were purchased from the same suppliers as listed in section 2.4.1.12. 
Again urine was collected in house. Clean Screen ZSDAU020 SPE cartridges were 
purchased from United Chemical Technologies (PA, USA). 
3.3.2 Preparation of Blank (drug-free) Blood and Urine  
Blood and urine were screened for common drugs of abuse prior to use by GC-
MS. Blank blood was prepared as outlined in section 2.4.1.3. 
3.3.3 I.S. Stock solutions 
I.S. stock solutions (100 µg/mL) were prepared by transferring 1 mL of each 1 
mg/mL I.S. reference solution (mephedrone-D3, methylone-D3, ethylone-D5, and 
MDPV-D8) to a 10 mL volumetric flask. This flask was then made up to the mark 
using MeOH, inverted several times and transferred to labelled amber glass 
bottles. An I.S. stock solution (10 µg/mL) of 25I-NBOMe-D3 was prepared by 
transferring 1mL of a 0.1 mg/mL reference solution to a 10 mL volumetric flask. 
This was then made up to the mark using MeOH, inverted several times and 
transferred to a glass amber bottle.  
3.3.4 Preparation of Working Solutions 
Where possible working solutions for calibrators and quality controls (QCs) were 
produced using drugs from different manufacturers or with different lot 
numbers. QC working and stock solutions were also produced by a different 
analyst. This was possible for all compounds with the exception of 25P-NBOME 
which was available only from one manufacture who at the time of this 
validation had only produced one lot. A second vial of this drug (same lot) was 
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purchased and both the QC stock solution and working solution were made by a 
different analyst.  
Stock solutions were prepared as detailed in section 2.4.1.12. Using these stock 
solutions, working solution mixtures were produced as detailed in section 
2.4.1.1. The drugs contained in each of the 4 mixes are shown in Table 3-1.  
The NBOMe solutions (working solutions 3 & 4) were further diluted by taking 1 
mL of the 10 µg/mL solution, transferring this up to a 10 mL volumetric flask and 
making up to the mark with MeOH, producing a 1 µg/mL solution. A 0.1 µg/mL 
solution was then subsequently produced by transferring 1 mL of the 1 µg/mL 
solution to a 10 mL volumetric flask and making it up to the meniscus using 
MeOH. It was these 1 and 0.1 µg/mL solutions which were used to produce 
calibrators and controls as the concentrations detected are much lower than 
those of the drugs contained in working solutions 1 & 2 due to their higher 
potency. Calibrator and QC solutions were stored for a maximum of 6 months, 
and stored at -20oC.  
Table 3-1: Analytes contained in each of the 4 drug mixes. 
Working Solution Number 
1 2 3 4 
Benzedrone 2-DPMP 25B-NBOMe Mescaline–NBOMe 
Butylone 3-MeO-PCE 25C-NBOMe 25P-NBOMe 
Ethylone 3-MeO-PCP 25D-NBOMe 25T4-NBOMe 
Flephedrone 5-APB 25E-NBOMe 25T7-NBOMe 
MDPV 6-APB 25H-NBOMe  
Mephedrone Methiopropamine 25I-NBOMe  
Methedrone Methoxetamine   
Methylone Naphyrone   
 
3.3.5 I.S. Working Solution  
A mixed I.S. working solution was then prepared by transferring 1 mL of each of 
the five I.S. stock solutions to a 10 mL volumetric flask. This flask was then 
made up to the mark using MeOH, thus giving a final concentration of 10 µg/mL 
for all I.S’s with the exception of 25I-NBOMe-D3 which had a final concentration 
of 1 µg/mL.  
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3.3.6 LOD & LLOQ Solutions 
In order to assess the methods LOD and LLOQ further solutions were made. To a 
new 10 mL volumetric flask, 1 mL of working solution 1 and 1 mL of working 
solution 2 was added. This was then made up to the mark using MeOH and 
inverted several times to give a final concentration of 1 µg/mL. To another clean 
10 mL volumetric flask, 1 mL of working solution 3 and 1 mL of working solution 
4 was added. This was again made up to the mark using MeOH and inverted 
several times producing a final concentration of 0.01 µg/mL. 
3.3.7 Calibration & QC Preparations 
Urine and blood calibrators and QCs were prepared by spiking 1 mL of either 
blood or urine with the volumes of each working solution or QC solution as 
outlined in Table 3-2 and Table 3-3. 
Table 3-2: Preparation of Calibrators: Volume of NPS and NBOMe solutions used when spiking 
1 mL of blood or urine.  
Level 
Amount Added (µL) Final Concentration 
Working 
Solutions 
1 & 2 
Working 
Solutions 
3 & 4 
Working 
Solutions 
3 & 4 
Working 
Solution 
1 & 2 
Working 
Solution 
3 & 4 
10 µg/mL 0.1 µg/mL 1 µg/mL mg/L µg/L 
1 5 5 0 0.05 0.5 
2 10 10 0 0.10 1 
3 20 20 0 0.20 2 
4 50 50 0 0.50 5 
5 100 0 10 1.00 10 
6 200 0 50 2.00 50 
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Table 3-3: Preparation of QCs: Volume of each NPS solution used when spiking 1 mL of blood 
or urine.  
QC 
Amount Added (µL) Final Concentration 
Working 
Solutions 
1 & 2 
Working 
Solutions 
3 & 4 
Working 
Solutions 
3 & 4 
Working 
Solution 
1 & 2 
Working 
Solution 
3 & 4 
10 µg/mL 0.1 µg/mL 1 µg/mL mg/L µg/L 
1 8 8 0 0.08 0.8 
2 42 42 0 0.42 4.2 
3 142 0 28 1.42 28.0 
 
3.3.8 Sample preparation  
I.S. mix (50 µl) and 1 mL of phosphate buffer (pH6) was added to all calibrators, 
QCs and samples before being vortexed for 30 seconds. Calibrators, QCs and 
samples were then centrifuged for 10 minutes at 4000 rpm. The supernatant of 
each calibrator, QC and sample was then transferred to ZSDAU020 Clean Screen 
SPE cartridges which had been conditioned using 2 mL MeOH, 2 mL dH2O 
followed by 2 mL phosphate buffer (pH 6). Columns were washed using 2 mL 
dH2O, 1 mL 0.1 M acetic acid and 2 mL MeOH. Analytes were eluted using 3 mL 
CH2Cl2/IPA/NH4OH (78:20:2) solution. Excess elution solvent was then 
evaporated to dryness using a gentle steam of nitrogen with no heat added, 
before derivatisation using 50 µL of PFPA:EtOAc (2:1). These were left to 
incubate at 70oC for 40 minutes before being evaporated to dryness once again 
under a gentle stream of nitrogen (room temperature). All calibrators and QCs 
were then reconstituted using 50 µL of EtOAc, vortexed for 30 seconds and 
transferred to labelled glass GC-MS vials containing limited volume inserts.  
3.3.9 Instrumentation  
Method validation was carried out using an Agilent GC-MSD 5975C series 
instrument in accordance with SWGTOX guidelines. Data was analysed using 
Agilent ChemStation software (version 02.02.1431). The instrument was fitted 
with a J&W Agilent DB-5ms low bleed column (30 m x 0.32 mm i.d.; film 
thickness 0.25 µm). The GC-MS parameters used were as summarised in Table 
3-4. The ions monitored were those listed in Table 2-5. Additional 
instrumentation was the same as that listed in section 2.4.1.12 
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Table 3-4: Summary of GC-MS Parameters.  
GC Parameters 
Column 
J&W Agilent DB-5ms low bleed column 
(30 m x 0.32 mm i.d.; film thickness 
0.25 µm) 
Injection Port Mode Splitless 
Injection Port Temperature 225oC 
Carrier Gas Helium 
Flow Rate 1.5 mL/min 
Transfer Line Temperature 250oC 
Initial Temperature 80oC 
Hold Time 2 min 
Ramp 1 25oC/min to 170oC 
Hold 1 min 
Ramp 2 5oC/min to 200oC 
Hold 1 min 
Ramp 3 15oC/min to 300oC 
Final Ramp 5oC/min to 300oC 
Final Hold 3 min 
MS Parameters 
Source Temperature 200oC 
Source Mode EI 
Scan Mode SIM 
Total Run Time 30 min 
 
3.3.10 Limit of Detection (LOD), Lower Limit of Quantification 
(LOQ) 
The limit of detection (LOD) was assessed by determining the lowest 
concentration at which the drug could be detected with a signal to noise (S/N) 
ratio greater than 3. S/N was calculated using Equation 3-1. Blood and urine (1 
mL) was spiked with various volumes (10-100 µl) of the 1 µg/mL LOD & LLOQ 
mixtures (section 3.3.6). The analytes were then extracted as detailed in section 
3.3.8 and analysed. All LODs were assessed after analyte extraction from the 
matrix as this could heavily impact upon the concentrations identified.  
Equation 3-1: Signal to Noise Ratio Calculation. 
𝑆𝑖𝑔𝑛𝑎𝑙 𝑡𝑜 𝑁𝑜𝑖𝑠𝑒 =
ℎ𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑎𝑛𝑎𝑙𝑡𝑦𝑒
𝑎𝑚𝑝𝑙𝑖𝑡𝑢𝑑𝑒 𝑜𝑓 𝑛𝑜𝑖𝑠𝑒
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In order to determine the lower level of quantitation (LLOQ) for each compound 
calibration standards and QCs were spiked with the LOD and LLOQ solutions 
described in section 3.3.6.(10-100 µl) and extracted. These were run alongside a 
set of calibrators and QC’s. The LLOQ was determined as the lowest 
concentration with a S/N ratio greater than 10 and at which identification bias 
and precision criteria were met. In the case of the NBOMe analytes this was 
decided as being the lowest non-zero calibrator. 
As the NBOMe concentrations previously identified in the literature show 
concentrations ranging from range from 0.441-7.5 ng/mL, it was important that 
the NBOMe method be sensitive enough to be applicable to forensic cases. 
Therefore, a cut-off level of 0.5 ng/mL was set when deciding which NBOMe 
compounds to validate the method for. 
3.3.11 Linearity 
Calibration standards were prepared by spiking blank blood and urine with NPSs 
as outlined in 3.3.7. The PAR of each analyte to its I.S. was calculated as per 
Equation 3-2.  
Equation 3-2: Peak Area Ratio Equation 
𝑃𝐴𝑅 =  
𝐴𝑛𝑎𝑦𝑡𝑒 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
𝐼. 𝑆. 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎
 
 
The I.S. used in this calculation for each analyte is shown in Figure 3-1.The PAR 
was then plotted against its concentration to give a calibration curve. The 
equation of the line and correlation coefficient (R2) was measured.  
In order for calibration curves to comply with SWGTOX guidelines, R2 values must 
be greater than 0.99 and QCs when plotted should not give accuracy values more 
than ±20%. 
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Figure 3-1: Analytes with the corresponding I.S. used to calculate PARs. 
 
The SIM ion ratios were monitored during the course of this validation to ensure 
that they remained constant throughout. This is important when developing a 
SIM method as the full mass spectrum is not available.  Monitoring ion ratios aids 
with interpreting whether an analyte is positive or not. Ratios were calculated 
using the abundance of each ion in Table 2-5 and inputting this information into 
Equation 3-3,Equation 3-4 or Equation 3-5.  
Equation 3-3: Target to qualifier 1 ion ratio 
𝑇𝐺𝑇 𝑡𝑜 𝑄1 𝑅𝑎𝑡𝑖𝑜 =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑇𝐺𝑇 𝐼𝑜𝑛 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑄𝑢𝑎𝑙𝑖𝑓𝑖𝑒𝑟 1 𝐼𝑜𝑛 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 
 
• Mephedrone
• Methiopropamine 
• Flephedrone
Mephedrone-D3
• Methylone
Methylone-D3
• Ethylone
• Butylone 
• 5-APB
• 6-APB
• Methoxetamine 
• 3-MeO-PCE
• 3-MeO-PCP
Ethylone-D5
• MDPV
• 2-DPMP
• Naphyrone
• Benzedrone
MDPV-D8
• All NBOMe compounds
25I-NBOMe-D3
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Equation 3-4: Target to qualifier 2 ion ratio 
𝑇𝐺𝑇 𝑡𝑜 𝑄2 𝑅𝑎𝑡𝑖𝑜 =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑇𝐺𝑇 𝐼𝑜𝑛 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑄𝑢𝑎𝑙𝑖𝑓𝑖𝑒𝑟 2 𝐼𝑜𝑛 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 
 
 
Equation 3-5: Qualifier 1 to qualifier 2 ratio 
𝑄1 𝑡𝑜 𝑄2 𝑅𝑎𝑡𝑖𝑜 =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑄𝑢𝑎𝑙𝑖𝑓𝑖𝑒𝑟 1 𝐼𝑜𝑛 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑄𝑢𝑎𝑙𝑖𝑓𝑖𝑒𝑟 2 𝐼𝑜𝑛 𝐴𝑏𝑢𝑛𝑑𝑎𝑛𝑐𝑒 
 
 
3.3.12 Bias, Precision and Accuracy  
Bias and precision were calculated by running calibration standards alongside 3 
replicates of each QC, low (QC1), medium (QC2) and high (QC3). The data from 
these QC’s was then entered into Equation 3-6 and Equation 3-7. This was 
carried out for 6 batches to calculate both the within-run and between-run 
precision using Equation 3-8 and Equation 3-9. Acceptable criteria for each 
calculation was set at ≤20%.  
The accuracy of the method was then determined using Equation 3-10 in order to 
determine how close to the true value the results from each QC were. In order 
to comply with SWGTOX guidelines an acceptable variance limit of ±20% was 
used. Again results were averaged across all 6 batches.  
Equation 3-6: Bias Calculation. 
𝐵𝑖𝑎𝑠 (%) = [
𝑀𝑒𝑎𝑛 𝑜𝑓 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑐.𝑥− 𝑡𝑟𝑢𝑒 𝑐𝑜𝑛𝑐.𝑥
𝑇𝑟𝑢𝑒 𝑐𝑜𝑛𝑐.𝑥
] 𝑥 100 
 
Equation 3-7: Precision Calculation. 
% 𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 𝑜𝑓 𝑉𝑎𝑟𝑖𝑎𝑡𝑖𝑜𝑛 (𝐶𝑉) =
𝑆𝑡𝑑 𝐷𝑒𝑣
𝑀𝑒𝑎𝑛 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒
 
 
Equation 3-8: Within-Run Precision Calculation 
𝑊𝑖𝑡ℎ𝑖𝑛 − 𝑟𝑢𝑛 𝐶𝑉 (%) = [
𝑆𝑡𝑑 𝐷𝑒𝑣 𝑜𝑓 𝑎 𝑠𝑖𝑛𝑔𝑙𝑒 𝑟𝑢𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝑀𝑒𝑎𝑛 𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑎 𝑠𝑖𝑛𝑔𝑙𝑒 𝑟𝑢𝑛 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
] x100 
 
Equation 3-9: Between-Run Precision Calculation. 
𝐵𝑒𝑡𝑤𝑒𝑒𝑛 − 𝑅𝑢𝑛 𝐶𝑉 (%) = [
𝑆𝑡𝑑 𝐷𝑒𝑣 𝑜𝑓 𝑚𝑒𝑎𝑛 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑐𝑜𝑛𝑐.
𝐺𝑟𝑎𝑛𝑑 𝑚𝑒𝑎𝑛 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
] 𝑥100 
 
Equation 3-10: Accuracy Calculation 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦(%) =
𝐴𝑐𝑡𝑢𝑎𝑙 𝑉𝑎𝑙𝑢𝑒
𝑇𝑟𝑢𝑒 𝑉𝑎𝑙𝑢𝑒
𝑥100 
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3.3.13 Carryover 
Analyte carryover was assessed for 2 different batches: NBOMes and the 
remaining NPSs. For the NPS carryover study 100 µL of each stock solution (100 
µg/mL) was added to a culture tube, evaporated to dryness, derivatised with 
50µL of PFPA:EtOAc (2:1), evaporated to dryness once more and reconstituted in 
50 µl of EtOAc. This was then injected in triplicate followed by an EtOAc blank. 
This blank was then examined for the presence of analytes from the previous 
three injections. The same procedure was used to test for any potential NBOMe 
carry over using 100 µL of each stock solution (10µg/mL). This was also done in 
triplicate.  
3.3.14 Selectivity 
Selectivity was assessed to determine if there was any other potential source for 
positive results. Interferences can be either caused by exogenous compounds, 
i.e. other analytes present in the sample, or by endogenous compounds i.e. the 
matrix itself. In order to assess exogenous compounds 100 µL of 100 µg/mL 
solutions of each analyte listed in Table 3-5 was added to culture tubes and 
evaporated to dryness. Once dry, samples were derivatised with 50 µL of 
PFPA:EtOAc, evaporated to dryness again and reconstituted in 50 µl of EtOAc. 
The analytes were assessed in groups, rather than all together. The same 
procedure was carried out using blank matrix i.e. blood or urine. The purchased 
blood was pooled from 50 donors and the urine was collected from 10 different 
donors.  
The selectivity of the method was then assessed by checking the data files from 
these samples and cross referencing these with the NPS SIM method, looking for 
peaks retention times close to the target analytes.  
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Table 3-5: Analytes used to assess method specificity. 
 
3.3.15 Stability  
Analyte stability was also investigated. Autosampler stability differs from other 
stability experiments in that the purpose is to assess whether analysing samples 
after a certain time period gives the same PAR and thus the same concentration. 
It therefore aims to answer the question that should instrument failure occur 
can you re-inject the sample and obtain the same result that would have been 
obtained had the sample been injected at t=0. The method analysed a large 
number of drugs, most of which did not have a commercially available 
deuterated I.S. and so the effects of analyte degradation may have significant 
impacts on the PAR calculated after each time point.  
Having knowledge of autosampler stability is also crucial for this method as 
batch run times may range from hours to days depending on the number of 
samples being analysed, total run time is 30 minutes so a maximum of 48 
Analytes 
6-MAM Diazepam Lidocaine Oxycodone 
7-
aminoclonazepam 
Diphenhydramine Lorazepam PCP 
Acetominophen DMAA MDA Pentobarbital 
Alprazolam Egonine MDEA Phenobarbital 
Amitriptyline EMDP MDMA Phentermine 
Amobarbital Ephedrine Meperidine Propofol 
Amphetamine Ethchlorvynol Mescaline Propoxyphene 
Baclofen Fentanyl Mescaline Protriptyline 
Benzoylecgonine Flunitrazepam Methadone Pseudoephedrine 
Butalbital Fluoxetamine Methamphetamine Secobarbital 
Caffeine Flurazepam Nicotine Secobarbital 
Carisoprodool GHB Nitrazepam Sibutramine 
Chlordiazepoxide Heroin Norchlordiazopoxide Temazepam 
Chlorpheniramine Hexobarbital Nordiazepam Thebaine 
Citalopram Hydrocodeine Norfluoxetine Tramadol 
Clonazepam Hydrocodone Nortriptyline Trazodone 
Cocaethylene Hydromorphone Olanzapine Triazolam 
Cocaine Ketamine Oxazepam αOH-alprazolam 
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injections can take place within a 24-hour time period. Should PAR’s alter over 
time the resulting concentrations calculated using these would also vary.  
In order to evaluate this, the 3 QC sample concentrations were analysed in 
triplicate to determine the concentration at time zero. The same samples were 
then left on the autosampler and re-injected at time 24, 48 and 72 hours.  
The PAR of each QC at time 0, 24 and 48 hours was then calculated using 
Equation 3-2. The recovery of each analyte was then calculated using Equation 
3-11. Analytes were identified as being unstable if their recovery fell out with 
the acceptable criteria of ±20%. As the vial contains both the analyte and its I.S. 
degradation will not have an effect on the PAR and thus the final concentration 
unless the analyte and its I.S. degrade at different rates.  
Equation 3-11: Autosampler stability recovery equation 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝑇𝑖𝑚𝑒 𝐹𝑖𝑛𝑎𝑙 𝑃𝐴𝑅
𝑇𝑖𝑚𝑒 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑃𝐴𝑅
𝑋 100 
The variation of analyte PA’s within these autosampler results was also 
monitored to show whether the analytes and I.S’s were themselves stable. This 
is particularly important for the NBOMe compounds as concentrations are low. 
Therefore, although the PAR may not change over the time, it may be that the 
analyte itself degraded to such a low concentration that it can no longer be 
detected.  
The effect of 3 freeze-thaw and fridge cycles was also investigated, to 
determine whether this affected concentrations detected. Again this is an 
important parameter to consider for NPS methods as samples may not initially be 
screened for these drugs. Should the results of a retrospective analysis be 
regarded as valid then it is important to know any stability limitations.  
Blank blood or urine samples (5 mL) were spiked with working solutions 1-4 as 
shown in Table 3-3, to produce 3 replicates of each QC concentration. All 
volumes added were multiplied by 5 to account for the larger blood or urine 
volume. This procedure was carried out twice for each matrix, giving a total of 
18 blood samples and 18 urine samples as depicted in Figure 3-2.  
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Figure 3-2: Schematic of blood and urine samples stored in the fridge and freezer 
 
From each tube 1 mL of sample was removed, and analysed. The remaining 
freeze/fridge thaw samples were then capped and either stored in the freezer (-
20oC) or fridge (4oC). Samples were then removed from the fridge and freezer, 
left to thaw and reanalysed after 24 hours. This was repeated twice with 
samples undergoing a total of 3 freeze or fridge thaw cycles. Again PARs were 
used to monitor the effect of freezer/ fridge thaw cycles on each analyte. 
Recovery was calculated in a similar manner to that of the autosampler stability, 
dividing the final PAR by the initial PAR and multiplying by 100. 
3.3.16 Case samples  
In order to verify whether the method was sufficiently robust for “real-life” 
samples, 12 blood samples were analysed, from a total of 8 different cases. 
Three blood samples were from a range of collection sites and only case 4 
identified whether the sample was collected anti or post-mortem as shown in 
Table 3-6. Prior to analysis this was the only information provided.  
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Table 3-6: Collection site of each sample received from NMS labs.  
Case No Site of collection 
1 
Cardiac Blood 
Cardiac Blood 
2 
No info 
No info 
3 No info 
4 Post mortem Blood 
5 Iliac Blood 
6 Blood 
7 Peripheral Blood 
8 
Cavity Blood 
No info 
Peripheral Blood 
 
These samples were previously analysed using LC-MS/MS by NMS laboratories. 
Samples were extracted and analysed as per section 3.3.8 and 3.3.9. Calibrators 
and QCs were extracted and analysed alongside each batch of samples (same 
concentrations as those stated in section 3.3.7).  
After analysis the concentrations and analytes detected were provided. No 
information was provided as to how the samples had been analysed. Two 
methanolic washes were run after the final QC and between each case sample to 
ensure carryover did not affect the results.  
3.4 Results & Discussion  
3.4.1 Limit of Detection (LOD) and Lower Limit of Quantitation 
(LLOQ) 
The LOD and LLOQ for each drug is shown in Table 3-7. The LLOD for 25T2 and 
25T7-NBOMe in blood was deemed too high and thus would not be applicable to 
forensic casework. These drugs were therefore excluded from the blood 
validation. They were however still quantifiable in urine at 0.5 µg/L and so were 
included for urine validation.  
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Table 3-7: LOD and LOQ for urine and blood.  
Drug 
URINE (µg/L) BLOOD (µg/L) 
LOD LLOQ LOD LLOQ 
METHIOPROPAMINE 0.5 5 0.5 10 
Flephedrone 0.5 5 0.5 10 
Mephedrone 1.0 10 1.0 10 
5-APB 0.5 10 0.5 20 
6-APB 0.5 10 0.5 20 
Methylone 1.0 10 1.0 10 
3-MeO-PCE 0.5 5 0.5 5 
Butylone 0.5 5 0.5 5 
Ethylone 1.0 10 1.0 20 
Methoxetamine 0.5 5 0.5 5 
Benzedrone 0.5 5 0.5 5 
3-MeO-PCP 0.5 5 0.5 5 
2-DPMP 0.5 10 0.5 10 
MDPV 1.0 10 1.0 10 
Naphyrone 1.0 20 1.0 50 
25B-NBOMe 0.2 0.5 0.4 0.5 
25C-NBOMe 0.2 0.5 0.4 0.5 
25D-NBOMe 0.2 0.5 0.4 0.5 
25E-NBOMe 0.3 0.5 0.4 0.5 
25H-NBOMe 0.2 0.5 0.3 0.5 
25I-NBOMe 0.2 0.5 0.4 0.5 
Mescaline-NBOMe 0.3 0.5 0.3 0.5 
25P-NBOMe 0.2 0.5 0.4 0.5 
25T2-NBOMe 0.4 0.5 1.0 n/a 
25T7-NBOMe 0.4 0.5 1.0 n/a 
 
3.4.2 Linearity  
All analytes followed an unweighted linear calibration model with the exception 
of flephedrone and methiopropamine which were quadratic. Both blood and 
urine methods produced correlation coefficients (R2)> 0.99 for all analytes as 
shown in Figure 3-3 to Figure 3-14, with the exception of flephedrone and MXE in 
urine and 3-MeO-PCP in blood.  
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Urine Calibration Curves 
 
Figure 3-3: Example calibration curves for mephedrone, methylone, methiopropamine and 
flephedrone in blood. 
 
 
Figure 3-4: Example calibration curves for 3-MeO-PCE, 3-MeO-PCP and methoxetamine in 
urine. 
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Figure 3-5: Example calibration curves for MDPV, benzedrone, 2-DPMP and naphyrone-1 in 
urine.  
 
 
Figure 3-6: Example calibration curves for 5-APB, 6-APB, butylone and ethylone in urine.  
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Figure 3-7: Example calibration curves for 25B, 25C, 25D, 25E and 25H-NBOMe in urine. 
 
 
Figure 3-8: Example calibration curves for 25I, mescaline, 25P. 25T4 and 25T7-NBOMe in 
urine. 
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Blood Calibration Curves 
 
Figure 3-9: Example calibration curves for mephedrone, methylone, methiopropamine and 
flephedrone in blood. 
 
 
Figure 3-10: Example calibration curves for 3-MeO-PCE, 3-MeO-PCP and methoxetamine in 
blood. 
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Figure 3-11: Example calibration curves for MDPV, benzedrone, 2-DPMP and naphyrone in 
blood. 
 
 
Figure 3-12: Example calibration curves for 5-APB, 6-APB, butylone and ethylone in blood. 
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Figure 3-13: Example calibration curves for 25B, 25C, 25D, 25E and 25H-NBOMe in blood. 
 
 
Figure 3-14: Example calibration curves for 25I, Mescaline and 25P-NBOMe in blood. 
 
The calculated SIM ratios observed for each drug alongside their %CV are shown 
in Table 3-8. Ratios of the target ion to Q1, target ion to Q2 and Q1 to Q2 were 
monitored throughout the validation (n=6). Table 2-5 lists the target and 
qualifier ions assigned to each analyte. Average %CV values were within the 
acceptable range (<20%) for all analytes tested.  
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Table 3-8: TGT and Qualifier ion ratios for each analyte monitored (n=6).  
Drug 
TGT to 
Q1 
Ratio 
%CV 
TGT to 
Q2 
Ratio 
%CV 
Q1 to 
Q2 
Ratio 
%CV 
METHIOPROPAMINE 0.9 10.2 1.6 4.5 1.7 6.2 
FLEPHEDRONE 1.0 13.6 2.2 6.4 2.5 7.4 
MEPHEDRONE-D3 1.7 6.9 140.3 8.1 90.3 14.2 
MEPHEDRONE 1.4 13.4 122.0 18.8 89.2 7.6 
5-APB 2.1 4.7 8.9 7.4 4.3 6.5 
6-APB 2.0 3.3 9.9 6.3 4.9 3.2 
METHEDRONE 18.3 3.2 16.5 16.9 0.8 11.9 
METHYLONE-D3 1.3 5.9 6.2 1.7 4.2 2.1 
METHYLONE 0.09 6.8 0.08 0.4 0.9 7.1 
3-MeO-PCE 5.6 6.3 6.5 2.6 1.2 7.9 
BUTYLONE 5.5 79 8.5 4.1 1.6 12.4 
ETHYLONE-D5 0.2 15.2 22.8 14.0 101.4 18.1 
ETHYLONE 1.9 3.7 21.7 9.3 11.3 13.9 
MXE 3.8 2.9 3.5 1.2 0.9 3.0 
BENZEDRONE 1.8 4.1 6.7 8.2 3.6 4.5 
3-MeO-PCP 0.3 5.9 4.7 16.6 15.4 11.1 
2-DPMP 0.1 9.0 2.4 3.5 21.9 6.6 
MDPV-D8 13.1 15.5 10.7 0.7 0.8 19.9 
MDPV 10.4 11.5 11.0 1.7 1.1 13.2 
Naphyrone 5.8 11.9 48.5 14.0 8.4 13.8 
25H-NBOMe 1.0 12.6 9.0 10.1 9.2 15.3 
25D-NBOMe 1.9 17.9 7.1 11.8 4.0 18.9 
25E-NBOMe 6.7 10.9 1.8 11.2 0.2 9.7 
Mescaline-NBOMe 3.6 3.6 7.5 2.4 2.0 1.3 
25P-NBOMe 1.7 17.5 4.3 11.1 8.9 8.4 
25C-NBOMe 11.1 13.4 3.2 10.0 0.3 18.4 
25B-NBOMe 3.0 10.4 26.2 7.3 8.0 13.9 
25I-NBOMe-D3 6.4 4.5 310.4 9.8 48.5 7.1 
25I-NBOMe 12.4 6.9 16.5 3.8 1.3 3.0 
25T4-NBOMe 3.2 9.3 1.3 11.3 0.4 12.7 
25T7-NBOMe 2.7 15.9 9.0 10.5 3.4 5.6 
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3.4.3 Precision & Bias 
The results for precision and bias for urine and blood methods are shown in 
Table 3-9 and Table 3-10 respectively.  
3.4.3.1 Urine Results 
The intra-day precision %CV results of all analytes extracted from urine were 
below the ≤20% limit. The intra-day urine results averaged at 8.9, 11.2 and 
11.4% across all analytes for the low, medium, and high QCs respectively. Three 
of the analytes extracted from urine had intra-day precision values <5%, 3-MeO-
PCE, 3-MeO-PCP and MDPV. All analytes met the criteria of precision ≤20% for all 
QCs.  
All urine inter-day precision results fell within the SWGTOX <20% criteria. The 
inter-day results averaged at 11.9, 11.4 and 10.3% across all analytes for the 
low, medium and high QCs respectively. NBOMes had the poorest inter-day %CV 
results averaging at 13.8, 15.7, 13.4% across all QCs. This is unsurprising as these 
produced the smallest PARs and therefore nominal changes in values had a larger 
impact on %CV results. 25C-, 25D- and 25I-NBOMes performed particularly poorly 
and although all had inter-day precision results <20% they were all >15%. 5-APB, 
benzedrone, MDPV, and naphyrone all performed well with inter-day QC results 
all <10%.   
The accuracy of each analyte in urine fell within the ±20% criteria although 
several QCs were at the bottom and top of this range. Methiopropamine and 25I-
NBOMe were the only urine analytes to have an accuracy within ±10%. A further 
5 analytes had an accuracy within ±15% of the expected value for all QCs 
(mephedrone, methoxetamine, benzedrone, 2-DPMP, 25E-NBOMe, and 25P-
NBOMe).  
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Table 3-9: Accuracy and precision data for urine QCs. 
 Intra day Precision (%CV) (n=18) Inter-day Precision (%CV) (n=18) Accuracy (%) (n=18) 
Drug QC 1 QC 2 QC 3 QC 1 QC 2 QC 3 QC 1 QC 2 QC 3 
METHIOPROPAMINE 7.6 8.5 12.4 14.8 8.6 11.9 109.8 106.8 101.8 
FLEPHEDRONE 10.6 6.2 12.4 11.5 9.5 17.5 102.3 118.9 115.4 
MEPHEDRONE 15.4 6.8 7.9 11.6 11.3 18.6 112.3 93.7 93.2 
5-APB 19.9 18.4 11.5 9.6 4.9 9.8 84.5 113.2 111.2 
6-APB 2.3 12.8 10.3 15.3 3.4 7.8 121.4 118.4 118.5 
METHYLONE 11.9 13.2 12.7 12.9 10.5 13.1 82.0 95.5 94.8 
3-MEO-PCE 0.2 3.3 2.0 8.0 13.1 1.6 99.8 119.0 105.6 
BUTYLONE 4.7 17.9 8.8 11.4 7.6 6.6 107.7 118.6 112.4 
ETHYLONE 11.1 9.7 11.8 14.1 8.8 2.1 119.0 115.5 109.7 
MXE 9.0 19.1 6.9 16.4 4.9 3.0 85.7 113.1 103.3 
BENZEDRONE 10.9 11.4 7.1 6.6 8.0 4.2 99.8 113.4 109.6 
3-MEO-PCP 1.6 3.9 3.1 9.3 9.1 11.7 93.9 120.0 114.5 
2-DPMP 7.7 16.0 16.1 6.6 11.4 1.7 108.0 113.5 114.1 
MDPV 2.8 4.5 3.3 7.6 9.6 8.1 100.2 120.0 109.6 
NAPHYRONE 14.9 15.7 7.9 3.6 7.2 7.1 96.1 119.0 114.5 
25B-NBOMe 14.2 6.9 12.3 11.3 7.9 12.3 85.2 105.6 115.7 
25C-NBOMe 8.8 18.2 19.5 17.9 16.3 16.7 80.8 111.8 93.9 
25D-NBOMe 10.4 16.3 16.4 17.8 18.7 19.7 87.5 119.3 86.2 
25E-NBOMe 10.8 7.5 13.2 8.3 16.9 9.7 99.9 98.9 86.5 
25H-NBOMe 8.9 15.8 18.7 17.5 19.8 14.7 83.5 92.5 84.8 
25I-NBOMe 13.8 1.5 14.6 15.9 16.6 15.8 92.8 95.4 109.3 
Mescaline-NBOMe 4.6 10.5 14.4 8.7 12.1 11.6 85.6 83.5 85.6 
25P-NBOMe 10.4 18.8 16.8 10.8 17.8 11.5 114.0 96.8 97.4 
25T4-NBOMe 4.1 13.5 15.1 19.5 19.3 6.4 88.9 92.1 80.0 
25T7-NBOMe 6.5 3.8 10.4 10.7 11.2 15.3 88.8 89.0 80.0 
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3.4.3.2 Blood Results 
The intra-day precision results of all analytes extracted from blood gave 
%CVs<20%. The intra-day blood precision results averaged at 10.7, 7.2 and 10.0% 
across all analytes for the low, medium and high QCs respectively. For blood 
only 3-MeO-PCE had intra-day precision <5%.  
All blood inter-day precision results fell within the SWGTOX <20% criteria 
averaging at 11.5, 8.5 and 8.0% across all analytes for the low, medium and high 
QCs respectively. Similar to the urine results NBOMes had the poorest inter-day 
%CV results averaging at 11.8, 12.1 and 12.4% across all QCs. Benzedrone had 
the best inter-day variation (0.7-2.9%) whereas 25P-NBOMe gave the highest 
%CVs with all 3 QCs >15%.  
The accuracy of each analyte in blood fell within the ±20% criteria with the 
exception of 25B-NBOMe (QC 2) and mescaline-NBOMe (QC 1). Since this method 
was validated additional deuterated NBOMe I.S. have become available which 
may produce better results. The average accuracy for the analytes across all QCs 
was 97.8% ranging from 80.5% -117.1%. Mephedrone was the most accurate 
compound with an accuracy ranging from 94.9% to 104.6%. Only 5 of the 
compounds had an average accuracy <±10%.  
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Table 3-10: Accuracy and precision data for blood QC’s. 
Blood Intra-day Precision (%CV) (n=18) Inter-day Precision (%CV) (n=18) Accuracy (%) (n=18) 
Drug QC 1 QC 2 QC 3 QC 1 QC 2 QC 3 QC 1 QC 2 QC 3 
METHIOPROPAMINE 17.2 12.2 10.6 17.7 10.9 5.3 87.8 113.7 119.0 
FLEPHEDRONE 7.8 13.2 10.8 15.6 12.5 6.5 88.1 102.7 106.6 
MEPHEDRONE 12.9 1.9 6.8 10.5 10.5 9.5 94.9 100.5 104.6 
5-APB 14.8 6.1 14.1 14.8 6.1 3.4 110.3 93.2 83.0 
6-APB 11.9 8.9 5.3 13.1 1.2 7.4 101.0 89.4 102.4 
METHYLONE 9.6 1.4 6.7 8.8 12.9 13.5 92.3 112.9 119.3 
3-MeO-PCE 3.7 1.8 0.5 5.7 4.9 1.6 116.9 119.1 115.3 
BUTYLONE 8.5 12.9 2.9 14.7 2.2 6.6 83.7 93.2 82.4 
ETHYLONE 8.3 6.4 13.7 14.1 0.2 0.3 84.4 95.1 97.8 
MXE 10.6 10.7 7.2 13.1 11.3 9.9 102.5 90.1 83.9 
BENZEDRONE 7.9 9.4 11.3 1.5 2.9 0.7 99.6 82.4 93.7 
3-MeO-PCP 8.2 2.2 10.6 5.6 8.3 3.6 114.3 84.9 87.6 
2-DPMP 11.7 15.1 11.1 15.0 5.2 11.8 84.0 80.5 91.9 
MDPV 4.1 12.4 14.4 3.4 5.6 2.1 106.1 84.5 91.8 
NAPHYRONE 15.8 10.2 14.6 6.2 3.6 3.1 117.8 115.5 85.5 
25B-NBOMe 19.8 4.6 9.9 16.5 14.1 10.2 85.1 75.6 80.8 
25C-NBOMe 15.5 4.8 13.7 14.7 13.6 12.0 102.2 108.0 92.2 
25D-NBOMe 5.8 2.0 8.4 11.5 9.2 12.4 98.5 97.7 92.6 
25E-NBOMe 12.8 2.7 10.5 14.9 13.4 19.5 93.6 107.2 107.3 
25H-NBOMe 8.7 1.5 8.6 15.7 6.0 15.4 116.9 112.5 102.9 
25I-NBOMe 3.4 3.2 10.3 4.2 7.7 8.3 110.1 90.0 81.1 
Mescaline-NBOMe 13.8 1.8 13.5 11.6 15.4 2.7 77.2 113.9 99.9 
25P-NBOMe 14.5 18.4 14.6 15.1 17.2 18.4 81.2 104.6 110.1 
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3.4.4 Carryover 
No carryover was seen using the method at the concentrations tested as shown 
in Figure 3-15 and Figure 3-16. Due to the low dose levels of NBOMe compounds, 
doses higher than those tested would not occur in “real life” cases. To date the 
highest NBOMe concentration detected is 7.5 ng/mL, which is well below the 
concentrations tested in this carryover study.(126)  
Synthetic cathinones on the other hand have the potential to be seen in higher 
concentrations than those tested and therefore carryover may be possible with 
these compounds.  
 
Figure 3-15: Example carryover chromatogram.  
Top chromatogram corresponds to NPS analytes and chromatogram below shows the 
subsequent EtOAc blank. 
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6 .0 0 8 .0 0 1 0 .0 0 1 2 .0 0 1 4 .0 0 1 6 .0 0 1 8 .0 0 2 0 .0 0 2 2 .0 0 2 4 .0 0 2 6 .0 0 2 8 .0 0
2 0 0 0 0 0
4 0 0 0 0 0
6 0 0 0 0 0
T im e - ->
A b u n d a n c e
T IC : 0 8 0 5 1 4 L N _ 1 5 .D \ d a ta .m s
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Figure 3-16: Example carryover chromatogram.  
Top chromatogram corresponds to NBOMe analytes and chromatogram below shows the 
subsequent EtOAc blank. 
 
3.4.5 Selectivity  
No interferences were observed for any of the analytes tested (Figure 3-17). 
Although peaks were observed using the method these were at differing 
retention times with different mass spectra and so would not affect the 
identification and quantification of the 28 NPSs being analysed. No matrix 
interferences were observed. The I.S. were successfully separated using both 
retention time and selected ions and thus would have no impact on the peak 
areas of their non-deuterated counterparts and vice versa.  
6 .0 0 8 .0 0 1 0 .0 0 1 2 .0 0 1 4 .0 0 1 6 .0 0 1 8 .0 0 2 0 .0 0 2 2 .0 0 2 4 .0 0 2 6 .0 0 2 8 .0 0
2 0 0 0 0 0 0
4 0 0 0 0 0 0
6 0 0 0 0 0 0
8 0 0 0 0 0 0
   1 e + 0 7
T im e -->
A b u n d a n c e
T IC : 0 4 1 0 L N _ 1 1 .D \ d a ta .m s
6 .0 0 8 .0 0 1 0 .0 0 1 2 .0 0 1 4 .0 0 1 6 .0 0 1 8 .0 0 2 0 .0 0 2 2 .0 0 2 4 .0 0 2 6 .0 0 2 8 .0 0
1 0 0 0 0 0
2 0 0 0 0 0
3 0 0 0 0 0
4 0 0 0 0 0
5 0 0 0 0 0
6 0 0 0 0 0
7 0 0 0 0 0
8 0 0 0 0 0
T im e -->
A b u n d a n c e
T IC : 0 4 1 0 L N _ 1 2 .D \ d a ta .m s
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Figure 3-17: Selectivity chromatograms.  
Chromatograms (a-f) correspond to the analytes listed in Table 3-5. Chromatogram (g) shows 
the chromatogram produced from a level 1 urine calibrator. Peaks present in chromatograms 
(a-f) do not related to any shown in (g) thus there was no observed cross over between 
method analytes and the analytes tested for during specificity testing. 
 
3.4.6 Stability  
3.4.6.1 Autosampler Urine and Blood Stability  
Autosampler urine results for each of the 3 QCs are shown in Table 3-11 through 
Table 3-16. All analytes tested had % recoveries within the acceptable criteria of 
±20% with the exception of 3-MeO-PCE, 25B-NBOMe, 25P-NBOMe, 25T4-NBOMe 
and 25T7-NBOMe. The lack of deuterated I.S’s may have affected these results 
as the PAR for these compounds was extremely low especially for QC1. As a 
result of this any small differences observed in the PARs highly impacted on the 
% recovery of these compounds. No analyte fell out with ±20% for all 3 QC’s in 
either matrix. This study does not also take into account the stability of the I.S’s 
themselves, which could also have impacted the results observed.  
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Table 3-11: Urine QC1 autosampler stability  
Analyte 
PAR (n=3) 
Recovery % 
T=0 T=24 T=48 
METHIOPROPAMINE 0.05 0.06 0.05 100.0 
FLEPHEDRONE 0.14 0.15 0.13 92.8 
MEPHEDRONE 0.12 0.10 0.11 86.7 
5-APB 0.30 0.25 0.31 103.3 
6-APB 0.49 0.44 0.47 95.9 
METHYLONE 0.15 0.13 0.13 86.7 
3-MEO-PCE 0.04 0.04 0.03 75.0 
BUTYLONE 0.41 0.35 0.38 92.7 
ETHYLONE 0.13 0.13 0.12 92.3 
MXE 0.12 0.13 0.12 100.0 
BENZEDRONE 0.11 0.10 0.12 109.1 
3-MEO-PCP 0.04 0.05 0.04 100.0 
2-DPMP 0.14 0.15 0.13 92.9 
MDPV 0.13 0.10 0.11 84.6 
NAPHYRONE 0.08 0.08 0.07 87.5 
25B-NBOMe 0.04 0.02 0.03 75.0 
25C-NBOMe 0.08 0.05 0.07 87.5 
25D-NBOMe 0.12 0.07 0.11 91.7 
25E-NBOMe 0.10 0.08 0.09 90.0 
25H-NBOMe 0.13 0.07 0.14 107.7 
25I-NBOMe 0.19 0.21 0.17 89.5 
Mescaline-NBOMe 0.08 0.06 0.08 100.0 
25P-NBOMe 0.05 0.03 0.04 80.0 
25T4-NBOMe 0.01 0.01 0.01 100.0 
25T7-NBOMe 0.01 0.02 0.01 100.0 
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Table 3-12: Urine QC2 autosampler stability. 
Analyte 
PAR (n=3) 
Recovery % 
T=0 T=24 T=48 
METHIOPROPAMINE 0.24 0.21 0.27 112.5 
FLEPHEDRONE 0.79 0.92 0.76 96.2 
MEPHEDRONE 0.58 0.48 0.59 101.7 
5-APB 1.80 1.50 1.50 83.3 
6-APB 2.50 2.30 2.30 92.0 
METHYLONE 1.78 1.65 1.72 96.6 
3-MEO-PCE 1.77 1.83 1.74 98.3 
BUTYLONE 2.30 2.10 2.00 87.0 
ETHYLONE 0.60 0.70 0.60 100.0 
MXE 0.93 0.99 0.96 103.2 
BENZEDRONE 1.10 1.01 1.02 92.7 
3-MEO-PCP 0.26 0.29 0.27 103.9 
2-DPMP 0.66 0.57 0.58 87.9 
MDPV 0.65 0.49 0.57 87.7 
NAPHYRONE 0.80 0.74 0.88 110.0 
25B-NBOMe 0.15 0.11 0.13 86.7 
25C-NBOMe 0.37 0.23 0.33 89.2 
25D-NBOMe 0.39 0.29 0.35 89.7 
25E-NBOMe 0.34 0.21 0.29 85.3 
25H-NBOMe 0.47 0.39 0.41 87.2 
25I-NBOMe 1.01 0.93 1.05 104.0 
Mescaline-NBOMe 0.30 0.29 0.33 110.0 
25P-NBOMe 0.27 0.17 0.22 81.5 
25T4-NBOMe 0.03 0.04 0.04 133.3 
25T7-NBOMe 0.04 0.04 0.03 75.0 
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Table 3-13: Urine QC3 autosampler stability  
Analyte 
PAR (n=3) 
Recovery % 
T=0 T=24 T=48 
METHIOPROPAMINE 0.50 0.54 0.47 94.0 
FLEPHEDRONE 1.87 1.78 1.70 90.9 
MEPHEDRONE 3.26 3.59 3.47 106.4 
5-APB 6.27 5.90 5.70 90.9 
6-APB 7.70 7.20 8.10 105.2 
METHYLONE 2.59 2.69 2.64 98.1 
3-MEO-PCE 5.58 5.10 5.10 91.4 
BUTYLONE 8.62 7.10 7.80 90.5 
ETHYLONE 2.48 2.00 2.00 80.7 
MXE 3.26 3.00 3.10 95.1 
BENZEDRONE 3.56 3.47 3.59 100.8 
3-MEO-PCP 0.80 0.88 0.76 95.0 
2-DPMP 2.99 2.91 3.16 105.7 
MDPV 3.12 2.64 3.05 97.8 
NAPHYRONE 2.95 2.54 2.61 88.5 
25B-NBOMe 1.17 1.10 1.05 89.7 
25C-NBOMe 1.37 1.69 1.16 84.7 
25D-NBOMe 1.15 1.20 0.94 81.7 
25E-NBOMe 1.21 1.20 1.01 83.5 
25H-NBOMe 1.43 1.70 1.46 102.1 
25I-NBOMe 1.19 1.03 1.09 91.6 
Mescaline-NBOMe 0.98 1.23 0.83 84.7 
25P-NBOMe 1.17 1.31 1.07 91.4 
25T4-NBOMe 0.46 0.44 0.40 87.0 
25T7-NBOMe 0.45 0.36 0.33 73.3 
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Table 3-14: Blood QC1 autosampler stability 
Analyte 
Par (n=3) 
Recovery % 
T=0 T=24 T=48 
METHIOPROPAMINE 0.05 0.07 0.06 120.0 
FLEPHEDRONE 0.11 0.09 0.12 109.1 
MEPHEDRONE 0.14 0.13 0.15 107.1 
5-APB 0.27 0.25 0.27 100.0 
6-APB 0.56 0.50 0.54 96.4 
METHYLONE 0.11 0.14 0.13 118.2 
3-MEO-PCE 0.04 0.04 0.04 100 
BUTYLONE 0.51 0.46 0.49 96.0 
ETHYLONE 0.14 0.14 0.14 100.0 
MXE 0.16 0.14 0.15 93.4 
BENZEDRONE 0.11 0.10 0.10 90.9 
3-MEO-PCP 0.05 0.05 0.05 100.0 
2-DPMP 0.13 0.13 0.14 107.7 
MDPV 0.12 0.14 0.13 108.3 
NAPHYRONE 0.08 0.07 0.07 87.5 
25B-NBOMe 0.04 0.05 0.05 125.0 
25C-NBOMe 0.08 0.06 0.07 87.5 
25D-NBOMe 0.12 0.13 0.10 83.3 
25E-NBOMe 0.10 0.12 0.11 110.0 
25H-NBOMe 0.13 0.17 0.12 92.3 
25I-NBOMe 0.19 0.23 0.21 110.5 
Mescaline-NBOMe 0.08 0.10 0.09 112.5 
25P-NBOMe 0.05 0.06 0.05 100.0 
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Table 3-15: Blood QC2 autosampler stability 
Analyte 
PAR (n=3) 
Recovery % 
T=0 T=24 T=48 
METHIOPROPAMINE 0.25 0.19 0.23 92.0 
FLEPHEDRONE 0.74 0.69 0.60 81.1 
MEPHEDRONE 0.64 0.58 0.57 89.1 
5-APB 1.58 1.43 1.52 96.2 
6-APB 2.57 2.32 2.45 95.3 
METHYLONE 1.81 1.88 1.78 98.3 
3-MEO-PCE 1.84 2.17 2.15 116.8 
BUTYLONE 2.57 2.32 2.50 97.3 
ETHYLONE 0.72 0.79 0.76 105.6 
MXE 1.42 1.52 1.55 109.2 
BENZEDRONE 2.76 2.45 2.50 90.6 
3-MEO-PCP 0.26 0.26 0.24 92.3 
2-DPMP 0.75 0.69 0.63 84.0 
MDPV 0.71 0.59 0.60 84.5 
NAPHYRONE 0.85 0.98 0.92 108.2 
25B-NBOMe 0.15 0.20 0.18 120.0 
25C-NBOMe 0.37 0.45 0.42 113.5 
25D-NBOMe 0.39 0.32 0.35 89.7 
25E-NBOMe 0.34 0.25 0.32 94.1 
25H-NBOMe 0.47 0.39 0.45 95.7 
25I-NBOMe 0.90 0.99 0.87 96.7 
Mescaline-NBOMe 0.30 0.32 0.28 93.3 
25P-NBOMe 0.27 0.36 0.30 111.1 
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Table 3-16: Blood QC3 autosampler stability 
Analyte 
PAR (n=3) 
Recovery % 
T=0 T=24 T=48 
METHIOPROPAMINE 0.63 0.67 0.53 84.1 
FLEPHEDRONE 1.65 1.90 1.93 115.8 
MEPHEDRONE 2.87 3.07 2.89 100.7 
5-APB 5.54 5.32 5.09 91.9 
6-APB 6.59 6.36 6.80 103.2 
METHYLONE 2.52 2.48 2.55 101.2 
3-MEO-PCE 4.02 4.18 4.05 100.7 
BUTYLONE 7.49 6.89 7.20 96.1 
ETHYLONE 2.88 2.22 2.48 86.1 
MXE 3.46 2.60 2.87 82.9 
BENZEDRONE 2.98 2.99 2.72 91.3 
3-MEO-PCP 0.82 0.72 0.68 82.9 
2-DPMP 3.05 2.78 2.71 88.9 
MDPV 2.47 3.14 2.55 88.9 
NAPHYRONE 3.09 3.05 3.07 99.4 
25B-NBOMe 1.17 1.26 1.37 117.1 
25C-NBOMe 1.37 1.35 1.27 92.7 
25D-NBOMe 1.15 1.08 1.11 96.5 
25E-NBOMe 1.21 1.32 1.45 119.8 
25H-NBOMe 1.43 1.34 1.40 97.9 
25I-NBOMe 1.19 1.26 1.23 103.4 
Mescaline-NBOMe 0.98 1.12 0.86 87.8 
25P-NBOMe 1.17 1.05 0.93 79.5 
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Blood samples showed slightly better autosampler stability averaging at 98.8% 
across all 3 QCs (ranging 79.5%-120.0%). Urine averaged at 93.6% across all QCs 
(ranging 75.0-133.3%).  
This is slightly misleading however, as it does not take into account the accuracy 
of each QC, and as blood has a higher number of % recovery rates greater than 
100% this inflates this value. This is illustrated by Figure 3-18 and Figure 3-19. 
From this we can see that more of the urine QC’s fell out with the ±20% cut-off 
point, 10%, in comparison to blood which only saw 1 QC (4%) fall out with this 
limit. However, 50% of the blood QC’s % recovery results fell within ±20% 
whereas only 40% of the urine QC’s did. This is further illustrated by the number 
of QC’s which had recovery results ranging ±5%, accounting for 30% of urine 
results versus only 25% of blood results.  
 
Figure 3-18: Accuracy of all urine QCs. 
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Figure 3-19: Pie chart showing the accuracy of all blood QCs. 
 
These results indicate that autosampler stability is not an issue with these 
compounds up to 48 hrs. As the reconstitution volume for these samples is so 
small (50 µl) it is much more likely that the sample will have evaporated before 
this point in time should re-injection be required. These results correlate with 
previously published validations which showed no significant degradation to 
samples up to 72 hrs stored on the autosampler. (201, 202) 
The peak area % recovery for each analyte QC in both blood and urine is shown 
in Table 3-17, full results can be found in Appendix 8. From Table 3-17 it is clear 
that degradation was seen for all compounds over the 48 hour period. Overall 
mephedrone-D3 was the most affected analyte in urine with an average loss of 
31% across all 3 QCs. Ethylone-D5 was the most affected analyte in blood with an 
average loss of 34% across all 3 QCs. This was in contrast to methylone-D3 which 
showed the least degradation in urine over the 48 hour period (-9%), and 25B-
NBOMe which showed the least degradation in blood (8%). 
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Table 3-17:Autosampler P.A. recovery for each drug and I.S. in each matrix.  
 
% Recovery 
Urine Blood 
QC1 QC2 QC3 QC1 QC2 QC3 
METHIOPROPAMINE -18.4 -5.3 -22.7 -1.0 -24.0 -34.8 
FLEPHEDRONE -24.3 -19.0 -25.2 -10.0 -33.1 -9.3 
MEPHEDRONE -25.2 -14.3 -12.4 -11.6 -26.5 -21.9 
5-APB -3.4 -25.0 -18.6 -10.3 -21.6 -25.1 
6-APB -10.3 -17.2 -5.8 -13.5 -22.3 -15.9 
METHYLONE -30.4 -15.4 -11.0 -21.8 -34.2 -35.3 
3-MeO-PCE -29.9 -11.6 -18.1 -10.3 -4.8 -17.9 
BUTYLONE -13.3 -21.8 -18.9 -13.9 -20.7 -21.7 
ETHYLONE -13.7 -10.0 -27.8 -10.3 -14.0 -29.8 
MXE -6.5 -7.1 -14.8 -15.9 -11.1 -32.4 
BENZEDRONE -7.7 -23.7 -16.4 -20.2 -21.8 -17.2 
3-MeO-PCP -6.5 -6.6 -14.9 -10.3 -24.8 -32.4 
2-DPMP -21.4 -27.7 -12.4 -5.5 -27.5 -19.4 
MDPV -28.4 -27.9 -19.0 -4.9 -27.1 -6.4 
NAPHYRONE -26.0 -9.5 -26.7 -23.2 -6.6 -9.9 
25B-NBOMe -36.5 -28.3 -26.5 -4.4 -10.0 -8.9 
25C-NBOMe -25.9 -26.2 -30.7 -33.1 -14.8 -27.9 
25D-NBOMe -22.4 -25.7 -33.1 -36.3 -32.7 -24.9 
25E-NBOMe -23.8 -29.4 -31.6 -15.9 -29.4 -6.8 
25H-NBOMe -8.8 -27.8 -16.4 -29.4 -28.2 -23.9 
25I-NBOMe -24.2 -14.0 -25.0 -15.5 -27.5 -19.6 
Mescaline-NBOMe -15.3 -9.0 -30.6 -14.0 -30.0 -31.8 
25P-NBOMe -32.3 -32.6 -25.1 -23.5 -16.6 -38.2 
25T4-NBOMe -15.3 10.3 -28.8 -17.5 -17.4 -22.5 
Mephedrone-D3 -15.3 -37.9 -39.9 -10.3 -18.5 -18.5 
Ethylone-D5 -18.4 -15.8 -18.1 -33.8 -33.0 -36.1 
Methylone-D3 -6.5 -10.0 -10.4 -12.2 -13.7 -9.3 
MDPV-D8 -19.7 -12.4 -12.7 -23.5 -25.0 -22.2 
NBOMe-D3 -15.4 -17.8 -17.1 -1.0 -24.0 -34.8 
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3.4.6.2 Fridge and Freezer Stability 
The fridge and freezer stability results were collected over a 7-day period. The 
results of these samples will differ from that of the autosampler stability to 
some degree at their will be more matrix present which may hence this process.  
The results for blood and urine QCs after 2 cool/warm and freeze/thaw cycles 
are shown in Table 3-18 to Table 3-21. These results show that analytes stored in 
the fridge underwent the largest degradation for both matrices. This is 
unsurprising as freezer storage has been shown to be more effective in reducing 
sample degradation. (203)  
A total of 8 analytes fell out with the acceptable criteria (±20%) after 2 
cool/warm fridge cycles for both QCs in urine: mephedrone, methylone, MXE, 2-
DPMP, 25E-NBOMe, 25I-NBOMe 25T2-NBOMe and 25T4-NBOMe. Only 25P-NBOMe 
fell out with the ±20% recovery required after 2 freeze/thaw cycles for both 
QC’s in urine.  
Only 5 analytes fell out with the acceptable criteria (±20%) after 2 cool/warm 
fridge cycles for both QCs in blood: mephedrone, 25C-NBOMe, 25I-NBOMe, 
mescaline-NBOMe and 25P-NBOMe. No analytes fell out with this range for both 
QCs tested after 2 freeze/thaw cycles in blood.  
Mephedrone and methylone were the least stable analytes after 2 cool/warm 
cycles with average recoveries of only 61.3% and 64.5% respectively. Previous 
studies looking at the stability of methylone have been inconclusive with prior 
work showing little to no degradation to samples after 72 h.(201, 204) The 
majority of these studies utilized some sort of preservative for the storage of 
their samples which was not the case here. This is important when comparing 
any of the results here to other previously published work as the use of 
preservatives may significantly reduce the degradation of these substances. The 
blood used in this work was diluted with saline solution and this may too have 
impacted on the results seen.  
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Table 3-18: Freeze thaw cycles on analyte stability in urine  
Urine Fridge Cool/Warm Cycle PAR (n=3) Freezer Thaw PAR (n=3) 
Drug 0 1 2 Recovery % 0 1 2 Recovery % 
METHIOPROPAMINE 0.24 0.21 0.16 66.7 0.24 0.26 0.20 83.3 
FLEPHEDRONE 0.79 0.60 0.69 87.3 0.79 0.75 0.76 96.2 
MEPHEDRONE 0.58 0.49 0.33 56.9  0.58 0.43 0.65  112.1 
5-APB 1.80 1.67 1.38 76.7 1.80 1.92 1.75 97.2 
6-APB 2.50 2.23 2.42 96.8 2.50 2.87 2.69 107.6 
METHYLONE 1.78 1.52 1.12 62.9 1.78 1.88 1.52 85.4  
3-MEO-PCE 1.77 2.22 1.55 87.6 1.77 2.46 2.05 115.8 
BUTYLONE 2.30 2.96 2.09 90.9 2.30 2.96 2.56 111.3 
ETHYLONE 0.60 0.90 0.57 95.0 0.60 0.68 0.73 121.7 
MXE 0.93 0.82 0.66 71.0 0.93 0.90 0.87 93.5 
BENZEDRONE 1.10 1.06 1.12 101.8 1.10 1.00 1.23 111.8 
3-MEO-PCP 0.26 0.29 0.27 103.8 0.26 0.31 0.32 123.1 
2-DPMP 0.66 0.31 0.30 45.5 0.66 0.76 0.78 118.2 
MDPV 0.65 0.68 0.66 98.5 0.65 0.75 0.62 95.4 
NAPHYRONE 0.80 0.88 0.76 95.0 0.80 1.10 0.94 117.5 
25B-NBOMe 0.15 0.12 0.18 120.0 0.15 0.15 0.16 106.7 
25C-NBOMe 0.37 0.32 0.38 102.7 0.37 0.30 0.35 94.6 
25D-NBOMe 0.39 0.38 0.34 87.2 0.39 0.34 0.37 94.9 
25E-NBOMe 0.34 0.33 0.27 79.4 0.34 0.27 0.29 85.3 
25H-NBOMe 0.47 0.44 0.38 80.9 0.47 0.38 0.41 87.2 
25I-NBOMe 1.01 0.87 0.70 69.3 1.01 0.96 0.92 91.1 
Mescaline-NBOMe 0.30 0.32 0.29 96.7 0.30 0.32 0.33 110.0 
25P-NBOMe 0.27 0.20 0.25 92.6 0.27 0.24 0.21 77.8 
25T4-NBOMe 0.03 0.03 0.02 66.7 0.03 0.04 0.04 133.3 
25T7-NBOMe 0.04 0.05 0.03 75.0 0.04 0.06 0.04 100.0 
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Table 3-19: Effects of fridge cool/warm and freeze thaw cycles on analyte stability in urine (QC3) 
Urine Fridge Cool/Warm Cycle PAR (n=3) Freezer Thaw PAR (n=3) 
Drug 0 1 2 Recovery % 0 1 2 Recovery % 
METHIOPROPAMINE 0.50 0.49 0.41 82.0 0.50 0.47 0.43 86.0 
FLEPHEDRONE 1.87 1.43 1.23 65.8 1.87 1.68 1.75 93.6 
MEPHEDRONE 3.26 2.59 2.37  72.7 3.26 3.67 3.33 102.1  
5-APB 6.27 5.00 5.30 84.5 6.27 6.31 6.09 97.1 
6-APB 7.70 7.23 6.51 84.6 7.70 8.22 8.04 104.4 
METHYLONE 2.59 1.95 1.46 56.4 2.59 2.34 2.60  100.4  
3-MEO-PCE 5.58 4.20 4.67 83.7 5.58 6.43 6.22 111.5 
BUTYLONE 8.62 8.58 8.31 96.4 8.62 9.62 9.70 112.5 
ETHYLONE 2.48 2.16 2.15 86.7 2.48 2.34 2.86 115.3 
MXE 3.26 2.92 2.56 78.5 3.26 3.15 2.91 89.3 
BENZEDRONE 3.56 3.45 3.10 87.1 3.56 3.30 3.40 95.5 
3-MEO-PCP 0.80 0.53 0.82 102.5 0.80 0.87 0.88 110.0 
2-DPMP 2.99 2.12 2.19 73.2 2.99 3.10 2.50 83.6 
MDPV 3.12 3.57 3.28 105.1 3.12 3.06 3.42 109.6 
NAPHYRONE 2.95 2.74 2.54 86.1 2.95 3.10 2.89 98.0 
25B-NBOMe 1.17 1.13 1.08 92.3 1.17 1.15 1.16 99.1 
25C-NBOMe 1.37 1.19 0.98 71.5 1.37 1.21 1.41 102.9 
25D-NBOMe 1.15 1.01 1.07 93.0 1.15 1.21 1.19 103.5 
25E-NBOMe 1.21 1.35 1.15 71.4 1.21 1.15 1.09 90.1 
25H-NBOMe 1.43 1.10 1.22 85.3 1.43 1.42 1.35 94.4 
25I-NBOMe 1.19 0.96 0.94 79.0 1.19 1.02 0.88 73.9 
Mescaline-NBOMe 0.98 0.68 0.63 64.3 0.98 111.00 0.91 92.9 
25P-NBOMe 1.17 1.15 0.85 72.6 1.17 1.20 0.93 79.5 
25T4-NBOMe 0.46 0.36 0.27 58.7 0.46 0.39 0.41 89.1 
25T7-NBOMe 0.45 0.40 0.25 55.6 0.45 0.37 0.44 97.8 
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Table 3-20: Effects of fridge cool/warm and freeze thaw cycles on analyte stability in blood (QC2) 
Blood Fridge Cool/Warm Cycle PAR (n=3) Freezer Thaw PAR (n=3) 
Drug 0 1 2 Recovery % 0 1 2 Recovery % 
METHIOPROPAMINE 0.25 0.33 0.26 104.0 0.25 0.19 0.27 108.0 
FLEPHEDRONE 0.74 0.76 0.65 87.8 0.74 0.88 0.79 106.8 
MEPHEDRONE 0.64 0.49 0.33 51.6 0.64 0.71 0.65 101.6 
5-APB 1.58 1.65 1.52 96.2 1.58 2.9 2.5 108.6 
6-APB 2.57 2.17 2.55 99.2 2.57 3.09 2.7 105.1 
METHYLONE 1.81 1.22 0.89 49.2 1.81 1.68 1.78 98.3 
3-MEO-PCE 1.84 1.63 1.77 96.2 1.84 2.36 2.24 121.7 
BUTYLONE 2.57 2.38 2.02 78.6 2.57 2.87 2.8 108.9 
ETHYLONE 0.72 0.99 0.86 119.4 0.72 0.74 0.87 120.8 
MXE 1.42 1.41 1.32 93.0 1.42 1.66 1.6 112.7 
BENZEDRONE 2.76 2.62 2.33 84.4 2.76 2.23 2.39 86.6 
3-MEO-PCP 0.26 0.21 0.15 57.7 0.26 0.29 0.23 88.5 
2-DPMP 0.75 0.7 0.65 86.7 0.75 0.92 0.88 117.3 
MDPV 0.71 0.63 0.6 84.5 0.71 0.77 0.69 97.2 
NAPHYRONE 0.85 0.59 0.62 72.9 0.85 0.78 0.76 89.4 
25B-NBOMe 0.15 0.14 0.14 93.3 0.15 0.19 0.11 73.3 
25C-NBOMe 0.37 0.4 0.28 75.7 0.37 0.32 0.34 91.9 
25D-NBOMe 0.39 0.32 0.33 84.6 0.39 0.35 0.47 120.5 
25E-NBOMe 0.34 0.37 0.27 79.4 0.34 0.26 0.28 82.4 
25H-NBOMe 0.47 0.34 0.4 85.1 0.47 0.51 0.41 87.2 
25I-NBOMe 0.9 0.88 0.64 71.1 0.9 0.87 0.92 102.2 
Mescaline-NBOMe 0.3 0.29 0.21 70.0 0.3 0.26 0.33 110.0 
25P-NBOMe 0.27 0.31 0.23 85.2 0.27 0.22 0.27 100.0 
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Table 3-21: Effects of fridge cool/warm and freeze thaw cycles on analyte stability in blood (QC3) 
Blood Fridge Cool/Warm Cycle PAR (n=3) Freezer Thaw PAR (n=3) 
Drug 0 1 2 Recovery % 0 1 2 Recovery % 
METHIOPROPAMINE 0.63 0.56 0.57 90.5 0.63 0.58 0.53 84.1 
FLEPHEDRONE 1.65 1.55 1.43 86.7 1.65 1.51 1.78 107.9 
MEPHEDRONE 2.87 2.74 1.83 63.8 2.87 2.65 2.77 96.5 
5-APB 5.54 5.6 4.32 78.0 5.54 5.55 5.39 97.3 
6-APB 6.59 5.79 6.98 105.9 6.59 6.72 6.09 92.4 
METHYLONE 2.52 2.84 2.25 89.3 2.52 2.68 2.21 87.7 
3-MEO-PCE 4.02 5.3 4.32 107.5 4.02 4.22 3.92 97.5 
BUTYLONE 7.49 7.24 6.81 90.9 7.49 6.49 7.11 94.9 
ETHYLONE 2.88 2.23 2.79 96.9 2.88 1.85 3.09 107.3 
MXE 3.46 2.39 2.55 73.7 3.46 3.30 3.00 86.7 
BENZEDRONE 2.98 2.12 2.32 77.9 2.98 2.39 2.81 94.3 
3-MEO-PCP 0.82 0.78 0.8 97.6 0.82 0.86 0.93 113.4 
2-DPMP 3.05 2.77 2.68 87.9 3.05 3.4 3.55 116.4 
MDPV 3.19 2.55 3.4 106.6 2.47 2.8 2.49 100.8 
NAPHYRONE 3.09 2.38 2.78 90.0 2.99 2.3 2.58 86.3 
25B-NBOMe 1.17 1.25 0.8 68.4 1.17 1.21 1.06 90.6 
25C-NBOMe 1.37 1.28 1.02 74.5 1.37 1.09 1.4 102.2 
25D-NBOMe 1.15 0.97 0.81 70.4 1.15 1.1 1.15 100.0 
25E-NBOMe 1.21 1.05 1.02 84.3 1.21 1.13 1.22 100.8 
25H-NBOMe 1.43 1.27 1.14 79.7 1.43 1.54 1.38 96.5 
25I-NBOMe 1.19 0.91 0.89 74.8 1.19 1.01 0.96 80.7 
Mescaline-NBOMe 0.98 1.07 0.73 74.5 0.98 1.1 0.81 82.7 
25P-NBOMe 1.17 0.82 0.87 74.4 1.17 1.09 0.82 70.1 
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Previously published NBOMe methods have shown this class of compound to be 
unaffected by freeze/thaw cycles and this was corroborated by this research, 
with these compounds having an average recovery rate of 94%, (70.1-
133.3%).(162) Of the stability data previously published it has been shown that 
25T2-NBOMe was the most unstable compound. Although this method does not 
contain this compound it does contain 25T4 and 25T7-NBOMe, which were shown 
here to be susceptible to degradation in the fridge, with only 64% of the analyte 
recovered after 2 cool/warm cycles (ranging 55.6-75.0%).(162)  
Again the lack of deuterated I.Ss may also have impacted on these results as the 
PAR for some compounds was extremely low, e.g. methiopropamine and 3-MeO-
PCP. As a result of this, any differences observed upon the PARs affected the 
recovery of these compounds. This work should therefore be repeated once 
deuterated reference standards become available to better show the stability of 
these compounds in these matrices.  
3.4.7 Case Samples 
Case 1 contained 25I-NBOMe at concentrations of 1.77 µg/L and 1.32 µg/L in the 
two blood samples received. This was the only NBOMe identified in this case. 
These results were within 10% of the results obtained by NMS laboratories which 
were 1.81 µg/L and 1.44 µg/L respectively. A chromatogram and mass spectra 
are shown in Figure 3-20. 
 
Figure 3-20: Extracted chromatogram of case 1 with the mass spectrum showing the 
monitored ions. 
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Case 2 contained only 25C-NBOMe at concentrations of 1.69 µg/L and 2.37 µg/L 
for the two blood samples. NMS found concentrations of 2.17 µg/L and 2.16 µg/L 
respectively. There was no information provided as to the collection sites of 
these blood samples; however, it may be that they were from the same site 
given the similarity of the two NMS results. The results obtained using this 
method differ slightly from those of NMS laboratories with concentrations lower 
(-22%) for the first sample and higher (+10%) for the second. In order to interpret 
these changes better further information would be required as to how each 
sample was stored, for example whether one was closer to the back of the 
freezer than the other. It is also not known whether they are from different sites 
where components in the blood may have affected the 25C-NBOMe 
concentration. It is also unknown whether samples underwent additional testing 
and as a result more freeze-thaw cycles. All these variables could have affected 
the concentrations of 25C-NBOMe in the samples and thus affected the 
concentrations detected. It is possible that these results are within the realms of 
“normal” experimental error as the concentrations are so low. The 
chromatogram and mass spectra for case 2 is shown in Figure 3-21. 
 
Figure 3-21: Extracted chromatogram of case 2 with the mass spectrum showing the 
monitored ions 
 
Case 3 - no analytes were detected. NMS were able to identify 25I-NBOMe at a 
concentration of 0.32 µg/L which is below the LOD (0.4 µg/L) for this method. It 
therefore follows that it was not detected by GC-MS.  
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Case 4 – no analytes were detected. NMS were able to detect 25I-NBOMe at a 
concentration of 1.55 µg/L. This case involved post-mortem blood and is the 
only sample where it is known whether the blood was drawn ante- or post- 
mortem. This sample therefore raises the question of post-mortem stability of 
these compounds as it appears there has been a significant reduction in the 
concentration. As the history of the storage conditions of the sample is not 
known, no conclusions can be drawn as to why the reduction in concentration 
has taken place. It is possible that components within the post-mortem blood 
have resulted in its degradation. In order to assess this, it would be interesting 
to analyse this sample for any metabolites which may be present.  
Case 5 contained the highest concentration of NBOMes detected for all samples 
testing positive for 25C-NBOMe (4.04 µg/L). Although there is no information 
available, the high concentration detected may indicate that this is a post- 
mortem sample, however without additional information this cannot be 
confirmed. The concentration detected was 11% lower than that by NMS, again 
the time interval between sample analysis will have contributed to this.  
 
Figure 3-22: Extracted chromatogram of case 5 with the mass spectrum showing the 
monitored ions. 
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Case 6 - no analytes were detected. NMS detected 25I-NBOMe at a concentration 
of 0.73 µg/L. Similar to case 4 it is possible that concentrations may have 
degraded and now fall below the LOD of this method.  
Case 7 contained less than 1 mL of blood; therefore, only 250 µl of sample was 
extracted as in section 3.3.8. All other steps remained the same. The results of 
this sample showed that it was clearly positive for methoxetamine only as shown 
in Figure 3-23. Case 7 was quantified as having a methoxetamine concentration 
of 7.6 mg/L. Although this falls out with the calibration range of the method the 
reduced volume concentration of 1.9 mg/250 mL was within the calibration 
range.  
 
Figure 3-23: Chromatogram of case 7 the mass spectrum showing the monitored ions.  
 
Case 8 tested positive for methylone (Figure 3-24) at concentrations of 0.11, 
0.08 and 10.6 mg/L. NMS were only able to quantify the 1st and 3rd sample 
relating to this case, identifying concentrations of 0.17 and 10 mg/L. This case 
highlights the importance of knowing where blood samples were collected as the 
methylone concentrations vary hugely between cavity and peripheral blood 
sites.  
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Figure 3-24: Chromatogram and mass spectra of Case 8 sample1.  
 
A summary of all results can been seen in Table 3-22.  
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Table 3-22: Summary of case results and comparison with NMS results.  
Case 
No 
Site of 
collection 
GC-MS Method NMS Results 
%Deviation  
Analyte Identified 
Concentration 
Detected 
Analytes Identified 
Concentrations 
Detected 
1 
Cardiac Blood 25I-NBOMe 1.77 µg/L 25I-NBOMe 1.81 µg/L (2.2%) 
Cardiac Blood 25I-NBOMe 1.32 µg/L 25I-NBOMe 1.44 µg/L (8.3) 
2 
No info 25C-NBOMe 1.69 µg/L 25C-NBOMe 2.17 µg/L (22.1) 
No info 25C-NBOMe 2.37 µg/L 25C-NBOMe 2.16 µg/L 9.7 
3 No info N.D. 25I-NBOMe 0.32 µg/L N/A 
4 
Post mortem 
Blood 
N.D. 25I-NBOMe 1.55 µg/L N/A 
5 Iliac Blood 25C-NBOMe 4.04 µg/L 25C-NBOMe 4.53 µg/L (10.8) 
6 Blood N.D. 25I-NBOMe 0.78 µg/L N/A 
7 
Peripheral 
Blood 
Methoxetamine 7.60 mg/L Methoxetamine 8.2 mg/L (10.8) 
8 
Cavity Blood Methylone 0.11 mg/L Methylone 0.17 mg/L (7.3) 
No info Methylone 0.08 mg/L Methylone Not Quantitated N/A 
Peripheral 
Blood 
Methylone 10.60 mg/L Methylone 10 mg/L (35.3) 
 
*ND- Not detected 
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Due to the compounds analysed by this GC-MS method, case samples were more 
difficult to come by than more commonly abused drugs such as heroin, cocaine 
or amphetamine. As a result, only 12 samples were currently available from NMS 
laboratories containing substances detected by this method. Unfortunately, 
these samples were all blood and no case samples were available to test the 
validity of the urine method.  
At the time of analysis, NMS only screened for flephedrone, mephedrone, 
methylone, ethylone, butylone methoxetamine, MDPV, naphyrone, 25B-NBOMe, 
25C-NBOMe and 25I-NBOMe and thus only held records relating to samples which 
were positive for these substances. Unfortunately, the samples tested did not 
test positive for any of the other compounds in this method.  
To date, this is the first known method for the identification of NBOMes in blood 
using GC-MS. Due to the low concentrations detected, all previously published 
methods for biological matrices have used LC-MS/MS. The method was unable to 
detect 25I-NBOMe in 3 of the 5 NBOMe samples due to low concentrations and 
although in some instances it was possible to detect and quantify NBOMes using 
this instrumentation it is much more challenging. Due to the small peak areas 
involved manual integration was required for the majority of the calibrators, 
QCs and samples which is much more time intensive. Although the integration 
parameters of ChemStation can be altered there is a trade-off between 
detecting peaks of interest and detecting everything on the chromatogram.  
The method itself was also relatively long taking 30 minutes per sample resulting 
in a maximum of 48 injections per day. It is therefore suggested that this 
method would be used for targeted analysis when NPS use was suspected, rather 
than a quantitative screening method.  
Instrument maintenance was also important when developing this method due to 
the low concentrations detected, making it important that the instrument 
remained clean throughout analysis. This may be a limitation if instrumentation 
is shared between different forensic disciplines.  
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3.5 Conclusion  
A robust and sensitive method for the simultaneous analysis of various NPSs in 
urine and blood was validated. The method was successfully able to identify and 
quantitate NBOMes in 5/8 samples, and thus was not able to compete alongside 
more sensitive techniques such as LC-MS/MS.  
The majority of analytes were separated both chromatographically and by their 
mass spectra. The method could also be easily updated to incorporate new NPSs 
as and when they become available.  
This method is of particular use for laboratories who do not possess an LC-MS/MS 
for the detection of NBOMes in acute fatalities. The method may be more 
applicable to urine cases as concentrations may be higher, although this would 
need further investigation using “real life” samples, especially since metabolites 
may be more relevant targets.  
3.6 Future Work  
Due to the long run-time of the GC-MS method it was not possible to complete 
all additional validation parameters listed in the SWGTOX guidelines.  
SWGTOX recommends that 3 freeze/thaw cycles are performed this was not 
possible due to time constraints. It is therefore suggested that this work is 
repeated to meet these standards. Further stability work should be carried out 
where spiked matrix is aliquoted into individual vials prior to fridge and freezer 
storage, thus removing the cool/warm, freeze thaw variable. This will give a 
better understanding as to whether it was the storage conditions themselves, or 
the effects of these cycles which caused fluctuations in the amount of analyte 
detected.  
SWGTOX does not provided a specific time period for assessing autosampler 
stability, however, the majority of publications evaluate this parameter up to 72 
hours. This was the initial plan for this validation, however, due to instrument 
failure the 72 hour samples were unable to be analysed.  
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Chapter 4: Stability of Mephedrone in Bovine 
Blood 
4.1 Cathinone Stability 
Knowing the stability of a drug is extremely important in forensic toxicology as it 
can affect the concentrations detected and alter any interpretations made from 
these concentrations.(205) It is therefore important for toxicologists to be aware 
of the time period between sample collection and analysis, the conditions the 
sample was transported under and additional factors such as degradation in post 
mortem cases as all will affect the concentrations detected and reported. 
Samples may be called into question in court and the defence may opt to have 
samples re-analysed at a later date. Samples may be re-analysed as detection 
methods within the laboratory improve, or if initial analysis was not 
confirmatory, i.e. the QC’s in a batch failed to pass the methods acceptable 
criteria. Knowledge of drug stability is therefore vital in all these instances. 
More recently with the appearance of NPSs, many laboratories performed 
retrospective analysis on samples where NPS use was suspected (189). Again, the 
stability of these drugs plays an important role when carrying out this analysis 
and interpreting results as the concentrations detected may differ significantly 
from when the sample was initially received.  
Previous work has shown that cathinone is unstable in its natural plant form 
(Khat) and that the fresh leaves must be consumed quickly in order to extract 
the drug (206). This instability is one of the many factors as to why it took over 
100 years of experimental work before cathinone was isolated from the plant 
(207). Cathinone stability in biological matrices is equally poor with various 
studies showing rapid loss of the target analyte over a short time period (165, 
208, 209). 
The stability of mephedrone has also been noted as being poor in various 
publications validating analytical methods (SWGTOX guidelines state that 
analyte stability should be investigated as part of method validation).(200) This 
is unsurprising as mephedrone is an analogue of cathinone, which is well 
documented as unstable.(207) Previous work has shown that mephedrone 
stability is affected by storage temperature and the use of preservatives; 
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however, the majority of this research only focuses on one variable at a time 
over a short period of time. (210, 211)  
4.2 Aims 
The aim of this study was to assess the stability of mephedrone and the effects 
of storage temperature and preservatives upon its stability. In order to ascertain 
the effect of preservatives upon blood samples unpreserved blood will need to 
be used as a control. When blood is drawn from individuals it goes directly into a 
bag which contains anti-coagulants already. As a result blood collected from 
blood banks cannot be used. Ethical issues surrounding the use of blood also 
prevents blood collection specifically for this project and hence unpreserved 
bovine blood was used, as this avoids these issues.  
4.3 Materials & Methods 
4.3.1 Chemicals 
Mephedrone and mephedrone-D3 reference standards (1 mg/mL) were purchased 
from Cerilliant (Dorset, England). Unpreserved bovine blood was donated from 
Sandyford Abattoir (Paisley, UK). Citric acid powder was from Sigma Aldrich 
(Dorset, England) and Fluoride/Oxalate tubes were from Teklab (Durham). SPE 
Cleanscreen® columns were purchased from Presearch (Hampshire, England). All 
other chemicals were of analytical grade and purchased from Sigma Aldrich 
(Dorset, England).  
4.3.2 Solution Preparations 
4.3.2.1 Citric Acid Solution 
A 0.8% citric acid solution was made by weighing 8 g of citric acid and dissolving 
this in 100 mL dH2O in a small beaker. This solution was then transferred to a 1 L 
volumetric flask, the empty beaker rinsed with more dH2O and these washes 
added to the 1 L volumetric flask. This was repeated several times until the 1 L 
flask had been made up to the mark. The volumetric flask was inverted several 
times to ensure thorough mixing.  
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4.3.2.2 Phosphate Buffer (pH6) 
 
Phosphate buffer (pH 6) was prepared by adding 12.14 g sodium dihydrogen 
orthophosphate and 1.62 g of potassium dihydrogen to a 1 L volumetric flask. 
This flask was then made up to the mark using dH2O before being pH adjusted to 
pH 6.  
4.3.2.3 Mephedrone and mephedrone-D3 solutions (10 µg/mL) 
 
To produce a 10 µg/mL solution of mephedrone, 1 mL of a 1 mg/mL reference 
solution was transferred to a 10 mL volumetric flask and made up to the mark 
using MeOH. This solution was inverted several times to ensure thorough mixing 
before being transferred to a labelled amber bottle for storage throughout the 
project. The same procedure was used to make a 10 µg/mL solution of 
mephedrone-D3 I.S. solution. A second 10 µg/mL mephedrone solution was made 
by a different analyst on a different day and used for the preparation of QCs.  
4.3.3 Blood preparation and storage 
Fresh, preservative free, bovine blood (1.25 L) was collected from the abattoir. 
Mephedrone (1 mg/mL) was transferred to a 1 L volumetric flask and made up to 
the mark using bovine blood, producing a final mephedrone concentration of 1 
mg/L. This solution was inverted several times and shaken to ensure the drug 
was thoroughly mixed throughout the blood solution. Aliquots of 1 mL were 
added to 120 individual 2.5 mL plastic vials to provide information on stability 
when no preservative has been added. A 250 mL aliquot of the mephedrone 
spiked blood was transferred to a separate beaker and spiked with 3.75 mL citric 
acid solution (0.8%). As with the unpreserved vials, 1 mL of the citric acid 
mephedrone spiked blood was added to 120 individual 2.5 mL plastic vials. The 
effect of sodium fluoride (1.67%)/potassium oxalate (0.20%) preservative was 
investigated by adding 1 mL of mephedrone spiked bovine blood to 120 
commercially manufactured preservative vials.  
Samples were then stored at 3 different temperatures (-20oC, 4oC and 20oC) as 
shown in Figure 4-1. Samples were stored individually to avoid the effects of 
freeze-thaw cycles and 20oC samples were also stored in the dark to avoid the 
143 
 
additional variable of light affecting stability. The remaining 250 mL bovine 
blood which was not spiked with mephedrone was stored at 4oC for use when 
preparing QCs and calibration standards.  
 
Figure 4-1: Storage conditions of mephedrone spiked bovine blood samples stored without 
preservative and with two types of preservative at different temperatures. 
 
4.4 Sample Analysis  
Samples were analysed daily for the first 7 days and weekly for a period of 10 
weeks. They were analysed in triplicate with freshly prepared calibrators and 
QCs run prior to each analysis.  
4.4.1 Calibrators, QCs and Sample Preparation 
Calibrators and QCs were prepared using the FMS amphetamine method. To all 
calibrator, QC and sample test tubes 5 mL of pH 6 phosphate buffer was added, 
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as well as I.S. (50 µl of 10 µg/mL mephedrone-D3). To the calibrator test tubes, 
mephedrone solution (10 µg/mL) was added in volumes from 0-200 µl and to the 
QC test tube 42 µl of mephedrone (10 µg/mL) was added as shown in Table 4-1. 
QC solutions were made using the QC mephedrone solution. Blank bovine blood 
(1 mL) was then added to the calibrators and QC.  Calibrators, QCs and samples 
were vortex mixed for 30 seconds, prior to being centrifuged for 10 minutes at 
3500 rpm.  
Table 4-1: Volume of mephedrone solution (10µg/mL) added to each test tube to produce 
calibrators and QC. 
 Mephedrone Solution 
(10µg/mL) volume (µL). 
Mephedrone 
Concentration (mg/L) 
Blank 0 0 
Calibration 1 10 0.1 
Calibration 2 25 0.25 
Calibration 3 50 0.5 
Calibration 5 100 1.0 
Calibration 6 200 2.0 
QC 42 0.42 
 
4.4.2 Extraction 
Extraction was carried out using SPE. Cleanscreen® columns were conditioned 
using 3 mL MeOH, 3 mL dH2O and 1 mL pH 6 phosphate buffer. The samples, 
calibrators and QCs were then loaded onto the columns before washing with 3 
mL dH2O, 1 mL of 1 M acetic acid and 3 mL MeOH. The columns were then left to 
dry under full vacuum for 5 minutes. Elution was carried out using 3 mL of 
CH2Cl2/IPA/NH3 (78/20/2). The samples, calibrators and QCs were then 
evaporated to dryness under a stream of nitrogen with no additional heat before 
derivatization with 50 µl of PFPA:EtOAc (2:1) for 20 mins at 60OC. This 
derivatization solution was then evaporated off again using a stream of nitrogen 
before the samples, calibrators and QCs were reconstituted in 250 µl EtOAc and 
transferred to GC vials for analysis.  
4.4.3 Instrumentation 
Analysis was carried out on a Bruker GC-MS/MS fitted with a DB5 column (30 m x 
0.25 mm, 0.25 µm). Helium was used as carrier gas at a flow rate of 1.5 mL/min. 
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The temperatures of the injection port, ion source and interface were 225oC, 
250oC and 200oC respectively. The injection port was operated in splitless mode. 
The initial oven temperature was 80oC, (held for 2 minutes), then increased to 
170oC at a rate of 25oC/min. The temperature was then ramped to 200oC at a 
rate of 5oC/min before a final ramp of 25oC/min to 300oC (hold time 2 minutes). 
The total analysis time was 23 minutes. The mass spectrometer was operated in 
single quadrupole EI mode (full scan mode from m/z 40 to m/z 450 amu). Data 
was processed using Xcaliber 1.4 software.  
4.5 Results 
Mephedrone was identified using m/z ions 204, 160 and 119 with 204 being used 
for quantitative analysis. Mephedrone-D3 was identified using ions 207, 163 and 
119 with 207 being used for quantitative analysis. Mephedrone and mephedrone-
D3 eluted at 13.1 minutes and 13.4 minutes respectively as shown in Figure 4-2.  
 
Figure 4-2: Example chromatogram showing an unpreserved blood sample stored at room 
temperature on day 35. 
 
The effect of preservatives and storage temperatures are shown in Figure 4-3 to 
Figure 4-5. Mephedrone concentrations were least stable when stored with no 
preservative, with mephedrone becoming undetectable in unpreserved samples 
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stored at room temperature after a period of 21 days as shown in Figure 4-3. 
After 1 day, unpreserved samples stored at room temperature decreased on 
average by 19%. Unpreserved samples stored in the fridge and freezer did not 
show any significant decrease in mephedrone concentrations until day 36 and 43 
respectively.  
 
Figure 4-3: Mephedrone concentrations of samples stored with no preservative over 10 
weeks at 3 different temperatures. 
 
Samples stored with citric acid preservative as shown in Figure 4-4 were the 
most stable over the 70-day period. The addition of citric acid to samples stored 
at room temperature had little effect on mephedrone preservation with samples 
seeing an average decrease of 17% after the 1st day. Mephedrone concentrations 
were again undetectable in room temperature stored samples after 21 days. 
Samples stored in fridge and freezer conditions using citric acid preservative 
remained relatively stable throughout the 10-week period.  
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Figure 4-4: Mephedrone concentrations of samples stored with citric acid preservative over 
10 weeks at 3 different temperatures. 
 
Fluoride/oxalate samples were stable when stored in the freezer as shown in 
Figure 4-5. Fridge samples were initially stable however concentrations rapidly 
decreased after 35 days becoming undetectable after 49 days. Room 
temperature samples preserved with fluoride/oxalate were stable for slightly 
longer than unpreserved or citrate preserved samples at room temperature. 
These became undetectable after 28 days; however mephedrone concentrations 
decreased by 23% on average after the first day.  
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Figure 4-5: Mephedrone concentrations of samples stored with fluoride/oxalate preservative 
over 10 weeks at 3 different temperatures. 
 
4.6 Discussion 
The data produced in this study correlate with several previous studies in that 
mephedrone is unstable at room temperature and to a lesser degree when stored 
in refrigerators.  
Johnson et al. investigated the effect of storage temperature on MDPV, 
mephedrone, BZP and TFMPP in three biological matrices (whole blood, plasma 
and urine) over a period of 14 days (211). They found that mephedrone rapidly 
degraded when stored at room temperature, unable to detect it by day 7. This 
differs greatly from this research which was able to find mephedrone at small 
concentrations up to day 21. Johnson et al. carried out their analysis using LC-
MS/MS with a lower LOD (2 ng/mL) than the method used here and their room 
temperature was maintained by a thermostat at 22oC. It is therefore unlikely 
that either of these variables is responsible for the elongation in detection time 
between these studies. The source of human whole blood was not provided in 
this publication, and therefore any preservatives and anti-coagulants used at the 
point of collection are unknown, although it is likely that they would have 
slowed degradation of mephedrone in samples. Therefore, it falls that a 
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component of human blood not present in bovine blood may cause the 
accelerated degradation seen in previous research.  
Maskell et al. investigated the stability of 4 NPSs including mephedrone and 
MDMA when stored in solutions of varying formalin concentration and pH at 4oC 
(212). In this study mephedrone degradation occurred at a faster rate with 
increased formalin concentration and with increasing pH. As a result, sample pH 
may be another reason that Johnson et al. were unable to detect mephedrone 
after 7 days in room temperature, as this information was not provided.   
This work was carried out prior to the GC-MS method validation described in 
Chapter 3. This was due to the on-going development of this method adding 
additional NPSs when they became available.   
The GC-MS was also operated in full scan mode opposed to SIM. This was to 
enable retrospective data mining to determine if any breakdown products could 
be identified. Unfortunately, this was not possible to do as the baseline of the 
GC-MS/MS was sufficiently high to mask peaks, and these were only identifiable 
when specific ions were extracted.    
4.7 Conclusion 
To maximise the stability of mephedrone, samples should be stored at -20oC and 
preserved using citric acid solution. Although fluoride/ oxalate was shown to 
preserve samples when stored at -20oC, degradation was still problematic at 4oC 
with a loss of 36% after 35 days. Regarding retrospective analysis, care should be 
taken when interpreting negative results in cases where the history supports 
mephedrone use. The time between death and post mortem investigation should 
also be taken into consideration as should the storage conditions of the sample 
in the lead up to toxicological analysis and screening.  
4.8 Further Work 
Cerilliant’s certificate of analysis states that they did not observe a decrease in 
the purity of methanolic mephedrone reference material over the course of a 
week when stored at -15oC to 40oC, and that methanolic mephedrone solutions 
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are stable for up to a year when refrigerated. This work suggests that this might 
not be the case. Future work on this topic would examine whether methanolic 
solutions of mephedrone are as unstable at room temperature as when the drug 
is in blood. Until this work is completed it is recommended that methanolic 
mephedrone solutions are stored in the freezer to prevent solution degradation. 
This study is also limited by the number of variables investigated. Future work 
should also look into the stability of mephedrone in additional biological 
matrices, the effect of light and additional preservatives which are commonly 
encountered by forensic laboratories. The effect of pH may also be a factor and 
was not investigated in this short study. Although the pH of blood is regulated to 
fall between 7.35 and 7.45 it may fall outside this in cases of ketoacidosis, and 
this in turn could affect the findings of this study. The pH of urine however 
varies much more and this may be a more important variable to consider when 
investigating the stability of mephedrone in urine samples.  
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Chapter 5: Immunoassay screening: cross- 
reactivity 
5.1 Enzyme-linked Immunosorbent Assay 
Prior to confirmatory analysis, samples typically undergo presumptive testing for 
a range of drug classifications. This allows forensic laboratories to have targeted 
analysis, reducing sample run time, overhead costs and the amount of sample 
used during testing. The most common presumptive tests for drugs of abuse are 
enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay (ELISA). 
These commercially produced assays allow samples to be screened either for 
specific drugs and their metabolites or for a specific drug group, indicating what 
drugs may be present within the sample. EIA and ELISA are commonly used due 
to the speed at which positive samples can be identified and because they have 
the potential for full and or semi-automation.  
All EIA and ELISA tests are based on the principle that each antigen has a 
corresponding antibody. ELISA and EIA kits are typically found in a 96 well plate 
format with anti-drug antibodies coated onto the inside of each well. Controls, a 
blank and samples are then added to individual wells before the addition of an 
enzyme conjugate. The drug and enzyme conjugate compete for antibody 
binding sites, hence this type of ELISA/EIA is termed competitive 
immunoassay.(213) Excess conjugate is removed through wash steps before the 
addition of a substrate. This substrate then produces a colour change indicating 
the amount of enzyme conjugate bound to the antibodies. The ELISA kits, which 
were purchased from Immunalysis, used in this project turn from yellow to blue 
to indicate the presence of bound enzyme conjugate, therefore the more 
intense the blue colour, the more enzyme conjugate has been able to bind to 
the antibodies contained within the well. The amount of enzyme conjugate able 
to bind inversely relates to the amount of drug present in the sample, as the 
drug competes with the enzyme conjugate and prevents binding occurring. This 
is illustrated further in Figure 5-1.  
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Figure 5-1: Immunalysis ELISA protocol. 
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5.1.1 ELISA Cross Reactivity  
In order to determine whether an assay is suitable for the detection of a 
particular drug or for a particular drug class, its cross reactivity is calculated as 
shown in Equation 5-1.  
Equation 5-1: Percentage Cross Reactivity.(214)  
𝐶𝑟𝑜𝑠𝑠 𝑅𝑒𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (%) =  
𝐴𝑝𝑝𝑎𝑟𝑒𝑛𝑡 𝑐𝑜𝑛𝑐. 𝑜𝑓 𝑡𝑎𝑟𝑔𝑒𝑡 𝑑𝑟𝑢𝑔
𝐶𝑜𝑛𝑐.  𝑜𝑓 𝑎𝑑𝑑𝑒𝑑 𝑑𝑟𝑢𝑔
𝑥100 
 
Cross reactivity relates to the level at which the target drug molecules bind to 
the antibody coated wells. This is important when dealing with different 
biological matrices, for example urine samples when metabolites are used to 
establish the presence of a drug. Cross reactivity can also be used to determine 
how the assay interacts with other substances which are not the specific drug it 
was designed to cross react with. Kits can be designed to be drug specific or 
drug group specific. For example, morphine will react with both an opiates kit 
and a morphine specific kit, the only difference being that there will be lower 
cross reactivity with the morphine kit as it should only test specifically for this 
opiate. However, this is not always the case, and with the sudden influx of new 
drugs onto the market, all with similar structures to drugs already identified by 
ELISA kits, it is likely that some of these will produce positive ELISA results.  
Mephedrone cross reactivity with methamphetamine ELISA kits has been shown, 
although no cut off levels were provided in this brief publication.(189) This 
publication also noted that mephedrone failed to cross-react with their 
amphetamine ELISA kits.  MDPV cross reactivity with a phencyclidine 
immunoassay kit has also recently been published with a cut-off concentration of 
6.2mg/L.(215)  
5.2 Point of Care Testing  
Point of care testing (POCT) is similar to ELISA, providing presumptive results as 
to whether a drug is present in a biological sample. Since these results are 
presumptive a follow up analysis should be carried out using alternative 
analytical methods for confirmation.  
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POCT is predominantly used in hospitals and work place testing and is sometimes 
referred to as near patient testing as it takes place away from the laboratory. Its 
main benefits are that it is non-evasive, simple to use and quick to perform.  
POCT uses lateral flow technology first commercially applied in 1985 to Unipaths 
Clearview home pregnancy test.(216)  Lateral (or vertical) flow assays consist of 
an absorbent pad to which the sample (in this case urine) is applied to. The 
sample then travels along the pad which contains antibodies specific to the 
target analyte or class of analytes being tested for. These antibodies are 
conjugated to coloured particles, typically colloidal gold nanoparticles or latex 
microspheres.  
 
Figure 5-2: Diagram of a lateral flow POCT. 
 
Any target analytes present in the sample bind to these colour conjugated 
antibodies, travelling further down the sample pad by capillary flow. The 
analytes and antibodies then reach the reaction membrane line (usually 
nitrocellulose or cellulose acetate) to which “anti-target” antibodies are bound. 
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In traditional lateral flow tests the sample and its conjugated antibodies travel 
over this area, and are immobilized by these “anti-target” antibodies. This 
creates a colour change resulting in a positive sample line appearing. This is 
shown in Figure 5-2.  
In this research the lateral flow tests used competitive binding, thus analyte 
contained within the sample bound to the “anti-target” antibodies preventing a 
colour change. After the test line unbound conjugate antibodies continue to 
travel until they reach a second membrane line. Here they become bound by 
another set of antibodies, again, causing a coloured line to appear known as the 
control line.  
Absence of this control line on a test shows that capillary flow of the sample has 
not occurred and therefore any negative results cannot be relied upon as the 
test has failed to work. 
5.3 Aims 
The aim of this work was to establish if any cross-reactivity was observed using 
amphetamine, methamphetamine and ketamine ELISA kits with various NPSs. 
The cross-reactivity of ketamine substitutes, methoxetamine, 3-MeO-PCE and 3-
MeO-PCP for various ketamine POCT was also investigated.  
5.4  Materials & Methods 
5.4.1 Chemicals & Reagents 
Amphetamine and methamphetamine Immunoassay® ELISA kits were purchased 
from AgriYork (Pocklington, UK). Ketamine Immunoassay® ELISA kits were 
donated from AgriYork (Pocklington, UK). The ELISA screening protocols used 
were accredited to ISO17025 for forensic purposes. WorldCassetteTM Rapid Test 
(Japan), Nal von Minden (Germany) and DRUGCHECK® Dip Drug Test (The 
Netherlands) for ketamine were also supplied by AgriYork (UK). 
Cerilliant Mephedrone, ethylone and methylone reference standards were 
purchased from Sigma-Aldrich (Dorset, UK). Naphyrone, 5-IAI, MDAI, 2-DPMP, 
butylone, 5-APB, 6-APB, methedrone, ketamine, 3-MeO-PCE, 3-MeO-PCP and MXE 
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were purchased from LGC Standards (Luckenwalde, Germany). MDPV and 
flephedrone were purchased from Toronto Research Company (Canada). PBS 
buffer was from Agriyork (Pocklington, UK). 
Expired red blood cell pouches were supplied by the Western Infirmary Hospital 
(Glasgow, UK). Urine was supplied by a willing donor. ELISA plates were washed 
using a Dynex plate washer and read with a Dynex MRX plate reader.  
5.4.2 Blank Blood Preparation 
These red blood cells had been collected according to the UK Blood Services 
guidelines (166:167) and were frozen upon arrival into the FMS department. The 
volume of red blood cells was measured once the contents of the pouch had fully 
defrosted and diluted 1:1 with 1% saline solution. Saline solution was prepared 
as per section 2.4.1.2.  
5.4.3 ELISA Methodology 
5.4.3.1 Amphetamine and Methamphetamine Kits 
A 100 µg/mL amphetamine solution was made by transferring 500 µL of a 1 
mg/mL reference standard to a 5 mL volumetric flask. It was then made up to 
the mark using MeOH. Using this solution, a 10 µg/mL amphetamine solution was 
then prepared by transferring 500 µl of the 10 µg/mL solution to a 5 mL 
volumetric flask. This was then made up to the mark using MeOH. This procedure 
was repeated using methamphetamine to give methamphetamine solutions of 
100 µg/mL and 10 µg/mL. Using these 2 solutions amphetamine and 
methamphetamine calibrators (levels 1-4) and QC’s (±50% the 25 ng/mL cut-off 
value) were prepared using the volumes specified in Table 5-1. Blood calibrators 
and QC’s and spiked samples were diluted 1:10.  
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Table 5-1: Solutions and volumes used to produce blood and urine amphetamine / 
methamphetamine levels and QC’s along with their final concentrations. 
 Level No 
Solution 
Used 
(µg/mL) 
Volume 
Used (µl) 
Concentration 
prior to 
dilution 
(ng/mL) 
Final 
Concentration 
(ng/mL) 
Blood 
1 N/A 0 0 0 
2 10 25 250 25 
3 10 100 1000 100 
4 100 50 5000 500 
-50% 10 13 130 13 
+50% 10 38 380 38 
 
To produce the spiked blood samples 1 mL aliquots of blank blood was 
transferred to clean glass culture tubes. These were then spiked with 100 µl of 
each drug solution (100 µg/mL) listed in section 5.4.1. These were then diluted 
1:10 using PBS buffer giving a final concentration of 1000 ng/mL. A 10 µL aliquot 
of calibrator (level), QC or drug was added to the wells in duplicate as shown in 
Figure 5-3. The plates were then left to incubate in the dark for 1 hour and 
washed before stop solution was added and the plates were read. This protocol 
was used for both amphetamine and methamphetamine ELISA kits.  
 
Figure 5-3: Diagram of amphetamine/ methamphetamine ELISA kits 
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5.4.3.2 Ketamine Kits Methodology 
A 100 µg/mL ketamine solution was made by transferring 500 µL of a 1 mg/mL 
reference standard to a 5 mL volumetric flask. It was then made up to the mark 
using MeOH. A 500 µL aliquot of this 100 µg/mL solution was then transferred to 
a fresh clean 5 mL volumetric flask and made up to the mark again with MeOH, 
giving a final concentration of 10 µg/mL. From the 10 µg/mL solution 500 µL was 
removed and transferred to another clean 5 mL volumetric flask, made up to the 
mark using MeOH, giving a final concentration of 1 ng/mL.  
The ketamine 1 and 10 µg/mL solutions were then used to spike 1 mL of blood or 
urine to produce calibrators. Controls were also made in blood and urine (±50% 
of the manufacturers cut off point). Blood calibrators and QC’s were diluted 1:10 
in PBS buffer whereas urine QC’s, calibrators and samples were diluted 1:20 as 
per manufacturer’s instructions. The solutions and volumes used to spike each 1 
mL of matrix are shown in Table 5-2. 
Table 5-2:Solutions and volumes used to produce blood and urine levels and QC’s along with 
their final concentrations.  
 Level No 
Solution 
Used 
(µg/mL) 
Volume 
Used (µl) 
Concentration 
prior to 
dilution 
(ng/mL) 
Final 
Concentration 
(ng/mL) 
Blood 
1 N/A 0 0 0 
2 1 100 100 10 
3 10 60 600 60 
4 10 300 3000 300 
-50% 1 50 50 5 
+50% 1 150 150 15 
Urine 
1 N/A 0 0 0 
2 10 20 200 10 
3 10 120 1200 60 
4 10 600 6000 300 
-50% 10 50 500 25 
+50% 10 150 1500 75 
 
As the 3 ELISA plates used contained 96 wells it was decided that a total of 8 
different analyte concentrations could be tested for each matrix, with each 
matrix being tested on a separate plate. The MXE, 3-MeO-PCE and 3-MeO-PCE 
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were prepared using 4 different working solutions, 0.01-5 mg/mL. The 5 mg/mL 
solution was prepared by weighing 5 mg of drug powders and adding 1 mL of 
MeOH. Using this solution a 1 mg/mL solution was prepared by transferring100µl 
to a fresh vial and adding 900 µl of MeOH. The 0.1 mL solution was prepared by 
transferring 100 µl of the 1 mg/mL solution to another fresh vial and again 
adding 900 µl of MeOH. The final solution of 0.01 mg/L was then made by 
transferring 100 µl of the 0.1 µl/mL solution to a fresh vial and adding 900 µl 
MeOH.  
This procedure was carried out for each of the 3 analytes. The volumes of each 
of these solutions used to spike 1 mL of each matrix are shown in Table 5-3. The 
resulting matrix concentration is also shown. As with the calibrators and QC’s 
blood and PBS spikes were diluted 1:10 and the urine spikes were diluted 1:20, 
the resulting concentrations after these dilutions are also shown in Table 5-3. 
Table 5-3: Concentrations of test sample after 1:10 and 1:20 dilutions. 
Sample No. 
Working 
Solution 
Conc. 
(mg/mL) 
Volume 
Used (µL) 
Resulting 
Conc 
(µg/mL) 
Conc. 1:10 
dilution 
(µg/mL) 
Conc 1:20 
dilution 
(µg/mL) 
1 5 100 1000 100 50 
2 5 100 500 50 25 
3 5 20 100 10 5 
4 1 50 50 5 2.5 
5 0.1 100 10 1 0.5 
6 0.1 50 5 0.5 0.25 
7 0.01 100 1 0.1 0.05 
8 0.01 10 0.1 0.01 0.005 
 
A 10 µL aliquot of each calibrator and QC was added to the wells in duplicate. A 
further 10 µL of MXE, 3-MeO-PCP, and 3-MeO-PCE at the concentrations listed in 
Table 5-3 were also added to wells in duplicate. This was carried out for drug 
samples in blood, urine and PBS solution. A summary of this is shown in Figure 
5-4. The numbers following the analyte name correspond to those listed as the 
sample No in Table 5-3. 
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Figure 5-4: Diagram of ketamine ELISA plate 
 
5.4.4 POCT Methodology 
Blank human urine samples were spiked with MXE at different concentrations 
(100, 250, 500 and 1000 µg/mL). POCT was then carried out on each of these 
samples using both the DRUGCHECK® Dip Drug Test and the WorldCassetteTM 
Rapid Test as per the manufacturer’s instructions. To the WorldCassetteTM Rapid 
Test 1-2 drops of spiked urine was added by Pasteur pipette to the sample hole. 
The kits were kept flat on the bench and only read once the control line had 
appeared. Nal von Minden and DRUGCHECK® Dip Drug Test use vertical flow and 
each test was directly placed into a small beaker containing 1-2 mL of spiked 
urine. Again readings were only taken after the appearance of the control line. 
Nal von Minden tests were used to test MXE urine samples at concentrations of 
50 µg/mL and 500 µg/mL. Positive and negative controls for each POCT were 
also carried out using blank urine and urine spiked at 10 µg/mL.  
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5.5 Results & Discussion 
5.5.1 ELISA  
5.5.1.1 Amphetamine & methamphetamine 
The percent cross reactivity’s of each drug at 0.1 mg/L with both plates is shown 
in Table 5-4. Those which gave positive results and successfully cross reacted are 
highlighted in pale green. Those which did not cross react to an extent to give a 
positive response are highlighted in pale red. From the Table 5-4 it is clear that 
ethylone cross reacted to the highest extent with both the amphetamine kit and 
the methamphetamine kit. The cut-offs for these drugs were not investigated 
due to the high price of the kits.  
Table 5-4: Percent cross reactivity for Immunalysis amphetamine and methamphetamine 
ELISA kits spiked with various new psychoactive substances 
DRUG 
AMPHETAMINE % CROSS 
REACTIVITY 
METHAMPHETAMINE % 
CROSS REACTIVITY 
2-DPMP 0.1 0.3 
5-IAI 0.1 0.4 
MDAI 0.7 0.6 
MDPV 0.1 0.3 
Naphyrone 0.1 0.3 
Butylone 0.6 1.0 
Flephedrone 0.8 1.3 
5-APB 1.2 1.8 
6-APB 1.3 1.8 
Ethylone 2.7 3.2 
Mephedrone 1.5 2.0 
Methedrone 1.3 1.8 
Methylone 1.2 1.8 
 
The results from this study correlated with  previous research that tested a 
variety of NPSs against various different amphetamine ELISA plates including 
Immunalysis.(217) During this study MDPV, Mephedrone, flephedrone and 
butylone were all found to have cross reactivities below 0.25% which was also 
the case in this short study. This previous study did not test any of the additional 
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NPSs listed in Table 5-4, nor did it examine cross-reactivity with 
methamphetamine ELISA kits.  
Although some of the NPSs tested did cross react sufficiently to produce positive 
results all were tested at 10 µg/mL. Therefore it is unlikely that blood false 
positives would routinely be seen due to the high concentrations needed. Urine 
false positives however may occur as concentrations can be much greater 
depending on the circumstances surrounding the case.  
5.5.1.2 Ketamine 
MXE, 3-MeO-PCE and 3-MeO-PCP all produced positive results using the 
Immunalysis ELISA kits in blood, urine and PBS solution at different 
concentrations. Concentrations at which each drug gave positive results 
(ketamine cut-off = 50 ng/mL) are shown below in Table 5-5. These 
concentrations are those of the original samples and not that of the samples 
after 1:10 or 1:20 dilution.  
Table 5-5: Sample concentrations at which ELISA provided positive results 
MATRIX 
MXE 
(µg/mL) 
3-MeO-PCE 
(µg/mL) 
3-MeO-PCP 
(µg/mL) 
BLOOD 10 100 50 
URINE 5 50 50 
PBS 5 10 10 
 
Cross reactivity was established by comparing measured ketamine 
concentrations with the actual concentrations of each drug added as shown in 
Table 5-6. 
Table 5-6: Cross reactivity of each drug in each matrix 
MATRIX MXE (%) 3-MeO-PCE (%) 3-MeO-PCP (%) 
Blood 0.1 0.01 0.02 
Urine 0.2 0.02 0.02 
PBS 0.3 0.02 0.07 
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False positive results for MXE blood samples are unlikely to be seen in case work 
due to the high concentrations needed (above 10µg/mL) before cross reactivity 
is observed. This is far higher than reported blood and serum concentrations for 
MXE toxicity which range between approximately 0.1µg/mL and 0.4µg/mL (95, 
96). In one reported fatality a femoral blood concentration of approximately 
8.5µg/mL was detected, which is still below the 10µg/mL cut off point, was 
found (98).  
Urine samples, however, could result in false positive results since a lower cut 
off value of 5µg/mL was observed. In one paper, urine samples were found to 
have MXE concentrations ranging from 2µg/mL to 165.3µg/mL in patients (n=6) 
suffering from acute toxicity.(97) It is likely that post mortem samples could 
have concentrations far greater than these. Had ketamine ELISA analysis been 
carried out on these 6 urine samples, 66% would have cross reacted sufficiently 
to produce a positive response.  
To date there is very little published toxicological information for either 3-MeO-
PCE or 3-MeO-PCP. Anecdotal evidence suggests that the recreational dose for 
both of these substances are much lower than that of ketamine or MXE and as a 
result toxicological concentrations are expected to be lower. 3-MeO-PCE and 3-
MEO-PCP only showed cross reactivity at much higher levels (10-100µg/mL) and 
therefore cross reactivity is unlikely to be seen with these substances and 
ketamine ELISA plates, unless in instances of acute toxicity. Higher cross 
reactivity may be a result of steric hindrance in the case of 3-MeO-PCP and due 
to the lack of oxygen double bond on the cyclohexane ring in both 3-Meo-PCP 
and 3-MeO-PCE as shown in Figure 5-5.  
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KETAMINE MXE
3-Meo-PCP 3-MeO-PCE  
Figure 5-5: Chemical structure of ketamine, MXE, 3-MeO-PCE and 3-MeO-PCP 
 
5.5.2 POCT  
Tests were positive if the analyte line failed to appear and negative if it did. Any 
faint lines at the analyte area were deemed negative regardless of how faint the 
line was as per manufacturer’s instructions. Cut off values for each POCT are 
shown below in Table 5-7.  
Table 5-7: Cut off values for ketamine POCT 
COMPOUND WorldCassetteTM DRUGCHECK® Nal von Minden 
Ketamine 500ng/mL 1,000ng/mL 1,000ng/mL 
Norketamine 50,000ng/mL 4,000ng/mL 1,000ng/mL 
 
WorldCassetteTM Rapid Test, DRUGCHECK® Dip Drug Test and the Nal von Minden 
Test showed no cross reactivity with MXE. The WorldCassetteTM Rapid Test 
produced a very faint line at concentrations 500µg/mL and 1mg/mL. Although 
this line was extremely faint these tests were deemed negative as per 
manufacturer’s instructions which note that any test producing any lines, no 
matter how faint should be treated as negative. These concentrations are much 
higher than would ever be seen in practise and therefore would not allow for the 
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detection of MXE on site. Test results for both POCT’s are shown in Figure 5-6, 
Figure 5-7 and Figure 5-8.  
 
Figure 5-6: DRUGCHECK® Dip Drug POCT results 
 
 
Figure 5-7: WorldCassetteTM Rapid Check POCT Results 
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Figure 5-8: Nal von Minden POCT results 
 
From this data it is clear that cross reactivity would not been seen in “real life” 
cases as no cross reactivity was observed with any POCT examined up to 1 
mg/mL. As previously discussed in chapter 1, section 1.3.5, typical MXE urine 
concentrations range from 2µg/mL to 165µg/mL, far lower than 1mg/mL.  
5.6 Conclusion 
This work shows that cross-reactivity may be observed using amphetamine, 
methamphetamine and ketamine Immunalysis ELISA kits in cases of severe NPS 
toxicity. Cross reactivity was seen using the amphetamine and 
methamphetamine kits for 5-APB, 6-APB, ethylone, mephedrone, methedrone 
and methylone. In addition to these substances, methamphetamine kits also 
cross-reacted with butylone and flephedrone.  
Cross reactivity was observed for MXE, 3-MeO-PCE and 3-MeO-PCP using the 
ketamine Immunalysis ELISA kit at concentrations ranging from 5-100 µg/mL. 
Cross-reactivity was seen for urine samples more so than blood, and therefore it 
is unlikely that cross-reactivity would be seen in “real-life” blood samples. 
Cross-reactivity may however be observed in urine samples.  
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These results indicate that care should be taken when confirming ELISA results, 
ensuring that any false positives are fully investigated and have not been caused 
by one of these NPSs which was not included on the confirmatory analysis panel. 
POCT’s did not show cross reactivity for methoxetamine, 3-MeO-PCE and 3-MeO-
PCP up to concentrations of 1 mg/mL. Care should be taken when interpreting 
ketamine POCT’s as these substances will not test positive. Therefore, a 
negative ketamine result does not mean that an individual has not used another 
ketamine type substance.  
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Chapter 6: Method Validation of 25B, 25C and 25I-
NBOMe in Urine and Hair using LC-MS/MS  
6.1 Introduction 
6.1.1 LC-MS/MS 
Liquid chromatography mass spectrometry (LC-MS) is a chromatographic 
technique, combining high performance liquid chromatography (HPLC) and mass 
spectrometry (MS). The LC column is packed with a sorbent (stationary phase) 
and a liquid (mobile phase) is pumped through under high pressure. The sample 
is injected and travels through the column separating different analytes 
depending on their interaction with the stationary phase versus their affinity 
with the mobile phase. If a molecule has a greater affinity for the stationary 
phase than the mobile phase more interactions will take place between that 
molecule and the stationary phase. This in turn increases the time it takes to 
travel through the column and reach the detector. If the molecule has a greater 
affinity for the mobile phase than that of the stationary phase fewer interactions 
between the molecule and the stationary phase will occur, reducing the time 
the molecule will take to travel through the instrument and reach the detector.  
The analyst is therefore able to control the retention times of analytes by 
altering the chosen column (i.e. selecting a different stationary phase) or by 
altering the mobile phase composition.(218) The LC mobile phase can be kept 
constant (isocratic) or altered over the run (gradient), in a similar way to how 
oven temperatures are controlled in GC.  
Before any molecules reach the mass analyser they must undergo ionisation. This 
can be achieved using a number of different techniques such as electrospray 
ionization (ESI), atmospheric pressure chemical ionization (APCI) and 
atmospheric pressure photo ionisation (APPI). The instrumentation used in this 
study utilised ESI and so this will be the only ionization method discussed briefly 
here. (219) 
In ESI the source generates analyte ions in solution prior to the mass analyser. 
Electrical energy is applied to the sample as it flows through a capillary 
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(typically stainless steel or quartz silica) which is sustained at a high voltage 
(2.5-6.0 kV) relative to its surrounding walls. The capillary can be operated in 
either positive or negative modes. In positive ESI the capillary is positively 
charged and thus attacks the negatively charged ions within the sample repelling 
the positive.  In negative ESI the opposite occurs. The resulting droplet spray is 
then either predominantly positive (positive ESI) or negative (negative ESI) 
depending on the charges applied to the capillary. The use of a nebulising gas at 
this stage such as nitrogen will increase the sample flow rate. (220) 
Droplet formation is dependent on several factors such as the diameter of the 
capillary, the applied potential inference (V0), the flow rate of the sample and 
the flow rate and temperature of any nebulising gas.  
Once a droplet is formed and expelled from the capillary it enters the 
desolvation region of the source, where aerosol formation takes place.  A drying 
gas such as nitrogen can be used to assist in aerosol formation. As the droplets 
travel through this region of the source the solvent is evaporated, reducing the 
size of the droplets until the ions contained within the droplet are expelled into 
the gaseous phase. The resulting ions are then sampled by the sampling skimmer 
cone before proceeding to the mass analyser.(220) This is shown in Figure 6-1. 
 
Figure 6-1: Schematic of aerosol formation. 
This fragmentation is known as a soft ionisation technique due to the limited 
number of fragments that are formed, thus retaining the molecular ion. As this is 
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a soft ionisation technique the resulting mass spectra produced can be very 
simple, making unique identification more difficult. The use of tandem MS 
however can overcome this limitation.(221)  
MS involves the ionisation of the analytes once they have left the column, and 
this can be achieved using a wide variety of mass analysers such as iontrap, 
quadrupole or time-of-flight. MS/MS is the combination of more than one MS 
mass analyser in the same instrument. The first mass analyser filters for the 
precursor ions, typically the molecular ion for the analyte of interest. The 
precursor ion is then fragmented to produce product ions, typically achieved by 
the use of high energy nitrogen gas. The second mass analyser then filters for 
the specific product ions. This achieves a highly sensitive and targeted analysis 
where the precursor ion and resulting product ions are monitored, ensuring that 
it is the analyte of interest. A schematic of an LC-MS/MS instrument is shown in 
Figure 6-2.  
 
Figure 6-2: Schematic of a LC-MS/MS instrument.  
Samples travel through the LC column to the MS/MS where they undergo ESI ionisation (at 
the interface between the LC and the MS/MS), separation, fragmentation, further separation 
and then detection.   
 
The use of LC-MS/MS in forensic toxicology laboratories has grown rapidly in the 
last 10 years, as more papers are published and instrumental costs fall. LC-
MS/MS is a highly specific technique allowing for the rapid analysis of multiple 
analytes simultaneously.(222) The relatively short run-times in comparison to 
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traditional GC-MS systems also make it appealing, coupled with the need for 
fewer sample clean up steps. GC-MS analysis is dependent on the analyte in 
question becoming volatile in the injection port, and thus the use of derivatising 
agents is common. This is not required in LC-MS analysis and so sample 
preparation time is also reduced.(223)  
6.1.2 Hair Analysis  
The analysis of hair poses significant benefits in forensic toxicology. Not only is 
it utilised when more conventional matrices such as blood and urine are not 
available, but it also provides an approximate timeline of drug use. This is 
particularly useful in cases of child custody, work place drug testing or in DFSA 
cases.(224-226)  
Each time drugs are administered to the body they are carried through the blood 
and are distributed to various tissues and fluids before being eliminated. As 
illustrated in Figure 6-3 drugs are deposited into the hair follicle via the blood 
and are trapped there permanently. The drug then grows out with the hair.  This 
is a simplistic model of how drugs are incorporated into hair and in reality other 
factors such as incorporation through sweat may play a part.(227) Many factors 
affect the rate at which drugs will be incorporated into the hair, with hair colour 
having significant impact.(228) 
 
Figure 6-3: Schematic of a hair follicle showing the incorporation of drug into hair.  
Drugs can also be present in hair samples due to contamination through the 
smoking or handling of drugs. In order to remove this external contamination, 
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hair samples must undergo thorough decontamination wash procedures.(228, 
229) However, it has been shown that it may not be possible to remove all 
external contamination from hair.(230) It is also important to ensure that hair is 
collected from acceptable sites, that an adequate volume is collected and that 
appropriate cut-off values are set. The Society of Hair Testing (SoHT) have 
recommended procedures, guidelines and cut-off values to help aid with the 
interpretation of hair concentrations.(231)  
Hair analysis is not a new technique having originally been applied to forensic 
analysis in the 1850’s when the presence of arsenic was identified in a body 
exhumed 11 years after burial.(232) Despite this matrix having such a long 
history, its use is still limited due to the long sample preparation, incubation 
times and limited compatibility with automation. The low concentrations 
detected often require highly sensitive instrumentation which not all 
laboratories have access to such as LC-MS/MS, and interpretation can be difficult 
due to changes in drug concentrations with time due to cosmetic treatments.  
Despite these difficulties, hair analysis in itself is relatively straight forward as 
no extensive metabolism or excretion occurs after the drug has been deposited. 
This makes is particular applicable to NPSs where the metabolites of these 
substances may not always be known, or commercially available. To date there 
has been no analysis of NBOMes in hair; as a result there are no recommended 
cut-off values from the SoHT.  
6.2 Aims  
The aim of this study was to establish a validated urine and hair method for the 
detection of 25B, 25C and 25I-NBOMe. The method should be fully validated in 
accordance with SWGTOX and SoHT guidelines.  
6.3 Materials & Methods 
6.3.1   Chemicals & Reagents 
All NBOMe reagents were purchased from Sigma Aldrich (Poole, UK). 
NaH2PO4.H2O, Na2HPO4 and NaOH were purchased from BDH (Poole, UK). HCOOH 
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and NH4CH3CO2 were purchased from Sigma Aldrich (Poole, UK). All other 
solvents were of analytical grade and were purchased from VWR (Poole, UK).  
Drug free urine and hair were provided from willing donors and screened prior to 
analysis. All analysis was carried out using pooled urine and hair samples from at 
least 10 donors. All solutions were prepared using Gilson PIPETMAN Classic™ 
accurate pipettes which had recently been calibrated in house. All urine was 
pipetted using an accurate Gilson MICROMAN® positive displacement pipette 
which had also recently been calibrated in house.   
6.3.1.1 2M NH4CH3CO2 
NH4CH3CO2 (3.85 g) was transferred to a 25 mL volumetric flask. This was then 
filled up to the mark with dH2O and inverted several times to ensure thorough 
mixing. This solution was then stored for up to 6 months in a labelled amber 
glass bottle at 4oC.  
6.3.1.2 0.1M pH7.4 Phosphate Buffer 
NaH2PO4.H2O (3.1 g) and Na2HPO4 (10.9 g) were weighed by accurate balance and 
dissolved in approximately 500 mL dH2O. This solution was then transferred to a 
1 L volumetric flask, made up to the mark with additional dH2O and inverted 
several times. This was stored at 4oC for up to 1 month in a clear glass bottle.  
6.3.1.3 Mobile Phase A  
HCOOH (1 mL) and 2 M NH4CH3CO2 (1 mL) were transferred to a 1 L volumetric 
flask. This was then made up to the 1 L mark with dH2O and mixed. This was 
stored at room temperature for up to 1 month in a clear glass bottle.  
6.3.1.4 Mobile Phase B  
HCOOH (1 mL) and 2 M NH4CH3CO2 (1 mL) were transferred to a 1 L volumetric 
flask. This was then made up to the 1 L mark with MeOH and mixed by inverting 
several times. This was stored at room temperature for up to 1 month in a clear 
glass bottle.  
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6.3.2 Preparation of Stock & Working Standards 
A stock solution (10 µg/mL) was prepared by transferring 1 mL of 25B-NBOMe, 
25C-NBOMe and 25I-NBOMe (100 µg/mL) to a 10 mL volumetric flask. This flask 
was then made up to the mark with MeOH before being stoppered and inverted 
several times to ensure thorough mixing. This calibration working solution was 
then transferred to a clean amber bottle, and stored at -20oC for up to 1 year. A 
second stock solution was made following the same procedure, by a different 
analyst producing the same final 10 µg/mL concentration. This was used for all 
QC’s.  
Three different working solutions were prepared at concentrations of 0.01, 0.1 
and 1 µg/mL from the calibration stock solution. The 1 µg/mL solution was 
prepared by transferring 1 mL of the 10 µg/mL solution to a 10 mL volumetric 
flask and making it up to the mark with MeOH. This 1 µg/mL solution was then 
used to make the 0.1 µg/mL solution by transferring 1 mL into a new 10 mL 
volumetric flask and making it up to the mark using MeOH. The same 1:10 
dilution was then carried out using the 0.1 µg/mL solution, making a 0.01 µg/mL 
solution. All solutions were transferred to labelled amber bottles which were 
stored at -20oC for up to 1 year.  
Another 3 working solutions were prepared from the QC stock solution to make 
QC working solutions (1, 0.1 and 0.01 µg/mL). Again these solutions were 
prepared by a different analyst, transferred to amber bottles and stored for up 
to 1 year at -20oC.  
A 1 µg/mL 25B-NBOMe-D3 I.S. solution was prepared. A 100 µg/mL 25B-NBOMe-D3 
solution was purchased, which was then transferred to a 10 mL volumetric flask 
using a Pasteur pipette. The flask was then made up to the mark using MeOH, 
inverted several times and stored at -20oC for up to 1 year. This was labelled as 
the stock solution. One mL of the stock solution was then transferred to another 
clean 10 mL volumetric flask and again made up to the mark using MeOH. This 
was inverted several times, and stored at -20oC for up to 1 year. The same 
procedure was followed by another student to make duplicate solutions for use 
when preparing QC’s.  
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6.3.3 Calibration & QC Preparation  
6.3.3.1 Urine Calibrators & QCs  
During this study it was not possible to purchase NBOMes with different lot 
numbers within the same company as only 1 lot had been produced. It was also 
not possible to buy all of these drugs from alternative companies as LGC only 
began selling these substances in the summer of 2015. No NBOMe standards are 
currently produced in the UK and the importation of these substances from the 
USA takes approximately 3 months, falling out with the completion time of this 
research. All QC solutions were prepared by a different analyst on different days 
to ensure the methods were as robust as possible.  
Urine calibrations and QCs were produced by spiking 1 mL of pooled drug-free 
urine with the relevant working solution as shown in Table 6-1 and Table 6-2. 
Table 6-1: Urine calibrator concentrations and the volumes of each working solution needed 
to produce them. 
Level 
Calibration 
Concentration 
(ng/mL ) 
NBOMe Standard 
Working 
Solution (0.01 
µg/mL) Volume 
(µl) 
NBOMe Standard 
Working 
Solution 
(0.1µg/mL) 
Volume (µl) 
NBOMe Standard 
Working 
Solution (1 
µg/mL) Volume 
(µl) 
1 0.1 10 0 0 
2 0.25 25 0 0 
3 1.0 100 0 0 
4 5.0 0 50 0 
5 25.0 0 0 25 
6 50.0 0 0 50 
7 100.0 0 0 100 
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Table 6-2: Urine QC concentrations and the volumes of each working solution needed to 
produce them. 
Level 
Calibration 
Concentration 
(ng/mL) 
NBOMe Standard 
Working 
Solution (0.01 
µg/mL) Volume 
(µl) 
NBOMe Standard 
Working 
Solution 
(0.1µg/mL) 
Volume (µl) 
NBOMe Standard 
Working 
Solution (1 
µg/mL) Volume 
(µl) 
QC 1 0.18 18 0 0 
QC 2 4.20 0 42 0 
QC 3 84.0 0 0 84 
 
6.3.3.2 Hair Calibrators & QCs 
Hair calibrations and QC’s were produced by spiking 40 mg of human hair with 
the below amounts from the relevant working solution as shown in Table 6-3 and 
Table 6-4.  
Table 6-3: Hair calibrator concentrations and the volumes of each working solution needed 
to produce them. 
Level 
Calibration 
Concentration 
(ng/mg) 
NBOMe Standard 
Working Solution (0.1 
µg/mL) Volume (µl) 
NBOMe Standard 
Working Solution (1 
µg/mL) Volume (µl) 
1 0.025 10 0 
2 0.05 20 0 
3 0.125 50 0 
4 0.250 100 0 
5 0.625 0 25 
6 1.25 0 50 
7 2.5 0 100 
 
Table 6-4: Hair QC concentrations and the volumes of each working solution needed to 
produce them. 
QC 
LEVEL 
Calibration 
Concentration 
(ng/mg) 
NBOMe Standard 
Working Solution (0.1 
µg/mL) Volume (µl) 
NBOMe Standard 
Working Solution (1 
µg/mL) Volume (µl) 
QC 1 0.105 42 0 
QC 2 1.05 0 42 
QC 3 2.10 0 84 
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6.3.4 Instrumentation  
Analysis of samples was carried out using an Agilent Technologies 6420 series 
triple quadrupole LC-MS/MS (Agilent, USA) coupled with an Agilent 1260 binary 
pump, autosampler, degasser and thermostated column compartment. An 
electrospray ionization (ESI) source was used in positive ionisation mode. The 
column used was a Phenomenex Gemini® 5 µm C18 110 Å (15 x 2 mm) with a 
Phenomenex Gemini C18 guard column (4 x 2.0mm).  
Urine samples were mixed and rotated using a Denley Spiramix 10 (Billinghurst, 
UK). A pierce Reacti-Vap™ III nitrogren (Thermoscientific, Loughborough, UK) 
manifold coupled with a Technie Dri-Block DB3 (Thermoscientific, Loughborough, 
UK) heating block was used for sample evaporation. A Sigma 4-16 centrifuge 
(Sigma-Aldrich, Dorset, UK) was used and hair samples were weighed using a 
Sartorius TE64-0CE accurate balance (Surrey, UK). All pipetting was carried out 
using Gilson PIPETMAN classic pipettes (Luton, UK). Positive displacement 
pipettes used were Gilson Microman® (Luton, UK). 
6.3.5 Operating conditions 
Isocratic elution of mobile phase A & B (50:50) was used, with a flow rate of 0.3 
mL/min. The total run time was 4 minutes with the column temperature kept at 
40oC. The gas temperature was 350oC with a flow of 11 L/min. The nebulizer was 
operated at 30 psi and the capillary voltage was 4000 V. LC and MS parameters 
are summarized in Table 6-5.  
Table 6-5: Summary of LC-MS/MS parameters 
LC Parameters 
Column Gemini® 5 µm C18 110 Å (15 x 2 mm) 
Mobile phase A & B (50:50) 
Flow rate 0.3 mL/min isocratic 
Injection volume 30µl 
Column temperature 40oC 
Run time 4 mins 
 
 
 
 
178 
 
Table6-5: Summary of LC-MS/MS parameters (cont.) 
MS Parameters 
Operating mode ESI 
Gas temperature 350oC 
Gas flow 11 L/min 
Nebulizer pressure 30 psi 
Capillary Voltage 4000 V 
Scan mode MRM 
 
The MRM transitions, dwell time, fragmentor voltage and collision energies used 
to monitor each of the analytes and I.S. are shown below in Table 6-6. All drugs 
had previously been optimised by another postgraduate student using Mass 
Hunter Optimiser software.  
Table 6-6: LCMS parameters used to monitor each NBOMe and I.S.  
Analyte Precursor Ion Product Ion Dwell Frag (V) CE (V) RT (mins) 
25B-NBOME-D3 383 124 50 110 20 2.2 
25B-NBOME 
380 121 50 115 20 2.2 
380 91 50 115 50 1.9 
25C-NBOME 
336 121 50 105 18 1.9 
336 91 50 105 50 1.9 
25D-NBOME 
428 121 50 120 20 1.8 
428 91 50 120 60 1.8 
 
An example chromatogram showing the elution time of all three analytes and the 
25B-NBOMe-D3 I.S is shown below in Figure 6-4.  
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Figure 6-4: Chromatogram showing the retention times for each analyte and I.S.  
 
6.3.6 LLE Urine Extraction Method 
As determined in section 2.5.3. LLE is a suitable method for the extraction of 
NBOMes from urine. This LLE method has also been used for the detection of 
these compounds previously in the literature.  
One mL aliquots of urine were transferred into glass culture tubes. Calibrators 
and QC’s were then produced by adding the relevant solution volumes to each 
tube as shown in Table 6-1 and Table 6-2. Calibrations were run in duplicate and 
QC’s were run in triplicate. To each tube 100 µl of 0.01 µg/mL 25B-NBOMe-D3 
I.S. was added, as well as 500 µl of 0.1 M NaOH solution. Extraction solvent (3 
mL) was then added to each test tube (50:50 hexane:EtOAc) and samples were 
rotated and mixed for 10 minutes using a Denley Spiramix 10. They were then 
centrifuged for 5 minute at 4000 rpm. These test tubes were then placed in the 
freezer (-20oC) for 5 minutes, freezing the bottom aqueous layer. The organic 
top layer was then decanted into another new glass culture tube. Samples were 
evaporated to dryness under nitrogen at room temperature. The samples were 
then reconstituted with 75 µl mobile phase mixture (50% mobile phase A: 50% 
mobile phase B). This solution was then transferred to autosampler vials for 
analysis by LC-MS/MS.  
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6.3.7 SPE Hair Extraction Method 
Hair QCs, QC’s and samples were washed with dH2O (3 mL) and CH2Cl2 (3 mL). 
Each wash was sonicated for 30 minutes at room temperature and any excess 
solvent was decanted into fresh 7 mL vials by pasteur pipette for later analysis. 
In between each wash any remaining solvent was evaporated to dryness using a 
gentle stream of nitrogen at room temperature. Hair was then cut into 1-2 mm 
segments and 40 mg (±1 mg) was weighed and transferred to new 7 mL vials. 
These were then spiked with 50µl of 25B-NBOMe-D3 (1 µg/mL). Calibrators and 
QC’s were made by adding the relevant solution volume as stated in Table 6-3 
and Table 6-4. To each vial, 3 mL of pH7.4 phosphate buffer were added before 
sonicating for 1 hour. Vials were then transferred to the oven where they were 
left to incubate overnight (12 hrs) at 40oC. Calibrators were run in duplicate and 
QC’s were run in triplicate. A schematic of this process is shown below in Figure 
6-5.  
After incubation, the samples were then centrifuged at 4000 rpm for 10 minutes. 
UCT Cleanscreen cartridges were conditioned using 2 mL MeOH, and 1 mL 0.1 M 
pH7.4 phosphate buffer. The supernatant from the centrifuged samples was then 
transferred to the conditioned SPE cartridges. SPE cartridges were then washed 
with 3 mL of dH2O and 1 mL of 1 M acetic acid before being dried for 10 minutes 
under vacuum. MeOH (3 mL) was then added to the cartridges before subsequent 
drying again under full vacuum for 1 minute. Elution was then carried out using a 
3 mL CH2Cl2/IPA/NH3 solution, before being evaporated to dryness under a slow 
stream of nitrogen, at room temperature. The samples were then reconstituted 
in 75 µl of mobile phase mixture (50% mobile phase A: 50% mobile phase B), 
vortex mixed for 30 seconds and transferred to vials for analysis by LC-MS/MS 
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Figure 6-5: Schematic of hair preparation prior to SPE clean up steps and LC-MS/MS analysis.  
 
6.3.8 Validation  
LC-MS/MS validation was carried out in accordance with ISO17025 standards and 
SWGTOX recommendations where possible. All parameters covered were the 
same as that for the GC-MS validation in Chapter 3 with the additional 
parameter of matrix effects.  
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6.3.8.1 Linearity 
Linearity was assessed by plotting the PAR of each NBOMe compound to I.S. 
against the corresponding concentration. The calibrators and QCs were prepared 
fresh each day using their respective working solutions. In order for the 
calibration to be deemed acceptable the calculated correlation coefficient (R2) 
had to be greater than 0.99. The concentrations of each QC were then 
calculated using the linear equation from each calibration curve. QCs were 
deemed acceptable if their accuracy fell within ±10% of the true value and their 
%CV values were <15%. The calibration model best suited to the analysis was also 
assessed for each drug.  
6.3.8.2 LOD and LOQ 
Both the instrumental and the experimental limits of detection were assessed. In 
order to assess the instrumental LOD, volumes ranging from 10-100 µl of a 1 
ng/mL mixed drug solution were evaporated and reconstituted in 75 µl of mobile 
phase and analysed. In order to determine the urine method LOD the same 
procedure was carried out, spiking 1 mL of urine with the same concentrations 
and extracting analytes as in section 6.3.6. A similar procedure was applied to 
hair samples, spiking 40 mg of hair with 10-100 µl of a 1 ng/mL mixed drug 
solution before extraction and analysis.  
LOD was determined as per section 3.3.10 using Equation 3-1. Hair analysis LOD 
results were then divided by 40 to produce the LOD per single mg of hair. 
6.3.8.3 Precision and Bias 
The accuracy and precision of each NBOMe extracted from urine was calculated 
using Equation 3-6 to Equation 3-10 as shown in section 3.3.12. In order to 
calculate intra-day precision triplicate analysis of QC1 (0.18 ng/mL), QC2 (4.20 
ng/mL) and QC3 (84.0 ng/mL) was carried out. The resulting values were 
averaged over 5 batches. Inter-day precision was calculated by analysing each 
QC in triplicate over a period of 5 batches and entering the data into Equation 
3-8 and Equation 3-9.  
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The same procedure was carried out for each NBOMe extracted from hair. In 
order to calculate intra-day precision triplicate analysis of QC1 (0.105 ng/mg), 
QC2 (1.05 ng/mg) and QC3 (2.10 ng/mg) was carried out.  
The percentage coefficient of variance (%CV) was then calculated, with values 
deemed to be acceptable when <20%.  
6.3.8.4 Carryover 
Carry over was assessed by triplicate injection of calibrator 7 followed by a 
mobile phase (50:50) flush. Carryover was deemed to have occurred if analytes 
were identified in the subsequent flush. This was carried out for both urine and 
hair validations. Calibrator 7 was deemed an acceptable level to assess as this is 
much higher than concentrations reported in literature and thus not likely to be 
encountered in samples.  
6.3.8.5 Selectivity 
In order to determine the selectivity of the method all analytes shown in Table 
6-7 were tested. In order to determine exogenous interferences, 100 µl of each 
10 µg/mL solution in Table 6-7 was transferred to a culture tube, evaporated to 
dryness and reconstituted in 75 µl of mobile phase. These were selected based 
on their high prevalence in everyday life such as paracetamol, caffeine and 
nicotine. GHB was chosen as it is endogenous to the human body, and the 
remaining drugs were chosen based on what was available at FMS. The same 
procedure was carried out using blank drug-free matrix from 10 different sources 
for both urine and hair to ensure that no components within the matrix itself 
interfered with the results.  
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Table 6-7: List of analytes used to check for interferences caused by exogenous compounds 
listed alphabetically.  
Analytes 
2-DPMP Cocaine Ketamine Norbuprenorphine 
3-MeO-PCE Codeine Lamotrigine Oxazepam 
3-MeO-PCP Cotinine Lignocaine Paracetamol 
5-APB Cyclizine Lorazepam Paroxetine 
6-APB Desipramine MDA Phenazepam 
6-MAM Diazepam MDEA Phenytoin 
7-
aminoflunitrazepam 
Diltiazem MDMA Pregabalin 
Amitriptyline Diphenhydramine MDPV Procyclidine 
Amphetamine Dipipanone Mephedrone Procyliding 
Atenolol DMD Methadone Promethazine 
Benzedrone Dosulepin Methamphetamine Propoxyphene 
Benzoylecgonine Doxepin Methandone-D9 Quetiapine 
Buprenorphine Ecgonine Methedrone Sertaline 
Butylone Ethylone Methiopropamine Sildenafil 
Caffeine Etizolam Methyl Ester Temazepam 
Chlordiazepoxide Flephedrone Methylone THC 
Chlorpheniramine Fluoxetine Mirtazapine THC-COOH 
Chlorpromazine Gabapentin Morphine Tramaol 
Citalopram GHB MXE Trazodone 
Clomipramine Haloperidol Naphyrone Venlafaxine 
Clonazepam Hydrocodine Nicotine Verapamil 
Cocaethylene Imipramine Nitrazepam Zolpidem 
 
Due to the short run-time of this method chromatographic separation between 
25B-NBOMe and its deuterated I.S was not always achieved, therefore it was 
necessary to ensure that neither were interfering with the others PA response. 
This was achieved by analysing 25B-NBOMe and 25B-NBOMe-D3 separately and 
examining the resulting data file for peaks after monitoring the respective MRM 
transitions.   
6.3.8.6 Matrix Effects & Extraction Efficiency 
Analyte ionisation suppression or enhancement is commonly encountered in LC-
MS. This may significantly affect concentrations detected, especially in the case 
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of suppression where concentrations may be reduced below that of 
quantification. In order to assess any suppression/ enhancement the Matuszewski 
method was used.(233) This method involved the analysis of 3 different batches 
of samples: pure standard, pre-extraction and post-extraction. Matrix effect was 
determined using QC3 calibrators for both hair and urine. Pooled matrix from at 
least 10 different individuals was used.  
Pure standard – 84 µl of 25B, 25C and 25I-NBOMe working standard mixture (1 
µg/mL) was added to 6 culture tubes. The methanolic solution was then 
evaporated to dryness using a steady stream of nitrogen at room temperature 
before reconstitution with 75 µl of mobile phase A and B mixture (50:50).  
Pre-extraction – QC3 samples (n=6) were produced as normal adding both I.S and 
drug mixture to each matrix prior to extraction. Samples were then extracted as 
in sections 6.3.6 and 6.3.7. 
Post-Extraction- Blank hair or urine calibrators (n=6) were extracted as normal 
without the addition of any I.S. or drug solution. Once extracted these blank 
matrix samples were spiked with 84 µl of drug mixture (1 µg/mL) and 50 µl of 
I.S. They were then evaporated to dryness using a steady stream of nitrogen and 
reconstituted in 75 µl mobile phase A and B mixture (50:50).  
All matrix samples were then analysed by LC-MS/MS with mobile phase flushes 
between each sample, after the highest level calibrator and between each QC to 
prevent carryover. Separate “pure standards” were made for each matrix being 
examined. Recovery, process efficiency and the matrix factor were then 
calculated using Equation 6-1 to Equation 6-3.  
Equation 6-1: Recovery % calculation 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (%) =
𝑃𝑟𝑒 − 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛 
𝑃𝑜𝑠𝑡 − 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛
𝑥 100 
 
Equation 6-2: Process efficiency calculation 
𝑃𝑟𝑜𝑐𝑒𝑠𝑠 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦: (%) =
𝑃𝑟𝑒 − 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛
𝑃𝑢𝑟𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
𝑥 100 
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Equation 6-3: Matrix factor calculation 
𝑀𝑎𝑡𝑟𝑖𝑥 𝐹𝑎𝑐𝑡𝑜𝑟 =
𝑃𝑜𝑠𝑡 − 𝑒𝑥𝑡𝑟𝑎𝑐𝑡𝑖𝑜𝑛
𝑃𝑢𝑟𝑒 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
𝑥 100 
 
No matrix effects are seen if the result of Equation 6-3 = 1. Suppression is 
determined if the result of Equation 6-3 <1 where as if it is > 1 then 
enhancement may be taking place. In order for the matrix factor to be deemed 
acceptable all results had to be within ±0.25.  
In section 2.4.1.12, recoveries were assessed by the addition of I.S. after the 
extraction had taken place and the comparison of these PAR’s with those of pure 
standards at the same concentration. Due to the possibility of matrix effects 
enhancing or suppressing the peak areas observed this approach is not 
appropriate for LC-MS. Therefore, extraction recovery was determined using 
Equation 6-1, eliminating the effect the matrix may have on the extraction 
procedure. 
6.3.8.7 Dilution Integrity 
The dilution of a sample may be necessary if the concentration detected in 
initial analyses is above the highest calibrator concentration, or the sample 
volume is below that required for the method. This method produces a wide 
concentration range, up to 100 ng/mL, and it is unlikely that urine samples will 
be received with concentrations higher than this, and thus low sample volume 
would be the most likely reason for sample dilution.  
Dilution integrity of urine samples was assessed by preparing 12 replicates of 
QC3 (84 ng/mL) and diluting these with the addition of 1 to 4 mL of blank urine, 
producing triplicate dilutions of 1:2. 1:3, 1:4 and 1:5. Each QC was then vortex 
mixed before transferring 1 mL of each diluted QC to separate culture tubes and 
extracting as in section 6.3.6. These were then run alongside calibrators and QCs 
prepared as in section 6.3.3.1. The concentration of each diluted calibrator was 
then calculated using the linear equation of each calibration curve.  
Hair samples would not undergo dilution but insufficient sample volume may be 
something which analysts encounter. In order to assess this, black rat hair 
samples (see Chapter 7) were analysed using 10, 20 and 40 mg of sample. 
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The dilution of each sample should not affect the calculated concentration. In 
order for integrity to be maintained, the mean concentration for each set of 
diluted QCs had to be within ± 15% of the true values, with %CV values <15%.  
6.3.8.8 Stability  
It is important that forensic toxicologists understand the stability of the samples 
they are interpreting as this may have an effect on the results obtained. In order 
to assess autosampler stability each QC was analysed in triplicate at 0, 24, 48 
and 72 hours after initial preparation. This is important as samples may not be 
analysed straight away, either due to the large number of samples being 
analysed or due to instrumental failure overnight or over a weekend.  
As NBOMe concentrations in biological matrices tend to be very low, the 
reconstitution volume for this method was reduced, as a result it is unlikely 
after 48 hours that any sample would remain in the vial to be analysed as it 
would have evaporated. In order to avoid sample evaporation, quadruple the 
amount of analyte and I.S. was used for this study. Samples were then 
reconstituted in quadruple the amount of mobile phase A and B mixture (50:50). 
This procedure was followed for both urine and hair calibrators.  
Another factor of analyte stability is its ability to undergo freeze/thaw and 
warm/cool cycles, as samples may need to be reanalysed, or analysed for 
additional drugs after initial screening. This is only a factor for samples which 
would be stored in fridge/ freezer environments and thus only applies to urine 
samples as hair samples would always be kept at room temperature.  
For the freeze/thaw and cool/warm stability, six of each urine QC were 
prepared as in section 6.3.3 with all volumes multiplied by 4, e.g. for QC1 4 mL 
of urine was spiked with 72 µl of NBOMe standard working solution (0.01 µg/mL). 
Each QC was then extracted and analysed as in sections 6.3.5, 6.3.6 and 6.3.7x. 
before storage. Three of each QC was stored at 4oC in order to assess the effects 
of cool/warm cycles and the remainder stored at -20oC to assess the effect of 
freeze/thaw cycles. These samples were then removed from storage, allowed to 
come to room temperature (22oC) and analysed as before. This was carried out a 
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total of 3 times to assess the impact of freeze- thaw cycles on these samples, 
alongside fresh calibrators and QCs.  
The PARs of each analyte were then plotted alongside the number of freeze 
thaws undergone to monitor for sample degradation. The analytes were 
considered stable if the PAR in comparison to those at time zero were within 
±20%.  
6.4 Validation Results & Discussion 
6.4.1 Linearity  
The three NBOMe compounds were linear over the extracted concentration range 
for both urine and hair analysis as shown in Figure 6-6 and Figure 6-7 
respectively. R2 values were >0.99. The peak area from the relevant MRM 
transition of each analyte to m/z 121 for the I.S. was used to calculate the PAR.  
 
Figure 6-6: Example urine calibration graphs for 25B, 25C and 25I-NBOMe. 
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Figure 6-7: Example hair calibration graphs for 25B, 25C and 25I-NBOMe. 
 
6.4.2 LOD and LOQ 
The instrumental LOD and extraction LODs for urine and hair were identified and 
calculated as well as the LOQs for each matrix. The results of these are shown in 
Table 6-8. All LOD results produced signal to noise ratios > 3, all LOQ results 
produced signal to noise rations >10. Hair extractions were carried out using 40 
mg of hair. The method LOD ranged from 250-500 pg/40 mg, which was 
detectable by the instrument, and higher than the urine LOD.  
Table 6-8: Summary of LODs for each NBOMe in each matrix.   
 
Instrumental 
(pg/mL)  
Urine (pg/mL) Hair (pg/mg) 
LOD LOD LOQ LOD LOQ 
25B-
NBOMe 
4 5 50 3 6.25 
25C-
NBOMe 
5 10 50 3 6.25 
215I-
NBOMe 
10 25 50 5 12.5 
 
The use of NBOMes have not been linked to DFSA cases as of yet and as there are 
no publications on the concentrations of NBOMes in hair it is unknown if these 
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limits would allow for the detection of single use exposure as required by the 
SOHT.(231)  
6.4.3 Precision & Bias 
The precision and bias for each analyte in urine and hair is shown below in Table 
6-9 and Table 6-10 respectively. Both methods showed suitable acceptability 
with all results within the SWGTOX suggested ±20%. Hair analysis showed better 
accuracy than urine analysis with results falling within ±10% of the true values.  
Intra-day precision results for urine QC’s were all <15%, ranging from 1.3-10.2%. 
25B-NBOMe showed the least intra-day precision, averaging at 2.3%, (1.3-3.4%). 
25I-NBOMe showed the most intra-day precision averaging at 7.3% (ranging 2.4-
14.9%).   
Urine inter-day precision results were all <15%, with the exception of 25I-NBOMe 
QC2, ranging from 4.1%-15.7%. Again 25B-NBOMe showed the least variation, 
averaging at 7.8% (4.3-12.7%), whereas 25I-NBOMe showed the most inter-day 
variation averaging at 9.1% (ranging 4.1-15.7%).  
25C-NBOMe showed the best accuracy results, all ranging within ±15%, where as 
25B and 25I-NBOMe fell within ±20% off the expected values. This is unexpected 
as 25B-NBOMe showed the most inter and intra-day precision. These stronger 
precision results are most likely due to the used of 25B-NBOMe-D3 as an I.S. As 
there is also a commercially available 25I-NBOMe-D3 standard available, this may 
produce better intra and inter day precision results.  
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Table 6-9: 25-B, 25-C and 25-I NBOMe intra-day and inter-day precision and accuracy in 
urine.  
Urine Results 25B-NBOMe 25C-NBOMe 25I-NBOMe 
Intra-day 
Precision 
(%CV) 
(n=18) 
QC 1 
(0.18 ng/mL) 
2.3 10.2 4.2 
QC 2 
(4.2 ng/mL) 
1.3 1.2 2.9 
QC 3 
(84.0 ng/mL) 
3.4 6.0 14.9 
Inter-day 
Precision 
(%CV) 
(n=18) 
QC 1 
(0.18 ng/mL) 
6.4 9.9 7.6 
QC 2 
(4.2 ng/mL) 
12.7 12.6 15.7 
QC 3 
(84.0 ng/mL) 
4.3 4.8 4.1 
Accuracy (%) 
(n=18) 
QC 1 
(0.18 ng/mL) 
80.3 105 118 
QC 2 
(4.2 ng/mL) 
117 98 99 
QC 3 
(84.0 ng/mL) 
104 114 113 
 
All intra-day hair precision results fell below <15%. Unlike urine results however, 
it was 25C-NBOMe which showed the least variability averaging at 4.9%, (ranging 
2.9-9.1%). 25B-NBOMe showed the largest intra-day variation averaging at 8.2% 
(ranging 2.6-12.1%).  
Hair inter-day precision results also showed variation <15%. All NBOMes 
performed roughly the same averaging at 7.1, 8.0 and 6.2% for 25B, 25C and 25I-
NBOMe respectively. Results ranged from 1.2-11.3%.  
Hair accuracy results were better than urine, all falling within ±10% of the 
expected value. 25B-NBOMe however gave the most accurate results (103-109%), 
closely followed by 25C-NBOMe (96-109%). Again this is unsurprising as the I.S. 
used was 25B-NBOMe-D3. Therefore, any differences observed in 25B-NBOMe 
analysis over the course of the validation should have been closely mimicked by 
25B-NBOMe.  
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Table 6-10: 25B, 25C and 25I- NBOMe intra-day and inter-day precision and accuracy in hair.  
Hair Results 25B-NBOMe 25C-NBOMe 25I-NBOMe 
Intra-day  
(n=18) 
QC 1 
(0.105 ng/mg) 
2.6 9.1 4.8 
QC 2 
(1.05 ng/mg) 
9.9 2.9 7.1 
QC 3 
(2.10 ng/mg) 
12.1 2.7 11.4 
Inter-day 
Precision 
(%CV) 
(n=18) 
QC 1 
(0.105 ng/mg) 
10.9 8.1 10.7 
QC 2 
(1.05 ng/mg) 
4.8 11.3 1.2 
QC 3 
(2.10 ng/mg) 
5.8 4.5 6.8 
Accuracy (%) 
(n=18) 
QC 1 
(0.105 ng/mg) 
109 96 102 
QC 2 
(1.05 ng/mg) 
104 105 110 
QC 3 
(2.10 ng/mg) 
103 109 94 
 
6.4.4 Carryover 
Carryover was observed after the highest urine standard as shown in Figure 6-8. 
The likelihood of having case samples with this concentration is extremely slim 
and it is therefore unlikely that this would result in carryover between case 
samples. However, if a high sample was observed the following sample would be 
re-injected after several flushes. The carryover observed was small in 
comparison to other standards accounting for <15% of the average area (n=6) for 
level 1 calibrators. It is therefore recommended that samples analysed after a 
high sample are re-injected and re-analysed.  
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Figure 6-8: Observed carryover after running highest standard (100 ng/mL) 
 
In order to determine an appropriate cut-off level for NBOMe concentrations 
identified in urine, a comparison was made between the flush after the highest 
calibration standard and the first calibration standard, the results of which are 
shown in Table 6-11. It is suggested from these results that to identify a sample 
as positive for the presence of 25B, 25C and 25I-NBOMe that the PA should be at 
least 3 times the peak found in the blank.  
Carryover may not be seen for newer LC-MS/MS models which contain specific 
flush ports, which flush the system for set amounts of time after each injection 
and therefore reduce the presence of carryover.  
Table 6-11: Carry over peak area versuss level 1 calibrator peak area. 
 MRM Transition Flush PA Level 1 PA % Difference 
25B-NBOMe 
428      121 509 2687 18.9% 
428      91 334 2132 15.7% 
25C-NBOMe 
366      121 750 5283 14.2% 
366      91 479 3953 12.1% 
25I-NBOMe 
380      121 1379 7754 17.8% 
380      911 807 4955 16.3% 
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6.4.5 Selectivity 
None of the analytes tested in Table 6-7 interfered with the urine or hair 
method as shown in Figure 6-9. Figure 6-9 (a) shows the chromatogram from 
each analyte tested overlaid and although there are peaks present around the 2 
minute mark these do not have the same retention times and therefore do not 
interfere with any of the analytes of interest as demonstrated by Figure 6-9 (b).  
 
Figure 6-9: Overlaid chromatograms of analytes used to examine method selectivity.  
Figure (a) shows the interference analytes alone, and (b) shows the interference analytes 
with the target analytes overlaid (Level 3 calibrator).  
 
I.S. and analyte interference results are shown in Figure 6-10. From these results 
it is clear that there is little interference caused between analyte and I.S. 
presence. Although there are peaks for the 25B-NBOMe transitions when I.S. was 
ran only, these are extremely low with peak areas of 50. Level 1 peak areas for 
25B-NBOMe hair calibrators (n=6) averaged at 1712, thus the carryover peak 
represents 2.9% of this value. Urine level 1 calibrators (n=6) averaged at 3507, 
thus the carryover peak represents 1.4% of this value.  It is therefore unlikely 
that the presence of either I.S. or analyte would significantly affect the other.  
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Figure 6-10: Analyte and I.S interference results.  
Figure (a) shows the results of 25B-NBOMe analysed without the presence of 25B-NBOMe-D3 
and figure (b) shows 25B-NBOMe-D3 analysed without the presence of 25B-NBOMe. 
 
There were no interfering peaks from either matrix tested in this method as 
shown in Figure 6-11 and Figure 6-12.  
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Figure 6-11: Blank pooled rat hair (n=55) showing no matrix interferences. 
(a) -25B-NBOMe, (b)- 25C-NBOMe, (c)-25I-NBOMe. 
 
 
 
Figure 6-12: Blank pooled human urine (n=10) showing no matrix 
interferences.  
(a) -25B-NBOMe, (b)- 25C-NBOMe, (c)-25I-NBOMe. 
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6.4.6 Stability 
6.4.6.1 Freeze Thaw Stability (-20oC) 
Repeated freeze thaws of urine samples stored at -20oC resulted in significant 
loss of sample over 3 freeze thaw cycles with an average loss of 32% across all 
analytes in QC1 as shown in Table 6-10.  
For QC1, 25I-NBOMe was the most affected analyte seeing a decrease of 35%. 
From Figure 6-13 it can be seen that most analytes were stable up to the 3rd 
freeze thaw cycle when concentrations significantly decreased, in particular for 
25I-NBOMe. The large increase in sample concentration was observed for the 
second freeze thaw cycle of 25I-NBOMe. This is most likely due to analysis error, 
as shown by the larger error bars associated with this point.   
 
Figure 6-13: Freeze thaw results for urine QC1 containing 25B,25C and 25I-NBOMes stored at 
-20oC. 
 
The same downward trend was also seen for QC2 and QC3 as shown in Figure 
6-14 and Figure 6-15. QC2 lost an average of 37% of each analyte where as QC3 
lost on average 58%. QC3 was the most affected losing on average 19% of 
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analytes after only 1 freeze thaw cycle. QC2 was within the ±20% range after 2 
freeze thaw cycles.  
 
Figure 6-14: Freeze thaw results for urine QC2 containing 25B, 25C and 25I-NBOMes stored 
at -20 oC. 
 
 
Figure 6-15: Freeze thaw results for urine QC3 containing 25B, 25C and 25I-NBOMes stored 
at -20oC. 
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6.4.6.2 Fridge Cool/ Warm Stability (+4oC) 
Samples may also be stored in the fridge and again a downward trend was shown 
for samples undergoing fridge thaw cycles. QC1 was stable up to 2 fridge thaw 
cycles, as shown in Figure 6-16. 25I-NBOMe showed an unsuspected increase 
after 2 fridge thaw cycles, however this was most likely due to analyst error as 
shown by the wider error bar associated with this point.  
 
Figure 6-16: Fridge thaw results for urine QC1 containing 25B, 25C and 25I-NBOMes stored at 
-4oC. 
 
  
Figure 6-17: Fridge thaw results for urine QC2 containing 25B, 25C and 25I-NBOMes stored at 
-4oC. 
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QC2 and QC3 were stable up to 1 fridge thaw cycle however after 3 cycles had 
lost 47% and 45% respectively as shown in Figure 6-17 and Figure 6-18. In both 
cased 25B-NBOMe was the most affected analyte losing 53% and 49% of analyte 
after the third cycle.  
  
Figure 6-18: Fridge thaw results for urine QC3 containing 25B, 25C and 25I-NBOMes stored at 
-4oC. 
 
These results show that any fridge/ freeze thaw cycles should be avoided when 
analysing for 25B, 25C and 25I-NBOMe. All QCs were stable for 1 thaw cycle 
however most analytes had lost more than 20% by the second cycle regardless of 
being stored in fridge (4oC) or freezer (-20oC).  
6.4.6.3 Autosampler Stability 
All analytes extracted from urine showed significant degradation whilst on the 
autosampler after 72 hours, with all QC1 and QC3 results failing to meet the 
<20% acceptability cut-off as shown in Table 6-12. Only the 25C and 25I-NBOMe 
QC2 met the ±20% requirements with recoveries of 84.6% and 89.5% respectively 
Table 6-12. 25B-NBOMe was the most affected analyte over the 72-hour time 
period, with an average recovery of 66.0% (50.9-75.0%). 25I-NBOMe was the least 
affected analysed over the 72-hour time period, with an average recovery of 
82.4% (77.8-89.5%). Recovery for all analytes did not decrease by more than 20% 
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after 24 hours, with average % recovery values of 96.5, 9.3 and 92.8% 
respectively for all 3 QC’s.  
Table 6-12: Urine autosampler results. 
  25B-NBOMe 25C-NBOMe 25I-NBOME 
Q1 (PAR) 
t=0 0.004 0.008 0.009 
t=24 0.004 0.007 0.008 
t=48 0.003 0.006 0.007 
t=72 0.003 0.005 0.007 
Recovery % 75.0 62.5 77.8 
Q2 (PAR) 
t=0 0.079 0.13 0.19 
t=24 0.079 0.13 0.18 
t=48 0.067 0.11 0.18 
t=72 0.057 0.11 0.17 
Recovery % 72.2 84.6 89.5 
Q3 (PAR) 
t=0 1.36 2.05 4.27 
t=24 1.22 1.83 4.05 
t=48 0.876 1.45 3.93 
t=72 0.692 1.325 3.41 
Recovery % 50.9 64.6 79.9 
 
Hair autosampler stability results are shown in Table 6-13. The stability of hair 
samples is particularly encouraging however, as due to instrument failure no 
data could be collected at the 48 and 72-hour time period. Therefore these 
samples were analysed again at 120 hour. Both 25C and 25I-NBOMe showed 
acceptable stability results over the 120-hour time period with recovery values 
±20% of the original. 25I-NBOMe however, fell slightly outside this for QC2 and 3 
with recoveries of 123.3 and 123.7%. On average 25C-NBOMe remained the 
truest to its original recovery with an average result of 101.7% across all 3 QC’s.  
It is much more likely that hair samples would not be able to be re-extracted 
due to limited sample volume and thus this parameter is more important for this 
matrix should instrument failure occur and reinjection of samples is necessary.   
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Table 6-13: Hair autosampler results.  
  25B-NBOMe 25C-NBOMe 25I-NBOME 
Q1 (PAR) 
t=0 0.12 0.15 0.15 
t=24 0.17 0.17 0.14 
t=120 0.14 0.13 0.17 
Recovery % 116.67 86.67 113.33 
Q2 (PAR) 
t=0 1.03 1.36 1.07 
t=24 1.46 1.82 1.00 
t=120 1.27 1.47 1.23 
Recovery % 123.30 108.09 114.93 
Q3 (PAR)  
t=0 2.19 2.79 2.25 
t=24 3.15 3.89 2.05 
t=120 2.71 3.08 2.61 
Recovery % 123.74 110.39 116.00 
 
It is not known why there is such a marked difference between urine and hair 
results for autosampler stability (50.9-89.5% and 86.67-12.7% respectively for 
each matrix). Both use different extraction techniques and it is possible that 
matrix contamination is still present in urine samples extracted by LLE, which 
are negatively affecting the concentrations of these samples.  It is also probable 
that as the PAR’s for urine samples are so small due to the wider concentration 
range of this calibration curve that any differences observed have a greater 
impact on the % recovery results.  
6.4.7 Matrix Effects and Extraction Efficiency 
The matrix effect, process efficiency (%) and recovery (%) for both urine and hair 
are shown below in Table 6-14 and Table 6-15. From this information it can be 
shown that no significant ion suppression or enhancement from the matrix was 
observed.  
LLE extraction of 25B, 25C and 25I-NBOMe from urine was extremely efficient 
with % recoveries ranging from 89-102%. Urine process efficiency was also good 
ranging from 89.4-102.6%.  
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Table 6-14: Matrix effects, process efficiency and recovery for urine QCs 1&3. 
 25B-NBOMe 25C-NBOMe 25I-NBOMe 
Matrix Effect 
QC1 1.05 1.17 1.03 
QC3 0.96 1.09 0.98 
Process 
Efficiency (%) 
QC1 103.9 104.1 95.0 
QC3 98.5 101.5 89.4 
Recovery (%) 
QC1 99.1 89.1 92.4 
QC3 102.6 92.9 89.5 
 
Hair extraction recovery (%) values were not as good as urine extraction, ranging 
from 80.5-107.5% over all compounds and QC levels. Matrix suppression was seen 
for 25I-NBOMe although this was within the ±0.25 limits of acceptability. 25I-
NBOMe process efficiency was also low averaging at 61.63% across both QC’s.  
Table 6-15: Matrix effects, process efficiency and recovery for hair QCs 1&3. 
  25B-NBOMe 25C-NBOMe 25I-NBOMe 
Matrix Effect 
QC1 1.05 1.12 0.82 
QC3 0.93 1.04 0.77 
Process 
Efficiency (%) 
QC1 98.21 93.30 68.28 
QC3 93.97 103.80 54.98 
Recovery (%) 
QC1 93.94 83.31 83.18 
QC3 86.99 107.46 80.48 
 
6.4.8 Dilution Integrity  
The dilution integrity for urine samples was assessed and the results are shown 
in Table 6-16. All dilution % accuracy results fall within the selected <20% 
criteria with the exception of the 1:4 dilution. For this particular dilution 25I-
NBOMe fell slightly out with the accepted <±20% limit, at +21.7% and 25B-NBOMe 
fell further outside this limit at +29%. 25C-NBOMe was the only analyte to 
remain within ±20% for all dilutions. 25B and 25I-NBOMe samples should 
therefore only undergo a maximum of 1:3 dilutions in order to comply with 
original precision and bias requirements. 25C-NBOMe is able to undergo a 1:4 
dilution if necessary, whilst retain acceptable accuracy results.  
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Table 6-16: Dilution integrity of urine samples. 
 25B-NBOMe 25C-NBOMe 25I-NBOMe 
 
Accuracy 
% 
%CV 
Accuracy 
% 
%CV 
Accuracy 
% 
%CV 
1:1 92.5 1.1 85.8 1.7 94.1 4.0 
1:2 115.8 0.9 103.0 5.6 117.9 5.2 
1:3 97.2 0.5 97.2 0.7 101.1 1.3 
1:4 129.0 1.0 113.1 1.8 121.7 1.9 
 
The brief hair study investigating the effects of limited sample weight showed 
that both 25B and 25C-NBOMe produced concentrations with accuracy results 
±15% when only 10 or 20 mg of hair was used. 25I-NBOMe on the other hand fell 
slightly out with these limits with a % accuracy result of 81.8% (-19.2%) as shown 
in Table 6-17. 
Due to limited sample volume it was not possible to analyse samples in triplicate 
and as a result the variation between the PARs of each sample may be due to 
analyst error. Ideally, once further hair samples become available this 
experiment should be repeated, with each weight analysed in triplicate.  
Table 6-17: Hair sample results.  
 
PAR 
Accuracy (%) 
10 mg 20 mg 40 mg  
25B-NBOMe 0.11 0.08 0.09 81.8 
25C-NBOMe 0.15 0.15 0.15 100.0 
25I-NBOMe 0.10 0.08 0.09 90.0 
 
6.4.9 Comparison of LC-MS/MS method with GC-MS method 
The LC-MS/MS method detailed in this chapter provided a much more robust and 
sensitive method when compared to the GC-MS method validated in Chapter 3. 
The MS/MS capabilities of the LC-MS/MS meant that the LOD and LOQ for urine 
samples were significantly lower. The LC-MS/MS method had an LOD ranging 5-25 
pg/mL in contrast to the GC-MS method which only detected down to 200 
pg/mL. The LC-MS/MS had a much better LOQ at 50 pg/mL in contrast to the GC-
MS method which was only able to quantitate as low as 500 pg/mL. This is 
unsurprising as previously published methods all use LC-MS/MS for the detection 
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for NBOMes in biological matrices. Although this method was validated for urine 
and hair, it is likely that had it been validated for blood and applied to samples 
received from NMS (Chapter 3), the NBOMe concentrations present would have 
been quantified. This was not possible however, as GC-MS analysis took place in 
Philadelphia, whereas this method was validated in Glasgow. Samples were 
unable to be transferred between institutions due to on-going collaborative 
research with NMS and the FRFRF. The cost of sample transfer would also be 
significant for such a small number of samples as they would be sent via 
international courier on dry-ice.  
The GC-MS analysis was carried out using a new column, with the injection port 
and liner changed after every 100 injections in order to keep the instrument as 
sensitive as possible. This additional maintenance was not required for the LC-
MS/MS method, making this method for the analysis of these 3 NBOMes less time 
consuming, more sensitive and more robust than that of the GC-MS method.  
6.5 Conclusion 
A simple and quick quantitative LC-MS/MS method for the analysis of 3 common 
NBOMes was developed and validated for hair and urine samples according to 
SWGTOX guidelines. The speed of this method allows for high sample 
throughput, with time limiting steps being the sample preparation itself. The use 
of LLE for urine provided a rapid and yet efficient sample extraction technique 
with recoveries ranging from 89.5-102%. Both methods cover a wide 
concentration range; 0.1-100 ng/mL for urine and 0.025-2.5 ng/mg for hair.  
To date there has been no previously published method for the detection of 
NBOMes in hair. Although the hair method is slightly more time consuming than 
that of the urine method, this could be improved by the use of an automated 
SPE system.  
6.6 Future Work  
Further work should be completed on the LC-MS/MS method to fully validate this 
to ISO17025 standards. Furthermore, the addition of newer NBOMes to the panel 
would be beneficial as and when more become available, in keeping with other 
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published methods and also keeping up with what drugs are available/ being 
abused. 
This method only examined hair and urine as these were the matrices collected 
during the rat studies (Chapter 7). It would therefore seem logical to expand this 
to include whole blood, plasma and serum, especially as concentrations would 
typically be low and thus MS/MS would be required for their detection.  
Autosampler stability should be re-examined. As loss of analytes has been 
shown, it may be useful to repeat this experiment analysing for the presence of 
metabolites alongside that of the parent compound.  
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Chapter 7: Detection of NBOMes in Rat Hair and 
Urine Samples 
7.1 Introduction 
In order for drugs to be excreted by the body they undergo metabolism, typically 
into more water soluble forms. Metabolism typically occurs in the liver, subject 
to route of administration, and it is here that these processes are catalysed by 
microsomal membrane bound enzymes in the hepatocytes such as the 
cyctochrome P450 system.(234) Many drugs undergo a combination of Phase I 
(oxidation, hydroxylation, de-alkylation and sulfoxide formation) and Phase II 
(conjugation) metabolism.(170) Phase I metabolism occurs via the CYP450 family 
of enzymes, specifically CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4, the 
latter of which is involved in the metabolism of around 55% of drugs.(235) As a 
result, metabolism via CYP3A4 is typically the first to be assessed during 
metabolism studies.  
Many drugs undergo rapid metabolism so that by the time of analysis it is not the 
parent drug which is analysed, but the metabolites. For this reason, it is 
important to know how particular drugs are processed by the body in order to 
determine which compounds will be present by the time of sample collection. 
For example, when analysing heroin it is not the parent drug diamorphine which 
is looked for, but instead 6-monoacetylmorphine and morphine.(236) By 
targeting metabolites, a much more sensitive and specific analysis can be 
achieved, thus enabling the toxicologist to provide a more accurate 
interpretation of results.  
In vivo studies are extremely rare and difficult to carry out due to various 
ethical issues and although there are alternative in-vitro methods available, 
these can be expensive, and are much more complex to carry out.(237) An 
alternative to this is the use of animal models. Rodents are typically used as the 
ideal animal model as they are small, easily housed, and cheaper than other 
animals. The results of these tests can then be compared to “real life” human 
case samples to establish if the same metabolites are seen and to the same 
degree. This method has been routinely used for other compounds such as 
synthetic cathinones.(101, 178-180, 238) When using rodents they are typically 
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placed into metabolism cages which contain a raised wire mesh floor across the 
bottom of the cage, allowing for the separation of urine and faeces from the 
rodent. (239)  
Another benefit of animal models is that these allow for the behavioural effects 
of compounds to be studied. As more NPSs are launched into the recreational 
drug market it becomes much more difficult for A&E staff to know the effects 
and behaviours exhibited by individuals on these drugs. As a result it is useful to 
use animal models to try and predict any adverse reactions which may be 
observed by users.  
The use of animal models allows for testing to be carried out on both traditional 
and untraditional matrices. Therefore allowing toxicologists the chance to study 
matrices which they may not routinely come into contact with but which may be 
of scientific interest, especially for compounds which are not routinely seen in 
post mortem samples.  
Many drugs cause the user to have reduced or heightened reactions to pain. 
Whether a drug has an analgesic effect can be determined by the use of tail flick 
experiments. These can be conducted using water baths or by placing the animal 
on a hot plate and monitoring the animal’s reaction to heat.(240, 241) An 
increase in the animal’s response time shows that the drug has an analgesic 
affect, whereas a reduction shows the drug enhancing pain. After time the 
effects may be reduced which signifies the animal has grown tolerant to the 
drug.  
This research involves the analysis of NBOMes which are hallucinatory stimulant 
drugs and although analgesia is commonly linked to central nervous system 
depressants, it has been observed in other stimulants such as amphetamines and 
synthetic cathinones.(242-244) Administering drugs to animal models allows for 
more in-depth analysis of their effects and more importantly their toxicity which 
ethically cannot be completed in human patients.  
There are however limitations to the use of animal models. Some drugs will not 
undergo metabolism the same way as humans do. As a result animals may or may 
not experience effects which are or aren’t shown in humans.(245)  
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7.2 Aims  
This work aims of this research was to extract 25B, 25C and 25I-NBOMe from rat 
hair by using a phosphate buffer incubation and SPE clean up method. Additional 
objectives including assessing any dose response relationship and determining 
whether the colour of hair affects concentration as seen with other 
phenethylamines. This work also aims to extract and quantitate 25B, 25C and 
25I-NBOMe from rat urine and identify any metabolites which may also be 
present.  
7.3 Materials & Methods 
7.3.1 Subjects 
Male Long Evans rats (Charles River, MA, USA) were used for this investigation. 
Animals were housed singly as shown in Figure 7-1, in a humidity and 
temperature controlled laboratory with 12:12 hour light:dark cycles. Animals 
entered the laboratory at age 3 weeks old and weighed 28-50g at the start of the 
study. Animals were given 7 days to acclimatise to their surroundings before any 
experimental work commenced and had ad libitum access to food and water. All 
procedures were conducted during the dark cycle, under protocols approved by 
the Institutional Animal Care and Use Committee (IACUC). The IACUC proposal 
and approval letter can be found in Appendix 12 and Appendix 13 respectively.  
All individuals assisting with this research had completed the Collaborative 
Institutional Training Initiative (CITI) and received hands-on training prior to any 
experimental work. Citi training certificates can be found in Appendix 14. 
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Figure 7-1: Diagram of rat housing 
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7.3.2 Chemicals  
Reference standards of 25B-NBOMe, 25C-NBOMe and 25I-NBOMe (10 mg powders) 
were purchased from Cayman Chemical Company. DMSO (Sigma Aldrich, MO, 
USA) was used as the injection vehicle in saline. Syringes and needles were 
purchased from Fisher scientific. Needles were replaced after each injection and 
syringes were changed daily for each drug used. 
HCOOH was purchased from Sigma Aldrich (MO, USA). MeOH, acetic acid and all 
other solvents and chemicals were all of analytical grade and all purchased from 
VWR (TX, USA). 
7.3.3 Instrumentation  
The instrumentation used for this work was the same of that listed in Chapter 6. 
The Agilent Technologies 6420 series triple quadrupole LC-MS/MS (Agilent, USA) 
was operated using the same parameters as those listed in Table 6-5.  
7.3.4 Injection Solutions 
Each NBOMe drug (5 mg) was dissolved initially in 100 µL of DMSO. This was then 
further diluted with 4.9 mL of saline solution in a 5 mL volumetric flask, giving a 
1 mg/mL solution. Saline was produced as per section 2.4.1.2. From this 
solution, 1.66 mL was transferred and further diluted with 3.34 mL saline 
solution to yield a concentration of 0.33 mg/mL. A further 1 mL of the 1 mg/mL 
solution was transferred to a volumetric flask and again made to the 5 mL mark 
by adding 4 mL of saline solution to produce the least concentrated solution of 
0.1 mg/mL. The 1 mg/mL solution was used for rats receiving the highest dose 
(0.1 mg/kg), the 0.33 mg/mL solution was used for rats receiving the medium 
dose (0.03 mg/kg) and the 0.1 mg/mL solution was used for rats receiving the 
lowest dose (0.01 mg/kg). Due to the little information available about NBOMe 
doses LSD was used as a guideline when determining suitable doses.(246)  
7.3.5 Tail Flicks and Injections 
Rats were weighed upon arrival and daily at 9 am (±1 hour) throughout the 
experiment. Rats were visually inspected during weighing for signs of distress 
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such as porphyrin staining. Rats, like all vertebrate, have Harderian glands, 
producing lipids to lubricate the eye. In the case of rats these glands also 
produce porphyrin, and when stressed, ill or poorly fed over produce porphyrin. 
This dries around the eye colouring the surrounding area red, known as porphyrin 
staining. Any rats which did not show significant weight gain over the 1-week 
grace period or which showed signs of distress were excluded from the 
experiment. This amounted to a total of 4 of the 59 rats received leaving 55 rats 
fit for experiments. All rats (n=55) were initially shaved after the 1-week grace 
period along their backs, collecting both black and white hair separately in clean 
7 mL vials. 
Each rat was injected intraperitoneally (IP) with either the low (30 µg/kg), 
medium (100 µg/kg) or high dose (300 µg/kg) of a single NBOMe drug as shown 
below in Figure 7-2. 
 
Figure 7-2: Schematic of rat dosing.  
 
The amount of solution injected into each rat was calculated as per Equation 7-1 
based on the rats weight. Control rats were injected with the equivalent volume 
of DMSO:saline solution.  
55 Rats
25B-NBOMe
(n=16)
300 µg/kg
(n=6)
100 µg/kg
(n=6)
30 µg/kg
(n=5)
25C-NBOMe
(n=15)
300 µg/kg
(n=5)
100 µg/kg
(n=5)
30 µg/kg
(n=5)
25I-NBOMe
(n=18)
300 µg/kg
(n=6)
100 µg/kg
(n=6)
30 µg/kg
(n=6)
Controls 
(n=5)
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Equation 7-1: Rat injection volume calculation  
𝐼𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑉𝑜𝑙𝑢𝑚𝑒 (𝑚𝐿) = 𝑑𝑜𝑠𝑒 (µ𝑔 𝑘𝑔⁄ ) 𝑥 𝑟𝑎𝑡 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔) 
 
Rats were then left in their cages for 15 minutes before tail flick experiments 
were commenced. Tails were marked 8 cm from the tip prior to the beginning of 
the experiment with a permanent marker to ensure consistent tail immersion 
throughout the experiment. Tail flicks were conducted on 3 occasions prior to 
injections to produce a baseline for each rat. Each rat was wrapped in a small 
towel, leaving only their tails exposed. The tails of each rat were then immersed 
up to the 8 cm pen mark in a water bath (52oC). The length of time taken from 
immersion to the rat “flicking” its tail out of the water was recorded by a 
stopwatch. The same individual recorded all time measurements to limit 
variability in this step.  
A rat from the highest dose group for each drug was left in a metabolism cage 
after its tail flick test until all experiments had been completed for that day. 
After returning the rat to its normal cage urine was collected from the bottom of 
the metabolism cage, transferred to vials by pasteur pipette and stored at -20oC 
for later analysis (see section 7.3.6). Only rats injected with the highest dose 
were kept in the metabolism cages as their urine was expected to provide the 
highest concentration of any detectable metabolites. This also reduced the 
number of animals which entered the metabolism cages as these can be stressful 
for the animals involved.(247) Having already lost 4 rats to stress it was deemed 
appropriate to keep the number of rats entering the metabolism cage as small as 
possible, should any show adverse signs. A different rat from each drug group 
was chosen each day to enter the metabolism cages, again to reduce any 
additional stress on the animals. Urine was pooled, and approximately 10 mL 
was collected over the 8-day period. Rats were injected over a period of 9 days 
at 10 am each day (±30 minutes). After 8 days of injections the rats were re-
shaved in the same place as the initial shaving, with shavings separated by dose 
and colour. Hair from animals receiving the same drug at the same dose was 
pooled and stored in vials for later analysis (see section 7.3.7). At the end of the 
study all rats were sacrificed using CO2 or frozen for further research out-with 
the remit of this thesis.  
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Tail flick data was analysed by SSPS software (version 19). This was used to test 
for any significant differences between the length of time of the tail flicks 
between the control group and those receiving doses of NBOMe’s.  
 
7.3.6 Urine Analysis  
Rat urine samples were analysed using the validated LC-MS/MS method discussed 
in Chapter 6. The three urine samples were analysed in triplicate. Samples were 
extracted as per the LLE urine extraction method described in 6.3.6. Calibrators 
and QCs were run alongside the samples, again prepared in accordance with 
chapter 6.  
In order to determine if any metabolites were present, the MRM method was 
altered to analyse for de-methylated metabolites using the MRM transitions 
shown in Table 7-1. These transitions relate to the parent compound minus 1, 2 
or 3 methyl groups.  
Table 7-1: MRM transitions monitored for demethylated metabolites. 
Drug -1 Methyl Group -2 Methyl Groups -3 Methyl Groups 
25B-NBOMe 366 352 338 
25C-NBOMe 322 308 294 
25I-NBOMe 414 400 386 
 
In order to identify if there were any additional metabolites present, the urine 
samples were also analysed using a Bruker QToF. This screening technique allows 
for the detection of compounds using their exact mass and can be used in a 
targeted way, where the exact mass of a substance is already known, or 
untargeted, where the QToF collects all the mass data relating to every 
molecule within a single sample.  
7.3.7 Hair Analysis  
Long-Evans rats were chosen specifically for this study as they grow both black 
and white hair as illustrated in Figure 7-3. This allows for the detection of drug 
in different coloured hair without the additional variables of drug dose, and 
individual rat metabolism. 
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Figure 7-3: Image of Long-Evans rat 
 
Rat hair samples were analysed in triplicate as per the validated LC-MS/MS 
method discussed in Chapter 6. Samples were washed and extracted as per the 
SPE hair extraction method described in 6.3.7. Calibrators and QCs were run 
alongside samples; again these were prepared in accordance with 6.3.3.2. Hair 
wash solutions were stored for analysis in order to determine whether any 
NBOMe concentrations could be a result of external contamination, i.e. by 
injection solution dripping onto the hair of the animal prior to injection, sweat, 
urine or faeces.  
7.4 Results & Discussion 
7.4.1 Tail Flicks 
Using the SSPS software package it was found that there was no statistically 
significant difference between the tail flick times of each drug group, or 
between drug groups and controls as illustrated by Figure 7-4 to Figure 7-6. 
There was also no statistically significant difference between differing doses or 
between the weight gains of each animal over the 8-day period. As a result these 
drugs were shown to not produce analgesia at the doses provided.  
The stability of these compounds in DMSO:Saline is also not known, and as a 
result it cannot be guaranteed that the rats received the same amount of drug 
each day, or whether the solution degraded over the course of the 8 days.  
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Figure 7-4: Average tail flick response times (seconds) from rats receiving 30, 100 and 300 
µg/kg doses of 25B-NBOMe.  
*B=25B-NBOMe 
 
 
Figure 7-5: Average tail flick response times (seconds) from rats receiving 30, 100 and 300 
µg/kg doses of 25C-NBOMe. 
*C=25C-NBOMe 
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Figure 7-6: Average tail flick response times (seconds) from rats receiving 30, 100 and 300 
µg/kg doses of 25I-NBOMe. 
*I-25I=NBOMe 
 
7.4.2 Behaviour 
As part of IACUC approval, all rats were monitored for 1-hour post injection. 
Rats injected with NBOMes were much more active than the control rats, 
displaying significant rearing, correlating with Poklis’ findings.(248) Head 
twitching was observed which is typical of 5-HT2A receptor activation, which has 
been identified by others. This was not quantified though as typically this 
involves mounting magnetics to the head of the rat so that the head twitches 
can be digitally recorded.(249) The mounting of magnets to the head of a rat 
involves surgery which fell out with the expertise of Arcadia University and the 
IACUC protocol. 
Rearing is another common behaviour shown in rats undergoing 5-HT2A receptor 
activity. While hallucinating, rats commonly rear and stretch in their cages. This 
can be monitored using an activity monitor such as a video path analyser.(250) 
Video path analysers were not available at Arcadia University and fell out with 
the purchasing limit of this project. Therefore, although rearing was observed in 
all drug dosed animals this was not quantified. These observations coupled with 
that of the head twitches shows strong indications that there was activity at the 
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5-HT2A receptors. This correlated with previously published research, where 
head twitch responses and rearing were also witnessed.(248)  
This study was conducted summer 2014 and at this time point very little 
information regarding doses was available. It was therefore not known what 
doses the rats would be able to handle without having adverse reactions such as 
seizures and possibly death. Due to the nature of the data collected from these 
animals they had to survive injections over multiple days. Since this research 
was carried out more rodent studies have been published using higher doses. The 
majority of these publications induced seizures and even death, which was not 
part of this IACUC proposal.(251, 252) 
7.4.3 Urine Samples  
All urine samples tested positive for their expected NBOMes as shown below in 
Figure 7-7. As seen with hair samples 25C-NBOMe provided the highest detected 
concentrations, however this was then followed by 25I-NBOMe, and finally 2B-
NBOMe. 
 
Figure 7-7: NBOMe concentrations detected in rat urine after dosing (300 µg/kg).  
 
The urine samples were then re-injected, with peaks being observed from MRM 
transitions relating to demethylation at one site as shown in Table 7-1. In order 
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to confirm whether these “metabolite peaks” were due to metabolites 
themselves or to de-methylation taking place in the LC-MS/MS, 100 µl of 25B, 
25C and 25I-NBOMe mixture (1 ng/mL) was evaporated and reconstituted in 75 µl 
of mobile phase. This was then analysed using the same method monitoring the 
demethylation ions as well as those of the parent. From this it is clear that 
demethylation of the parent compound is not occurring in the LC-MS/MS, as the 
reference standard compounds only produced peaks for the parent MRM 
transitions and not those associated with demethylation. This is shown in Figure 
7-8 to Figure 7-10. 
 
Figure 7-8: Chromatogram showing comparison of 25B-NBOMe rat urine sample (a), with 25B-
NBOMe reference drug (b). The parent drug is shown in the top chromatogram with the 
metabolite peaks in the other 2. 
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Figure 7-9: Chromatogram showing comparison of 25C-Urine rat sample (a), with 25C-NBOMe 
reference drug (b).  
The parent drug is shown in the top chromatogram with the metabolite peaks in the other 2. 
 
 
Figure 7-10: Chromatogram showing comparison of 25I-Urine rat sample (a), with 25I-NBOMe 
reference drug (b).  
The parent drug is shown in the top chromatogram with the metabolite peaks in the other 2. 
 
The urine samples were analysed by LC-QToF to determine if there were any 
additional metabolites which could be identified, however this was unsuccessful. 
The method was able to detect the parent compound in unextracted 
calibrations, but was not able to detect any analytes in the rat urine samples, 
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parent or metabolite. This could in part be due to a sensitivity issue, as previous 
analysis was completed using MS/MS which is a more sensitive analytical 
technique. The QToF instrument used in this project was 1st generation, and 
therefore not as sensitive as those currently on the market. It may be that a 
more up to date instrument would have been able to detect metabolites in these 
samples as instrument sensitivity has improved.  
Due to the electronegative effects of the Br, Cl, or I atoms, it is predicted that 
o-demethylation would be occurring at the position meta on these atoms (a) 
however this cannot be confirmed without the use of additional techniques such 
as nuclear magnetic resonance. The o-demethylation is likely to occur at this 
position as the halogen group (B, C or I) would be able to stabilize the negative 
charge on the oxygen molecule.  
 
Figure 7-11: Chemical structure of 25X-NBOMe showing 3 sites for possible o-demethylation 
to take place (a-c).  
 
7.4.4 Hair Samples  
As predicted, the black hair incorporated all drugs to a higher degree than the 
white hair. A dose-dependent concentration increase was observed in the black 
hair as illustrated by Figure 7-12 to Figure 7-14.  
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Figure 7-12: Overlaid chromatograms of black rat hair from each dose of 25B-NBOMe 
 
 
Figure 7-13: Overlaid chromatograms of black rat hair from each dose of 25C-NBOMe 
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Figure 7-14: Overlaid chromatograms of black rat hair from each dose of 25I-NBOMe 
 
25C-NBOMe incorporated into the black hair to the greatest extent for 300 ug/kg 
doses in comparison to 25B-NBOMe and 25I-NBOMe, +92%. 25C-NBOMe also 
incorporated into the hair of rats receiving the medium dose to the greatest 
degree, +10% in comparison to 25B-NBOMe and +37% in comparison to 25I-
NBOMe. Of rats receiving the lowest dose of drug, hair from those administered 
25B-NBOMe yielded the highest concentration of 37 pg/mg; 43% more than 25C-
NBOMe rats and 62% more than 25I-NBOMe rats. Drugs were only detected and 
quantified in white hair from rats receiving the highest concentration of drug as 
illustrated in Table 7-2.  
Concentrations marked with * fell below that of the level 1 calibrator (25 pg/mg) 
and thus were calculated using the LOQ calibration curve which was run on the 
same day.  
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Table 7-2: Concentration of each NBOMe detected in each hair sample.  
Drug 
Dose 
(ug/kg) 
Black Hair White Hair 
Concentration 
(pg/mg) 
STDEV 
(pg/mg) 
Concentration 
(pg/mg) 
STDEV 
(pg/mg) 
25B-
NBOMe 
30 37 ±3.3 Not Detected 
100 51 ±0.7 Not detected 
300 92 ±1.5 22* ±0.3 
25C-
NBOMe 
30 21* ±2.8 Not detected 
100 57 ±3.3 11* ±1.0 
300 143 ±1.0 30 ±0.4 
25I-NBOMe 
30 14* ±1.6 Detected 
100 36 ±0.8 Detected 
300 92 ±4.3 Detected 
 
Overall, 25C-NBOMe> 25B-NBOMe > 25I-NBOMe when it came to the 
incorporation of each drug into black hair. This may be in part due to the 
electronegativity or size of the halogen ion on each NBOMe, with chlorine > 
bromine > iodine. Chlorine has already been shown to positively affect 
incorporation rates, although further work would need to be carried out in order 
to better assess this.(253)  
The basicity of a drug is an important factor affecting the incorporation of drugs 
into hair. As the size of atoms increase their basicity decreases, and thus it 
follows that 25C-NBOMe incorporates greater than 25B-NBOMe and 25I-
NBOMe.(254) These observations were seen regardless of hair colour with 25C-
NBOMe being the only drug to be detected in white hair with a concentration 
above that of the level 1 calibrator.  
The recovery of the method could also be responsible for this pattern as 25C-
NBOMe extracted better from hair (averaging 95%) followed by 25B-NBOMe and 
then 25I-NBOMe. It is not known whether the buffer incubation step allowed for 
the extraction of each drug equally or that if it favoured the extraction of 25C-
NBOMe. In order to determine whether each drug incorporated or extracted to a 
different degree further work would need to be carried out. A more powerful 
incubation solvent such as NaOH should be used to identify if this provides a 
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higher recovery rate and whether this impacts on the concentration of each drug 
detected.  
The water and CH2Cl2 washes for each hair concentration were analysed as well 
as those from a blank rat hair sample. Both blanks (white and black) resulted in 
no detectable traces of NBOMes. DH2O sample washes resulted in little to no 
NBOMe drugs detected (all distinguishable peaks had an area <500). This was not 
the case with the CH2Cl2 washes however, which did result in identification of 
NBOMes, although the PARs of these results were significantly lower than that of 
the level 1 calibrator, as shown in Figure 7-15.  
 
Figure 7-15: PARs of hair samples from rats dosed with 25B, 25C or 25I-NBOMe (300 µg/kg) 
and the PARs of a level 1 calibrator. 
 
In order to assess whether the amount of NBOMe detected in the CH2Cl2 washes 
could be altered by the CH2Cl2 incubation time, 40 mg of hair from rats dosed 
with 25B-NBOMe (300 µg/kg) was initially washed with dH2O before washing with 
CH2Cl2 for 15, 30 and 45 minutes under sonication. This was done in duplicate 
and the PAR of each was calculated. The results are shown below in Figure 7-16, 
alongside the PAR of the 25B-NBOMe rat sample following extraction. From this 
we can see that although 25B-NBOMe was detected in the washes, its PAR was 
approximately 20 times higher in the sample. We can also see that sonication of 
samples for different time periods did not affect the amount of 25B-NBOMe 
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detected in the washes, indicating that only surface contamination was 
removed.  
 
Figure 7-16: PAR of 25B-NBOMe rat hair samples washed for 15, 30 and 45 minutes and the 
amount found in the hair sample following extraction.  
    
7.5 Conclusion 
There was no analgesia observed at the doses given to the rats and as a result 
tolerance and dependence could not be assessed using the tail flick method. In 
order to better assess whether these drugs cause analgesia, tolerance and 
dependence higher concentrations would have to be used applying additional 
techniques.  
Black hair concentrations ranged from 37-92 pg/mg for rats dosed with 25B-
NBOMe, 31-143 pg/mg for rats dosed with 25C-NBOMe and 14-92 pg/mg for rats 
dosed with 25I-NBOMe. White hair from rats administered 25B-NBOMe was only 
positive from those receiving the highest dose (300 µg/kg), with 22 pg/mg 
detected. White hair from rats dosed with 25C-NBOMe was positive from animals 
receiving the medium and high doses (100 µg/kg and 300 µg/kg) with 11 pg/mg 
and 30 pg/mg detected respectively. All white hair from rats receiving 25I-
NBOMe tested positive, but all were below the LOQ for this method.  Although 
this indicates that each NBOMe incorporated into the black hair much more than 
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white, this cannot be confirmed without further testing on the extraction 
method itself.   
The incorporation of each NBOMe improved with the basicity of each drug, the 
size, and electronegativity of the halogen group.  
Urine NBOMe concentrations ranged from 7-16 pg/mL from rats administered 
doses of 300 µg/kg. A possible o-demethylated metabolite was identified in each 
sample, although this was not confirmed due to low concentrations detected.  
7.6 Future Work  
This research should be repeated using similar doses to those now published in 
the literature after stability studies have been conducted with these substances 
in DMSO and saline. Additional NBOMes should also be investigated, in particular 
mescaline-NBOMe as recreational doses for this substance are reported to be 
much higher than other NBOMes.(133) To date there have been no published 
mescaline-NBOMe case reports to support this claim and thus the use of animal 
models, and tail flick testing could help determining the accuracy of these 
remarks. Repeating this study at higher doses would also allow further 
investigations into potential dependency of the drug, establishing the length of 
time it took for tail-flick times to return to their baseline values.  
The identification of a possible metabolite in each of the urine samples should 
be further investigated, with the development and enhancement of a QToF 
method or if standards are developed. It may be that as the rats received such 
small amounts of drug that human urine from case samples may facilitate the 
identification of metabolites better as concentrations would be higher. 
Alternatively, the use of human liver microsomes could be used to identify 
metabolites.  
All rats used in this experiment were male, which again is another possible area 
of further work as previous publications have shown gender to be an important 
factor affecting the incorporation of drugs into hair.(253, 255-257)  
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The study of additional NBOMe compounds and their incorporation rates into hair 
would not only further the information available on NBOMe compounds but 
would allow further investigation into the effects different functional groups 
have on this process.   
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Chapter 8: Conclusion & Future Work  
8.1 Conclusion  
NPS pose a significant challenge to forensic toxicologists and clinical 
practitioners alike. It is difficult to keep up to date with what is currently being 
used within the recreational market, and by the time analysts are aware of the 
current substances these will have no doubt been replaced. The variation of 
substances between countries and regions makes the sharing of information 
much more difficult, as what is contained within a branded product in one 
geographical area may be completely different in another area. As a result, 
getting accurate information to law enforcement, toxicologists, health 
professionals and users is much more difficult.  
A GC-MS method for the simultaneous quantification of 25 analytes in urine and 
23 analytes in blood was successfully developed and validated. This method 
utilised SPE for sample clean-up and PFPA:EtOAc derivatisation. This method was 
validated to SWGTOX 2013 guidelines. The GC-MS was operated in SIM mode to 
enhance sensitivity, with a lowered injection port temperature of 225oC to 
prevent analyte degradation at the injection port.  
The extraction of various NPS substances from urine, blood, plasma and serum 
using a variety of cartridges was assessed. Cleanscreen CSDAU133 cartridges 
provided the best recovery rates for blood and urine whereas Cleanscreen 
ZSDAU020 cartridges proved to be the optimum for plasma and serum samples. 
The extraction efficiency of two LLE methods was also evaluated; however 
neither method recovered all analytes from urine. As the GC-MS method looked 
for 10 and 8 NBOMe compounds in urine and blood respectively, instrument 
sensitivity was paramount. As LLE is a relatively crude extraction method, and as 
this instrument was used by more than one individual, it was only applied to 
urine samples. SLE was also investigated for the extraction of NPS from blood, 
urine, serum and plasma. This method extracted 68% of analytes to a greater 
extent than the CSDAU0133 SPE method. The CSDAU133 SPE cartridge performed 
better for the extraction of NPS from urine with 64% of analytes achieving higher 
recovery rates using this method.  
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The developed method was applied to 12 blood samples from 8 different cases 
obtained from NMS labs, Willow Grove, PA. These samples were found to contain 
25C-NBOMe, 25I-NBOMe, methoxetamine and methylone. Previous analysis, 
including the NMS labs method, for NBOMes has utilised LC-MS/MS due to the 
high potency of these substances and therefore the low concentrations identified 
within clinical and forensic laboratories. Although this GC-MS method was not 
able to identify NBOMes in all 8 samples confirmed positive by NMS laboratories, 
it was possible to identify and quantitate these substances in 5 samples. It is not 
known if this was due to a lack of sensitivity of the method or due to issues with 
the long term stability of the NBOMes in question. 
The stability of mephedrone samples in bovine blood was assessed over a period 
of ten weeks. Bovine blood was spiked at 1 mg/L and stored at room 
temperature (20oC), in the fridge (4oC) or in the freezer (-20oC). Samples were 
individually aliquoted to prevent any effects from freeze thaw cycles. The effect 
of preservatives was also investigated with samples stored unpreserved, with 
citrate preservative or with fluoride/oxalate preservative. Samples stored at 
room temperature were stored in the dark to mimic the conditions of the fridge 
and freezer and thus avoiding the additional variable of light. Samples were 
analysed daily for 1 week and then weekly for the remaining time period. This 
work identified that mephedrone samples should be stored at -20oC with the 
addition of a citrate preservative. Mephedrone could not be detected in 
unpreserved samples stored at room temperature after 21 days.  
The cross reactivity of NPS analytes with amphetamine, methamphetamine and 
ketamine ELISA kits was assessed. Cross reactivity was identified for 5-APB, 6-
APB, butylone, ethylone, flephedrone, mephedrone, methedrone and methylone 
using the methamphetamine kit. Cross-reactivity was also seen when using the 
amphetamine kit for 5-APB, 6-APB, ethylone, mephedrone, methedrone and 
methylone, however this was to a lesser extent. Methoxetamine, 3-MeO-PCE and 
3-MeO-PCP all cross reacted with the ketamine ELISA kit.  
Another screening technique used in clinical settings is the POCT. POCT cross-
reactivity is important as many NPS users will come into contact with A&E 
services and thus correct identification of the substances people have ingested 
can be crucial for their treatment. Three different POCT were examined, 
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WorldCassette™, DRUGCHECK® and Nal von Minden. Cross reactivity using each 
of the POCT was seen when using 1 mg/mL concentrations, however these are 
far higher than have been reported in the literature and so cross reactivity in a 
“real-life” setting would be unlikely.  
A LC-MS/MS method for the simultaneous detection and quantification of 25B-, 
25C- and 25I-NBOMe in urine and hair was established and validated using 
SWGTOX 2013 guidelines. This method covered a wide concentration range for 
forensic and clinical application. Urine samples were extracted using a simple 
NaOH and hexane:EtOAc LLE using 1 mL of sample. Hair samples were extracted 
using SPE after a 12-hour incubation in pH 7.4 phosphate buffer. Total 
instrument run-time was 4 minutes. As NBOMe compounds are so potent, hair 
concentrations are expected to be extremely low. As a result 40 mg of hair was 
used, which allowed the instrument to detect concentrations as low as 3-5 
pg/mg.  
No analgesic effects were seen after Long Evans rats were administers 25B-, 25C- 
or 25I-NBOMe at doses of 30, 100 or 300 µg/kg over an 8-day period. Urine 
collected from rats receiving 300 µg/kg doses of each NBOMe tested positive 
using the previously mentioned LC-MS/MS method, with concentrations ranging 
from 7-12 pg/mL. The o-demethylated metabolites of each NBOMe were also 
identified in these urine samples. White and black hair from the rats was also 
collected and analysed by LC-MS/MS. All black hair samples tested positive for 
the presence of NBOMes regardless of the dose with concentrations identified 
ranging from 21-143 pg/mg. 25I-NBOMe was identified in white hair for all doses 
although concentrations fell below the method LOQ. 25B-NBOMe was only 
identified in rats receiving the 300 µg/kg dose (22 pg/mg) and 25C-NBOMe was 
only identified in rats dosed at 100 µg/kg (11 pg/mg) and 300 µg/kg (30 pg/mg). 
A dose response relationship was seen with all black hair samples. 
Although it is likely that laboratories will move towards new instrumentation for 
the detection of NPS such as UPLC-QToF, this thesis highlights that they can be 
detected using current equipment. In particular, the identification of NBOMes 
using GC-MS is important as although it was not able to detect the presence of 
these substances in all samples tested, it was able to identify them in 62.5% of 
samples. This is important in the case of developing nations and small 
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laboratories which may not see NPS frequently enough to warrant large 
investments into new instrumentation.  
8.2 Future Work  
The constant influx of new substances onto the recreational market means that 
the GC-MS and LC-MS/MS methods discussed here will need to be updated and 
re-validated to SWGTOX guidelines to include these. It is likely in the future that 
screening instruments such as UPLC-QToF will replace GC-MS and LC-MS/MS for 
the identification of NPS and that these instruments will be used for more 
targeted analysis only.  
The optimisation of the SLE extraction procedure should occur to ensure that a 
fair comparison between SPE and SLE takes place. This involves looking at 
cartridges from different manufactures, and using different elution solvents 
which did not occur here due to the limited number of cartridges supplied by 
Biotage®. Examining other SPE cartridges as and when new versions are 
launched should also take place to ensure that CSDAU cartridges remain the 
optimum cartridge for the extraction of the analytes examined in this thesis.  
The LC-MS/MS urine and hair method should be expanded to include more 
NBOMes which are now commercially available. These methods should also be 
applied to case samples to ensure their applicability to “real-life” scenarios. 
This is particularly important for the LC-MS/MS hair method as the 
concentrations in hair remain unknown. It may be that the calibration levels in 
the hair method need adjusted as and when this information becomes available.  
Further work on the analgesic properties of NBOMes should also take place. In 
particular comparing the doses of mescaline-NBOMe to identify if the trip reports 
are correct in stating higher doses of this substance are required to obtain 
recreational effects.  
Finally, both the GC-MS and LC-MS/MS method should be used to assess the 
current prevalence of these substances within the living population, ensuring 
that the analytes included in these methods are still seen in forensic and clinical 
work. There is a financial implication in looking for many analytes at once as 
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these need to be included in calibrators and QCs. It may be that although this 
method is able to detect and quantify these substances, they appear too 
infrequently to all be included in routine analysis. 
   
234 
 
Chapter 9: Reference List 
1. . (Public Health Wales, 2015), vol. 2015. 
2. J. Tripod, E. Sury, K. Hoffmann, Zentralerregende Wirkung eines neuen 
Piperidinderivates. Experientia 10, 261-262 (1954). 
3. M. H. Baumann, J. S. Partilla, K. R. Lehner, Psychoactive “bath salts”: 
Not so soothing. European Journal of Pharmacology 698, 1-5 (2013). 
4. S. Elliott, Cat and mouse: the analytical toxicology of designer drugs. 
Bioanalysis 3, 249-251 (2011). 
5. "The Challenge of New Psychoactive Substances," Global SMART 
Programme  (Vienna, 2013). 
6. L. A. King, R. Sedefov, Early-warning system on new psychoactive 
substances. Operating quidelines. Luxembourg: European Monitoring 
Centre for Drugs and Drug Addiction 71,  (2007). 
7. A. European Monitoring Centre for Drugs and Drug, European Drug Report 
2014: Trends and Developments.  (2014). 
8. D. Wood et al., Recreational use of mephedrone (4-methylcathinone, 4-
MMC) with assiciated sympathomimetric toxicity. Journal of Medical 
Toxicology 6, 327 (2010). 
9. F. Schifano et al., Mephedrone (4-methylmethcathinone; 'meow meow'): 
chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 
214, 593-602 (2011). 
10. P. Adamowicz, B. Tokarczyk, R. Stanaszek, M. Slopianka, Fatal 
mephedrone intoxication—a case report. Journal of analytical toxicology 
37, 37-42 (2013). 
11. J. M. Prosser, L. S. Nelson, The Toxicology of Bath Salts: A Review of 
Synthetic Cathinones. J Med Toxicol 8, 33-42 (2011). 
12. G. D. Survey, in mixmag. (2011), vol. 2012. 
13. E. Gebissa, Leaf of Allah: Khat & Agricultural Transformation in Harerge, 
Ethiopia.  (East African Publishers, 2004). 
14. @BBCNews. (@BBCNews, 2014), vol. 2015. 
15. Khat (Qat): Assessment of Risk to the Individual and Communities in the 
UK.  (Home Office, London, 2005). 
16. P. Griffiths et al., Khat use and monitoring drug use in Europe: the 
current situation and issues for the future. Journal of ethnopharmacology 
132, 578-583 (2010). 
17. H. Shapiro, The Essential Guide to Drugs and Alcohol.  (DrugScope, 2007). 
18. R. H. F. Manske, T. B. Johnson, Synthesis of ephidrine and structurally 
smilar compounds II. The synthesis of some ephedrine homologs and the 
resolution of ephedrine. Journal of Analytical Chemistry 51, 1906-1909 
(1929). 
19. J. P. Kelly, Cathinone derivatives: A review of their chemistry, 
pharmacology and toxicology. Drug Testing and Analysis 3, 439-453 
(2011). 
20. D. P. I. Wood D.M, "Technical report on mephedrone," EMCDDA RISK 
ASSESSMENTS  (EMCDDA, Lisbon, 2010). 
21. "Annual Report 2011: The state of the drugs problem in Europe,"  
(Eurpoean Monitoring Centre for Drugs and Drug Addiction, 2011). 
22. S. Gibbons, 'Legal Highs' - novel and emerging psychoactive drugs: a 
chemical overview for the toxicologist. Clinical Toxicology 50, 15-24 
(2012). 
235 
 
23. A. R. Winstock et al., Mephedrone, new kid for the chop? Addiction 106, 
154-161 (2011). 
24. "Emergency Department Visits After Use of a Drug Sold as "Bath Salts"- 
Michigan, November 13, 2010- March 31, 2011,"  (2011). 
25. M. C. Van Hout, T. Bingham, “A Costly Turn On”: Patterns of use and 
perceived consequences of mephedrone based head shop products 
amongst Irish injectors. International Journal of Drug Policy 23, 188-197 
(2012). 
26. ACMD report on the consideration of the cathinones. Home Office. 2010. 
27. S. D. Brandt, H. R. Sumnall, F. Measham, J. Cole, Second generation 
mephedrone. The confusing case of NRG-1. BMJ 341, c3564 (2010). 
28. M. Coppola, R. Mondola, Synthetic cathinones: Chemistry, pharmacology 
and toxicology of a new class of designer drugs of abuse marketed as 
“bath salts” or “plant food”. Toxicology Letters 211, 144-149 (2012). 
29. H. A. Spiller, M. L. Ryan, R. G. Weston, J. Jansen, Clinical experience 
with and analytical confirmation of “bath salts” and “legal 
highs”(synthetic cathinones) in the United States. Clinical Toxicology 49, 
499-505 (2011). 
30. T. M. Penders, R. Gestring, Hallucinatory delirium following use of MDPV: 
"Bath Salts". Gen Hosp Psychiatry 33, 525-526 (2011). 
31. D. P. Kasick, C. A. McKnight, E. Klisovic, “Bath salt” ingestion leading to 
severe intoxication delirium: two cases and a brief review of the 
emergence of mephedrone use. The American journal of drug and alcohol 
abuse 38, 176-180 (2012). 
32. T. M. Penders, R. E. Gestring, D. A. Vilensky, Excited delirium following 
use of synthetic cathinones (bath salts). General hospital psychiatry 34, 
647-650 (2012). 
33. M. Levine, R. Levitan, A. Skolnik, Compartment syndrome after "bath 
salts" use: a case series. Ann Emerg Med 61, 480-483 (2013). 
34. A. D. O'Connor, A. Padilla-Jones, R. D. Gerkin, M. Levine, Prevalence of 
Rhabdomyolysis in Sympathomimetic Toxicity: a Comparison of 
Stimulants. J Med Toxicol 11, 195-200 (2015). 
35. K. S. Hagan, L. Reidy, Detection of synthetic cathinones in Victims of 
Sexual Assault. Forensic Science International 257, 71-75 (2015). 
36. S. Elliott, J. Evans, A 3-year review of new psychoactive substances in 
casework. Forensic science international 243, 55-60 (2014). 
37. N. Bajaj, D. Mullen, S. Wylie, Dependence and psychosis with 4-
methylmethcathinone (mephedrone) use. BMJ Case Reports 2010, 497-
503 (2010). 
38. J. E. Robinson, A. E. Agoglia, E. W. Fish, M. C. Krouse, C. J. Malanga, 
Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in 
C57BL/6J mice: comparison to cocaine. Behavioural brain research 234, 
76-81 (2012). 
39. K. M. Creehan, S. A. Vandewater, M. A. Taffe, Intravenous self-
administration of mephedrone, methylone and MDMA in female rats. 
Neuropharmacology 92, 90-97 (2015). 
40. J. Corkery, Schifano, F. and Ghodse, H., in Pharmacology, L. Gallelli, Ed. 
(InTech- open access, Rijeka, Croatia, 2012),  chap. 355, pp. 355-380. 
41. F. Schifano, J. Corkery, A. H. Ghodse, Suspected and confirmed fatalities 
associated with mephedrone (4-methylmethcathinone, "meow meow") in 
the United Kingdom. J Clin Psychopharmacol 32, 710-714 (2012). 
42. P. Kriikku et al., Methylenedioxypyrovalerone (MDPV) in Finland. 
Toxichem Krimtech 78, 293-296 (2011). 
236 
 
43. B. J. Warrick et al., Lethal serotonin syndrome after methylone and 
butylone ingestion. Journal of Medical Toxicology 8, 65-68 (2012). 
44. J. M. Pearson et al., Case Report: Three Fatal Intoxications Due to 
Methylone. J Anal Toxicol 36, 444-451 (2012). 
45. M. R. Meyer, J. Wilhelm, F. T. Peters, H. H. Maurer, Beta-keto 
amphetamines: studies on the metabolism of the designer drug 
mephedrone and toxicological detection of mephedrone, butylone, and 
methylone in urine using gas chromatography-mass spectrometry. 
Analytical and Bioanalytical Chemistry 397, 1225-1233 (2010). 
46. A. J. Pedersen, L. A. Reitzel, S. S. Johansen, K. Linnet, In vitro 
metabolism studies on mephedrone and analysis of forensic cases. Drug 
Testing and Analysis 5, 430-438 (2013). 
47. A. a. M. Winstock, J., in Report on the risk assessment of mephedrone in 
the framework of the Council Decision on new psychoactive substances. 
(Luxembourg, 2011),  chap. 4. 
48. A. Winstock, L. Mitcheson, J. Marsden, Mephedrone: still available and 
twice the price. The Lancet 376, 1537 (2010). 
49. M. F. Wood D.M, Dargan P. I., 'Our favourite drug': prevalence of use and 
preference for mephedrone in the London night-time economy 1 year 
after control. Journal of Substance Use 2, 91-97 (2012). 
50. C. Meehan. (University of Ulster, 2010). 
51. S. D. Brandt, S. Freeman, H. R. Sumnall, F. Measham, J. Cole, Analysis of 
NRG 'legal highs' in the UK: identification and formation of novel 
cathinones. Drug Test Anal 3, 569-575 (2011). 
52. "Satistics on Drug Misus: England, 2011,"  (The NHS Information Centre, 
2011). 
53. "Early Warning system Progress Report,"  (EMCDDA, UK, 2011). 
54. P. Kriikku, L. Wilhelm, O. Schwarz, J. Rintatalo, New designer drug of 
abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from 
apprehended drivers in Finland. Forensic Science International 210, 195-
200 (2011). 
55. S. McNamara, Stokes, S. and Coleman, N., Head shop compound abuse 
amongst attendees of the drug treatment centre board. The Irish Medical 
Journal 103, 136-137 (2010). 
56. C. L. German, A. E. Fleckenstein, G. R. Hanson, Bath salts and synthetic 
cathinones: An emerging designer drug phenomenon. Life sciences 97, 2-8 
(2014). 
57. U. N. O. o. D. a. Crime, "The challenge of new psychoactive substances,"  
(Vienna, 2013). 
58. Q. Li et al., in Novel Psychoactive Substances, P. I. D. M. Wood, Ed. 
(Academic Press, Boston, 2013), pp. 285-316. 
59. A. L. Weiner, L. Vieira, C. A. McKay, M. J. Bayer, Ketamine abusers 
presenting to the emergency department: a case series. J Emerg Med 18, 
447-451 (2000). 
60. J. Copeland, P. Dillon, The health and psycho-social consequences of 
ketamine use. International Journal of Drug Policy 16, 122-131 (2005). 
61. D. Shewan, P. Dalgarno, Ecstasy and neurodegeneration. ...such as 
ketamine. BMJ : British Medical Journal 313, 424-424 (1996). 
62. R. Shahani, C. Streutker, B. Dickson, R. J. Stewart, Ketamine-associated 
ulcerative cystitis: a new clinical entity. Urology 69, 810-812 (2007). 
63. K. Shahzad, A. Svec, O. Al-Koussayer, M. Harris, S. Fulford, Analgesic 
ketamine use leading to cystectomy: A case report. British Journal of 
Medical and Surgical Urology 5, 188-191 (2012). 
237 
 
64. S. C. Baker et al., Nerve hyperplasia: a unique feature of ketamine 
cystitis. Acta Neuropathologica Communications 1, 64-64 (2013). 
65. A. Garcia-Larrosa et al., in Actas Urol Esp. (2011 AEU. Published by 
Elsevier Espana, Spain, 2012), vol. 36, pp. 60-64. 
66. A. R. Winstock, L. Mitcheson, D. A. Gillatt, A. M. Cottrell, The prevalence 
and natural history of urinary symptoms among recreational ketamine 
users. BJU International 110, 1762-1766 (2012). 
67. P. I. Dargan, H. C. Tang, W. Liang, D. M. Wood, D. T. Yew, Three months 
of methoxetamine administration is associated with significant bladder 
and renal toxicity in mice. Clinical Toxicology 52, 176-180 (2014). 
68. D. Wood et al., Recreational ketamine: from pleasure to pain. BJU 
international 107, 1881-1884 (2011). 
69. C. J. A. Morgan, H. V. Curran, Ketamine use: a review. Addiction 107, 27-
38 (2012). 
70. M. Wright, Pharmacologic effects of ketamine and its use in veterinary 
medicine [Anesthesia]. Journal of the American Veterinary Medical 
Association 180, 1462-1471 (1982). 
71. K. Moore, F. Measham, “It's the most fun you can have for twenty quid”: 
Motivations, Consequences and Meanings of British Ketamine Use. 
Addiction Research & Theory 16, 231-244 (2008). 
72. Erowid, in Ketamine. (2015), vol. 2015. 
73. EMCDDA, "Technical report on 2-(3-methoxyphenyl)- 2-
(ethylamino)cyclohexanone (methoxetamine),"  (Lisbon, 2014). 
74. O. Corazza et al., Phenomenon of new drugs on the Internet: the case of 
ketamine derivative methoxetamine. Human Psychopharmacology: 
Clinical and Experimental 27, 145-149 (2012). 
75. A. Kjellgren, K. Jonsson, Methoxetamine (MXE)–a phenomenological study 
of experiences induced by a “legal high” from the Internet. Journal of 
psychoactive drugs 45, 276-286 (2013). 
76. H. Morris, J. Wallach, From PCP to MXE: a comprehensive review of the 
non-medical use of dissociative drugs. Drug Testing and Analysis 6, 614-
632 (2014). 
77. M. Naughton, G. Clarke, O. F. O′Leary, J. F. Cryan, T. G. Dinan, A review 
of ketamine in affective disorders: Current evidence of clinical efficacy, 
limitations of use and pre-clinical evidence on proposed mechanisms of 
action. Journal of Affective Disorders 156, 24-35 (2014). 
78. A. B. Hopper et al., Ketamine Use for Acute Agitation in the Emergency 
Department. The Journal of Emergency Medicine 48, 712-719 (2015). 
79. C. Ball, R. Westhorpe, Intravenous induction agents: ketamine. 
Anaesthesia and intensive care 30, 115 (2002). 
80. R. Giorgetti, D. Marcotulli, A. Tagliabracci, F. Schifano, Effects of 
ketamine on psychomotor, sensory and cognitive functions relevant for 
driving ability. Forensic Science International 252, 127-142 (2015). 
81. K. Sałat et al., Antidepressant-like effects of ketamine, norketamine and 
dehydronorketamine in forced swim test: Role of activity at NMDA 
receptor. Neuropharmacology 99, 301-307 (2015). 
82. D. European Monitoring Centre for, A. Drug, Report on the risk assessment 
of ketamine in the framework of the joint action on new synthetic drugs. 
3 (2002).  (Office for Official Publ. of the European Communities, 2002), 
vol. 3. 
83. M. C. Parkin et al., Detection of ketamine and its metabolites in urine by 
ultra high pressure liquid chromatography–tandem mass spectrometry. 
Journal of Chromatography B 876, 137-142 (2008). 
238 
 
84. S. M. R. Wille, V. Di Fazio, N. Samyn, Drug‐facilitated sexual crime by use 
of ketamine and diazepam by a gynaecologist. Drug testing and analysis 
5, 730-735 (2013). 
85. A. Cottrell et al., The destruction of the lower urinary tract by ketamine 
abuse: a new syndrome? BJU international 102, 1178-1179 (2008). 
86. D. J. Nutt, L. A. King, L. D. Phillips, Drug harms in the UK: a multicriteria 
decision analysis. The Lancet 376, 1558-1565 (2010). 
87. J. Ward, S. Rhyee, J. Plansky, Methoxetamine: a novel ketamine analog 
and growing health-care concern. Clinical Toxicology 49, 874-875 (2011). 
88. H. Morris. (@vice, 2011), vol. 2015. 
89. Erowid. (2011), vol. 2015. 
90. L. Muetzelfeldt et al., Journey through the K-hole: phenomenological 
aspects of ketamine use. Drug and alcohol dependence 95, 219-229 
(2008). 
91. J. C. Lilly, The scientist: A novel autobiography.  (Lippincott Williams & 
Wilkins, 1978). 
92. R. C. Baselt, Disposition of Toxic Drugs and Chemicals in Man.  
(Biomedical Publications, California, ed. 10th, 2014), pp. 2211. 
93. M. Licata, G. Pierini, G. Popoli, A fatal ketamine poisoning. J Forensic Sci 
39, 1314-1320 (1994). 
94. @fox6now. (@fox6now, 2013). 
95. D. Wood, S. Davies, M. Puchnarewicz, A. Johnston, P. Dargan, Acute 
toxicity associated with the recreational use of the ketamine derivative 
methoxetamine. European Journal of Clinical Pharmacology 68, 853-856 
(2012). 
96. K. E. Hofer et al., Ketamine-like Effects After Recreational Use of 
Methoxetamine. Annals of Emergency Medicine 60, 97-99 (2012). 
97. S. Férec et al. (EDP Sciences), vol. 25, pp. 47-56. 
98. M. Wikstrom, G. Thelander, M. Dahlgren, R. Kronstrand, An accidental 
fatal intoxication with methoxetamine. J Anal Toxicol 37, 43-46 (2013). 
99. S. C. Turfus et al., Use of human microsomes and deuterated substrates: 
an alternative approach for the identification of novel metabolites of 
ketamine by mass spectrometry. Drug Metab Dispos 37, 1769-1778 (2009). 
100. C. D. Rosenbaum, S. P. Carreiro, K. M. Babu, Here today, gone 
tomorrow...and back again? A review of herbal marijuana alternatives 
(K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, 
methoxetamine, and piperazines. J Med Toxicol 8, 15-32 (2012). 
101. M. R. Meyer et al., Ketamine-derived designer drug methoxetamine: 
metabolism including isoenzyme kinetics and toxicological detectability 
using GC-MS and LC-(HR-)MSn. Anal Bioanal Chem 405, 6307-6321 (2013). 
102. B. L. Roth et al., The ketamine analogue methoxetamine and 3-and 4-
methoxy analogues of phencyclidine are high affinity and selective ligands 
for the glutamate NMDA receptor. PloS one 8, e59334 (2013). 
103. Seth Troxler: "Ketamine is the heroin of our time".  (2015). 
104. J. R. Archer, P. I. Dargan, S. Hudson, D. M. Wood, Analysis of anonymous 
pooled urine from portable urinals in central London confirms the 
significant use of novel psychoactive substances. QJM 106, 147-152 
(2013). 
105. E. D. Bouso, E. A. Gardner, J. E. O'Brien, B. Talbot, P. V. Kavanagh, 
Characterization of the pyrolysis products of methiopropamine. Drug 
testing and analysis 6, 676-683 (2014). 
106. DrugScope, DrugScope | DRUG INFORMATION | MPA.  (2015). 
239 
 
107. J. M. Corkery, S. Elliott, F. Schifano, O. Corazza, A. H. Ghodse, MDAI (5,6-
methylenedioxy-2-aminoindane; 6,7-dihydro-5H-
cyclopenta[f][1,3]benzodioxol-6-amine; ‘sparkle’; ‘mindy’) toxicity: a 
brief overview and update. Human Psychopharmacology: Clinical and 
Experimental 28, 345-355 (2013). 
108. M. Coppola, R. Mondola, 5-Iodo-2-aminoindan (5-IAI): Chemistry, 
pharmacology, and toxicology of a research chemical producing MDMA-like 
effects. Toxicology Letters 218, 24-29 (2013). 
109. H. Lee, D. Wood, S. Hudson, J. H. Archer, P. Dargan, Acute Toxicity 
Associated with Analytically Confirmed Recreational use of 
Methiopropamine (1-(thiophen-2-yl)-2-methylaminopropane). Journal of 
Medical Toxicology 10, 299-302 (2014). 
110. J. Welter et al., 2-methiopropamine, a thiophene analogue of 
methamphetamine: studies on its metabolism and detectability in the rat 
and human using GC-MS and LC-(HR)-MS techniques. Anal Bioanal Chem 
405, 3125-3135 (2013). 
111. W. H. Organization, "WHO Expert Committee on Drug Dependence," WHO 
Technical Report Series No. 991 (Italy, 2014). 
112. M. Baron, M. Elie, L. Elie, An analysis of legal highs: do they contain what 
it says on the tin? Drug Test Anal 3, 576-581 (2011). 
113. G. Hölzemann et al. (Google Patents, 2008). 
114. L. E. J. Kennis et al., New 2-substituted 1, 2, 3, 4-tetrahydrobenzofuro 
[3, 2-c] pyridine having highly active and potent central α 2-antagonistic 
activity as potential antidepressants. Bioorganic & medicinal chemistry 
letters 10, 71-74 (2000). 
115. E. J. Glamkowski, M. C. Jones. (Google Patents, 1985). 
116. in MDMA & Empathogenic Drugs. (Bluelight Forum, 2015), vol. 2015. 
117. P. Dawson et al., The effects of benzofury (5-APB) on the dopamine 
transporter and 5-HT2-dependent vasoconstriction in the rat. Progress in 
Neuro-Psychopharmacology and Biological Psychiatry 48, 57-63 (2014). 
118. A. Shulgin, Pihkal: A Chemical Love Story.  (Transform Press, 1995). 
119. R. Heim, Freie Universitat, Berlin (2004). 
120. W. Lawn, M. Barratt, M. Williams, A. Horne, A. Winstock, The NBOMe 
hallucinogenic drug series: Patterns of use, characteristics of users and 
self-reported effects in a large international sample. Journal of 
Psychopharmacology 28, 780-788 (2014). 
121. F. S. Bersani et al., 25C-NBOMe: Preliminary Data on Pharmacology, 
Psychoactive Effects, and Toxicity of a New Potent and Dangerous 
Hallucinogenic Drug. BioMed Research International 2014, 6 (2014). 
122. ohlone, in Trip Reports. (Bluelight Forum, 2015), vol. 2015. 
123. . (2012), vol. 2015. 
124. J. L. Poklis et al., Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and 
tissues determined by high performance liquid chromatography with 
tandem mass spectrometry from a traumatic death. Forensic Science 
International 234, e14-e20 (2014). 
125. V. B. Kueppers, C. T. Cooke, 25I-NBOMe related death in Australia: A case 
report. Forensic science international 249, e15-e18 (2015). 
126. S. J. Stellpflug, S. E. Kealey, C. B. Hegarty, G. C. Janis, 2-(4-Iodo-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): 
clinical case with unique confirmatory testing. J Med Toxicol 10, 45-50 
(2014). 
240 
 
127. M. R. Braden, J. C. Parrish, J. C. Naylor, D. E. Nichols, Molecular 
interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and 
Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol 
Pharmacol 70, 1956-1964 (2006). 
128. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist 
designer drug. Clinical Toxicology 51, 174-177 (2013). 
129. Y. N. A. Soh, S. Elliott, An investigation of the stability of emerging new 
psychoactive substances. Drug testing and analysis 6, 696-704 (2014). 
130. . (2015). 
131. D. Zuba, K. Sekuła, A. Buczek, 25C-NBOMe – New potent hallucinogenic 
substance identified on the drug market. Forensic Science International 
227, 7-14 (2013). 
132. P. Nikolaou, I. Papoutsis, M. Stefanidou, C. Spiliopoulou, S. Athanaselis, 
2C-I-NBOMe, an “N-bomb” that kills with “Smiles”. Toxicological and 
legislative aspects. Drug and chemical toxicology 38, 113-119 (2014). 
133. BLUELIGHT. (2010), vol. 2015. 
134. J. M. Corkery, S. Elliott, F. Schifano, O. Corazza, A. H. Ghodse, 2-DPMP 
(desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and 
D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): A 
preliminary review. Prog Neuropsychopharmacol Biol Psychiatry 39, 253-
258 (2012). 
135. EMCDDA, "EMCDDA–Europol 2009 Annual Report on the implementation of 
Council Decision 2005/387/JHA,"  (Lisbon, 2010). 
136. J. M. Corkery, S. Elliott, F. Schifano, O. Corazza, A. H. Ghodse, 2-DPMP 
(desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and 
D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): a 
preliminary review. Progress in Neuro-Psychopharmacology and Biological 
Psychiatry 39, 253-258 (2012). 
137. E. Tyrkko, A. Pelander, R. A. Ketola, I. Ojanpera, In silico and in vitro 
metabolism studies support identification of designer drugs in human 
urine by liquid chromatography/quadrupole-time-of-flight mass 
spectrometry. Anal Bioanal Chem 405, 6697-6709 (2013). 
138. B. WIKI. (2013), vol. 2015. 
139. M. Durham, Ivory wave: the next mephedrone? Emerg Med J 28, 1059-
1060 (2011). 
140. P. Kriikku et al., Prevalence and blood concentrations of desoxypipradrol 
(2-DPMP) in drivers suspected of driving under the influence of drugs and 
in post-mortem cases. Forensic Sci Int 226, 146-151 (2013). 
141. D. M. Wood, P. I. Dargan, Use and acute toxicity associated with the novel 
psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-
DPMP). Clinical Toxicology 50, 727-732 (2012). 
142. J. Hillebrand, D. Olszewski, R. Sedefov, Legal highs on the Internet. 
Substance use & misuse 45, 330-340 (2010). 
143. D. M. Wood, S. Davies, A. Calapis, J. Ramsey, P. I. Dargan, Novel drugs--
novel branding. QJM 105, 1125-1126 (2011). 
144. A. J. M. Forsyth, Virtually a drug scare: Mephedrone and the impact of the 
Internet on drug news transmission. International Journal of Drug Policy 
23, 198-209 (2012). 
145. K. O'Brien, C. Chatwin, C. Jenkins, F. Measham, New psychoactive 
substances and British drug policy: A view from the cyber-psychonauts. 
Drugs: education, prevention and policy 22, 217-223 (2015). 
146. K. Meyers et al., The availability and depiction of synthetic cathinones 
(bath salts) on the Internet: Do online suppliers employ features to 
241 
 
maximize purchases? International Journal of Drug Policy 26, 670-674 
(2015). 
147. S. Nakamoto, Bitcoin: A peer-to-peer electronic cash system. Consulted 1, 
28 (2008). 
148. Europol, "EMCDDA Joint Report on a new psychoactive substance: 4-
methylmethcathinone (mephedrone),"  (2010). 
149. BBCNews. (BBCNews, 2015), vol. 2015. 
150. in 2015-16. (2015). 
151. J. van Amsterdam, D. Nutt, W. van den Brink, Generic legislation of new 
psychoactive drugs. Journal of Psychopharmacology 27, 317-324 (2013). 
152. A. Travis, Ban on legal highs would technically cover alcohol, cigarettes 
and coffee.  (2015). 
153. A. Travis, Theresa May's legal highs ban is unenforceable, say government 
advisers.  (2015). 
154. @BBCNews, Legal highs: Psychoactive Substances Bill 'will brand young 
people criminals'.  (2015). 
155. A. Stanczuk, N. Morris, E. A. Gardner, P. Kavanagh, Identification of (2-
aminopropyl)benzofuran (APB) phenyl ring positional isomers in Internet 
purchased products. Drug Testing and Analysis 5, 270-276 (2013). 
156. J. Welter, P. Kavanagh, M. Meyer, H. Maurer, Benzofuran analogues of 
amphetamine and methamphetamine: studies on the metabolism and 
toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-
MS and LC-(HR)-MSn techniques. Analytical and Bioanalytical Chemistry 
407, 1371-1388 (2015). 
157. P. Armenian, R. R. Gerona, The electric Kool-Aid NBOMe test: LC-TOF/MS 
confirmed 2C-C-NBOMe (25C) intoxication at Burning Man. The American 
Journal of Emergency Medicine 32, 1444.e1443-1444.e1445 (2014). 
158. J. L. Poklis, B. L. Mason, A. Poklis, L. E. Wise, paper presented at the 
Society of Forensic Toxicologists Annual Meeting, Grand Rapids, MI,  2014. 
159. P. Adamowicz, B. Tokarczyk, Simple and rapid screening procedure for 
143 new psychoactive substances by liquid chromatography-tandem mass 
spectrometry. Drug Testing and Analysis,  (2015). 
160. D. Pasin, S. Bidny, S. Fu, Analysis of New Designer Drugs in Post-Mortem 
Blood Using High-Resolution Mass Spectrometry. Journal of Analytical 
Toxicology 39, 163-171 (2015). 
161. M. McGrath, L. Nisbet, B. K. Logan, K. S. Scott, paper presented at the 
Society of Forensic Toxicologist Annual Meeting, Grand Rapids, MI,  2014. 
162. J. L. Poklis, D. J. Clay, A. Poklis, High-Performance Liquid 
Chromatography with Tandem Mass Spectrometry for the Determination of 
Nine Hallucinogenic 25-NBOMe Designer Drugs in Urine Specimens. Journal 
of Analytical Toxicology 38, 113-121 (2014). 
163. S. Odoardi, M. Fisichella, F. S. Romolo, S. Strano-Rossi, High-throughput 
screening for new psychoactive substances (NPS) in whole blood by DLLME 
extraction and UHPLC–MS/MS analysis. Journal of Chromatography B 
1000, 57-68 (2015). 
164. L. J. Marinetti, H. M. Antonides, Analysis of synthetic cathinones 
commonly found in bath salts in human performance and postmortem 
toxicology: method development, drug distribution and interpretation of 
results. Journal of analytical toxicology 37, 135-146 (2013). 
165. L. K. Sorensen, Determination of cathinones and related ephedrines in 
forensic whole-blood samples by liquid-chromatography-electrospray 
tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life 
Sci 879, 727-736 (2011). 
242 
 
166. N. Nic Daeid, K. A. Savage, D. Ramsay, C. Holland, O. B. Sutcliffe, 
Development of gas chromatography–mass spectrometry (GC–MS) and 
other rapid screening methods for the analysis of 16 ‘legal high’ cathinone 
derivatives. Science & Justice 54, 22-31. 
167. J. L. Poklis, J. Charles, C. E. Wolf, A. Poklis, High-performance liquid 
chromatography tandem mass spectrometry method for the determination 
of 2CC-NBOMe and 25I-NBOMe in human serum. Biomedical 
Chromatography 27, 1794-1800 (2013). 
168. K. Y. Rust, M. R. Baumgartner, A. M. Dally, T. Kraemer, Prevalence of 
new psychoactive substances: A retrospective study in hair. Drug Testing 
and Analysis 4, 402-408 (2012). 
169. A. J. P. Martin, R. L. M. Synge, A new form of chromatogram employing 
two liquid phases. Journal of Biochemistry 35, 1358-1368 (1941). 
170. Clarke's Analtyical Forensic Toxicology. S. Jickells, A. Negrusz, Eds.,  
(Pharmaceutical Press, London, 2008). 
171. . (documents, 2015). 
172. M. C. McMaster, in GC/MS. (John Wiley & Sons, Inc., 2008), pp. 37-46. 
173. E. de Hoffmann, V. Stroobant, Mass Spectrometry: Principles and 
Applications.  (Wiley, 2013). 
174. P. M. Uthe. (Google Patents, 1969). 
175. R. J. Flanagan, A. A. Taylor, I. D. Watson, R. Whelpton, Fundamentals of 
Analytical Toxicology.  (Wiley, 2008). 
176. G. Vas, K. Vekey, Solid-phase microextraction: a powerful sample 
preparation tool prior to mass spectrometric analysis. J Mass Spectrom 
39, 233-254 (2004). 
177. A. A. S. Marais, J. B. Laurens, Rapid GC–MS confirmation of amphetamines 
in urine by extractive acylation. Forensic Science International 183, 78-86 
(2009). 
178. M. R. Meyer, P. Du, F. Schuster, H. H. Maurer, Studies on the metabolism 
of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone 
(MDPV) in rat and human urine and human liver microsomes using GC–MS 
and LC–high-resolution MS and its detectability in urine by GC–MS. Journal 
of Mass Spectrometry 45, 1426-1442 (2010). 
179. M. R. Meyer, D. Prosser, H. H. Maurer, Studies on the metabolism and 
detectability of the designer drug β-naphyrone in rat urine using GC-MS 
and LC-HR-MS/MS. Drug Testing and Analysis 5, 259-265 (2013). 
180. M. R. Meyer, C. Vollmar, A. E. Schwaninger, E. Wolf, H. H. Maurer, New 
cathinone-derived designer drugs 3-bromomethcathinone and 3-
fluoromethcathinone: studies on their metabolism in rat urine and human 
liver microsomes using GC-MS and LC-high-resolution MS and their 
detectability in urine. J Mass Spectrom 47, 253-262 (2012). 
181. C. Hanson, Recent Advances in Liquid-Liquid Extraction.  (Elsevier 
Science, 2013). 
182. Clarke's Analysis of Drugs and Poisons. A. C. Moffat, M. D. Osselton, B. 
Widdop, Eds.,  (Pharmaceutical Press, 2004), vol. 2. 
183. L. Alders, Liquid-liquid Extraction: Theory and Laboratory Practice.  
(Elsevier Publishing Company, 1959). 
184. N. J. K. Simpson, Solid-Phase Extraction: Principles, Techniques, and 
Applications.  (CRC Press, 2010). 
185. S. Jickells, A. Negrusz, Clarke's Analytical Forensic Toxicology.  
(Pharmaceutical Press, 2008). 
243 
 
186. M. J. Telepchak, G. Chaney, T. F. August, Forensic and Clinical 
Applications of Solid Phase Extraction. Forensic science and medicine 
(Humana Press, 2004). 
187. K. Zech, R. W. Frei†, Selective Sample Handling and Detection in High-
Performance Liquid Chromatography. Journal of Chromatography Library, 
39B (Elsevier Science, 1989). 
188. R. N. Rao, K. G. Prasad, K. V. S. Kumar, B. Ramesh, Diatomaceous earth 
supported liquid extraction and LC-MS/MS determination of elvitegravir 
and ritonavir in rat plasma: application to a pharmacokinetic study. 
Analytical Methods 5, 6693-6699 (2013). 
189. H. Torrance, G. Cooper, The detection of mephedrone (4-
methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci Int 202, 
e62-63 (2010). 
190. S. Broecker, S. Herre, B. Wüst, J. Zweigenbaum, F. Pragst, Development 
and practical application of a library of CID accurate mass spectra of more 
than 2,500 toxic compounds for systematic toxicological analysis by LC–
QTOF-MS with data-dependent acquisition. Analytical and Bioanalytical 
Chemistry 400, 101-117 (2011). 
191. H. J. Hübschmann, Handbook of GC-MS: Fundamentals and Applications.  
(Wiley, 2015). 
192. . (2015), vol. 2015. 
193. Record et al., paper presented at the NEAFS, Hershey, PA,  2014. 
194. D. Springer, G. Fritschi, H. H. Maurer, Metabolism of the new designer 
drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of 
PPP and 4′-methyl-α-pyrrolidinopropiophenone (MPPP) studied in rat urine 
using gas chromatography-mass spectrometry. Journal of Chromatography 
B 796, 253-266 (2003). 
195. D. R. Knapp, Handbook of Analytical Derivatization Reactions.  (Wiley, 
1979). 
196. J. F. Wyman et al., Postmortem Tissue Distribution of MDPV Following 
Lethal Intoxication by “Bath Salts”. Journal of Analytical Toxicology 37, 
182-185 (2013). 
197. L. Laskowski et al., Evolution of the NBOMes: 25C- and 25B- Sold as 25I-
NBOMe. Journal of Medical Toxicology 11, 237-241 (2015). 
198. C. Chen, C. Kostakis, R. J. Irvine, J. M. White, Increases in use of novel 
synthetic stimulant are not directly linked to decreased use of 3,4-
methylenedioxy-N-methylamphetamine (MDMA). Forensic Science 
International 231, 278-283 (2013). 
199. B. K. Logan, D. T. Stafford, I. R. Tebbett, C. M. Moore, Rapid Screening 
for 100 Basic Drugs and Metabolites in Urine Using Cation Exchange Solid-
Phase Extraction and High-Performance Liquid Chromatography with 
Diode Array Detection. Journal of Analytical Toxicology 14, 154-159 
(1990). 
200. Scientific Working Group for Forensic Toxicology (SWGTOX) Standard 
Practices for Method Validation in Forensic Toxicology. Journal of 
Analytical Toxicology 37, 452-474 (2013). 
201. M. Concheiro, S. Anizan, K. Ellefsen, M. Huestis, Simultaneous 
quantification of 28 synthetic cathinones and metabolites in urine by 
liquid chromatography-high resolution mass spectrometry. Analytical and 
Bioanalytical Chemistry 405, 9437-9448 (2013). 
202. D. Ammann, J. M. McLaren, D. Gerostamoulos, J. Beyer, Detection and 
Quantification of New Designer Drugs in Human Blood: Part 2 – Designer 
Cathinones. Journal of Analytical Toxicology 36, 381-389 (2012). 
244 
 
203. R. Karinen, E. L. Øiestad, W. Andresen, A. Smith-Kielland, A. 
Christophersen, Comparison of the stability of stock solutions of drugs of 
abuse and other drugs stored in a freezer, refrigerator, and at ambient 
temperature for up to one year. Journal of analytical toxicology 35, 583-
590 (2011). 
204. K. Ellefsen et al., Quantification of methylone and metabolites in rat and 
human plasma by liquid chromatography-tandem mass spectrometry. 
Forensic Toxicology 33, 202-212 (2015). 
205. O. H. Drummer, Postmortem toxicology of drugs of abuse. Forensic 
Science International 142, 101-113 (2004). 
206. P. Kalix, Cathinone, a Natural Amphetamine. Pharmacology & Toxicology 
70, 77-86 (1992). 
207. J. S. Chappell, M. M. Lee, Cathinone preservation in khat evidence via 
drying. Forensic Sci Int 195, 108-120 (2010). 
208. F. Sporkert, F. Pragst, R. Bachus, F. Masuhr, L. Harms, Determination of 
cathinone, cathine and norephedrine in hair of Yemenite khat chewers. 
Forensic Science International 133, 39-46 (2003). 
209. B. D. Berrang, A. H. Lewin, F. I. Carroll, Enantiomeric .alpha.-
aminopropiophenones (cathinone): preparation and investigation. The 
Journal of Organic Chemistry 47, 2643-2647 (1982). 
210. K. Tsujikawa et al., Degradation pathways of 4-methylmethcathinone in 
alkaline solution and stability of methcathinone analogs in various pH 
solutions. Forensic Science International 220, 103-110 (2012). 
211. R. D. Johnson, S. R. Botch-Jones, The stability of four designer drugs: 
MDPV, mephedrone, BZP and TFMPP in three biological matrices under 
various storage conditions. J Anal Toxicol 37, 51-55 (2013). 
212. P. D. Maskell et al., Stability of 3,4-Methylenedioxymethampetamine 
(MDMA), 4-Methylmethcathinone (Mephedrone) and 3-
Trifluromethylphenylpiperazine (3-TFMPP) in Formalin Solution. Journal 
of Analytical Toxicology 37, 440-446 (2013). 
213. E. I. Miller, H. J. Torrance, J. S. Oliver, Validation of the Immunalysis 
microplate ELISA for the detection of buprenorphine and its metabolite 
norbuprenorphine in urine. J Anal Toxicol 30, 115-119 (2006). 
214. Clarke's Analysis of Drugs and Poisons. A. C. Moffat, D. M. Osselton, B. 
Widdop, Eds.,  (Pharmaceutical Press, London, 2004), vol. 1. 
215. A. M. Macher, T. M. Penders, False-positive phencyclidine immunoassay 
results caused by 3,4-methylenedioxypyrovalerone (MDPV). Drug Testing 
and Analysis 5, 130-132 (2013). 
216. P. S. M. Reddy, Advanced Synthetic Materials in Detection Science. RSC 
Detection Science (Royal Society of Chemistry, 2014). 
217. M. J. Swortwood, W. L. Hearn, A. P. DeCaprio, Cross-reactivity of 
designer drugs, including cathinone derivatives, in commercial enzyme-
linked immunosorbent assays. Drug Testing and Analysis 6, 716-727 
(2013). 
218. H. H. Maurer, Advances in analytical toxicology: the current role of liquid 
chromatography–mass spectrometry in drug quantification in blood and 
oral fluid. Analytical and bioanalytical chemistry 381, 110-118 (2005). 
219. A. P. Bruins, Mechanistic aspects of electrospray ionization. Journal of 
Chromatography A 794, 345-357 (1998). 
220. C. S. Ho et al., Electrospray Ionisation Mass Spectrometry: Principles and 
Clinical Applications. The Clinical Biochemist Reviews 24, 3-12 (2003). 
221. J.-S. Kang, in Tandem Mass Spectrometry - Applications and Principles,, 
J. Prasain, K, Ed. (2012),  chap. 21. 
245 
 
222. S. K. Grebe, R. J. Singh, LC-MS/MS in the Clinical Laboratory - Where to 
From Here? Clin Biochem Rev 32, 5-31 (2011). 
223. V. Viette, D. Hochstrasser, M. Fathi, LC-MS (/MS) in clinical toxicology 
screening methods. Chimia (Aarau) 66, 339-342 (2012). 
224. P. Kintz, M. Villain, V. Cirimele, Hair analysis for drug detection. 
Therapeutic drug monitoring 28, 442-446 (2006). 
225. M. Villain, V. Cirimele, P. Kintz, Hair analysis in toxicology. Clinical 
chemistry and laboratory medicine 42, 1265-1272 (2004). 
226. P. Kintz, Value of hair analysis in postmortem toxicology. Forensic science 
international 142, 127-134 (2004). 
227. P. Kintz, A. Salomone, M. Vincenti, Hair Analysis in Clinical and Forensic 
Toxicology.  (Elsevier Science, 2015). 
228. R. Wennig, Potential problems with the interpretation of hair analysis 
results. Forensic Sci Int 107, 5-12 (2000). 
229. D. L. Blank, D. A. Kidwell, External contamination of hair by cocaine: an 
issue in forensic interpretation. Forensic science international 63, 145-
156 (1993). 
230. P. Kintz, Segmental hair analysis can demonstrate external contamination 
in postmortem cases. Forensic Sci Int 215, 73-76 (2012). 
231. G. A. Cooper, R. Kronstrand, P. Kintz, Society of Hair Testing guidelines 
for drug testing in hair. Forensic Sci Int 218, 20-24 (2012). 
232. L. C. Gautam, Michael D, Hair Analysis in Forensic Toxicology. Forensic 
Magazine,  (2013). 
233. B. K. Matuszewski, M. L. Constanzer, C. M. Chavez-Eng, Matrix effect in 
quantitative LC/MS/MS analyses of biological fluids: a method for 
determination of finasteride in human plasma at picogram per milliliter 
concentrations. Analytical Chemistry 70, 882-889 (1998). 
234. M. D. Tingle, N. A. Helsby, Can in vitro drug metabolism studies with 
human tissue replace in vivo animal studies? Environmental Toxicology 
and Pharmacology 21, 184-190 (2006). 
235. Cyprotex, Everything you neede to know about ADME, but were too afraid 
to ask. ADME Guide (cyprotex, 2006). 
236. C. E. Inturrisi et al., The pharmacokinetics of heroin in patients with 
chronic pain. New England Journal of Medicine 310, 1213-1217 (1984). 
237. P. Maurel, The use of adult human hepatocytes in primary culture and 
other in vitro systems to investigate drug metabolism in man. Advanced 
Drug Delivery Reviews 22, 105-132 (1996). 
238. M. Meyer, J. Wilhelm, F. Peters, H. Maurer, Beta-keto amphetamines: 
studies on the metabolism of the designer drug mephedrone and 
toxicological detection of mephedrone, butylone, and methylone in urine 
using gas chromatography–mass spectrometry. Analytical and 
Bioanalytical Chemistry 397, 1225-1233 (2010). 
239. C. J. Pfeiffer, G. H. Gass, A Simple, Inexpensive Metabolism Cage for 
Small Mammals. Canadian Journal of Comparative Medicine and 
Veterinary Science 27, 69-70 (1963). 
240. M. Cecchi, N. Capriles, S. J. Watson, H. Akil, Differential responses to 
morphine-induced analgesia in the tail-flick test. Behav Brain Res 194, 
146-151 (2008). 
241. F. V. Abbott, R. Melzack, C. Samuel, Morphine analgesia in the tail-flick 
and Formalin pain tests is mediated by different neural systems. 
Experimental Neurology 75, 644-651 (1982). 
246 
 
242. S. Dalal, R. Melzack, Potentiation of opioid analgesia by psychostimulant 
drugs: a review. Journal of pain and symptom management 16, 245-253 
(1998). 
243. J. Connor, E. Makonnen, A. Rostom, Comparison of analgesic effects of 
khat (Catha edulis Forsk) extract, D-amphetamine and ibuprofen in mice. 
J Pharm Pharmacol 52, 107-110 (2000). 
244. P. B. Pail, K. M. Costa, C. E. Leite, M. M. Campos, Comparative 
pharmacological evaluation of the cathinone derivatives, mephedrone and 
methedrone, in mice. Neurotoxicology 50, 71-80 (2015). 
245. J. C. Crabbe, J. K. Belknap, K. J. Buck, Genetic animal models of alcohol 
and drug abuse. SCIENCE-NEW YORK THEN WASHINGTON-, 1715-1715 
(1994). 
246. C. D. Barnes, L. G. Eltherington, Drug Dosage in Laboratory Animals: A 
Handbook.  (University of California Press, 1973). 
247. E. Tarland, Effect of metabolism cage housing on rodent welfare.  (2007). 
248. J. L. Poklis, B. L. Mason, A. Poklis, L. E. Wise, in SOFT. (Grand Rapids, MI, 
2014), pp. S-28. 
249. A. L. Halberstadt, M. A. Geyer, Characterization of the head-twitch 
response induced by hallucinogens in mice: detection of the behavior 
based on the dynamics of head movement. Psychopharmacology 227, 727-
739 (2013). 
250. W. H. Pan, C. R. Lee, L. H. Lim, A new video path analyzer to monitor 
travel distance, rearing, and stereotypic movement of rats. J Neurosci 
Methods 70, 39-43 (1996). 
251. A. Bosak, F. LoVecchio, M. Levine, Recurrent seizures and serotonin 
syndrome following “2C-I” ingestion. Journal of Medical Toxicology 9, 
196-198 (2013). 
252. M. J. Burish, K. L. Thoren, M. Madou, S. Toossi, M. Shah, Hallucinogens 
causing seizures? A case report of the synthetic amphetamine 2, 5-
dimethoxy-4-chloroamphetamine. The Neurohospitalist 5, 32-34 (2015). 
253. Y. Nakahara, R. Kikura, Hair analysis for drugs of abuse XIII. Effect of 
structural factors on incorporation of drugs into hair: the incorporation 
rates of amphetamine analogs. Archives of toxicology 70, 841-849 (1996). 
254. M. B. Smith, J. March, March's Advanced Organic Chemistry: Reactions, 
Mechanisms, and Structure.  (Wiley, 2007). 
255. S. B. Deeming, C. W. Weber, Hair analysis of trace minerals in human 
subjects as influenced by age, sex, and contraceptive drugs. The 
American journal of clinical nutrition 31, 1175-1180 (1978). 
256. E. J. Cone, D. Yousefnejad, W. D. Darwin, T. Maguire, Testing human hair 
for drugs of abuse. II. Identification of unique cocaine metabolites in hair 
of drug abusers and evaluation of decontamination procedures. Journal of 
analytical toxicology 15, 250-255 (1991). 
257. Y. Nakahara, M. Shimamine, K. Takahashi, Hair analysis for drugs of 
abuse. III. Movement and stability of methoxyphenamine (as a model 
compound of methamphetamine) along hair shaft with hair growth. 
Journal of analytical toxicology 16, 253-257 (1992). 
 
  
247 
 
Appendices 
 
248 
 
 
Appendix 1: Mass spectra of analytes after PFPA derivatisation. 
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Flephedrone mass spectrum after PFPA derivatisation 
 
Mephedrone mass spectrum after PFPA derivatisation 
 
 
 
 
5-APB mass spectrum after PFPA derivatisation  
6-APB mass spectrum after PFPA derivatisation  
Methylone mass spectrum after PFPA derivatisation 
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3-MeO-PCE mass spectrum after PFPA derivatisation 
 Butylone mass spectrum after PFPA derivatisation 
 Ethylone mass spectrum after PFPA derivatisation 
Methoxetamine mass spectrum after PFPA derivatisation 
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2-DPMP mass spectrum after PFPA derivatisation 
MDPV mass spectrum after PFPA derivatisation 
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25H-NBOMe mass spectrum after PFPA derivatisation 
25D-NBOMe mass spectrum after PFPA derivatisation 
25E-NBOMe mass spectrum after PFPA derivatisation 
 
251 
 
Mescaline-NBOMe mass spectrum after PFPA derivatisation 
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25N-NBOMe mass spectrum after PFPA derivatisation 
25T7-NBOMe mass spectrum after PFPA derivatisation 
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Appendix 2: Mass spectra of analytes after MSTFA derivatisation. 
Mephedrone mass spectrum after MSTFA derivatisation 
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25D-NBOMe mass spectrum after MSTFA derivatisation 
25E-NBOMe mass spectrum after MSTFA derivatisation 
Mescaline-NBOMe mass spectrum after MSTFA derivatisation 
25P-NBOMe mass spectrum after MSTFA derivatisation 
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25C-NBOMe mass spectrum after MSTFA derivatisation 
25B-NBOMe mass spectrum after MSTFA derivatisation 
25I-NBOMe mass spectrum after MSTFA derivatisation 
25N-NBOMe mass spectrum after MSTFA derivatisation 
25T4-NBOMe mass spectrum after MSTFA derivatisation 
25T2-NBOMe mass spectrum after MSTFA derivatisation 
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25T7-NBOMe mass spectrum after MSTFA derivatisation 
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Appendix 3: Mass spectra of analytes after TFAA derivatisation. 
Methiopropamine mass spectrum after TFAA derivatisation 
Flephedrone mass spectrum after TFAA derivatisation 
Mephedrone mass spectrum after TFAA derivatisation 
5-APB mass spectrum after TFAA derivatisation 
6-APB mass spectrum after TFAA derivatisation 
3-MeO-PCE mass spectrum after TFAA derivatisation 
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Methylone mass spectrum after TFAA derivatisation  
Butylone mass spectrum after TFAA derivatisation 
Ethylone mass spectrum after TFAA derivatisation  
Methoxetamine mass spectrum after TFAA derivatisation 
Benzedrone mass spectrum after TFAA derivatisation  
3-MeO-PCP mass spectrum after TFAA derivatisation 
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MDPV mass spectrum after TFAA derivatisation  
2-DPMP mass spectrum after TFAA derivatisation  
Naphyrone mass spectrum after TFAA derivatisation  
25H-NBOMe mass spectrum after TFAA derivatisation 
25D-NBOMe mass spectrum after TFAA derivatisation 
25E-NBOMe mass spectrum after TFAA derivatisation 
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Mescaline-NBOMe mass spectrum after TFAA derivatisation 
 
25P-NBOMe mass spectrum after TFAA derivatisation 
25C-NBOMe mass spectrum after TFAA derivatisation 
25B-NBOMe mass spectrum after TFAA derivatisation 
25I-NBOMe mass spectrum after TFAA derivatisation 
25T2-NBOMe mass spectrum after TFAA derivatisation 
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25N-NBOMe mass spectrum after TFAA derivatisation 
25T7-NBOMe mass spectrum after TFAA derivatisation 
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Appendix 4: Mass spectra of analytes after TMSI derivatisation. 
 
3-MeO-PCE mass spectrum after TMSI derivatisation 
 
3-MeO-PCP mass spectrum after TMSI derivatisation 
 
Methoxetamine mass spectrum after TMSI derivatisation 
 
 
 
 
2-DPMP mass spectrum after TMSI derivatisation 
 
Naphyrone mass spectrum after TMSI derivatisation 
 
MDPV mass spectrum after TMSI derivatisation 
264 
 
 
25H-NBOMe mass spectrum after TMSI derivatisation 
 
25D-NBOMe mass spectrum after TMSI derivatisation 
 
25E-NBOMe mass spectrum after TMSI derivatisation 
 
Mescaline-NBOMe mass spectrum after TMSI derivatisation 
 
25P-NBOMe mass spectrum after TMSI derivatisation 
 
25C-NBOMe mass spectrum after TMSI derivatisation 
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25B-NBOMe mass spectrum after TMSI derivatisation 
 
25I-NBOMe mass spectrum after TMSI derivatisation 
 
25N-NBOMe mass spectrum after TMSI derivatisation 
 
25T4-NBOMe mass spectrum after TMSI derivatisation 
 
25T2-NBOMe mass spectrum after TMSI derivatisation 
 
25T7-NBOMe mass spectrum after TMSI derivatisation 
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Appendix 5: Average peak areas of analytes after derivatisation at each temperature and each incubation time 
PFPA.  
TEMPERATURE 24oC 37oC 50oC 70oC 
INCUBATION TIME 20 MINS 40 MINS 20 MINS 40 MINS 20 MINS 40 MINS 20 MINS 40 mins 
 
AVG %CV AVG %C.V. AVG % C.V. AVG %CV AVG %CV AVG %CV AVG %CV AVG %CV 
25B-NBOME 2105701 3.6 2504570 5.2 4244681 13.3 3762591 5.4 3670253 7.8 2707283 5.4 3200421 28.4 1524970 11.6 
25C-NBOME 3513788 2.4 4925203 10.4 5503196 7.5 4133332 9.5 3994884 6.7 3076087 3.2 4403348 6.1 2836258 11.2 
25D-NBOME 3932827 6.5 6399257 12.6 8116595 23.8 5799487 7.4 5423849 12.4 4230023 2.7 6204035 4.6 3866235 12.7 
25E-NBOME 3687305 9.8 6564222 1.8 6364609 12.9 5532153 7.0 5211808 12.8 3993611 1.8 5938545 3.6 3632574 12.3 
25H-NBOME 4262327 2.7 7005366 8.2 7061705 16.9 6233248 9.2 5804158 11.6 4631684 4.5 6682308 5.8 4239265 12.5 
25I-NBOME 915670 4.9 721080 5.7 5491689 20.1 2973294 5.6 2902121 11.6 2504135 17.3 774536 6.9 466842 12.1 
25N-NBOME 457853 13.7 870257 15.3 1002858 1.3 996294 21.5 1105198 12.2 816689 14.0 1612858 8.6 853920 15.5 
25P-NBOME 4192535 2.8 5393820 8.9 5822820 13.1 5339110 5.0 5108221 7.3 3658583 4.2 5545259 4.7 3370650 13.7 
25T2-NBOME 1165422 2.1 876312 15.1 1866410 8.8 1108390 36.5 949575 4.0 573127 6.3 1224907 23.1 563990 20.7 
25T4-NBOME 546985 8.0 434885 4.2 1868777 8.6 1364033 26.9 1058152 1.6 703060 1.1 1133597 17.1 325853 23.5 
25T7-NBOME 936758 6.6 592659 17.3 1188352 14.8 849238 46.9 712458 7.5 387116 5.3 992144 31.4 400034 23.5 
2-DPMP 581515 10.6 947793 4.1 930176 17.9 868722 4.3 752819 11.6 624772 0.0 847342 6.3 564644 12.5 
3-MEO-PCE 3157441 1.7 5064590 5.2 5476374 32.4 4411894 12.4 4049420 12.3 3398859 1.8 4379442 13.5 2991923 13.0 
3-MEO-PCP 1365264 9.5 1403293 6.7 2806468 83.3 1154145 7.7 1137819 11.7 926989 1.4 1306895 4.9 834494 13.5 
5-APB 4463953 11.4 7344962 3.5 6298220 6.9 6298220 6.9 5852911 12.3 4761858 5.5 6876632 3.2 4311728 9.5 
6-APB 4812617 3.7 7630914 6.7 7238264 12.8 6005884 6.1 5926034 8.5 4863066 2.3 6489215 3.7 4208685 12.5 
267 
 
 
BENZEDRONE 3667164 13.1 7268245 11.0 7599427 33.7 6976481 8.4 6298832 10.8 5230642 0.9 7931314 7.2 4921790 9.5 
BUTYLONE 5836308 14.3 9917665 5.5 8380222 3.9 8233994 10.7 7984216 11.1 6556727 0.1 9497740 5.0 6209998 17.6 
ETHYLONE 1686385 10.2 2823908 6.1 2390671 3.3 2401559 12.6 2289297 6.5 1941727 0.0 2831936 5.6 1831142 17.4 
FLEPHEDRONE 1982662 15.3 2767969 12.7 1752083 15.6 1535275 38.1 2270071 11.4 1717255 2.5 2635889 2.4 1524509 23.3 
MDPV 4192048 4.1 8579133 3.5 7516640 6.3 7332130 2.8 6919086 11.8 5843390 6.2 8215615 5.6 5205325 13.8 
MEPHEDRONE 584318 5.1 1079169 10.2 837729 7.7 822358 29.7 959918 11.0 787525 8.7 1148247 2.0 683280 16.8 
MESCALINE NBOME 3437569 10.1 5361762 2.6 5662009 13.9 5228510 6.9 5048671 8.2 3732599 3.1 5656966 4.5 3387991 15.5 
METHIOPROPAMINE 1178785 9.8 2916088 7.9 2019404 12.3 1496617 25.7 2352143 13.4 1508280 5.4 2668527 3.8 1435544 29.1 
METHOXETAMINE 1781058 5.9 3509882 8.1 2604987 11.5 2799352 14.0 2746721 12.9 2321266 4.8 3330469 11.8 2063738 19.8 
METHYLONE 593104 4.5 1867611 5.9 1731194 11.9 1674569 15.4 1625026 14.1 1283936 0.5 1892738 1.9 1162741 11.5 
NAPHYRONE 2644897 12.4 6654953 6.1 4358618 47.6 5469075 10.5 5754016 11.1 4838097 7.8 7107451 4.5 4432547 14.6 
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MSTFA 
TEMPERATURE 24oC 37oC 50oC 70oC 
INCUBATION TIME 20 MINS 40 MINS 20 MINS 40 MINS 20 MINS 40 MINS 20 MINS 40 mins 
 
AVG %CV AVG %C.V. AVG % C.V. AVG %CV AVG %CV AVG %CV AVG %CV AVG %CV 
25B-NBOME 937856 1 369536 2 1074240 2 951265 8 1099776 7 1000015 8 985164 10 801541 19 
25C-NBOME 1089888 2 1003456 2 975936 5 946125 7 1099776 8 1010545 9 954156 11 821451 18 
25D-NBOME 1835520 4 2080256 1 1958912 1 2215612 5 2302976 9 2212345 9 2015211 15 195124 16 
25E-NBOME 1705472 5 2003456 4 179072 2 1652152 6 2108928 10 2100981 7 1954121 16 2015412 20 
25H-NBOME 270656 2 374464 1 1153541 4 1572135 6 2195968 5 2015641 4 1851261 16 1901521 15 
25I-NBOME 205248 5 1389056 5 1280512 5 1502136 6 1747968 5 1601451 5 1520412 15 1015412 17 
25N-NBOME 389632 4 285376 3 320008 5 365201 4 420480 5 384516 6 360152 15 301541 21 
25P-NBOME 880896 4 1836544 4 1840440 5 1851264 5 2041856 4 1984513 6 1541241 19 104124 16 
25T2-NBOME 362515 5 410215 5 317376 6 401562 5 420480 6 381541 3 321564 12 251241 15 
25T4-NBOME 157056 3 1147904 2 1051951 1 951621 3 1181184 9 1167541 5 1100001 12 100145 20 
25T7-NBOMe 83052 4 365779 1 388800 2 402152 1 423040 6 401254 2 384512 12 301245 10 
2-DPMP 960120 1 1246720 2 1177344 3 974160 2 845126 11 801541 1 764512 18 678454 11 
3-MEO-PCE 873408 2 971392 1 890515 2 691904 2 551251 5 541645 4 501425 16 489154 11 
3-MEO-PCP 200992 5 387648 3 378208 1 209612 5 201564 8 195461 5 150241 15 101541 14 
5-APB 121136 5 845681 3 807168 5 751215 5 701564 1 701564 6 605184 16 541245 15 
6-APB 743104 6 1523712 3 1283072 1 901536 2 912115 5 891542 3 701564 19 645124 19 
BENZEDRONE 449968 5 455424 5 393600 1 340736 1 320315 8 281567 4 255554 15 200154 21 
BUTYLONE 124130 4 139712 4 132451 1 110125 1 112025 8 102451 5 95145 15 78451 22 
ETHYLONE 105692 5 676800 1 135104 2 105102 2 120125 9 134651 6 112456 10 101245 16 
MDPV 1256640 6 1329664 2 1005504 3 1325792 5 995152 7 874561 9 851645 11 764154 19 
MEPHEDRONE 557568 7 561088 3 460160 4 451233 4 420152 6 384569 9 356481 12 281541 13 
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MESCALINE NBOME 985702 5 977344 2 956736 5 991520 3 1088512 9 984555 8 874512 14 701541 11 
METHOXETAMINE 203008 4 351168 2 217600 6 221520 5 191522 9 177775 5 184574 16 161245 18 
METHYLONE 809088 5 905728 3 801521 7 759152 6 684152 4 568749 6 554785 17 501245 19 
NAPHYRONE 1927168 3 2045440 1 457216 1 630464 4 548645 5 504516 5 454545 18 401245 21 
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TFAA 
TEMPERATURE 24oC 37oC 50oC 70oC 
INCUBATION TIME 20 MINS 40 MINS 20 MINS 40 MINS 20 MINS 40 MINS 20 MINS 40 mins 
 
AVG %CV AVG %C.V. AVG % C.V. AVG %CV AVG %CV AVG %CV AVG %CV AVG %CV 
25B-NBOME 880576 3 813971 4 893312 8 829184 5 867200 6 943432 9 787521 10 652312 15 
25C-NBOME 1146368 5 292800 5 770112 4 1096192 4 945472 7 1277952 10 1150496 11 782152 15 
25D-NBOME 1042304 1 531776 5 1150464 5 1149280 6 1121120 8 1189888 12 1015360 16 801234 19 
25E-NBOME 703872 2 734910 1 66960 1 719040 2 541560 8 754488 13 565696 16 402512 16 
25H-NBOME 1023200 6 417280 3 1126080 1 1045888 3 1144320 8 1187328 10 1078176 18 901254 15 
25I-NBOME 85080 9 71488 2 421952 3 283712 4 685681 5 746481 9 672128 19 546212 14 
25N-NBOME 133664 5 90112 5 106752 6 274816 5 214790 6 292736 9 254251 21 201512 16 
25P-NBOME 957568 2 277760 3 1071616 4 1075458 6 1108480 9 1161216 8 1114304 15 1052311 19 
25T2-NBOME 44774 1 225746 1 221952 5 282081 4 241632 11 292736 6 215404 15 201520 21 
25T4-NBOME 198976 2 185748 5 142472 6 202081 5 192265 9 207744 5 201856 19 182512 20 
25T7-NBOME 26246 3 144192 7 185552 1 94656 5 186720 8 190720 4 133440 16 126530 25 
2-DPMP 311756 5 1804288 5 1836896 2 1907712 6 1816704 6 1499648 3 1307648 16 1835520 16 
3-MEO-PCE 257042 1 618448 1 584512 3 621056 5 584156 9 185760 2 124256 10 611264 16 
3-MEO-PCP 110752 2 87072 3 75812 3 76812 5 135744 5 141440 1 126592 10 115212 15 
5-APB 3688629 3 312832 3 1064448 2 1000688 3 1097728 8 1027840 3 1329664 9 1147904 14 
6-APB 3761448 1 707072 3 855872 1 909312 2 740928 5 941696 3 1266176 9 1100288 10 
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TEMPERATURE 24oC 37oC 50oC 70oC 
INCUBATION TIME 20 MINS 40 MINS 20 MINS 40 MINS 20 MINS 40 MINS 20 MINS 40 mins 
 
AVG %CV AVG %C.V. AVG % C.V. AVG %CV AVG %CV AVG %CV AVG %CV AVG %CV 
BENZEDRONE 1318421 2 1539072 3 1861120 8 2001920 1 1343488 6 1611264 8 1241664 8 1204480 19 
BUTYLONE 1067458 2 1364480 2 1547456 1 1661440 1 1660144 6 1332736 9 1223680 10 1004448 18 
ETHYLONE 1158369 3 1600448 1 758400 5 1603072 5 1562816 5 1472000 10 1591328 10 1569280 19 
FLEPHEDRONE 441135 1 373056 1 58992 5 520128 4 388224 5 441920 15 224960 15 201664 23 
MDPV 1551299 1 1612541 2 2164736 4 2387968 6 2005568 5 2191360 10 1951621 17 1907200 20 
MEPHEDRONE 409762 2 775296 1 401920 6 886208 6 881968 5 841408 9 795584 19 740880 21 
MESCALINE NBOME 185216 1 214720 5 1093312 2 1000215 5 1062400 6 1156608 8 951201 21 861400 19 
METHIOPROPAMINE 227978 1 248192 1 31584 3 307264 4 156928 3 308240 9 99416 16 131712 18 
METHYLONE 2648561 2 1294848 4 400128 5 330816 5 1958912 3 810880 9 1722368 19 1081856 17 
METHOXETAMINE 648260 3 298176 4 441720 4 1285623 4 700672 2 132416 8 564912 20 1245256 16 
NRG-1 858004 6 415488 5 888576 3 914496 2 904272 5 841516 6 90360 16 820768 15 
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TMSI 
TEMPERATURE 24oC 37oC 50oC 70oC 
INCUBATION TIME 20 MINS 40 MINS 20 MINS 40 MINS 20 MINS 40 MINS 20 MINS 40 mins 
 
AVG %CV AVG %C.V. AVG % C.V. AVG %CV AVG %CV AVG %CV AVG %CV AVG %CV 
25B-NBOME 1418240 5 770816 2 1570304 3 580736 4 921984 5 616160 6 829440 10 560000 16 
25C-NBOME 1016768 6 1086144 2 1144834 4 1093824 5 1128448 4 1123328 3 1096736 11 879040 15 
25D-NBOME 1290272 4 1135104 3 1333760 1 1015488 1 897088 6 1020032 7 1296736 15 954240 15 
25E-NBOME 331776 7 1184256 1 1756672 1 310144 3 375424 9 877632 10 611840 16 632384 18 
25H-NBOME 1012672 1 928000 4 1421312 1 586688 4 672832 10 787520 11 942016 11 748480 19 
25I-NBOME 1078336 3 328384 3 1193472 2 507200 6 688640 2 879424 5 809920 9 503104 21 
25N-NBOME 1010688 3 744576 3 1637376 3 1406848 2 1374912 6 931264 9 1038080 15 1114112 22 
25P-NBOME 319872 2 471488 1 535616 1 400544 5 418304 4 289792 2 400320 15 345344 16 
25T2-NBOME 1045120 4 633600 4 1637376 1 830720 1 1305088 3 1200640 3 551744 18 411712 13 
25T4-NBOME 711792 2 727648 4 790656 2 472576 2 243968 3 554624 4 454208 20 293504 14 
25T7-NBOME 515648 1 540704 5 612736 4 591042 2 44568 2 424576 6 536512 21 568640 15 
2-DPMP 1413504 1 1380192 3 1475072 1 830656 5 1214976 1 1133056 6 817984 13 122928 15 
3-MEO-PCE 594240 6 190784 1 794624 1 296640 1 170688 1 700640 8 233216 13 281920 18 
3-MEO-PCP 1032544 5 980800 1 1052160 4 985615 6 885617 5 559744 9 869216 19 770560 21 
MDPV 2068992 3 2405376 5 2707456 3 2661888 6 2613248 1 2431488 9 154280 18 1514496 20 
MESCALINE NBOME 1476096 4 1031936 4 4419072 2 1174016 1 1345024 1 1364800 10 2436608 15 2564608 19 
METHOXETAMINE 389440 2 345344 8 648260 5 536064 2 336448 2 602176 11 630784 16 600064 17 
NRG-1 2017792 2 1362944 2 2280448 1 175616 3 1616896 4 805184 10 1847808 20 1478464 10 
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Appendix 6: SPE blood, urine serum and plasma cartridge comparison data 
BLOOD 
CSDAU ZSDAU XCEL I OASIS 206 502 
% 
Recovery 
% CV 
% 
Recovery 
% CV 
% 
Recovery 
% CV 
% 
Recovery 
% CV 
% 
Recovery 
% CV 
% 
Recovery 
% CV 
25B-NBOMe 86 11 76 8 43 1 6 12 26 14 2 7 
25C-NBOMe 83 7 49 2 31 2 6 7 47 13 2 2 
25D-NBOMe 102 4 86 4 59 1 4 13 85 12 36 2 
25ENBOMe 110 6 80 8 55 2 2 5 77 15 101 6 
25H-NBOMe 99 10 53 5 76 1 10 2 41 14 38 3 
25I-NBOMe 90 8 63 18 50 1 23 4 49 6 14 9 
25N-NBOMe 17 18 81 5 16 6 2 13 18 12 17 3 
25P-NBOMe 39 11 22 15 27 1 2 9 69 13 25 9 
25T2-NBOMe 69 7 79 14 53 2 2 10 111 10 27 5 
25T4-NBOMe 105 9 74 13 22 2 0 3 61 10 36 8 
25T7-NBOMe 101 11 95 9 106 1 2 7 83 4 40 9 
2-DPMP 88 6 39 11 18 12 30 7 39 9 18 6 
3-MeO-PCE 37 3 40 5 30 17 27 14 45 11 25 3 
5-APB 49 2 45 9 35 2 16 11 47 3 32 2 
6-APB 22 7 27 11 12 2 14 12 26 2 31 4 
BENZEDRONE 4 3 32 11 3 8 28 9 47 3 41 5 
BUTYLONE 43 6 42 17 40 5 11 8 53 4 34 2 
ETHYLONE 24 1 115 15 92 2 13 6 40 10 33 5 
FLEPHEDRONE 65 5 16 14 68 9 9 9 47 4 33 3 
MDPV 106 8 17 8 52 14 15 8 41 2 45 13 
MEPHEDRONE 112 9 29 1 92 4 27 12 45 9 65 16 
Mescaline-NBOMe 5 11 2 5 49 12 7 13 52 2 46 3 
METHIOPROPAMINE 26 8 35 7 57 15 52 5 26 8 24 7 
METHOXETAMINE 53 9 19 13 49 11 7 5 56 2 45 6 
NAPHYRONE 36 10 39 5 38 5 12 13 35 5 40 5 
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URINE 
CSDAU ZSDAU XCEL I OASIS 206 502 
% 
Recovery 
% CV 
% 
Recovery 
% CV 
% 
Recovery 
% CV 
% 
Recovery 
% CV 
% 
Recovery 
% CV 
% 
Recovery 
% CV 
25B-NBOMe 85 3 82 6 49 1 12 1 65.0 2 5 4 
25C-NBOMe 85 2 83 6 46 2 10 6 64.7 9 5 10 
25D-NBOMe 102 2 103 7 66 1 11 8 109 1 21 14 
25E-NBOMe 110 1 101 8 63 2 34 3 102 1 22 13 
25H-NBOMe 139 10 99 7 96 3 40 16 67 6 14 12 
25I-NBOMe 89 1 90 4 54 3 10 1 65 9 8 1 
25N-NBOMe 55 5 98 9 18 6 26 7 39 59 9 14 
25P-NBOMe 64 1 76 7 38 1 7 7 60 3 10 15 
25T2-NBOMe 102 8 97 10 70 2 31 10 108 14 36 9 
25T4-NBOMe 105 5 95 9 59 2 26 6 88 8 6 7 
25T7-NBOMe 104 9 101 10 106 1 45 5 64 7 97 3 
2-DPMP 115 11 105 5 27 19 107 6 23 6 12 10 
3-MeO-PCE 93 7 86 6 96 10 43 10 50 4 78 10 
5-APB 90 19 35 6 95 7 94 15 68 8 55 17 
6-APB 85 15 35 7 94 6 90 12 71 7 57 12 
BENZEDRONE 43 17 36 4 15 14 124 13 70 3 61 6 
BUTYLONE 94 9 35 6 44 12 119 14 77 4 58 2 
ETHYLONE 82 3 38 4 43 2 87 9 69 4 51 5 
FLEPHEDRONE 81 4 34 3 32 17 76 12 63 5 50 4 
MDPV 97 5 36 4 105 6 102 8 82 3 63 3 
MEPHEDRONE 101 6 49 7 43 4 91 7 67 4 61 2 
Mescaline-NBOMe 9 8 5 5 50 9 12 2 6 3 43 9 
METHIOPROPAMINE 13 2 23 5 80 13 15 15 78 7 31 4 
METHOXETAMINE 61 8 35 2 70 10 62 4 49 5 56 3 
NAPHYRONE 37 7 95 3 113 2 63 5 77 6 50 4 
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PLASMA 
CSDAU ZSDAU XCEL I 206 502 
% Recovery % CV % Recovery % CV % Recovery % CV % Recovery % CV % Recovery % CV 
25B-NBOMe 30 1 117 4 25 10 42 19 1 6 
25C-NBOMe 25 1 76 3 46 8 45 18 2 5 
25D-NBOMe 40 1 117 3 77 11 77 16 3 6 
25E-NBOMe 37 1 111 3 76 8 71 16 37 6 
25H-NBOMe 24 1 37 2 51 6 52 15 16 5 
25I-NBOMe 45 1 36 4 47 12 45 16 39 3 
25N-NBOMe 10 2 105 3 1 13 28 18 8 8 
25P-NBOMe 23 3 63 5 56 17 43 12 19 6 
25T2-NBOMe 38 8 66 5 37 10 79 10 27 6 
25T4-NBOMe 37 6 64 6 30 8 59 12 56 6 
25T7-NBOMe 28 8 115 4 28 5 112 14 86 5 
2-DPMP 89 3 79 5 20 13 10 8 15 6 
3-MeO-PCE 18 11 21 4  14 60 3 56 6 
5-APB 63 5 12 3 6 11 45 8 48 10 
6-APB 3 12 45 2 4 13 47 10 38 6 
BENZEDRONE 39 13 18 2  11 48 3 38 5 
BUTYLONE 64 1 45 3 101 12 57 14 44 6 
ETHYLONE 35 1 67 4 79 13 62 3 41 5 
FLEPHEDRONE 67 5 27 1  5 52 12 38 4 
MDPV 57 2 35 8 109 2 56 4 34 6 
MEPHEDRONE 88 3 62 7  3 47 18 41 6 
Mescaline-NBOMe 2 4 41 4 3 7 4 16 38 5 
METHIOPROPAMINE 15 2 17 5 27 6 17 15 18 4 
METHOXETAMINE 56 9 19 6 12 8 66 16 56 3 
NAPHYRONE 27 10 40 2 37 6 39 10 42 4 
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SERUM 
CSDAU ZSDAU XCEL I 206 502 
% Recovery % CV % Recovery % CV % Recovery % CV % Recovery % CV % Recovery % CV 
25B-NBOMe 51 1 43 16 71 9 45 19 2 4 
25C-NBOMe 42 1 85 20 52 9 46 20 3 3 
25D-NBOMe 61 1 111 13 84 15 81 18 37 5 
25ENBOMe 59 2 108 14 81 16 73 15 25 2 
25H-NBOMe 4 1 81 12 52 7 38 16 41 6 
25I-NBOMe 59 2 118 16 80 9 46 16 15 6 
25N-NBOMe 8 2 118 14 20 3 16 15 18 9 
25P-NBOMe 36 1 62 13 42 9 39 14 29 6 
25T2-NBOMe 46 3 65 15 81 7 71 17 69 6 
25T4-NBOMe 46 8 61 15 70 10 55 13 37 5 
25T7-NBOMe 53 6 107 16 94 12 102 14 41 6 
2-DPMP 97 8 95 13 11 12 40 16 36 4 
3-MeO-PCE 47 3 50 14 36 14 42 14 32 2 
5-APB 71 5 24 16 69 11 32 12 48 5 
6-APB 51 12 27 15 49 13 41 14 37 5 
BENZEDRONE 35 13 25 12 40 11 38 10 47 4 
BUTYLONE 65 1 65 11 87 12 64 9 28 5 
ETHYLONE 74 2 64 7 79 13 67 15 25 10 
FLEPHEDRONE 63 5 52 4 50 4 68 16 37 4 
MDPV 76 2 46 15 100 19 52 19 32 5 
MEPHEDRONE 126 3 52 16 101 4 67 16 40 6 
Mescaline-NBOMe 3 4 13 10 10 6 4 10 90 10 
METHIOPROPAMINE 33 2 43 9 34 8 26 16 38 9 
METHOXETAMINE 53 10 58 8 20 5 41 12 40 12 
NAPHYRONE 28 7 23 12 33 6 45 10 47 11 
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Appendix 7: Comparison of SLE and SPE recovery rates for various NPS from blood, urine, plasma and serum.  
 BLOOD URINE PLASMA SERUM 
 SLE (%) SPE (%) DIF (%) SLE (%) SPE (%) DIF (%) SLE (%) SPE (%) DIF (%) SLE (%) SPE (%) DIF (%) 
25B-NBOMe 78 67 +11 73 81 -8 71 82 -11 71 89 -18 
25D-NBOMe 78 71 +7 72 83 -11 69 89 -20 69 86 -16 
25E-NBOMe 79 54 +25 73 79 -6 69 86 -17 70 85 -15 
25H-NBOMe 77 72 +5 71 88 -17 72 89 -17 70 101 -30 
25I-NBOMe 83 60 +23 72 77 -5 66 83 -16 67 127 -60 
25N-NBOMe 99 102 -2 108 127 -19 142 143 -1 46 35 +12 
25P-NBOMe 82 64 +18 75 74 +1 64 84 -20 68 112 -43 
25T2-NBOMe 55 61 -5 73 53 +20 66 100 -34 66 109 -43 
25T4-NBOMe 68 56 +12 73 55 +19 63 94 -31 63 124 -61 
25T7-NBOMe 45 60 -15 68 49 +19 68 96 -28 69 145 -76 
2-DPMP 90 103 -13 80 72 +8 70 70 +0 124 30 +94 
3-MEO-PCE 74 51 +23 61 74 -13 43 70 -27 32 55 -23 
3-MEO-PCP 75 49 +26 59 67 -8 39 69 -30 19 53 -33 
5-APB 77 46 +31 49 81 -32 41 93 -52 40 84 -44 
6-APB 81 40 +40 48 83 -35 34 98 -64 33 78 -45 
BENZEDRONE 142 132 +10 10 86 +22 77 106 -29 100 21 +79 
BUTYLONE 61 65 -4 62 56 +6 71 65 +6 83 29 +54 
ETHYLONE- 20 65 -46 18 69 -51 15 74 -58 19 30 -11 
FLEPHEDRONE 71 91 -21 108 63 +45 97 59 +39 120 85 +35 
MDPV 79 63 +16 59 74 -14 64 75 -11 70 75 -5 
MEPHEDRONE 82 43 +40 75 41 +34 22 65 -43 43 56 -13 
MESCALINE-NBOMe 72 74 -2 73 88 -15 74 91 -17 69 63 +7 
METHIOPROPAMINE 43 90 -47 101 54 +47 112 49 +62 145 88 +57 
METHYLONE 79 56 +23 65 76 -11 52 67 -16 55 54 +1 
MXE 88 58 +30 62 94 -32 23 87 -63 16 66 -50 
NAPHYRONE 117 70 +47 69 93 -24 56 92 -36 34 66 -33 
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Appendix 8: Autosampler peak area for urine and blood samples.  
Urine QC1 
Analyte 
 
P.A. (n=3) 
 
t=0 t=24 t=48 
% 
Recovery 
METHIOPROPAMINE 25512 28523 20807 -18.4 
FLEPHEDRONE 71434 71307 54098 -24.3 
MEPHEDRONE 61229 47538 45775 -25.2 
5-APB 245030 199412 236767 -3.4 
6-APB 400215 350964 358969 -10.3 
METHYLONE 59909 48980 41712 -30.4 
3-MeO-PCE 32671 31906 22913 -29.9 
BUTYLONE 334874 279176 290230 -13.3 
ETHYLONE 106179 103694 91652 -13.7 
MXE 98012 103694 91652 -6.5 
BENZEDRONE 522356 452960 482187 -7.7 
3-MeO-PCP 32671 39882 30551 -6.5 
2-DPMP 664817 679440 522369 -21.4 
MDPV 617330 452960 442004 -28.4 
NAPHYRONE 379895 362368 281275 -26.0 
25B-NBOMe 1764 790 1120 -36.5 
25C-NBOMe 3528 1975 2614 -25.9 
25D-NBOMe 5292 2765 4108 -22.4 
25E-NBOMe 4410 3160 3361 -23.8 
25H-NBOMe 5734 2765 5228 -8.8 
25I-NBOMe 8380 8295 6348 -24.2 
Mescaline-NBOMe 3528 2370 2988 -15.3 
25P-NBOMe 2205 1185 1494 -32.3 
25T4-NBOMe 441 395 373 -15.3 
25T7-NBOMe 441 790 373 -15.3 
Mephedrone-D3 510241 475381 416137 -18.4 
Ethylone-D5 816765 797646 763764 -6.5 
Methylone-D3 399395 376767 320865 -19.7 
MDPV-D8 4748692 4529598 4018221 -15.4 
NBOMe-D3 44104 39501 37344 -15.3 
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Urine QC2 
Analyte 
 
P.A. (n=3) 
 
t=0 t=24 t=48 
% 
Recovery 
METHIOPROPAMINE 131275 110213 124378 -5.3 
FLEPHEDRONE 432115 482838 350101 -19.0 
MEPHEDRONE 317249 251916 271789 -14.3 
5-APB 1327570 1037252 995384 -25.0 
6-APB 1843848 1590452 1526255 -17.2 
METHYLONE 883868 777683 748186 -15.4 
3-MeO-PCE 1305444 1265447 1154645 -11.6 
BUTYLONE 1696340 1452152 1327178 -21.8 
ETHYLONE 442523 484051 398153 -10.0 
MXE 685911 684586 637045 -7.1 
BENZEDRONE 4467169 3805045 3406747 -23.7 
3-MeO-PCP 191760 200535 179169 -6.6 
2-DPMP 2680302 2147401 1937170 -27.7 
MDPV 2639691 1846012 1903770 -27.9 
NAPHYRONE 3248850 2787855 2939154 -9.5 
25B-NBOMe 7268 5126 5212 -28.3 
25C-NBOMe 17928 10719 13230 -26.2 
25D-NBOMe 18897 13515 14032 -25.7 
25E-NBOMe 16474 9787 11626 -29.4 
25H-NBOMe 22773 18175 16437 -27.8 
25I-NBOMe 48939 43341 42095 -14.0 
Mescaline-NBOMe 14536 13515 13230 -9.0 
25P-NBOMe 13083 7923 8820 -32.6 
25T4-NBOMe 1454 1864 1604 10.3 
25T7-NBOMe 1938 1864 1203 -37.9 
Mephedrone-D3 546981 524824 460659 -15.8 
Ethylone-D5 737539 691501 663589 -10.0 
Methylone-D3 496555 471323 434992 -12.4 
MDPV-D8 4061063 3767371 3339948 -17.8 
NBOMe-D3 48454 46603 40090 -17.3 
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Urine QC3 
Analyte 
 
P.A. (n=3) 
 
t=0 t=24 t=48 
% 
Recovery 
METHIOPROPAMINE 255121 266111 197302 -22.7 
FLEPHEDRONE 954151 877180 713645 -25.2 
MEPHEDRONE 1663386 1769145 1456675 -12.4 
5-APB 4511622 40835747 3674266 -18.6 
6-APB 5540589 49833454 5221325 -5.8 
METHYLONE 1267979 1220370 1128906 -11.0 
3-MeO-PCE 4015128 35298696 3287501 -18.1 
BUTYLONE 6202581 49141322 5027942 -18.9 
ETHYLONE 1784501 13842626 1289216 -27.8 
MXE 2345756 20763939 1998285 -14.8 
BENZEDRONE 18794764 16972690 15711315 -16.4 
3-MeO-PCP 575646 6090755 489902 -14.9 
2-DPMP 15785490 14233581 13829459 -12.4 
MDPV 16471815 12912940 13348054 -19.0 
NAPHYRONE 15574313 12423813 11422433 -26.7 
25B-NBOMe 59455 53834 43701 -26.5 
25C-NBOMe 69618 82709 48279 -30.7 
25D-NBOMe 58438 58728 39123 -33.1 
25E-NBOMe 61487 58728 42036 -31.6 
25H-NBOMe 72667 83198 60765 -16.4 
25I-NBOMe 60471 50408 45366 -25.0 
Mescaline-NBOMe 49800 60196 34545 -30.6 
25P-NBOMe 59455 64111 44533 -25.1 
25T4-NBOMe 23375 21534 16648 -28.8 
25T7-NBOMe 22867 17618 13735 -39.9 
Mephedrone-D3 512798 492798 419791 -18.1 
Ethylone-D5 719557 6921313 644608 -10.4 
Methylone-D3 489567 453669 427616 -12.7 
MDPV-D8 5279428 4891265 4376411 -17.1 
NBOMe-D3 50816 48940 41620 -18.1 
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Blood QC1 
Analyte 
 
P.A. (n=3) 
 
t=0 t=24 t=48 
% 
Recovery 
METHIOPROPAMINE 18501 22649 18320 -1.0 
FLEPHEDRONE 40703 29121 36639 -10.0 
MEPHEDRONE 51803 42063 45799 -11.6 
5-APB 204627 183312 183469 -10.3 
6-APB 424412 366624 366938 -13.5 
METHYLONE 73800 83915 57699 -21.8 
3-MeO-PCE 30315 29330 27181 -10.3 
BUTYLONE 386518 337294 332962 -13.9 
ETHYLONE 106103 102655 95132 -10.3 
MXE 121260 102655 101927 -15.9 
BENZEDRONE 511632 442960 408222 -20.2 
3-MeO-PCP 37894 36662 33976 -10.3 
2-DPMP 604656 575848 571511 -5.5 
MDPV 558144 620144 530689 -4.9 
NAPHYRONE 372096 310072 285756 -23.2 
25B-NBOMe 1726 1798 1650 -4.4 
25C-NBOMe 3453 2158 2310 -33.1 
25D-NBOMe 5179 4675 3301 -36.3 
25E-NBOMe 4316 4315 3631 -15.9 
25H-NBOMe 5611 6113 3961 -29.4 
25I-NBOMe 8201 8271 6931 -15.5 
Mescaline-NBOMe 3453 3596 2971 -14.0 
25P-NBOMe 2158 2158 1650 -23.5 
Mephedrone-D3 370024 323563 305329 -17.5 
Ethylone-D5 757878 733248 679515 -10.3 
Methylone-D3 670907 599395 443840 -33.8 
MDPV-D8 4651200 4429598 4082222 -12.2 
NBOMe-D3 43161 35959 33006 -23.5 
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Blood QC2 
Analyte  
P.A. (n=3) 
 
t=0 t=24 t=48 % Recovery 
METHIOPROPAMINE 101638 71518 77204 -24.0 
FLEPHEDRONE 300848 259723 201401 -33.1 
MEPHEDRONE 260193 218318 191331 -26.5 
5-APB 1112299 834532 871852 -21.6 
6-APB 1809247 1353926 1405288 -22.3 
METHYLONE 1081451 1078344 712055 -34.2 
3-MeO-PCE 1295336 1266388 1233212 -4.8 
BUTYLONE 1809247 1353926 1433968 -20.7 
ETHYLONE 506871 461035 435926 -14.0 
MXE 999662 887055 889060 -11.1 
BENZEDRONE 12984599 11185990 10150188 -21.8 
3-MeO-PCP 183037 151733 137661 -24.8 
2-DPMP 3528424 3150340 2557847 -27.5 
MDPV 3340241 2693769 2436045 -27.1 
NAPHYRONE 3998880 4474396 3735269 -6.6 
25B-NBOMe 6086 6810 5480 -10.0 
25C-NBOMe 15013 15323 12787 -14.8 
25D-NBOMe 15825 10897 10656 -32.7 
25E-NBOMe 13796 8513 9743 -29.4 
25H-NBOMe 19071 13280 13701 -28.2 
25I-NBOMe 36518 33711 26488 -27.5 
Mescaline-NBOMe 12173 10897 8525 -30.0 
25P-NBOMe 10955.52 12258.72 9133.8 -16.6 
Mephedrone-D3 406551 376410 335669 -17.4 
Ethylone-D5 703987 583589 573587 -18.5 
Methylone-D3 597487 573587 400031 -33.0 
MDPV-D8 4704565 4565710 4060075 -13.7 
NBOMe-D3 40576 34052 30446 -25.0 
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Blood QC3 
Analyte 
 
P.A. (n=3) 
 
t=0 t=24 t=48 
% 
Recovery 
METHIOPROPAMINE 308427 281260 201196 -34.8 
FLEPHEDRONE 807786 797603 732657 -9.3 
MEPHEDRONE 1405057 1288758 1097087 -21.9 
5-APB 3815088 3146785 2856737 -25.1 
6-APB 4538164 3761946 3816466 -15.9 
METHYLONE 1584732 1270633 1025044 -35.3 
3-MeO-PCE 2768349 2472474 2273042 -17.9 
BUTYLONE 5157944 4075442 4040964 -21.7 
ETHYLONE 1983295 1313132 1391888 -29.8 
MXE 2382708 1537903 1610773 -32.4 
BENZEDRONE 13703712 130852868 11343415 -17.2 
3-MeO-PCP 564688 425881 381647 -32.4 
2-DPMP 14025611 121662533 11301711 -19.4 
MDPV 11358446 137417393 10634451 -6.4 
NAPHYRONE 14209553 133478678 12803045 -9.9 
25B-NBOMe 54452 52441 49583 -8.9 
25C-NBOMe 63760 56187 45964 -27.9 
25D-NBOMe 53521 44950 40173 -24.9 
25E-NBOMe 56313 54938 52478 -6.8 
25H-NBOMe 66552 55771 50669 -23.9 
25I-NBOMe 55383 52441 44516 -19.6 
Mescaline-NBOMe 45609 46614 31125 -31.8 
25P-NBOMe 54452 43701 33659 -38.2 
Mephedrone-D3 489567 419791 379615 -22.5 
Ethylone-D5 688644 591501 561245 -18.5 
Methylone-D3 628862 512352 401978 -36.1 
MDPV-D8 4598561 43763501 4170373 -9.3 
NBOMe-D3 46540 41620 36192 -22.2 
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Appendix 9: Amphetamine ELISA instruction sheet. 
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Appendix 10: Methamphetamine ELISA instruction sheet. 
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Appendix 11: Ketamine ELISA instruction sheet. 
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Appendix 12: IACUC letter of approval. 
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Appendix 13: IACUC protocol. 
 
To be filled in by IACUC Office ---IACUC Form 2011 
IACUC Number ________________                                                                             Use Level ______ 
Date Received _____________  Date Reviewed: ______________  Date Approved: _______________ 
 
 
All protocols must be typed.  Submit (1) an original, clipped, single-sided signed copy of the protocol to the 
Secretary, IRB/IACUC,38 Heinz Hall; and(2) electronic copy (PDF) to IRB_IACUC@arcadia.edu.Written 
approval from the IACUC must be obtained before initiating any research, teaching, or testing involving 
vertebrate animals or animal by-products. 
 
Protocol Title:  Evaluation of Behavioral and Pharmacological Parameters of new recreational drugs known 
as NB2OMe’s 
 
Estimated dates of protocol: From: __Aug 2013_____ to _May 2014_ (not to exceed 3 years) 
 
New proposal:  __YES__  
 
or Revision of IACUC Number __     __________ approval date ___     ____ 
 
or 3-year Resubmission of IACUC Number____     ___________ approval date __     __________ 
 
Funding Sponsor/Agency__None_________________________________________ 
 
Principal Investigator (Arcadia faculty only): ___Lorna A Nisbet, BSc, MSc, ____________ 
 
Department: ____ Chemistry & Physics_________  extension: __4098___________ 
 
E-mail address: __nisbetl@arcadia.edu _________ emergency contact #:__(267)-475-7335 
 
Co-Investigator ____Karen S Scott, PhD._______________________________________________  
 
Status (student/staff/faculty): __Faculty_____________________  extension: __2675 __________ 
 
E-mail address: ____scottk@arcadia.edu _____ emergency contact #:(267)401-4627___________ 
 
Co-Investigator _____Joshua Blustein, PhD _______________________________________________  
 
Status (student/staff/faculty): __Faculty_____________________  extension: ___4002__________ 
 
E-mail address: ____blustein@arcadia.edu_____ emergency contact #:__(215)939-2332__________ 
 
Co-Investigator _____ Alysha Andrews, BS_____ 
_______________________________________________  
 
Status (student/staff/faculty): __Student_____________________  extension: ___N/A__________ 
 
E-mail address: _____Aandrews@arcadia.edu____ emergency contact #:_(717)799-4323___________ 
 
Co-Investigator _____Alysia Kosmach, BS _______________________________________________  
 
Status (student/staff/faculty): __Student_____________________  extension: ___N/A__________ 
 
E-mail address: ____Akosmach@arcadia.edu_____ emergency contact #:__(570)814-3022__________ 
 
Co-Investigator _____Alex Krotulski, BS_______________________________________________  
 
Status (student/staff/faculty): __Student_____________________  extension: ___N/A__________ 
 
E-mail address: ____Akrotulski@arcadia.edu _____ emergency contact #:__(610)468-5616__________ 
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Co-Investigator _____Aileen Lu, BS_______________________________________________  
 
Status (student/staff/faculty): __Student_____________________  extension: __N/A__________ 
 
E-mail address: ____Alu@arcadia.edu _____ emergency contact #:__(914)325-2500__________ 
 
Co-Investigator _____Kevin Picirilli , BS_______________________________________________  
 
Status (student/staff/faculty): __Student_____________________  extension: ___N/A__________ 
 
E-mail address: ____Kpicirilli@arcadia.edu _____ emergency contact #:__(440)539-0408__________ 
 
 
Species of Animals: ___Ratusrattus________________weight _50g______  age___3-4 weeks______ 
 
Strain: ___Long Evans____________  Source: __Harlan Laboratories_______ 
 
Number of animals in each category: 
Category C:  No pain or 
distress beyond that involved in 
the restraint, injections, or 
collection of samples. 
Category D:  potential for pain or 
distress but relief is provided by 
analgesics and/or sedatives as appropriate. 
Category E: pain or distress 
not relieved by sedatives or 
analgesics. 
525             
 
************************************************************************************** 
Committee Action: 
Tabled: ____________  Approval Pending: _________Approved: _________ Disapproved ________ 
Ayes: _________  Nays: _____________  Abstentions: _______________ Absent: ____________ 
 
CFurperson of IACUC: _______________________________  Date: ______________________ 
 
1. Does the study involve animals in Humane Use Category D or E?  
IF YES,  Complete and attach IACUC Form B – Alternatives.  
 Yes  No 
 
2. Does the study involve anesthetic, analgesic, tranquilizing, or neuromuscular blocking agents?  
IF YES,  Complete and attach IACUC Form C – Anesthetic and analgesic agents 
 Yes  No 
 
3. Does the study involve a survival surgery? 
IF YES, Complete and attach IACUC Form D - Surgery: 
 Yes  No 
 
4. What will be the final disposition of animals? 
      a.  transfer to different protocol:  Provide protocol IACUC approval number ________________________ 
      b.  Euthanasia-complete and attach IACUC Form E-Euthanasia  
      c. Adoption – complete and attach IACUC Adoption release Form 
 
 
5. Do you or any member of your research group, spouses or any dependent children have any interest (i.e. any property of financial 
interest including stock in the sponsor company, patents, trademarks, copyrights or licensing, supplemental research grants or 
consulting arrangements) in the test drug/product, device, or research procedure that is the subject of this study? 
 IF YES, please complete a Conflict of Interest Disclosure Form available through the Arcadia University Grants 
Office.  Please discuss how these conflicts will be managed during the period of the trial. 
5a. In addition, for industry-sponsored trials, please attach the documentation submitted to the sponsor as required by 21CFR54.1, 
if applicable. 
 Yes  No 
 
 
6. Has the Principal Investigator and all co-investigators completed the animal CITI training modules? 
 IF YES, attach copy of certification.   
 Yes  No 
7.  Has the Principal Investigator and all co-investigators completed the Instructor Training form (if appropriate)? 
   IF YES, attach copy of certification. 
 Yes  No 
8. Has the Principal Investigator and all co-investigators signed the Animal Health Emergency Protocol document?  Yes  No 
9. Does the study involve using controlled substances? 
IF YES, have DEA rep  sign below 
           DEA representative signature if study involves controlled substances  __________________________________________ 
 Yes  No 
 
  Check all attachments that apply: 
IACUC Face Sheet/Animal Submission Proposal 
 
Page 298 of 364 
 
 
Y? 
Principal Investigator (PI) Signature(Must be Arcadia faculty member) 
 
 Form A - Protocol Summary 
Printed Name of PI:  
Lorna Nisbet 
Date:       
 Form B – Alternatives (if Item #1 checked) 
 
 
Co-Investigator’s Signature 
 
 
Printed Name of Co-Investigator:       
Dr Karen Scott 
Date:        Form C – Anesthetic and analgesic agents (If  Item 
#2checked) 
 
 
Co-Investigator’s Signature 
 
 Form D – Surgery  (If Item #3 checked) 
Printed Name of Co-Investigator:       
Dr Joshua Blustein 
Date:       
 
 
 
Co-Investigator’s Signature 
 
 Form E – Euthanasia (If item 4b checked) 
Printed Name of Co-Investigator:       
Alysha Andrews 
Date:        Conflict of Interest Disclosure Form (If Item #5 
checked) 
 
 
Co-Investigator’s Signature 
 
 Copy of CITI Lab Animal Course certification 
Printed Name of Co-Investigator:       
Alysia Kosmach 
Date:       
 Copy of grant application (minus appendices) 
 
 
Co-Investigator’s Signature 
 
 
Printed Name of Co-Investigator:       
Alex Krotulski 
Date:       
 
 
 
Co-Investigator’s Signature 
 
 
Printed Name of Co-Investigator:       
Aileen Lu 
Date:       
 
 
 
Co-Investigator’s Signature 
 
 
Printed Name of Co-Investigator:       
Kevin Picirilli 
Date:       
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STUDENT INVESTIGATOR’S ASSURANCE 
 
I certify that the information provided is complete and correct.  
 
I understand that as Student Investigator, I have responsibility for the care and use of the animals in these 
proposed research/teaching activities.  I agree to comply with all Arcadia University policies and procedures, 
as well as with all applicable federal, state, and local laws regarding the protection of animals in research, 
teaching, and testing including, but not limited to, the following: 
 the project will be performed by qualified personnel according to the research project/protocol, 
 obtain necessary review by the AU IACUC if changes are made in the research 
project/protocol, and 
 I agree to meet with my faculty advisor (PI of the study)on a regular basis to review study 
progress.   
 
 
I acknowledge that the completion of this work occurs within the oversight of the Arcadia University 
Institutional Animal Care and Use Committee.  This oversight includes, but is not limited to, the following: 
 written IACUC approval must be obtained prior to any animal use or initiation of the project, 
 ANYrevision to the protocol must be approved by the IACUC PRIOR to implementing 
changes, 
 renewal of the protocol is required on an annual basis (completion and submission of IACUC 
Form F), 
 on-going protocols must be approved de novo every three years, 
 submission of a termination report is required at the completion of the project, and 
 failure to provide proper animal care or follow the approved protocol or AU IACUC guidelines 
may result in the suspension of the project or loss of Arcadia University animal use 
certification. 
 
 
I have read and understand the above.  
 
 
_______________________________________            Alysha Andrews____________      
____________________ 
Student Investigator Signature   Printed Name                
Date 
 
____________________________________     __Alysia 
Kosmach_____________________     _________ 
Student Investigator Signature   Printed Name                
Date 
 
____________________________________     __Alex 
Krotulski______________________     _________ 
Student Investigator Signature   Printed Name                
Date 
 
____________________________________     __Aileen 
Lu__________________________     _________ 
Student Investigator Signature   Printed Name                
Date 
 
____________________________________     __Kevin 
Piccirilli______________________     _________ 
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Student Investigator Signature   Printed Name                
Date 
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PRINCIPAL INVESTIGATOR(FACULTY) ASSURANCE  
 
By my signature as Principle Investigator on this research application, I certify that the student investigators 
are knowledgeable about the regulations and policies governing use of animals and have sufficient training 
and experience to conduct this particular study in accord with the approved project/protocol.  In addition,  
 I agree to meet with the student investigators on a regular basis to review study progress. 
 Should problems arise during the course of the study, I agree to be available to supervise the 
student investigators in solving them. 
 I assure that the student investigators have completed all required educational IACUC and 
Occupational Health and Safety programs as required (CITI Training). 
 I agree to abide by regulations that govern use of controlled substances (if applicable). 
 I agree to assume responsibility for the final disposition of the animals. 
 If I will be unavailable (such as on sabbatical, leave or vacation), I will arrange for an alternate 
faculty member to assume responsibility during my absence, and I will advise the IRB by letter 
of such an arrangement. This alternate faculty member will need to have passed all appropriate 
IACUC and Occupational Health and Safety programs (CITI Training).  
 I am responsible for documentation of any adverse events related to the research project and 
notification of the faculty advisor (if primary investigator is a student), Animal Care 
Representative, and the CFur of AU IACUC by e-mail IRB_IACUC@arcadia.eduwithin 24 
hours of incidence. 
 Any failure to provide proper animal care or follow the approved protocol or AU IACUC 
guidelines may result in the suspension of the project or loss of Arcadia University animal 
use certification. 
 
 
_____________________________________ Lorna A Nisbet______________________
 ____________ 
Principal Investigator(Faculty) signature  Printed Name    Date 
 
 
The Principal Investigator must be a member of the Arcadia University faculty. The Principal 
Investigator is considered the responsible party for legal and ethical performance of the project. 
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ANIMAL HEALTH EMERGENCY PROTOCOL 
 
If an animal is found dead: 
1. Immediately remove animal from cage and: 
a.  Place it in a bag labeled with Animal ID, Date/Time found, Name of 
individual who found animal    
b.  Place bag in small necropsy refrigerator 
2. Visually inspect all of the other animals in the facility/room 
3. Immediately contact one of the following (must speak with person):  
a. Dr. Blustein (215-939-2332) 
b. Dr. Scott (267-401-4627)  
c. If unable to reach contact Dr. Hoffman (215) 572-2195 
4. Must also immediately notify the Faculty Animal Care Representative 
a. Dr. Wright (wrightm@arcadia.edu, Office:267-620-4827, Cell: 267-241-
8241) 
 
If an animal appears to be in distress (e.g., bloody nose, wheezing/panting/labored 
breathing, lying on side/lethargy, rapid weight loss >20%, self mutilation, abnormal 
vocalization, diarrhea): 
1. Check food and water access. 
2. Visually inspect all of the other animals in the facility/room. 
3. Immediately contact one of the following (must speak with person) 
a. Dr. Blustein (215-939-2332) 
b. Dr. Scott (267-401-4627) 
c. If unable to reach contact Dr. Hoffman (215) 572-2195 
4. Must also immediately notify the Faculty Animal Care Representative 
a. Dr. Wright (wrightm@arcadia.edu, Office:267-620-4827, Cell: 267-241-
8241) 
 
My signature below indicates that I have read and agree to abide by the above Animal Health Emergency 
Protocol:  
 
____________________________________Lorna A 
Nisbet____________________________     _________ 
Principal Investigator(Faculty) signature  Printed Name   Date 
____________________________________Karen S Scott____________________ ________________ 
Co- investigator Signature   Printed Name                Date 
 
____________________________________Joshua 
Blustein_____________________________     _________ 
Co-Investigator Signature   Printed Name                Date 
 
____________________________________Alysha 
Andrews_____________________________     _________ 
Co-Investigator Signature   Printed Name                Date 
 
____________________________________Alysia 
Kosmach_____________________________     _________ 
Co-Investigator Signature   Printed Name                Date 
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____________________________________Alex Krotulski 
_____________________________     _________ 
Co-Investigator Signature   Printed Name                Date 
 
____________________________________Aileen Lu_____ 
_____________________________     _________ 
Co-Investigator Signature   Printed Name                Date 
 
 
____________________________________Kevin 
Piccirilli_____________________________     _________ 
Co-Investigator Signature   Printed Name                Date 
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List any drugs or medications the animals will receive.  If it is a controlled drug, put (c) next to the 
drug.  For all drugs, include dose (mg/kg), concentration (mg/ml) and mode of administration (i.e., 
oral, subcutaneous injection, intraperitoneal injection, intramuscular injection, etc.)  Provide a 
reference for the use of the drug at this dose. 
 
Drug       dose  concentration        route     reference 
25T2-NB2OMe   30µg/kg   30 µg/ml IP                A-E (Below) 
                                                                100µg /kg       100µg/ml IP A-E (Below) 
                                                                300µg/kg         300 µg/ml               IP A-E (Below) 
  
25T4- NB2OMe                                     30µg/kg    30 µg/ml   IP                A-E (Below) 
                                                               100µg /kg          100µg/ml  IP A-E (Below) 
                                                               300µg/kg           300 µg/ml               IP A-E (Below) 
 
25T7- NB2OMe 30µg/kg    30 µg/ml   IP                A-E (Below) 
                                                               100µg /kg          100µg/ml  IP A-E (Below) 
                                                               300µg/kg           300 µg/ml               IP A-E (Below) 
 
25H- NB2OMe                                     30µg/kg    30 µg/ml   IP                A-E (Below) 
                                                              100µg /kg          100µg/ml  IP A-E (Below) 
                                                              300µg/kg           300 µg/ml                IP A-E (Below) 
 
25I- NB2OMe                                       30µg/kg    30 µg/ml   IP                A-E (Below) 
                                                               100µg /kg          100µg/ml  IP A-E(Below) 
                                                               300µg/kg           300 µg/ml               IP A-E (Below) 
  
25B- NB2OMe                                      30µg/kg    30 µg/ml   IP                A-E (Below) 
                                                               100µg /kg          100µg/ml  IP A-E (Below) 
                                                               300µg/kg           300 µg/ml               IP A-E (Below) 
 
25E- NB2OMe                                      30µg/kg    30 µg/ml  IP                A-E (Below) 
                                                               100µg /kg          100µg/ml  IP A-E (Below) 
                                                               300µg/kg           300 µg/ml               IP A-E (Below) 
  
25D- NB2OMe                                      30µg/kg    30 µg/ml  IP                A-E (Below) 
                                                               100µg /kg          100µg/ml  IP A-E (Below) 
                                                               300µg/kg           300 µg/ml               IP A-E (Below) 
 
25C- NB2OMe                                       30µg/kg    30 µg/ml  IP                A-E (Below) 
                                                               100µg /kg          100µg/ml  IP A-E (Below) 
                                                               300µg/kg           300 µg/ml               IP A-E (Below) 
 
25N- NB2OMe                                      30µg/kg    30 µg/ml  IP                A-E (Below) 
                                                               100µg /kg          100µg/ml  IP A-E (Below) 
                                                               300µg/kg           300 µg/ml               IP A-E (Below) 
 
25P- NB2OMe                                      30µg/kg    30 µg/ml  IP                A-E (Below) 
                                                               100µg /kg          100µg/ml  IP A-E (Below) 
                                                               300µg/kg           300 µg/ml               IP A-E (Below) 
 
Mescaline- NB2OMe                             30µg/kg    30 µg/ml  IP                A-E (Below) 
                                                               100µg /kg          100µg/ml  IP A-E (Below) 
                                                               300µg/kg           300 µg/ml               IP A-E (Below) 
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Methiopropamine                                   5mg/kg  5mg/ml  IP                 G (Below) 
                                                               10mg/kg           10mg/ml IP  G(Below) 
                                                               20 mg/kg         20 mg/ml IP  G(Below) 
 
Fluoroephedrone                                    5 mg/kg           5 mg/ml IP                   I (Below) 
                                                                10 mg/kg        10 mg/ml   IP                   I (Below) 
                                                                20 mg/k          20 mg/ml   IP                   I (Below) 
 
5-APB                                                    6mg/kg  6mg/ml  IP                 M(Below) 
                                                               18 mg/kg         18 mg/ml IP  M(Below) 
                                                               30 mg/kg         30 mg/ml IP  M(Below) 
 
6-APB                                                    6mg/kg  6mg/ml  IP                 M(Below) 
                                                               18 mg/kg         18 mg/ml IP  M(Below) 
                                                               30 mg/kg         30 mg/ml IP  M(Below) 
 
MDAI                                                     0.5 mg/kg          0.5 mg/ml IP                   H(Below) 
                                                                3 mg/kg              3 mg/ml IP                   H(Below) 
                                                               5 mg/kg 5 mg/ml IP                  H(Below) 
 
Methedrone                                              0.5 mg/kg         0.5 mg/ml IP                  C(Below) 
                                                                 3 mg/kg   3 mg/ml IP                  C(Below) 
                                                                 5 mg/kg   5 mg/ml IP                  C(Below) 
 
3-Me-O-PCE                                          25 mg/kg            25 mg/ml IP               N(Below) 
                                                                40 mg/kg             40 mg/ml IP               N(Below) 
                                                               60 mg/kg             60 mg/ml IP               N (Below) 
 
Camfetamine                                         2mg/kg  2mg/ml  IP                 O(Below) 
                                                               6 mg/kg           6 mg/ml IP  O(Below) 
                                                             10 mg/kg           10 mg/ml IP  O(Below) 
 
5-IAI                                                      0.5mg/kg    0.5mg/ml  IP                F (Below) 
                                                               1.0 mg/kg          1.0mg/ml  IP F (Below) 
                                                               1.5mg/kg           1.5mg/ml               IP F  (Below) 
 
Butylone                                                2mg/kg  2mg/ml  IP                P(Below) 
                                                               6 mg/kg           6 mg/ml IP P(Below) 
                                                             10 mg/kg           10 mg/ml IP                 P(Below) 
 
Ethylone                                                 2mg/kg  2mg/ml  IP                P (Below) 
                                                               6 mg/kg           6 mg/ml IP P (Below) 
                                                             10 mg/kg           10 mg/ml IP P (Below) 
 
Methoxetamine                                    12.5 mg/kg           12.5 mg/ml IP              I &N (Below) 
                                                              20 mg/kg             20 mg/ml IP              I &N(Below) 
                                                              30 mg/kg             30 mg/ml IP              I &N (Below) 
 
Benzedrone                                            60µg/kg    30 µg/ml  IP                R (Below) 
                                                               0.4mg /kg          0.4mg/ml  IP R (Below) 
                                                               1.2mg/kg           1.2mg/ml               IP R (Below) 
 
3-MeO-PCP                                          2.5mg/kg    2.5mg/ml  IP                N (Below) 
                                                               3mg /kg          3mg/ml  IP N (Below) 
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                                                               5mg/kg           5mg/ml                      IP N (Below) 
 
Desoxypipradol                                      0.4 mg/kg         0.4 mg/ml IP                 L(Below) 
                                                               1.2 mg/kg  1.2 mg/ml IP                 L (Below) 
                                                               2 mg/kg 2  mg/ml IP                L (Below) 
 
MDPV                                                  60µg/kg    60 µg/ml  IP                 J(Below) 
                                                               0.4mg /kg          0.4mg/ml  IP  J(Below) 
                                                               1.2mg/kg           1.2mg/ml               IP  J(Below) 
 
Naphyrone                                             0.4 mg/kg          0.4 mg/ml IP                  K(Below) 
                                                               1.2 mg/kg  1.2 mg/ml IP                  K(Below) 
                                                               2 mg/kg 2 mg/ml IP                 K(Below) 
 
Azacylonol                                             2mg/kg  2mg/ml  IP                Q(Below) 
                                                               6 mg/kg           6 mg/ml IP  Q(Below) 
                                                             10 mg/kg           10 mg/ml IP  Q(Below) 
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Example: 
Drug  dose  concentration      route     reference 
LSD                    0.03, 0.1 and 0.3mg/kg                       IP            B 
 
Number of Animals, Species, and Humane use Categories: 
The Animal Welfare Act requires annual reporting of animal use according to the following categories. 
 
Estimate the total number of animals that will be used in each Humane Use Category in the proposed study. 
 
Humane Use Categories 
 Description: animals 
requested 
C No or minimal pain and/or stress (with or without the use of pain-relieving agents and 
techniques).  No pain or distress beyond that involved in the restraint, injections, or collection 
of samples.  For comparison, no pain relieving drugs would be given under normal 
circumstances for a human patient going through the same procedure. 
525 
 
D Pain and/or stress that does not become intolerable and thereby distressful.  Potential for pain 
or distress but relief is provided by analgesics and/or sedatives as appropriate.  The USDA 
regards survival and non-survival surgery to fall in this category.   This category includes all 
procedures in which the animal may experience pain, discomfort, or distress which would be 
treated with the use of anesthetics, analgesics, or tranquilizers.  Therefore, this category 
includes euthanasia via anesthetic overdose. 
0 
E Pain and/or stress that reaches the level of distress.  Pain or distress not relieved by sedatives 
or analgesics.  This category includes procedures expected to cause pain, discomfort, or 
distress but the administration of normal anesthetics, analgesics, or tranquilizers cannot be 
used without adversely affecting the experimental results. 
0 
 Total Animals Requested 525 
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Description of Project: 
 
1. How would you explain to a non-scientist the goals and objectives of the proposed work? 
  
New psychoactive substances (NPS’s) have become an integral part of the UK and USA recreational 
drug market. These substances are marketed as “legal” and not for human consumption to negate controls 
via medicines acts and are thus wrongly deemed by users to be safe. Mephedrone was the first such 
substance to be marketed in this way appearing in 2007, and IT gained rapid popularity amongst 
recreational drug users. Since the control of mephedrone both in the UK and USA many more substances 
such as aminoindanes, NBOMe’s and additional synthetic cathinones have been rapidly produced to 
replace this substance on the “legal” market. NB2OMe’s in particular are a relatively new class of drugs 
that are structurally similar and thought to potentiate similar behavior to 2C-I. They are often classified as 
“Legal Highs” due to these structural similarities and the fact that they were not classified as illegal. 2C-I 
is a Schedule I drug, due to the potential dangers and side effects experienced when recreationally abused. 
NBOMe’S are thought to potentiate similar behavioral and pharmacological effects as their 2C-I 
derivative such as analgesia, tolerance and metabolism.  
 A search on PubMed with the keywords NB2OMe’s and analgesia revealed no published data on 
NB2OMe’s producing analgesia. To date very few articles have been published on these drugs with the 
majority focusing on accident and emergency case reports and the medical treatment of individuals who 
have overdosed. Research has also shown that these N-benzyphenethylamine 2C derivatives are potent 
serotonin 2A (5-HT2A) receptor antagonists with similar effects to LSD and other potent hallucinogenic 
drugs. Due to their high potency NB2OMe’s are typically administered in liquid form or on “blotters”, 
again similar to LSD. Recent research has commented on the lack of animal studies or toxicological 
information for these drugs. 
 A search on PubMed with the keywords cathinone and analgesia revealed 4 results although these 
were for cathinone itself and not for any synthetic cathinones. Further searches using individual synthetic 
cathinone names alongside analgesia produced no results.  As analgesia has been shown with cathinone it 
is likely that it will also be seen in these newer synthetic cathinones whose structures are based on 
cathinone.   
 A search on PubMed with the keywords aminoindanes and analgesia produced 1 result although 
this focused on 2-aminoindane and not the 5-aminoindane proposed in this application. This research was 
carried out on mice that developed tolerance and displayed signs of analgesia. It is likely that this would 
also be seen with the 5-aminoindane compound.  
 Overall, the present study will investigate the gaps within the existing research of NPSs and their 
ability to produce analgesia. Analgesia and tolerance will be tested using a tail-flick test (52oC). If tail-
flick latency is significantly longer than the baseline, analgesia is present. Tolerance will be defined when 
tail-flick latency returns to baseline for three consecutive days. Once tolerance is achieved, withdrawal 
effects of each rat will be observed, using the tail-flick test and behavior within the cage. The present 
study will collect fur and urine samples from the rats. The fur urine and feces samples will be analyzed to 
find different possible metabolites that may be present for all of the drugs stated above at three different 
doses. The use of Long Evans rats will allow further hair analysis work to establish if drug incorporation 
occurs at different rates depending if white or black hair is analyzed. The animals will then be euthanized 
and stored for further work determining whether drugs and their metabolites can be detected in various 
tissue samples including bone.  
 
2. How would you explain to a non-scientist the ways the proposed animal use might benefit 
human or animal health, the advancement of knowledge, or the good of society? 
 
The proposed work will help further the knowledge of drug tolerance, analgesia, withdrawal and 
metabolism. The study will examine the individual effects NPS’s have on analgesia, tolerance, 
withdrawal in Long Evans rats and examine the presence of parent drugs and metabolites in both fur, 
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urine, feces and various other tissue samples collected during the study, allowing better pharmacological 
and toxicological understanding of these drugs.  
 
 
3. Are they any adverse events (such as death, excessive weight loss, body temperature fluctuation, 
heart rate/respiration changes, etc.) expected or documented in the literature relevant to this 
particular study?  If yes, please describe and provide a detailed course of action to minimize 
adverse events.  You may need to adjust your sample size accordingly. 
 
Yes. Increased heart rate may be encountered due to the stimulant and psychedelic nature of some of 
these drugs. The rats will not be receiving doses that will cause dangerous stimulation effects only enough 
to examine the behavioral effect the drugs may potentiate. To date no published animal studies exist 
although research has shown NBOMe drugs have similar potency to LSD, cathinone derivatives are 
similar to methamphetamine and cathinone and aminoinanes are similar to amphetamines. The rats will 
be examined by comparing with the control group (the group dosed with saline solution only) to assess if 
they exhibit signs of hyper-activity, agitation and anxiety. If a rat is experiencing a great deal of 
stimulation that may be dangerous, the rat will be no longer be dosed and no longer be included in the 
experiment. 
 
Project Summary:  Provide enough information so that the IACUC members can review the 
rationale and purpose of the proposed study.  Detail of experimental procedures, justification of animal 
numbers, and training and experience of personnel completing the procedures should also be provided. 
Use additional pages if necessary. 
 
Procedure: 
 
Prior to commencing these experiments, full training in handling of rats and administration of drugs via 
i.p. injection will be received. In the initial stages of the research, Dr. Blustein will be on site to monitor 
all injections. Rats will be purchased about 3 weeks prior to commencing the experiment. In batches of 35 
rats, 15 rats will be administered drug A, 15 rats will be administered drug B and 5 rats will be used as a 
control group.  The rats will be randomly assigned to three groups of 5, a total of 15 rats per drug. Each 
group containing 5 rats will be dosed and given the tail flick testfor 10 days or until tolerance is achieved. 
The rats will be weighed prior to each injection to determine the volume of solution for injection. For 
example the first group containing 15 rats will be injected with 25B-NB2OMe; 5 rats will be individually 
injected with 30µg/kg i.p, a different set of 5 rats will be individually injected with 100µg/kgi.p, and the 
last set of 5 rats will be individually injected with 300µg/kg i.p. of 25B-NB2OMe alone. The second 
group containing 15 rats will for example be individually injected with 25C-NB2OMe; 5 rats will be 
individually injected with 30µg/kg i.p of 25C-NB2OMe alone, 5 rats will be individually injected 
100µg/kg i.p of 25C-NB2OMe alone, and 5 rats will be individually injected with 300µg/kg i.p25C-
NB2OMe alone. There will be 5 separate rats which will be individually injected with saline to serve as a 
control group. This protocol will be applied to each drug listed previously (page 8-11). This will result in 
a total of 15 experiments (30 drugs to be tested, testing two drugs during each experiment). Analyzing 
multiple drugs at once reduces the numbers of control rats needed as the same controls can be used for 
each drug set. All rats will be housed separately so that no stresses interfere with the study. All injections 
will be given every 24 hours and administered with a sterile needle, 27G x ½’’ attached to a 1cc 
tuberculin syringe.  All drugs will be administered via intraperitoneal injection. Figure 1 is a scheme 
representing one complete experiment. 
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Each rat will be weighed and given a tail-flick test using Fisher Scientific Isotope 220 warm 
water immersion bath (52oC) to measure the baseline tail-flick latency. Rats will be weighed daily thought 
the duration of the study. The rats will be wrapped in a soft cloth and the first 8cm of their tail lowered 
into the 52oC warm water while a stopwatch is started simultaneously. The first 8cm of each rats tail will 
be marked with permanent marker resulting to ensure consistency between days. Once the tail flicks out 
of the water, the latency will be recorded. If the tail does not flick out of the water in 20 seconds, the trial 
is ended and a maximum latency of 20 seconds is recorded. All of the rats throughout the experiment will 
545 rats total
35 rats per 
experiment
Tail-Flick 
Experiment 
Daily
15 rats per 
drug
5 rats
*Low dose 
for ~10 days
Urine and faeces 
collection ~1 hour 
each day for a 
randomly chosen rat
Withdrawal 
monitoring 
for ~10 days
Reshave rats
Euthanized 
and frozen
5 rats
*Medium 
dose for ~10 
days
Urine and faeces 
collection ~1 hour 
each day for a 
randomly chosen 
rat
Withdrawal 
monitoring 
for ~10 days
Reshave rats
Euthanized 
and frozen
5 rats
*High dose 
for ~10 days
Urine and faeces 
collection ~1 hour 
each day for a 
randomly chosen rat
Withdrawal 
monitoring 
for ~10 days
Reshave rats
Euthanized 
and frozen 
5 rats for 
control 
group
Shave all rats 
Day 0
Figure 1: schematic representing one complete experiment. 
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be placed in metabolism cages for collection of urine. There will be 6 metabolism cages in which 
randomly chosen rats will be placed in daily.  The rats will be placed on a metal wire insert within the 
cage until they urinate. If they do not urinate within one hour, the rats will be placed back in their 
bedding. Feces will also be collected. Personal protective equipment (lab coat, gloves, and masks) will be 
worn when handling during urine and feces collection and cage cleaning. The collected urine/ feces will 
be used for analysis of any remaining unmetabolized parent drug plus metabolites by GC/MS for phase I 
metabolites and LC/MS/MS for phase II metabolites and using an UPLC-qTOF. The collected urine will 
be refrigerated prior to analysis. Fur samples will also be collected from the rats for analysis to determine 
the presence of both parent drug and phase I metabolites by GC/MS. For fur collection, the back of the rat 
will be shaved using standard clippers on Day 0 and Day 20 of the experiment. Long Evans rats where 
specifically chosen for this study as they have both black and white fur. The fur will be collected to 
ensure both black and white fur is obtained. From this an understanding of the processes of incorporation 
into the fur can be evaluated.  The rats will not be under any physical pain or subjected to stress during 
the urine and fur collection procedures. 
  
Table 1 is a conversion table that represents the amount of powdered drug needed to mix the 
desired concentrations explained below. 
 
Table 1: Conversion Table 
Drug 
Drug free 
weight 
Drug salt 
weight 
Salt weight/Free 
weight 
Weight 
required 
(mg) 
Weight 
needed (mg) 
25B-NB2OMe 380 416 1.1 5 5.5 
25C-NB2OMe 335 371 1.1 5 5.5 
25D-NB2OMe 315 351 1.1 5 5.5 
25E-NB2OMe 329 365 1.1 5 5.5 
25H-NB2OMe 301 337 1.1 5 5.5 
25I-NB2OMe 427 463 1.1 5 5.5 
25N-NB2OMe 346 382 1.1 5 5.5 
25P-NB2OMe 343 379 1.1 5 5.5 
25T2-NB2OMe 361 397 1.1 5 5.5 
25T4-NB2OMe 375 411 1.1 5 5.5 
25T7-NB2OMe 375 411 1.1 5 5.5 
Mescaline-NB2OMe 331 367 1.1 5 5.5 
Methiopropamine 155 191 1.2 275 330 
Fluoroephedrone 181 217 1.2 275 330 
5-APB 175 211 1.2 450 540 
6-APB 175 211 1.2 450 540 
MDAI 177 213 1.2 75 90 
Methedrone 192 228 1.2 75 90 
3-MeO-PCE 233 269 1.1 1000 1100 
Camfetamine 201 237 1.2 150 180 
5-IAI 259 295 1.1 75 82.5 
Butylone 221 257 1.2 150 180 
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Ethylone 221 257 1.2 150 180 
Methoxetamine 247 283 1.1 500 550 
Benzedrone 253 289 1.1 15 16.5 
3-MeO-PCP 273 309 1.1 100 110 
Desoxypipradol 251 287 1.1 50 55 
MDVP 275 311 1.1 15 16.5 
Naphyrone 281 317 1.1 50 55 
AzacyClonol 267 303 1.1 150 165 
 
Lorna nisbet will mix each drug from powder, and personal protective equipment (lab coat, gloves, and 
masks) will be worn when handling the drugs. Lorna Nisbet will mix each of the NB2OMe solutions 
using the following algorithm: xmg of each drug (where x stands for the weight needed in table 1 above) 
will be dissolved in 5ml of 0.9%NaCl saline to yield a ymg/5 ml solution (where y refers to the weight 
required column in table1). Reverse osmotic water will be added to the 5ml glass bottle and an orange 
rubber stopper will be inserted into the bottle before being inverted several times to ensure the drug is 
thoroughly mixed in solution. The bottle will then be placed on a test-tube shaker and shaken until all 
particulate matter has been dissolved into solution. This “stock solution” will then be used to make 
appropriate working solutions.  
 
For example a 5mg NB2OMe per 5ml of saline stock solution will yield a solution of 1mg per ml. 
Therefore; a rat weighing 1000g will be injected with 0.3cc and 0.3mg of NB2OMe. And so in reality if a 
rat weighs 250g then the rat will be injected with 0.075cc of solution and receive 0.075 mg of NB2OMe. 
This solution will be use to dose the rats at the highest concentration. 
1.66ml of the 5mg NB2OMe per 5 ml of saline solution will be transferred to a separate 5ml glass bottle.  
This solution will be further diluted by adding 5 ml saline solution to yield a 0.33 mg per ml solution. 
This solution will be used to administer each drug at the middle concentration. Therefore; a rat weighing 
1000g will be injected with 0.33cc and 0.1mg of NB2OMe. And so in reality if a rat weighs 250g then the 
rat will be injected with 0.082cc of solution and receive 0.0025 mg of NB2OMe 
1ml of the 5mg NB2OMe per 5 ml of saline solution will be transferred to a separate 10ml glass bottle. 
This solution will be further diluted by adding 10 ml saline solution to yield a 0.1 mg per ml solution. 
This solution will be used to administer each drug at the lowest concentration. Therefore; a rat weighing 
1000g will be injected with 0.3cc and 0.03mg of NB2OMe. And so in reality if a rat weighs 250g then the 
rat will be injected with 0.075cc of solution and receive 0.0075 mg of NB2OMe. 
 
This will be repeated for each other the other drugs in a similar manner.  
 
Each individual vial containing a single drug, will be carried from the locked refrigerator (key held only 
by Dr. Blustein) housed in the locked Behavioral Neuroscience Lab to a digital analytical balance, with 
glass sliding doors to prevent fluctuations in atmospheric pressure which will ensure minimal variability 
in powder weight each time each drug is weighed. The analytical balance is accurate to 0.1mg.  The 
balance is housed in Boyer Hall Room 323 of the Arcadia University Forensic Science Department. A 
weighing boat will be placed on the balance tray prior to adding the individual drug powder and the scale 
will be zeroed using the 0/T function. Then using a standard chemical spatula made of non-reactive 
metal each powder will be transferred to a plastic weighing boat and sliding glass doors will be closed and 
each powder will be weighed individually.  
 
Prior to injection, the prepared drug solutions will be removed from the refrigerator and allowed to 
equilibrate to room temperature for a minimum of ten minutes. 15 minutes, 20minutes and 25 minutes 
after the injection, the rats will be given the tail-flick test to measure analgesia. Tolerance will be defined 
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Form A: Protocol Summary  
(additional pages may be included as needed) 
Page 313 of 364 
when tail-flick latency returns to baseline for three consecutive days. Baseline measurements will be 
taken on day one of testing prior to injection. Any withdrawal symptoms will be observed once tolerance 
has been established, by observing any differences in analgesia using the tail-flick test. At this point in the 
experiment the rats will no longer be dosed with any drug and will not be in any physical harm or under 
any stress. When this study is complete all animals will be euthanized. We confirm that no high school 
students will be involved in the duration of the experiment. 
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The Institutional Animal Care and Use Committee should determine that “…The principal investigator has 
considered alternatives to procedures that may cause more than momentary or slight pain or distress to the animals, 
and has provided a written narrative description of the methods and sources… used to determine that alternatives 
were not available.” [Federal Animal Welfare Act (9 CFR 2.31(d)iii] 
 
The investigator needs to examine recent scientific advances to determine if the experiment could be refined to 
make it less stressful through the use of better procedures or the use of anesthetics, analgesics, or tranquilizers.    
The investigator should also consider reduction in animal numbers, and/or replacement of the animal model with a 
species lower on the phylogenetic scale or a non-in vivo model. 
 
1. Literature Search:  The investigator should complete a literature search to determine that the proposed 
experiments do not unnecessarily duplicate previous experiments, minimize pain and distress, and alternative 
models are not available for the study. (Specify database(s), date searched, years covered, and keywords 
utilized.) 
Journals Cited: Journal of Pharmacology and Experimental Techniques, Psychopharmacology, Addiction 
Biology, Neuropsychopharmacology, Journal of Clinical Pharmacology, Toxicology Letters, Anesthesiology, 
Annals of Emergency Medicine, European Neuropsychopharmacology, Xenobiotica, British Journal of 
Pharmacology, Journal of Medical Toxicology, Anesthesia and Analgesia, PubMed, Dates Searched: June 
1stthrough August 14th, 2013. Covered years spanning 1982 to 2013. Keywords:NB2OMe, NBOMe, 25I-
NBOMe, 25C-NBOMe, 2C-I, Analgesia, Dosage, Metabolites in hair, Metabolites in urine. 
 
2. Review of Scientific Journals: (specify which journals) 
Journal of Pharmacology and Experimental Techniques, Psychopharmacology, Addiction Biology, 
Neuropsychopharmacology, Journal of Clinical Pharmacology, Toxicology Letters, Anesthesiology, Annals of 
Emergency Medicine, European Neuropsychopharmacology, Xenobiotica, British Journal of Pharmacology, 
Journal of Medical Toxicology, and Anesthesia and Analgesia.  
 
 
3. Discussion with colleagues: (specify which colleagues) 
 
 
 
4. Are alternative models or methods available that would minimize the use of living animals?    
NOX / YES     If yes, describe why these methods are not being used in the proposed study. 
  
 
 
5. Does the proposed study duplicate previous work?   
NOX / YES       If yes, explain why duplication is necessary. 
 
 
 
The 3 R’s of Animal Research first presented by William Russell and Rex Burch indicate the need for Refinement 
(minimize the suffering and distress of animals), Reduction (minimize the minimal number of animals used), and 
replacement (substitution for conscious living higher animals of insentient) 
W.M.S. Russell and R.L. Burch. The Principles of Humane Experimental Technique 
http://altweb.jhsph.edu/pubs/books/humane_exp/het-toc
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The Institutional Animal Care and Use Committee should determine that “…researchers consider alternatives to 
painful procedures and that, with regard to painful procedures, researchers must consult a veterinarian; use adequate 
tranquilizers, anesthetics, and analgesics; and provide for adequate pre- and post-surgical care. Moreover, exceptions 
to these standards may be made only when specified by research protocol and explained in a report mandated in the 
Act.” [Federal Animal Welfare Act] 
 
Note:  Undergraduate and graduate students, your faculty sponsor will be responsible for providing information for 
this section. 
 
6. Will the animals be anesthetized?   NO X   YES      
If yes: 
A.  Identify the name of the agent, dose of the agent (mg of drug/kg body weight); and route of administration.  
      
 
B.  What will be the maximum duration of anesthesia? 
      
 
C.  How will depth of anesthesia be monitored? 
      
 
D.  How will you determine if supplemental doses of anesthetic are necessary? Provide dosage and frequency of 
administration. 
      
 
E.  Describe post-anesthetic care. 
      
 
7. Will the animals receive analgesics?   NOX       YES 
If yes 
A.  Identify the name of the agent, dose of the agent (mg of drug/kg body weight); and route of administration.  
8. B.  Describe the procedure for determining supplemental doses of analgesics.  Provide dosage and frequency of 
administration.  
 
 
9. Will the animals receive tranquilizing agents (other than already listed under anesthesia)? NOX YES      
If yes, answer A and B. 
A.  Identify the name of the agent, dose of the agent (mg of drug/kg body weight); and route of administration. 
      
B.  Describe the procedure for determining supplemental doses of tranquilizing agents.  Provide dosage and 
frequency of administration.       
 
Will the animals receive neuromuscular blocking agents?   NOX  YES      
If yes, answer A and  B. 
A.  Identify the name of the agent, dose of the agent (mg of drug/kg body weight); and route of administration.                      
      
B.  Describe the procedure for determining the appropriate level of anesthesia in animals exposed to the paralyzing 
agent.       
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Investigator: _________________________Veterinarian: ____________________ 
Signature                     Signature 
Form D-Surgery (additional pages may be included as needed) 
Page 316 of 364 
Check Appropriate Surgery: 
 Type of surgical Procedure 
      Terminal (non-survival) surgery will be performed. 
      Survival surgery will be performed once per animal 
      Multiple survival surgery will be performed 
      Non-survival second surgery will be performed 
 
1. All survival surgery procedures must occur under aseptic conditions.  Describe the physical location in the 
laboratory to be used for survival surgery and the methods employed to maintain aseptic conditions and 
technique. 
      
 
2. Describe the personnel training and expertise in the surgical model, include pre-, intra-, and post-surgical 
experience. 
      
 
3. Describe procedures for monitoring and administering appropriate levels of anesthetics and analgesics.  Be sure 
to include how you will monitor the depth of anesthesia and how the level of anesthetic will be increased if 
necessary. 
      
 
4. Describe the entire surgical procedure.  Be sure to include preparation of the surgical site, anesthesia, surgical 
procedure, and post-surgical care. 
      
 
5. Multiple survival Surgeries are not normally approved.  Provide scientific justification for the need to conduct 
multiple survival surgeries. 
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The Institutional Animal Care and Use Committee should determine that “…researchers consider 
alternatives to painful procedures and that, with regard to painful procedures, researchers must consult a 
veterinarian; use adequate tranquilizers, anesthetics, and analgesics; and provide for adequate pre- and 
post-surgical care. Moreover, exceptions to these standards may be made only when specified by research 
protocol and explained in a report mandated in the Act.” [Federal Animal Welfare Act] 
 
1. Will the animals be euthanized?   NO   YES X 
If yes: 
A.  Identify the name of the agent, dose of the agent (mg of drug/kg body weight); and route of 
administration. Carbon dioxide is used to euthanize the rats that have not been adopted. The rats are 
placed in a large trashcan. The top of the can is fitted with a spout where the hose for the carbon dioxide 
is attached to the tank. The gas is administered for 10 minutes and then the rats remain in the can for 30 
minutes. 
 
 
 
2. How will euthanization be confirmed? 
After 30 minutes, the rats will be checked to make sure there are no signs of breathing. Paw pinch reflect 
and corneal blink reflex will also be checked.  
 
 
 
 
3. All euthanized animals must be placed in a bag and grouped by treatment (for drug studies).  The bag 
must be labeled with PI name, Study ID, Date of Death, and any corresponding drugs used during the 
course of the study. Bags must be placed in the freezer in the Animal Facility unless a necropsy 
(autopsy) has been ordered by either the PI, Animal Care Representative, or Veterinarian.  If a necropsy 
has been ordered, animals should be placed in individual, labeled bags in the necropsy refrigerator.  
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Appendix 15: Tail flick data. 
 Tail Flick Time (seconds) 
Drug Type Drug Dose Baseline  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
25I-NBOMe 300 1.53 1.82 2.37 1.62 1.78 2 2.16 2.31 2.22 
1.42 2.41 1.53 2.31 1.9 2.41 1.84 1.44 2.75 
1.58 2.22 1.81 3 2.81 2.81 2.31 2.87 2.68 
1.36 2 2.03 1.94 2.13 2.03 1.85 2.06 2.28 
1.83 2.75 2.44 3.4 3.72 2.47 2.62 2.59 2.81 
1.15 1.62 2.18 2.79 2.71 2.25 1.94 1.78 1.97 
100 2.99 2.33 3.13 1.75 3.75 3.25 3.56 3.03 3.5 
1.92 2.41 2.75 3.16 2.69 2.81 2.56 2.56 2.15 
1.86 1.91 2.75 3.03 2.25 2.19 2.22 2.91 2.83 
1.39 2.44 2.94 2.41 2.5 2.5 2.57 2.79 2.78 
1.87 2.16 2.38 2.32 2.22 2.34 2.56 3.03 2.57 
1.43 2.28 2.41 2.41 2.13 1.94 2.06 1.69 1.85 
30 1.36 1.72 1.91 1.37 2.22 2.22 1.81 2.16 2.44 
1.66 1.66 1.94 1.66 2.56 1.69 1.69 1.94 1.87 
1.77 1.56 1.71 1.97 2.09 2.25 2.18 1.75 2.87 
2.6 3.12 2.14 3.25 2.65 2.62 2.97 2.5 2.4 
1.76 3.03 2.38 2.53 2.13 2.13 2.19 1.85 2.16 
ARCADIA UNIVERSITY 
IACUC Animal Use Proposal 
 
 
 Tail Flick Time (seconds) 
Drug Type Drug Dose Baseline  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
1.62 1.84 2.53 2.18 2.34 1.81 3.12 3.47 2.19 
25B-NBOMe 300 1.6 1.64 1.96 1.94 1.65 2 1.57 2.66 1.67 
1.74 1.78 2.06 2.28 2.25 2.5 2.38 2 2.1 
1.42 1.47 2 2.09 2.38 1.9 2.22 1.97 2.31 
1.73 1.97 2.53 2.66 2.47 1.81 2.38 2.25 2.59 
1.53 2.25 2.4 3.21 2.56 2.9 3.41 2.5 2.16 
1.39 1.69 2.41 2.97 2 2.25 2.62 2.88 2.31 
100 1.28 1.44 1.57 1.6 1.65 1.57 1.72 1.72 1.66 
1.52 1.62 1.97 1.46 2.32 1.8 2.16 2.09 1.84 
2.05 2.69 2.28 2.56 2.72 2.87 3.38 2.93 2.56 
1.52 2.1 2.28 2.34 2.35 2.31 2.5 2.41 2.5 
2.11 2.19 1.78 2.82 2.75 2.19 2.59 2.38 2.78 
1.65 2.41 1.97 2.6 2.69 2.53 2.25 2.19 2.66 
30 
30 
1.5 1.43 2.34 1.65 2.06 2.25 1.81 2.5 2.16 
1.78 2.35 2.5 2.9 2.12 2.31 1.69 2.16 2.56 
1.97 3.04 2.5 2.63 2.69 2.22 3.19 2.5 2.4 
2.48 1.81 2.16 2.09 2.31 2.07 2.44 2.44 1.85 
1.69 2.47 1.95 2.06 2.34 2.25 2.56 2.84 2.35 
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 Tail Flick Time (seconds) 
Drug Type Drug Dose Baseline  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
25C-NBOMe 300 2.44 2.47 2.79 2.57 2.44 2.18 1.79 2.87 1.81 
2.48 2.35 2.81 3.25 1.88 3.32 2.87 2.97 2.19 
2.22 1.72 2.47 2.06 2.03 1.94 2.35 2.65 1.96 
1.15 2.44 2.03 1.85 1.91 2.18 2.35 2.94 1.94 
1.45 1.37 2.34 2.34 1.69 2.07 2.78 2.6 2.07 
100 1.86 2.21 1.62 1.82 2.56 1.81 1.68 2.06 2.97 
2.1 1.81 2.4 2.18 2.6 2.41 2.75 2.78 2.25 
1.47 1.88 2.18 2.53 2.25 1.91 2.03 2.72 2.35 
1.92 2.28 1.97 3.12 2.94 2.66 2.53 2.32 2.22 
1.75 2.19 1.79 2.12 2.38 2.19 2.6 2.44 2.19 
30 1.43 1.9 1.4 1.69 2.06 1.84 2.03 2.53 3.4 
1.32 1.66 1.72 2.16 1.85 1.97 2.69 2.03 1.91 
2.61 2.34 1.94 2.46 2.34 2.38 2.19 2.63 2.1 
1.2 1.9 1.65 2.44 1.91 1.97 2.38 2.12 1.75 
1.14 1.93 1.75 2.47 2.03 2.34 2.38 2.56 1.78 
CONTROL  0 1.51 2.34 2.6 2.87 2.44 1.81 2.75 3.31 2.44 
1.81 2.1 1.53 1.87 1.66 1.78 2.06 1.94 1.69 
1.95 2.25 2.22 2.34 2.06 2.53 3.03 2.22 2.04 
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 Tail Flick Time (seconds) 
Drug Type Drug Dose Baseline  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
1.92 2.47 1.84 2.38 2.41 2.13 2.38 2.66 1.97 
1.12 1.43 1.66 1.97 1.31 2.65 1.53 2.03 1.47 
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Appendix 16: Presentations, posters and awards in support of this thesis.  
 
Posters 
 Lorna A Nisbet, and Karen S Scott: Comparison of SPE cartridges for the 
extraction of 25 new psychoactive substances, Society of Forensic 
Toxicology (SOFT) - Orlando, October 2014. 
 Lorna A Nisbet, Jakub Klobut and Karen S Scott: Optimization of 
derivatization for new psychoactive substances (cathinones & NBOMe’s) 
United Kingdom and Ireland Association of Forensic Toxicology 
(UKIAFT)-Leicester, September 2014.  
 Lorna A Nisbet, Fiona M Wylie and Karen S Scott: Short term stability of 
mephedrone in blood and the impact of storage conditions on 
concentrations detected by GC-MS, American Academy of Forensic 
Science (AAFS)- Seattle, February 2014. 
 Lorna A Nisbet, and Karen S Scott: Comparison of SPE cartridges for the 
extraction of 25 new psychoactive substances, Society of Forensic 
Toxicology (SOFT) - Orlando, October 2014. 
Presentations 
 Lorna A Nisbet, Rafael Venson, Fiona M Wylie and Karen S Scott: Analysis 
and detection of 25B, 25C and 25I-NBOMe in rat hair using SPE/LE/MSMS, 
SOFT- Atlanta, October 2015. 
 Lorna A Nisbet, and Karen S Scott: Comparison of SPE and SLE columns for 
the extraction of 23 novel psychoactive substances from blood and urine, 
AAFS- Orlando, February 2015. 
 Lorna A Nisbet, and Karen S Scott: Comparison of SPE cartridges for the 
extraction of 25 new psychoactive substances, UKIAFT- Leicester, 
September 2014. 
Awards 
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 Excellence in SPE Award –SOFT annual meeting, Orlando, USA, October 
2014.  
Lorna A Nisbet, Fiona M Wylie and Karen S Scott (2014). Short term 
stability of mephedrone in blood and the impact of storage conditions on 
concentrations detected by GC-MS. 
 UKIAFT Student Poster Award –UKIAFT annual meeting, Leicester, UK, 
August 2014.  
Lorna A Nisbet, Jakub Klobut and Karen S Scott (2014), Optimization of 
derivatization for new psychoactive substances (cathinones & NBOMe’s)  
 Toxicology Section Best Poster Award - AAFS annual meeting, Seattle, 
USA, February 2014.  
Lorna A Nisbet, Fiona M Wylie and Karen S Scott (2014). Short term 
stability of mephedrone in blood and the impact of storage conditions on 
concentrations detected by GC-MS. 
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AAFS 2014 - SEATTLE 
SHORT TERM STABILITY OF MEPHEDRONE IN BLOOD AND THE 
IMPACT OF STORAGE CONDITIONS ON CONCENTRATIONS DETECTED 
BY GC-MS 
 
Lorna A.Nisbet*, 1,2 BSc.(hons), MSc , Dr Fiona M. Wylie1, BSc (hons), PhD, Dr Karen S. Scott2 BSc 
(hons.), PhD 
1 Forensic Medicine & Science, University of Glasgow, Scotland, UK 
2 Forensic Science Department, Arcadia University, Glenside, PA 19038 
 
After attending this presentation, attendees will understand the implications of 
different storage conditions upon mephedrone concentrations in blood.  
This presentation will impact the forensic science community by offering 
forensic toxicologists and pathologists more information about optimum sample 
storage conditions to reduce potential sample degradation and loss between the 
time of sample collection and sample analysis. 
Introduction: The time between sample collection and sample analysis varies 
greatly from case to case; therefore knowledge of analyte stability is of extreme 
importance. Not only does it help the toxicologist select the most suitable 
sample for analysis, it also ensures optimum storage conditions and preservatives 
are used to limit any sample degradation. This in turn aids the interpretation of 
concentrations of any drugs detected and their significance.  
Mephedrone first appeared on sale to the public in 2007, and remains one of the 
most routinely detected “bath salts” or novel psychoactive substances (NPS) in 
the UK and the US. At the time, the majority of toxicology laboratories were not 
equipped to test for this compound, however since developing methods for its 
analysis many have performed retrospective testing on samples to investigate 
the presence of this drug.  Previous work has shown mephedrone to be unstable 
in biological matrices. This research was intended to ascertain the effects of 
various storage temperatures and preservatives in preventing analyte 
degradation and determine the optimum conditions.  
Method: Preservative free bovine blood was spiked with of mephedrone 
(1mg/L). This was divided into separate aliquots (1mL) enabling the examination 
of the stability of the drug in blood stored 1) without preservative;2) with citric 
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acid preservative (8%); and 3) with sodium fluoride (1.67%)/potassium oxalate 
(0.20%) at three different temperatures (-20oC, -4oC and 20oC). Aliquots were 
tested daily for 7 days and then weekly over a period of 10 weeks. Samples were 
analysed in triplicate and calibrations and controls were run during each 
analysis. Samples were extracted using solid phase extraction (SPE) prior to 
derivatization with PFPA:EtOAc (2:1) and analysed using a Bruker GC-MS/MS with 
a DB5 column (30m x 0.25mm, 0.25 µm) in splitless mode. The total run time 
was 25 minutes, and mephedrone-D3 was used as the I.S..  
Results: Samples stored at 20oC were the most effected with mephedrone 
becoming undetectable after a period of 21 days regardless of any preservative 
present. After 1 day samples stored at 20oC saw a loss of on average 19% ranging 
from 17% with citrate solution to 21% with fluoride oxalate. Refrigerated samples 
preserved with fluoride/oxalate and citrate preservatives were initially stable 
however fluoride/oxalate rapidly decreased after 5 weeks, with a total loss of 
96% over the 10 week period. Refrigerated samples preserved with citrate 
solution showed no significant decrease over the 10 week period. Refrigerated 
samples stored with no preservative saw a 41% drop after 5 weeks and a 74% 
reduction in concentrations across the 10 week period. Samples stored at -20oC 
were stable under all conditions over the 10 week period.  
Conclusion: To maximize stability of mephedrone, samples should be stored at -
20oC and preserved using citrate solution as this prevents any oxidative losses 
occurring. Although fluoride/oxalate was shown to preserve samples when 
stored at -20oC, degradation was still problematic at 4oC after 5 weeks seeing a 
36% decrease. This in turn would affect reported concentrations from 
laboratories which store samples at 4oC prior to analysis before archiving them 
at -20oC.  Regarding retrospective analysis, analysts should be cautious in 
interpreting negative results in cases where the history indicates mephedrone 
use. The sample history must be taken into consideration. Further work is 
underway to investigate potential degradation products; cross validation with 
human blood is also being planned.  
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STABILITY, MEPHEDRONE, PRESERVATIVES 
SOFT 2014- GRAND RAPIDS  
 
COMPARISON OF SPE CARTRIDGES FOR THE EXTRACTION OF 25 
NEW PSYCHOACTIVE SUBSTANCES 
 
Lorna A.Nisbet*, 1,2MSc, Karen S. Scott2 PhD 
1 Forensic Medicine & Science, University of Glasgow, Scotland, UK 
2 Forensic Science, Arcadia University, Glenside, PA 19038 
_______________________________________________________________________________________ 
 
Introduction: New psychoactive substances (NPS) have appeared on the 
recreational drug market at an unprecedented rate. Sample clean-up is a critical 
step in toxicological analysis; not only does it improve sensitivity and selectivity 
of results, but it also increases the lifetime of the instruments.  
Objective: The aim of this study was to determine the most suitable SPE 
cartridge to use for the extraction of various NPS from a range of different 
matrices: blood, urine, plasma and serum.  
Method: Blank methanol, urine, blood, plasma and serum samples (1 mL) were 
all spiked with 200µL of 10µg/mL solutions of various different NPS 
(methiopropamine, flephedrone, mephedrone, MDPV, 2-DPMP,butylone, 
ethylone, naphyrone, 5-APB, 6-APB, 3-MeO-PCE, methoxetamine, benzedrone, 
25B-NBOMe , 25C-NBOMe , 25D-NBOMe , 25E-NBOMe , 25H-NBOMe, 25I-NBOMe, 
Mescaline-NBOMe, 25N-NBOMe, 25P-NBOMe, 25T2-NBOMe, 25T4-NBOMe and 
25T7-NBOMe). To each sample 1mL of 0.1M phosphate buffer (pH6) was added 
before centrifugation for 10 minutes at 4000rpm. Samples were then extracted 
using various different solid phase extraction cartridge; UCT’s XCEL1, ZSDAU020, 
CSDAU133, XRDAH206, XRDAH502, XRPCH50z as well as WatersOasis. ZSDAU020, 
CSDAU133, XRDAH206, XRDAH502, XRPCH50z cartridges were conditioned using 
CH3OH, dH2O and phosphate buffer before loading samples. Columns were 
washed using dH2O, 0.1M acetic acid and CH3OH. Samples were eluted using 
methylene chloride; iso-propanol; ammonium hydroxide (78:20:2). Samples were 
loaded directly to the XCEL I cartridges and washed with 2%acetic acid/ 98% 
methanol before elution with methylene chloride; iso-propanol; ammonium 
hydroxide (78:20:2). Oasis cartridges were conditioned with MeOH and dH2O 
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prior to loading samples. These were then washed using 2% acetic acid and 
MeOH prior to elution with 95% MeOH with 5% NH4OH. Internal standards 
(mephedrone-D3, methylone-D3, ethylone-D5, MDPV-D8 and 25I-NBOMe-D3) were 
added to the collection tubes prior to elution. Post extraction, samples were 
evaporated using a stream of nitrogen, derivatized using 50µL of PFPA:ethyl 
acetate at 70oC for 40 minutes, before being evaporated again and reconstituted 
in 100µL of ethyl acetate. Samples were analysed by GC-MS.   
Results: No drugs were detected (LOD <5 – 30 ng/mL) using the XRPCH50z 
cartridge. For urine samples, overall the UCT CSDAU cartridge had the best 
recovery with an average recovery rate of 71% (ranging 9 - 163% excluding 
methoxetamine and benzedrone which were undetected). Overall, blood 
samples had the best recovery rates with CSDAU SPE cartridges, averaging 60% 
(ranging 8 - 112% (excluding methoxetamine, benzedrone and mescaline-NBOMe 
which were undetected). Plasma and serum samples were best extracted using 
the ZSDAU cartridges with average recovery rates of 71% (ranging 5%- 156%) and 
70% (ranging 12-167%) respectively.  
Conclusion: This study has shown that when analysing urine and blood samples 
the smaller bed size of theCSDAU cartridges is preferable and when analysing 
plasma and serum samples ZSDAU cartridges should be used. XRPCH50z 
cartridges, using the method tested, are not recommended for sample clean-up 
of NPS compounds.  
KEYWORDS: SPE, Novel psychoactive substances, NBOMes, Cathinones 
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After attending this presentation, attendees will be able to compare supported 
liquid extraction (SLE) and solid phase extraction (SPE) columns and identify the 
correct choice for optimum recovery of cathinones and NBOMes from a variety of 
biological matrices.  
This presentation will impact on the forensic community by increasing awareness of 
extraction options for the determination of novel psychoactive substances in forensic 
toxicological samples.  
Supported liquid extraction columns are now commercially available and pose an 
alternative to solid phase extraction (SPE).SLE has commercial benefits over SPE 
in that it does not produce the same amount of solvent waste and can be carried 
out in fewer steps depending on the type of SPE column being compared.   
Recently there has been an influx of new synthetic substances to the 
recreational drug market with laboratories struggling to keep apace in this “cat 
and mouse” game. To improve detection rates it is vital that laboratories are 
using the optimum sample preparation technique to allow to maximum analyte 
recovery and sample throughput.  
The aim of this research was to determine whether SLE+ columns can be used as 
a possible alternative sample extraction method for the detection of synthetic 
cathinones and NBOMes and to evaluate which clean up method produces the 
maximum recovery across a range of 25 drugs.  
Blank methanol, urine and blood samples (1 mL) were spiked with 100µL of 
10µg/mL solutions of various different NPS (methiopropamine, flephedrone, 
mephedrone, MDPV, 2-DPMP,butylone, ethylone, naphyrone, 5-APB, 6-APB, 3-
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MeO-PCE, methoxetamine, benzedrone, 25B-NBOMe , 25C-NBOMe , 25D-NBOMe , 
25E-NBOMe , 25H-NBOMe, 25I-NBOMe, Mescaline-NBOMe, 25N-NBOMe, 25P-
NBOMe, 25T2-NBOMe, 25T4-NBOMe and 25T7-NBOMe). Urine samples were pH 
adjusted to 10.8 using 1% ammonium hydroxide (NH4OH).  To each sample 
prepared for SPE, 1mL of 0.1M phosphate buffer (pH6) was added before 
centrifugation for 10 minutes at 4000rpm. UCT’s ZDSAU020 columns were 
conditioned using MeOH, dH2O and phosphate buffer before loading samples. 
Columns were washed using dH2O, 0.1M acetic acid and methanol. Samples were 
eluted using methylene chloride; iso-propanol; NH4OH (78:20:2). For SLE, 
following pH adjustment with 1% ammonium hydroxide, samples were loaded 
directly to Biotage’s SLE+ columns. The sample was held on the column for 5 
minutes before being eluted with 2x4mL of ethyl acetate. Internal standards 
(mephedrone-D3, methylone-D3, ethylone-D5, MDPV-D8 and 25I-NBOMe-D3) were 
added to the collection tubes prior to elution. Post extraction, samples were 
evaporated using a stream of nitrogen, derivatized using 50µL of PFPA:ethyl 
acetate at 70oC for 40 minutes, before being evaporated again and reconstituted 
in 100µL of ethyl acetate. Samples were analysed by GC-MS with the SLE and SPE 
results being compared directly to unextracted methanolic standards at the 
same concentration. 
All drugs were successfully extracted from each matrix using both SPE and SLE 
columns. For blood, SLE+ columns provided a higher recovery rate of drug than 
the SPE columns, with an average increase of 10% (recovery ranging from -47% to 
80%). SPE extracted urine samples more efficiently providing an average of 5% 
increase in recovery rates (recovery ranging -47% to 92%). 
In conclusion when analysing blood samples SLE+ should be used whereas SPE is 
more efficient for the extraction of these analytes from urine.  
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Introduction: NBOMes are phenethylamine derivatives of the 25C-X series, first 
mentioned in Ralf Heim’s PhD thesis in 2004. These were further developed by 
David Nichol with the addition of a 2-methoxybenzyl (MeOB) onto the nitrogen 
(N) of the phenethylamine, hence the term NBOMe. The first mention of 
recreational abuse appeared in 2010, with NBOMe’s now routinely associated 
with the “club drug” scene.  They are administered either in liquid form or on 
blotters due to their high potency and similarities to LSD. (119)  
Due to NBOMes’ toxicity, adverse effects and fatalities have been reported. To 
date, analytical methods have been published for blood, urine, vitreous humour, 
brain, liver, bile and gastric contents; however no hair analysis has been 
published. (124) 
Objective: The objective of this research was to extract 25B-NBOMe, 25C-NBOMe 
and 25I-NBOMe from rat hair by using a phosphate buffer incubation and SPE 
clean up method. Additional objectives including assessing any dose response 
relationship and determining whether the colour of hair affects concentration as 
seen with other phenethylamines. 
Methods: Long Evans rats (59) were partially shaved prior to first dose. The rats 
were shaved along their backs ensuring that both white and black hair was 
collected separately. Rats were then split into 4 groups, receiving saline, 25B-
NBOMe, 25C-NBOMe and 25I-NBOMe respectively. Rats receiving NBOMes were 
subdivided into dose groups (5-6 rats per dose group), receiving 0.03 mg/kg, 0.1 
mg/kg or 0.3 mg/kg. Each rat was dosed for a period of 10 consecutive days 
before being re-shaved; with white and black hair collected separately for 
analysis.  
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Hair was washed with dH2O and Ch2Cl2, cut into small segments, and 40mg was 
transferred into a 7 mL vial. Next,100 µl of 0.01 µg/mL 25B-NBOMe-D3 was 
added to the vial along with 2 mL of 0.1 M pH 7.4 phosphate buffer. Vials were 
sonicated for 60 minutes and incubated 12hrs overnight at 40oC. Sample vials 
were then centrifuged at 4000rpm and the supernatant was transferred to SPE 
cartridges conditioned with 2 mL MeOH and 1 mL 0.1M pH7.4 phosphate buffer. 
Cartridges were then washed using 3 mL dH2O, 1 mL 1M acetic acid and 3 mL 
MeOH before eluting with 3 mL of CH2Cl2/IPA/NH4 (78:20:2). Eluents were 
evaporated to dryness with nitrogen before being reconstituted in mobile phase 
and analysed by LC-MSMS.   
Results: All drugs were successfully detected in black hair regardless of dose.  
Black hair incorporated all drugs to a higher degree than the white hair, with 
only the white hair from rats receiving the 300 mg/kg dose testing positive. Only 
the white hair from the 25C-NBOMe and 25I-NBOMe 300 µg/kg rats could be 
quantitated (4 pg/mg each). The concentration increase in black hair was dose-
dependent, (2-30 pg/mg). 25I-NBOMe incorporated into the hair the greatest 
extent, approximately 80% more than 25C-NBOMe and 250% more than 25B-
NBOMe.  
Conclusion: The use of SPE followed by LC-MSMS analysis allowed for the 
detection of NBOMes in rat hair. To our knowledge this is the first example of 
NBOMes being successfully analysed in hair samples, despite the low 
concentrations administered. 
KEYWORDS: NBOMe, hair testing, LC/MSMS. 
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